multiomics O
data O
) O
and O
analysis O
( O
i O

Methylation-Sensitive-Random O
Amplified O
Polymorphic O
DNA-Polymerase O
Chain O
Reaction O
(MS-RAPD-PCR) O
is O
a O
restriction O
enzyme O
digestion O
and O
PCR-based O
method O
for O
the O
analysis O
of O
DNA O
methylation O
changes O


DAC O
suppressed O
lung B-Disease
cancer I-Disease
growth O
in O
a O
dose-dependent O
manner O
in O
vivo O

Compared O
to O
the O
state-of-the-art O
methods O
, O
our O
Monte O
Carlo O
method O
can O
quantify O
the O
global O
potential O
landscape O
( O
or O
emergence O
behavior O
) O
of O
GRN O
for O
a O
high O
dimensional O
system O

Understanding O
these O
mechanisms O
may O
allow O
prevention O
of O
β-cell O
dedifferentiation O
or O
induction O
of O
cell O
redifferentiation O
for O
restoration O
of O
the O
functional O
β-cell O
mass O

The O
advantageous O
cost O
versus O
coverage O
balance O
of O
MeDIP-seq O
has O
made O
it O
the O
method O
of O
choice O
to O
replace O
or O
complement O
array-based O
methods O
for O
population O
epigenetic O
studies O

In O
this O
review O
, O
some O
of O
them O
are O
presented O
and O
briefly O
commented O
upon O

Every O
protein O
in O
the O
synapse O
undergoes O
some O
form O
of O
turnover O
, O
some O
with O
half-lives O
of O
only O
hours O

We O
identified O
significant O
( O
FDR O
p-value O
≤ O

1333 O
For O
further O
resources O
related O
to O
this O
article O
, O
please O
visit O
the O
WIREs O
website O

The O
majority O
of O
epigenetic O
analyses O
of O
eating B-Disease
disorders I-Disease
investigated O
methylation O
at O
candidate O
genes O
( O
n O
= O
13 O
) O
, O
focusing O
on O
anorexia O
and O
bulimia B-Disease
nervosa I-Disease
in O
very O
small O
samples O
with O
considerable O
sample O
overlap O
across O
published O
studies O

The O
mechanisms O
involved O
in O
ensuring O
that O
environmentally O
induced O
epigenetic O
changes O
perpetuate O
across O
the O
life O
course O
remain O
unclear O

Throughout O
this O
cycle O
, O
the O
endometrium O
exhibits O
different O
transcriptional O
networks O
according O
to O
the O
genes O
expressed O
in O
each O
phase O

It O
reveals O
from O
the O
single-cell O
data O
the O
combinatorial O
regulatory O
interactions O
among O
genes O
that O
control O
the O
dynamic O
progression O
through O
successive O
cell O
states O

Here O
we O
propose O
a O
potential O
role O
of O
adult O
stem O
cells O
in O
maintaining O
epigenetic O
states O
provides O
a O
useful O
basis O
for O
formulating O
such O
epidemiologically-relevant O
concepts O

© O
2017 O
AACR O

258 O
: O
The O
complexity O
of O
the O
mammalian O
genome O
is O
regulated O
by O
heritable O
epigenetic O
mechanisms O
, O
which O
provide O
the O
basis O
for O
differentiation O
, O
development O
and O
cellular O
homeostasis O

An O
enhanced O
understanding O
of O
posttranscriptional O
mechanisms O
would O
help O
to O
clarify O
some O
remaining O
enigmatic O
issues O
in O
primary O
and O
secondary O
hemostasis O
, O
which O
cannot O
be O
thoughtfully O
explained O
by O
genetics O
or O
biochemistry O
alone O

Cytosine O
nucleotide O
(CpG) O
methylation O
changes O
in O
CoA O
in O
each O
of O
450,000 O
CpG O
loci O
were O
determined O

We O
therefore O
sought O
to O
investigate O
the O
association O
between O
cumulative O
and O
recent O
use O
of O
marijuana O
with O
epigenetic O
age O
acceleration O
(EAA) O
as O
estimated O
from O
blood O
DNA O
methylation O

The O
scholarship O
presented O
in O
these O
volumes O
suggests O
that O
rigorous O
, O
relational O
developmental O
theory-predicated O
research O
about O
the O
plastic O
, O
mutually O
influential O
relations O
among O
individual O
and O
ecological O
processes O
will O
enable O
developmental O
science O
to O
better O
describe O
, O
explain O
, O
and O
optimize O
the O
fundamental O
relational O
process O
of O

Conclusion O
: O
These O
analyses O
support O
the O
use O
of O
precision O
epigenetic O
methods O
as O
part O
of O
the O
initial O
diagnosis O
and O
care O
of O
stable O
CHD O
and O
can O
meaningfully O
reduce O
cost O

Here O
, O
we O
focus O
on O
the O
interplay O
between O
metabolic O
rewiring O
and O
epigenetic O
landscape O
in O
the O
context O
of O
tumourigenesis B-Disease
and O
highlight O
recent O
advances O
in O
the O
use O
of O
small-molecule O
drug O
targets O
for O
therapy O

387 O
: O
Epigenetics O
has O
become O
a O
fundamental O
scientific O
discipline O
with O
various O
implications O
for O
biology O
and O
medicine O

As O
a O
result O
, O
several O
methods O
have O
been O
developed O
to O
explore O
epigenetic O
alterations O
at O
low O
, O
medium O
, O
and O
high O
scales O
, O
focusing O
on O
DNA O
methylation O
and O
histone O
modification O
detection O

582 O
: O
Spatial O
omics O
techniques O
generate O
spatially O
resolved O
, O
comprehensive O
data O
about O
molecules O
that O
define O
the O
identity O
and O
function O
of O
cells O
in O
tissues O

Our O
tool O
will O
be O
useful O
for O
highly O
sensitive O
epigenetic O
studies O
based O
on O
a O
small O
quantity O
of O
sample O

Emerging O
evidence O
points O
to O
a O
role O
of O
epigenetics O
in O
the O
pathogenesis O
of O
OA O
, O
but O
research O
in O
this O
area O
is O
still O
in O
its O
early O
stages O

272 O
: O
Highly O
proliferative O
tissues O
such O
as O
the O
gut O
, O
skin O
, O
and O
bone O
marrow O
lose O
millions O
of O
cells O
each O
day O
to O
normal O
attrition O
and O
challenge O
from O
different O
biological O
adversities O

Recent O
studies O
in O
a O
number O
of O
species O
, O
from O
yeast O
to O
humans O
, O
have O
begun O
to O
dissect O
the O
cis- O
and O
trans-regulatory O
genetic O
mechanisms O
that O
shape O
patterns O
of O
population O
epigenomic O
variation O
at O
the O
level O
of O
single O
epigenetic O
marks O
, O
as O
well O
as O
at O
the O
level O
of O
integr O

This O
will O
allow O
new O
levels O
of O
understanding O
of O
cell O
fate O
decisions O
, O
identity O
, O
and O
function O
in O
normal O
development O
, O
physiology O
, O
and O
disease B-Disease


It O
should O
be O
noted O
that O
the O
study O
of O
the O
role O
of O
epigenetics O
in O
food B-Disease
allergy I-Disease
is O
still O
in O
its O
infancy O
, O
and O
lags O
behind O
research O
on O
epigenetics O
in O
other O
fields O
such O
as O
cancer B-Disease
and O
autoimmune O
diseases O

Epigenetic O
modifications O
contribute O
to O
a O
change O
in O
gene O
expression O
while O
maintaining O
the O
DNA O
sequence O

Experiments O
in O
mice O
show O
that O
the O
loss O
of O
BRG1 O
inhibits O
cellular O
reprogramming O
, O
while O
studies O
using O
human O
cells O
demonstrate O
that O
the O
overexpression O
of O
BRG1 O
enhances O
reprogramming O

477 O
: O
It O
has O
been O
estimated O
that O
the O
heritable O
component O
of O
bipolar O
disorder B-Disease
ranges O
between O
80 O
and O
90 O
% O

Emerging O
evidence O
is O
consistent O
with O
the O
idea O
that O
epigenetic O
processes O
are O
involved O
in O
embedding O
the O
impact O
of O
early-life O
experience O
in O
the O
genome O
and O
mediating O
between O
social O
environments O
and O
later O
behavioral O
phenotypes O

Three O
studies O
used O
microarray-based O
technologies O
to O
examine O
DNA O
methylation O
across O
the O
genome O
of O
anorexia O
nervosa O
and O
binge-eating O
disorder B-Disease
patients O

jetbrains O

97 O
( O
0 O

However O
, O
to O
date O
, O
gene O
discovery O
approaches O
have O
only O
mapped O
a O
minority O
of O
the O
heritability O
of O
these O
common O
diseases O
, O
and O
most O
disease-associated O
variants O
have O
been O
found O
to O
be O
non-coding O
, O
suggesting O
mechanisms O
of O
disease-association O
through O
transcriptional O
regulatory O
effects O

Among O
the O
four O
identified O
frequent O
clusters O
, O
two O
of O
them O
separate O
the O
tumor B-Disease
sample O
from O
normal O
sample O
in O
10 O
out O
of O
11 O
cancer B-Disease
types O
, O
which O
indicates O
that O
consistent O
epigenetic O
landscape O
changes O
exist O
in O
multiple O
cancer B-Disease
types O

We O
have O
made O
substantial O
usability O
improvements O
to O
user O
interfaces O
, O
enhanced O
functionality O
, O
made O
identification O
of O
data O
tracks O
of O
interest O
easier O
and O
created O
new O
tools O
for O
preliminary O
data O
analyses O

Thus O
, O
we O
have O
developed O
a O
computational O
approach O
, O
DXM O
, O
to O
deconvolve O
the O
methylation O
profiles O
of O
major O
allelic O
subpopulations O
from O
the O
bisulfite O
sequencing O
data O
of O
a O
heterogeneous O
sample O

Therefore O
, O
psychoanalysis O
, O
which O
has O
proven O
to O
reduce O
the O
intergenerational O
transmission O
of O
trauma B-Disease
from O
a O
behavioral O
perspective O
, O
can O
play O
a O
positive O
role O
in O
regulating O
DNA O
changes O
caused O
by O
environmental O
stress O

Intriguing O
as O
it O
is O
, O
this O
hypothesis O
requires O
further O
study O
, O
as O
does O
the O
distinctly O
uneven O
historiography O
of O
the O
Famine O
in O
relation O
to O
the O
Irish O
mental O
hospitals O

176 O
: O
The O
epigenome O
dynamically O
regulates O
gene O
expression O
and O
guides O
cellular O
differentiation O
throughout O
the O
lifespan O
of O
eukaryotic O
organisms O

After O
postdoctoral O
work O
, O
he O
became O
a O
faculty O
member O
at O
the O
Beckman O
Research O
Institute O
of O
the O
City O
of O
Hope O
( O
Duarte O
, O
CA O
) O
in O
1991 O

Last O
but O
not O
least O
we O
have O
discussed O
the O
limitations O
, O
different O
uses O
of O
CRISPR/Cas9 O
and O
dCas9 O
in O
the O
area O
of O
genetic O
engineering O

Genome O
- O
wide O
association O
studies O
investigated O
genes O
potentially O
involved O
in O
fibromyalgia O
pathogenesis O
highlighting O
that O
genetic O
factors O
are O
possibly O
responsible O
for O
up O
to O
50% O
of O
the O
disease B-Disease
susceptibility O

Human O
studies O
have O
included O
the O
theory-driven O
approach O
of O
candidate-gene O
studies O
( O
CGS O
) O
, O
as O
well O
as O
the O
increasingly O
popular O
exploratory O
approach O
of O
epigenome-wide O
association O
studies O
( O
EWAS O
) O

At O
the O
model O
's O
core O
was O
the O
modular O
assembly O
of O
regulators O
, O
operators O
, O
and O
structural O
genes O

473 O
: O
Background O
: O
Intra-sample O
cellular O
heterogeneity B-Disease
presents O
numerous O
challenges O
to O
the O
identification O
of O
biomarkers O
in O
large O
Epigenome-Wide O
Association O
Studies O
( O
EWAS O
) O

We O
review O
the O
current O
knowledge O
in O
the O
field O
regarding O
epigenetic O
regulation O
of O
microglial O
identity O
and O
function O
, O
provide O
an O
exemplary O
analysis O
that O
demonstrates O
the O
advantages O
of O
performing O
joint O
transcriptomic O
and O
epigenomic O
profiling O
of O
single O
microglial O
cells O
and O
discuss O
how O
comprehensive O
epigenetic O
analyses O
may O

The O
demand O
for O
identifying O
( O
diagnosing O
) O
targeted O
SNPs O
or O
other O
variations O
, O
as O
well O
as O
the O
application O
of O
genome-wide O
screens O
, O
is O
continuously O
directing O
the O
development O
of O
new O
technologies O

If O
validated O
, O
this O
mechanism O
would O
present O
a O
challenging O
but O
not O
impossible O
target O
for O
medical O
intervention O

Changes O
of O
epigenetic O
marks O
including O
DNA O
methylation O
, O
histone O
modifications O
, O
and O
non-coding O
RNA's O
can O
induce O
changes O
in O
gene O
transcription O
leading O
to O
physiological O
long-term O
changes O
or O
even O
transgenerational O
inheritance O

728 O
: O
Cardiovascular B-Disease
diseases I-Disease
( O
CVDs O
) O
remain O
the O
leading O
cause O
of O
mortality O
worldwide O
and O
also O
inflict O
major O
burdens O
on O
morbidity O
, O
quality O
of O
life O
, O
and O
societal O
costs O

599 O
: O
The O
epigenetic O
nature O
of O
cancer B-Disease
encourages O
the O
development O
of O
inhibitors O
of O
epigenetic O
pathways O

717 O
: O
Forensic O
genetics O
developed O
from O
protein-based O
techniques O
a O
quarter O
of O
a O
century O
ago O
and O
became O
famous O
as O
" O
DNA O
fingerprinting O
, O
" O
this O
being O
based O
on O
restriction O
fragment O
length O
polymorphisms O
( O
RFLPs O
) O
of O
high-molecular-weight O
DNA O

We O
questioned O
them O
about O
the O
scope O
of O
their O
field O
, O
opportunities O
in O
different O
areas O
of O
specialization O
, O
and O
ELSI O
in O
the O
conduct O
of O
research O
and O
knowledge O
translation O

The O
epigenomic O
signature O
is O
frequently O
associated O
with O
a O
cell O
of O
origin O
, O
as O
well O
as O
with O
tumor B-Disease
stage O
and O
differentiation O
, O
which O
all O
reflect O
its O
high O
heterogeneity B-Disease
across O
and O
within O
various O
tumors B-Disease


In O
particular O
, O
exposure O
to O
environmental O
and O
occupational O
toxicants O
may O
contribute O
to O
the O
occurrence O
of O
adverse O
birth O
outcomes O
, O
neurodevelopmental O
deficits O
, O
and O
increased O
risk O
of O
cancer B-Disease
and O
other O
multifactorial O
diseases O
such O
as O
diabetes B-Disease
and O
asthma O

A O
lot O
of O
PROTACs O
have O
already O
been O
designed O
in O
the O
field O
of O
epigenetics O
, O
and O
their O
synthesis O
and O
characterization O
highly O
contributed O
to O
structural O
optimization O
and O
improved O
mechanistic O
understanding O
of O
these O
molecules O

) O
as O
related O
to O
its O
clinical O
manifestations O
, O
rather O
than O
genetic O
factors O

The O
article O
concludes O
that O
while O
research O
labelled O
epigenetics O
contributes O
significantly O
to O
our O
knowledge O
about O
chromatin O
and O
the O
genome O
, O
it O
does O
not O
, O
as O
is O
often O
claimed O
, O
rehabilitate O
Lamarck O
or O
overthrow O
the O
fundamental O
biological O
principles O
of O
gene O
regulation O
, O
which O
are O
based O
on O

Our O
approach O
utilizes O
machine O
learning O
techniques O
to O
achieve O
an O
AUC O
value O
of O
0 O

Anthropologists O
and O
human O
biologists O
are O
interested O
in O
epigenetics O
specifically O
, O
as O
it O
provides O
a O
potential O
link O
between O
the O
environment O
and O
the O
genome O
, O
as O
well O
as O
a O
new O
layer O
of O
complexity O
for O
the O
study O
of O
human O
biological O
variation O

These O
individual O
differences O
are O
produced O
epigenetically O
by O
the O
two-way O
interaction O
between O
the O
brain O
and O
hormones O
, O
immune O
system O
mediators O
and O
the O
autonomic O
nervous B-Disease
system I-Disease

The O
development O
of O
epigenetics O
provides O
a O
basis O
for O
the O
search O
for O
genetic O
markers O
associated O
with O
the O
major O
histocompatibility O
complex O

Osteoporosis O
and O
osteoporotic B-Disease
vertebral I-Disease
fracture I-Disease
( O
OVF O
) O
are O
associated O
with O
high O
medical O
costs O
and O
can O
lead O
to O
poor O
quality O
of O
life O

0 O
is O
developed O
providing O
well-organized O
compendium O
of O
methylation O
events O
and O
statistical O
analysis O
associated O
with O
several O
diseases O

ca O
and O
the O
github O
repository O
at O
https://github O

It O
is O
therefore O
imperative O
to O
incorporate O
into O
" O
precision O
medicine O
" O
a O
better O
understanding O
of O
how O
these O
differences O
affect O
the O
efficacy O
of O
pharmacological O
, O
behavioral O
and O
psychosocial O
interventions O

Summary O
: O
It O
is O
the O
combined O
application O
of O
technological O
advances O
to O
probe O
epigenetic O
modifications O
at O
a O
genome-wide O
scale O
and O
methodological O
advances O
aimed O
at O
causal O
inference O
( O
including O
Mendelian O
randomization O
and O
integrative O
genomics O
) O
that O
will O
elucidate O
the O
interplay O
between O
circulating O
lipids O
and O
ep O

729 O
: O
Background O
: O
Estimates O
of O
biological O
age O
derived O
from O
DNA-methylation O
patterns-known O
as O
the O
epigenetic O
clock-are O
associated O
with O
mortality O
, O
physical O
and O
cognitive O
function O
, O
and O
frailty O
, O
but O
little O
is O
known O
about O
their O
relationship O
with O
sedentary O
behavior O
or O
physical O
activity O

Recent O
genome-wide O
epigenetic O
studies O
in O
disease-discordant O
monozygotic O
twins O
emphasize O
the O
power O
of O
this O
design O
to O
successfully O
identify O
epigenetic O
changes O
associated O
with O
complex O
traits O

Finally O
, O
the O
potential O
functions O
of O
aberrantly O
methylated O
ncRNAs O
were O
predicted O
, O
suggestiong O
that O
ncRNAs O
and O
coding O
genes O
cooperatively O
mediate O
pathway O
dysregulation O
during O
the O
development O
and O
progression O
of O
breast B-Disease
cancer I-Disease

We O
further O
experimentally O
validate O
DXM O
predicted O
allelic O
subpopulation-methylation O
profiles O
in O
four O
Diffuse O
Large O
B-Cell O
Lymphomas O
( O
DLBCLs O
) O

Jirtle's O
research O
interests O
are O
in O
epigenetics O
, O
genomic O
imprinting O
and O
the O
fetal O
origins O
of O
disease B-Disease
susceptibility O

With O
the O
utilization O
of O
constructs O
often O
with O
large O
sizes O
and O
the O
wide O
array O
of O
cell O
types O
used O
to O
read O
out O
the O
effect O
of O
epigenetic O
editing O
in O
different O
biological O
applications O
, O
it O
is O
evident O
that O
ongoing O
optimalization O
of O
transfection O
protocols O
tailored O
to O
each O
specific O
experimental O
setup O
is O

5mC O
removal O
has O
recently O
been O
associated O
with O
the O
activation O
of O
enhancers O
, O
opening O
the O
possibility O
that O
5mC O
may O
globally O
contribute O
to O
the O
expression O
of O
genes O
defining O
cell O
identities O

Epigenetic O
mechanisms O
function O
alongside O
the O
DNA O
sequence O
to O
modulate O
gene O
expression O
and O
ultimately O
influence O
protein O
production O

26 O
: O
Behavioral O
epigenetics O
is O
revealing O
new O
pathways O
that O
lead O
individuals O
from O
early O
adversity O
exposures O
to O
later-in-life O
detrimental O
outcomes O

Our O
study O
highlights O
that O
placental O
post-processing O
techniques O
must O
be O
considered O
in O
the O
evaluation O
and O
interpretation O
of O
epigenetic O
studies O

Rather O
than O
investigating O
genetic O
and O
epigenetic O
factors O
independently O
, O
an O
integrative O
etiological O
research O
paradigm O
based O
on O
the O
combination O
of O
genomic O
, O
transcriptomic O
, O
and O
epigenomic O
analyses O
is O
required O

Further O
, O
these O
comparative O
epigenomic O
studies O
have O
begun O
to O
show O
promise O
toward O
enhancing O
our O
understanding O
of O
how O
regulatory O
programs O
evolve O

Here O
, O
we O
want O
to O
provide O
general O
guidelines O
on O
how O
to O
design O
studies O
on O
epigenetic O
inheritance O
in O
plants O
and O
to O
consider O
critical O
points O
during O
data O
analysis O
and O
interpretation O

We O
conclude O
a O
genetic O
basis O
of O
inheritance O
cannot O
be O
ruled O
out O
and O
thus O
transgenerational O
epigenetic O
inheritance O
has O
not O
been O
adequately O
established O
by O
the O
original O
study O

Eight O
classes O
of O
medicinal O
products O
were O
discussed O
and O
prioritised O
based O
on O
the O
existing O
level O
of O
science O
to O
support O
early O
evaluation O
in O
children O
: O
inhibitors O
of O
menin O
, O
DOT1L O
, O
EZH2 O
, O
EED O
, O
BET O
, O
PRMT5 O
and O
LSD1 O
and O
a O
retinoic O
acid O
receptor O
alpha O

Epigenetic O
changes O
may O
be O
responsible O
for O
'metabolic O
memory' O
and O
development O
of O
micro- O
and O
macrovascular O
complications O
of O
diabetes B-Disease

869 O
gene O
segments O
analyzed O
, O
transcriptional O
activities O
were O
up- O
or O
downregulated O
in O
the O
transgenomic O
cell O
clones O

This O
evidence O
not O
only O
supports O
the O
essential O
role O
psychoanalysis O
has O
in O
influencing O
human O
behavior O
, O
but O
also O
suggests O
that O
it O
affects O
not O
only O
the O
individuals O
who O
undergo O
it O
but O
their O
offspring O
, O
as O
well O
, O
via O
the O
epigenetic O
passage O
of O
DNA O

05 O
) O
methylation O
changes O
in O
65 O
different O
CpG O
sites O
located O
in O
75 O
genes O
in O
CoA O
subjects O

Here O
are O
presented O
the O
main O
advantages O
and O
disadvantages O
of O
different O
approaches O
to O
methylation O
analysis O

Conclusion O
: O
This O
web O
resource O
would O
be O
helpful O
for O
research O
community O
engaged O
in O
studying O
epigenetic O
biomarkers O
for O
appropriate O
prognosis O
and O
diagnosis O
of O
diseases O
and O
its O
various O
stages O

Some O
investigations O
have O
shown O
that O
epigenetic O
phenomena O
changes O
occur O
in O
the O
cardiac O
differentiation O
of O
stem O
cells O

Epigenetics O
is O
an O
evolving O
field O
and O
could O
be O
highly O
relevant O
to O
many O
paediatric O
cancers B-Disease
; O
the O
biology O
is O
multifaceted O
and O
new O
targets O
are O
frequently O
emerging O

Using O
this O
framework O
we O
compare O
a O
widely O
used O
state-of-the-art O
reference-based O
algorithm O
(called O
constrained O
projection O
) O
to O
two O
non-constrained O
approaches O
including O
CIBERSORT O
and O
a O
method O
based O
on O
robust O
partial O
correlations O

The O
concept O
that O
environmental O
influences O
can O
cause O
stable O
, O
heritable O
changes O
in O
gene O
expression O
has O
been O
embraced O
with O
such O
enthusiasm O
that O
the O
study O
of O
epigenetics O
has O
found O
its O
place O
in O
virtually O
every O
medical O
biology O
field O

A O
growing O
body O
of O
evidence O
implicates O
epigenetic O
aberrations O
in O
this O
intractable O
disease B-Disease
, O
including O
specific O
modifications O
affecting O
the O
three O
main O
cell O
types O
involved O
in O
SSc O
pathogenesis O
: O
immune O
cells O
, O
endothelial O
cells O
and O
fibroblasts O

60 O
: O
Understanding O
epigenetic O
processes O
holds O
immense O
promise O
for O
medical O
applications O

256 O
: O
Epigenetics O
is O
emerging O
as O
an O
important O
field O
in O
cancer B-Disease
epidemiology O
that O
promises O
to O
provide O
insights O
into O
gene O
regulation O
and O
facilitate O
cancer B-Disease
control O
throughout O
the O
cancer B-Disease
care O
continuum O

In O
general O
, O
most O
methods O
require O
a O
DNA O
amplification O
step O
to O
provide O
the O
amounts O
of O
DNA O
needed O
for O
the O
SNP O
detection O
step O

Additionally O
, O
the O
review O
also O
focuses O
on O
understanding O
recent O
methodologies O
related O
to O
epigenome O
profiling O
using O
NGS O
methods O
ranging O
from O
library O
preparation O
, O
different O
sequencing O
platforms O
and O
analytical O
techniques O
to O
evaluate O
various O
epigenetic O
modifications O
such O
as O
DNA O
methylation O
and O
histone O
modifications O

715 O
: O
As O
an O
individual O
becomes O
addicted O
to O
a O
drug O
of O
abuse O
, O
nerve O
cells O
within O
the O
brain O
's O
reward O
circuitry O
adapt O
at O
the O
epigenetic O
level O
during O
the O
course O
of O
repeated O
drug O
exposure O

Haystack O
is O
generally O
applicable O
to O
any O
epigenetic O
mark O
and O
provides O
an O
important O
tool O
to O
investigate O
the O
mechanisms O
underlying O
epigenetic O
switches O
during O
development O

Second O
, O
an O
epigenome-wide O
association O
study O
( O
EWAS O
) O
on O
1011 O
longitudinal O
samples O
( O
385 O
individuals O
followed O
up O
to O
18 O
years O
) O
was O
performed O
to O
identify O
age-varying O
methylation O
sites O
using O
these O
methods O

In O
this O
introduction O
, O
the O
authors O
present O
the O
basics O
of O
epigenetics O
in O
a O
way O
that O
is O
designed O
to O
make O
this O
exciting O
field O
accessible O
to O
a O
wide O
readership O

Further O
implication O
of O
stochastic O
epigenetic O
variability O
in O
adaptation O
is O
found O
in O
bottlenecked O
invasive O
species O
populations O
and O
populations O
using O
a O
bet-hedging O
strategy O

Meanwhile O
, O
the O
discovery O
of O
new O
epigenetic O
marks O
continues O
, O
and O
there O
are O
many O
useful O
methods O
for O
epigenome O
analysis O
applicable O
to O
primary O
tumor B-Disease
samples O
, O
in O
addition O
to O
cancer B-Disease
cell O
lines O

Here O
we O
present O
a O
protocol O
for O
identification O
and O
quantification O
of O
cytosine O
modifications O
that O
combines O
a O
robust O
and O
efficient O
method O
to O
generate O
single O
nucleosides O
from O
genomic O
DNA O
samples O
followed O
by O
direct O
LC-MS/MS O
analysis O

The O
epigenetic O
age O
was O
calculated O
based O
on O
the O
Horvath O
algorithm O
, O
GrimAge O
and O
SkinBloodAge O
were O
calculated O
using O
the O
Horvath O
online O
calculator O
, O
and O
p-value O
for O
significance O
was O
corrected O
using O
the O
FDR O
method O
for O
multiple O
testing O
corrections O

Furthermore O
, O
new O
technological O
advances O
such O
as O
epigenome O
editing O
and O
DNAzymes O
will O
allow O
targeted O
alterations O
of O
the O
epigenome O
in O
the O
future O
and O
provide O
novel O
therapeutic O
tools O

The O
1,200 O
genes O
that O
differ O
appear O
at O
first O
glance O
insufficient O
to O
describe O
what O
makes O
us O
human O
and O
them O
apes O

Epigenetic O
mechanisms O
play O
an O
important O
role O
in O
modulating O
the O
chromatin O
structure O
and O
regulating O
gene O
transcription O

Epigenetic O
alterations O
comprise O
several O
different O
aberrations O
, O
such O
as O
changes O
in O
histone O
modifications O
, O
DNA O
methylation O
, O
and O
microRNA O
levels O
, O
and O
occur O
in O
the O
most O
important O
signalling O
pathways O
in O
RCC O
, O
such O
as O
the O
von O
Hippel-Lindau O
disease B-Disease
tumour B-Disease
suppressor O

This O
toolkit O
has O
been O
coopted O
to O
support O
the O
dynamic O
nature O
of O
genomes O
in O
lineages O
across O
the O
eukaryotic O
tree O
of O
life O

The O
aim O
of O
the O
present O
paper O
is O
to O
reveal O
a O
hidden O
history O
of O
epigenetics O
, O
by O
means O
of O
a O
multicenter O
approach O

Early O
or O
late O
environmental O
influences O
such O
as O
intrauterine O
malnutrition O
or O
sedentary O
lifestyle O
have O
been O
shown O
to O
lead O
to O
an O
increased O
risk O
of O
diabetes B-Disease

We O
benchmark O
DXM O
's O
performance O
and O
demonstrate O
improvement O
over O
existing O
methods O

Greatest O
efforts O
were O
invested O
in O
studying O
DNA O
methylation O
in O
comparison O
to O
histone O
modifications O
and O
miRNA O
studies O

Recent O
studies O
indicate O
that O
the O
TME O
imposes O
metabolic O
constraints O
on O
immune O
cells O
, O
inducing O
them O
to O
attain O
a O
tolerogenic O
state O
, O
incompetent O
of O
mounting O
effective O
tumor B-Disease
eradication O

Epigenetic O
multiplexing O
approaches O
such O
as O
Multiplexed O
Error-robust O
FISH O
( O
MERFISH O
) O
, O
introduced O
by O
Lu O
et O
al O

His O
expertise O
is O
in O
cellular O
and O
molecular O
biology O

Such O
approaches O
will O
substantially O
increase O
the O
field's O
ability O
to O
establish O
the O
precise O
epigenetic O
mechanisms O
underlying O
drug O
addiction O
, O
and O
could O
lead O
to O
novel O
treatments O
for O
addictive O
disorders O

The O
finding O
of O
pleiotropy O
highlights O
the O
value O
of O
using O
the O
Research O
Domain O
Criteria O
( O
RDoC O
) O
framework O
in O
future O
studies O
of O
the O
genetics O
of O
stress-related B-Disease
psychiatric I-Disease
disorders I-Disease
, O
and O
not O
trying O
simply O
to O
link O
genes O
to O
multifaceted O
clinical O
syndromes B-Disease
, O
but O
to O
more O
limited O
phenotypes O


We O
conclude O
that O
with O
current O
analytic O
goals O
microarrays O
still O
outperform O
bisulphite O
sequencing O
for O
precise O
quantification O
of O
DNA O
methylation O

317 O
: O
Besides O
known O
genetic O
aberrations O
, O
epigenetic O
alterations O
have O
emerged O
as O
common O
hallmarks O
of O
many O
cancer B-Disease
types O
, O
including O
lung B-Disease
cancer I-Disease

So O
far O
, O
the O
best O
investigated O
externally O
visible O
characteristics O
are O
eye O
, O
hair O
and O
skin O
colour O
, O
as O
well O
as O
geographic O
ancestry O
and O
age O

Recently O
, O
a O
growing O
number O
of O
epigenetic O
clocks O
have O
been O
developed O
in O
non-model O
animals O
and O
we O
here O
review O
these O
studies O

With O
the O
development O
of O
drugs O
that O
target O
the O
specific O
epigenetic O
mechanisms O
involved O
in O
the O
regulation O
of O
gene O
expression O
, O
development O
and O
utilization O
of O
epigenetic O
tools O
are O
an O
appropriate O
and O
effective O
approach O
that O
can O
be O
clinically O
applied O
to O
the O
treatment O
of O
various O
diseases O

In O
this O
state-of-the-art O
review O
, O
we O
consolidate O
the O
latest O
findings O
on O
environmentally O
induced O
adverse O
effects O
on O
5hmC O
patterns O
in O
mammalian O
genomes O

Comparing O
cellular O
compartments O
, O
we O
found O
that O
the O
spliceosome O
of O
whole O
cell O
RNA-seq O
was O
more O
closely O
recapitulated O
by O
cytosolic O
RNA-S3EQ O
than O
nuclear O
RNA-seq O

g O

Personalized O
medicine-customized O
treatment O
tailored O
to O
the O
individual-offers O
a O
solution O

Neuroimaging O
tool O
development O
presents O
a O
unique O
set O
of O
challenges O
in O
order O
to O
identify O
and O
validate O
CNS O
radiotracers O
for O
HDACs O
and O
other O
histone-modifying O
enzymes O

Despite O
their O
accuracy O
and O
utility O
, O
epigenetic O
age O
biomarkers O
leave O
many O
questions O
about O
epigenetic O
ageing O
unanswered O

We O
highlight O
the O
challenges O
and O
opportunities O
in O
this O
approach O

561 O
: O
The O
epigenomic O
era O
has O
revealed O
a O
well-connected O
network O
of O
molecular O
processes O
that O
shape O
the O
chromatin O
landscape O

Here O
we O
discuss O
key O
features O
of O
the O
method O
and O
debunk O
misconceptions O
using O
empirical O
data O

6 O
: O
Epigenetic O
mechanisms O
comprising O
of O
DNA O
methylation O
, O
histone O
modifications O
and O
gene O
silencing O
by O
RNA O
interference O
have O
been O
strongly O
linked O
to O
the O
development O
and O
progression O
of O
various O
diseases O

The O
most O
prevalent O
ELSI O
experienced O
or O
witnessed O
by O
respondents O
were O
in O
obtaining O
timely O
access O
to O
epigenetic O
data O
in O
existing O
databases O
, O
and O
in O
the O
communication O
of O
epigenetic O
findings O
by O
the O
media O

Herein O
, O
we O
report O
the O
first O
large-scale O
study O
of O
26 O
318 O
compounds O
with O
a O
quantitative O
measure O
of O
biological O
activity O
for O
55 O
protein O
targets O
with O
epigenetic O
activity O

The O
degree O
to O
which O
tumour B-Disease
samples O
are O
contaminated O
with O
normal O
tissue O
can O
be O
estimated O
and O
corrected O
for O

The O
implications O
for O
diagnosis O
include O
the O
potential O
to O
identify O
stochastically O
disrupted O
progenitor O
cells O
years O
before O
cancer B-Disease
develops O
, O
and O
to O
target O
drugs O
to O
epigenetic O
drivers O
of O
gene O
expression O
instability O
rather O
than O
to O
mean O
effects O
per O
se O

We O
conclude O
by O
assessing O
some O
opportunities O
, O
challenges O
, O
and O
techniques O
for O
epigenetic O
research O
in O
both O
model O
and O
non-model O
plants O
, O
in O
particular O
for O
advancing O
understanding O
of O
the O
regulation O
of O
genome O
function O
by O
epigenetic O
mechanisms O

Epigenetic O
mechanisms O
, O
DNA O
methylation O
and O
histone O
modifications O
, O
alter O
chromatin O
structure O
and O
the O
accessibility O
of O
DNA O

Whereas O
chemical O
processes O
like O
DNA O
methylation O
or O
histone O
modifications O
are O
well-accepted O
epigenetic O
mechanisms O
, O
we O
herein O
propose O
the O
existence O
of O
an O
additional O
quantum O
physics O
layer O
of O
epigenetics O

In O
this O
chapter O
, O
we O
discuss O
the O
interplay O
between O
these O
three O
key O
elements O
, O
reveal O
how O
epigenetic O
modifications O
may O
mediate O
genetic O
susceptibility O
of O
food B-Disease
allergies I-Disease
, O
and O
explain O
why O
epigenetic O
modifications O
may O
be O
the O
key O
in O
environmental O
factors O
mediated-gene O
expression O
, O
leading O

Findings O
support O
significant O
associations O
between O
attachment-related O
dimensions O
and O
epigenetic O
status O
in O
studies O
which O
considered O
different O
populations O
, O
age O
ranges O
, O
attachment O
measures O
and O
peripheral O
tissues O

0 O
supports O
label-free O
and O
isotopic O
labeling O
, O
different O
organisms O
, O
known O
sequence O
mutations O
in O
diseases O
, O
different O
derivatization O
strategies O
, O
and O
unusual O
PTMs O
( O
such O
as O
acyl-derived O
modifications O
) O

Peaks O
predicted O
to O
be O
co-localized O
by O
only O
a O
very O
small O
number O
of O
tools O
, O
discovered O
to O
be O
only O
marginally O
overlapping O
, O
or O
found O
to O
represent O
significant O
outliers O
to O
the O
approximation O
model O
are O
removed O
from O
the O
results O
, O
providing O
concise O
and O
high O
quality O
epigenetic O
datasets O

Such O
strategies O
can O
also O
be O
repurposed O
to O
normalize O
gene O
expression O
changes O
that O
occur O
secondary O
to O
the O
genetic O
defect O

We O
describe O
a O
large-scale O
coordinated O
study O
of O
allelic O
and O
non-allelic O
effects O
on O
DNA O
methylation O
, O
histone O
mark O
deposition O
, O
and O
gene O
expression O
, O
detecting O
the O
interrelations O
between O
epigenetic O
and O
functional O
features O
at O
unprecedented O
resolution O

294 O
: O
DNA O
methylation O
at O
cytosines O
followed O
by O
guanines O
, O
CpGs O
, O
forms O
one O
of O
the O
multiple O
layers O
of O
epigenetic O
mechanisms O
controlling O
and O
modulating O
gene O
expression O
through O
chromatin O
structure O

Because O
epigenetic O
alterations O
are O
principally O
reversible O
, O
this O
may O
offer O
new O
opportunities O
for O
treatment O
of O
IEM O
patients O

686 O
: O
Background O
: O
High-throughput O
sequencing O
has O
been O
widely O
applied O
to O
uncover O
the O
molecular O
mechanisms O
underlying O
neurological O
and O
psychiatric B-Disease
disorders I-Disease

, O
the O
frequency O
and O
quality O
of O
maternal O
care O
modifying O
the O
brain O
and O
future O
behavior O
of O
the O
offspring O
each O
generation O
) O

, O
Cum O
Laude O
, O
from O
the O
University O
of O
Leiden O
, O
The O
Netherlands O

Menin O
inhibitors O
should O
be O
moved O
rapidly O
into O
paediatric O
development O
, O
in O
view O
of O
their O
biological O
rationale O
, O
strong O
preclinical O
activity O
and O
ability O
to O
fulfil O
an O
unmet O
clinical O
need O

Social O
and O
biographical O
conditions O
, O
as O
well O
as O
material O
exposures O
, O
all O
modulate O
our O
biology O
with O
consequences O
for O
risk O
predispositions O
and O
health O
conditions O


While O
the O
viruses B-Disease
may O
differ O
in O
significant O
ways O
from O
each O
other O
and O
cellular O
chromatin O
, O
the O
role O
of O
epigenetics O
appears O
to O
be O
relatively O
similar O

Ternary O
classification O
using O
only O
DNAm O
far O
exceeds O
the O
classification O
accuracy O
of O
simply O
assigning O
all O
classes O
as O
the O
most O
prevalent O
class O
(63 O

287 O
: O
Postmitotic O
neurons O
are O
subject O
to O
a O
vast O
array O
of O
environmental O
influences O
that O
require O
the O
nuclear O
integration O
of O
intracellular O
signaling O
events O
to O
promote O
a O
wide O
variety O
of O
neuroplastic O
states O
associated O
with O
synaptic O
function O
, O
circuit O
formation O
, O
and O
behavioral O
memory O

We O
developed O
a O
new O
epigenetic O
age O
prediction O
model O
compatible O
across O
the O
450 O
k O
, O
EPICv1 O
, O
and O
EPICv2 O
microarrays O
and O
validated O
it O
on O
2095 O
samples O

In O
conclusion O
, O
we O
demonstrate O
that O
the O
plasticity O
of O
DNA O
methylomes O
is O
impacted O
by O
myriad O
genetics O
and O
physiological O
factors O
, O
and O
that O
DNA O
methylation O
biomarkers O
are O
accurate O
predictors O
of O
age O
, O
sex O
and O
sterilization O
status O

Childhood O
abuse O
, O
but O
not O
neglect O
, O
predicted O
faster O
epigenetic O
aging O
; O
results O
did O
not O
differ O
by O
chronic B-Disease
stress I-Disease
status O

In O
2007 O
, O
he O
was O
a O
featured O
scientist O
on O
the O
NOVA O
television O
program O
on O
epigenetics O
titled O
' O
Ghost O
in O
Your O
Genes O
' O
and O
was O
nominated O
for O
Time O
Magazine O
's O
' O
Person O
of O
the O
Year O
' O

However O
, O
it O
is O
not O
clear O
if O
the O
observed O
epigenetic O
changes O
represent O
a O
cause O
or O
a O
consequence O
of O
the O
disease B-Disease

To O
date O
, O
although O
several O
reports O
have O
demonstrated O
the O
occurrence O
of O
epigenetic O
alterations O
in O
a O
wide O
range O
of O
inflammatory O
rheumatic O
conditions O
, O
epigenomic O
information O
is O
rarely O
used O
in O
a O
clinical O
setting O

COCOA O
is O
the O
first O
such O
tool O
for O
DNA O
methylation O
data O
and O
can O
also O
analyze O
any O
epigenetic O
signal O
with O
genomic O
coordinates O

From O
a O
conceptual O
point O
of O
view O
, O
intriguing O
similarities O
can O
be O
found O
between O
Darwin's O
( O
early O
) O
conception O
of O
habit O
and O
contemporary O
views O
on O
epigenetic O
inheritance O

542 O
: O
Hybridization O
is O
a O
major O
source O
of O
evolutionary O
innovation O

The O
emergence O
of O
single-cell O
sequencing O
has O
enhanced O
our O
understanding O
of O
the O
epigenetic O
mechanisms O
governing O
tumor B-Disease
heterogeneity B-Disease
by O
revealing O
the O
distinct O
epigenetic O
layers O
of O
individual O
cells O
( O
chromatin O
accessibility O
, O
DNA/RNA O
methylation O
, O
histone O
modifications O
, O
nucleosome O
localization O
) O
and O
the O
diverse O

412 O
: O
Epigenetics O
continues O
to O
emerge O
as O
an O
important O
target O
class O
for O
drug O
discovery O
and O
cancer B-Disease
research O

The O
Personalized O
Lifestyle O
Medicine O
Institute O
presented O
Jirtle O
with O
the O
Research O
and O
Innovation O
Leadership O
Award O
in O
2019 O

Methods O
for O
detecting O
DNA O
methylation O
have O
become O
increasingly O
more O
specific O
and O
sensitive O
over O
time O

507 O
: O
Background O
: O
Epigenetic O
clocks O
are O
mathematical O
models O
used O
to O
estimate O
epigenetic O
age O
based O
on O
DNA O
methylation O
at O
specific O
CpG O
sites O

``` O
Dr O
``` O

Moreover O
, O
in O
rare O
cases O
of O
PD O
, O
duplication O
or O
triplication O
of O
SNCA O
gene O
leads O
to O
alpha-synuclein O
accumulation O
, O
with O
triplication O
producing O
a O
more O
severe O
phenotype O
than O
duplication O
, O
suggesting O
that O
SNCA O
expression O
level O
determines O
the O
severity O
of O
the O
pathology O

Advances O
in O
sequencing O
technology O
have O
broadened O
the O
target O
for O
epigenetic O
studies O
from O
specific O
genes O
to O
genome-wide O
analyses O

Understanding O
methamphetamine O
toxicity O
is O
key O
beyond O
the O
field O
of O
drug O
abuse O
since O
it O
allows O
getting O
an O
insight O
into O
the O
molecular O
mechanisms O
which O
operate O
in O
a O
variety O
of O
neuropsychiatric O
disorders O

113 O
: O
Cancer B-Disease
disparities O
in O
incidence O
and O
death B-Disease
rates O
exist O
among O
various O
racial O
and O
ethnic O
groups O

Functional O
analysis O
revealed O
that O
these O
regions O
are O
linked O
with O
cell O
identities O

707 O
: O
Psoriasis O
is O
a O
chronic O
inflammatory O
skin O
disease B-Disease
, O
the O
prevalence O
of O
which O
is O
increasing O

The O
paper O
concludes O
with O
preliminary O
recommendations O
for O
how O
ethnographic O
methods O
can O
be O
integrated O
into O
epigenomics O
research O
designs O
in O
order O
to O
elucidate O
the O
manner O
in O
which O
disadvantage O
translates O
into O
disparities O
in O
the O
burden O
of O
illness B-Disease

It O
is O
characterized O
by O
abundant O
autoantibodies O
that O
form O
immune O
complex O
with O
autoantigens O
and O
deposit O
in O
organs O
and O
cause O
tissue O
damage O
by O
inducing O
inflammation B-Disease

Data O
emerging O
from O
the O
world's O
behavioral O
epigenetics O
laboratories O
support O
the O
idea O
that O
a O
person's O
genes O
alone O
cannot O
determine O
if O
, O
for O
example O
, O
he O
or O
she O
will O
end O
up O
shy O
, O
suffering O
from O
cardiovascular O
disease B-Disease
, O
or O
extremely O
smart O

Epigenetics O
, O
or O
the O
study O
of O
heritable O
( O
mitotically O
and/or O
meiotically O
) O
changes O
in O
gene O
activity O
that O
are O
not O
brought O
about O
by O
changes O
in O
the O
DNA O
sequence O
, O
can O
explain O
some O
types O
of O
ill O
health O
in O
offspring O
, O
which O
have O
been O
exposed O
to O
stressors O
during O

These O
methods O
, O
although O
promising O
and O
innovative O
, O
can O
present O
several O
technical O
and O
analytical O
pitfalls O

This O
perspective O
describes O
recent O
advances O
in O
the O
discovery O
of O
epigenetic O
biomarkers O
in O
lung B-Disease
cancer I-Disease
, O
specifically O
those O
that O
result O
in O
the O
methylation O
of O
DNA O
at O
CpG O
sites O

Understanding O
mechanisms O
that O
underlie O
increased O
psychosis O
risk O
is O
of O
great O
importance O
for O
the O
development O
of O
novel O
preventive O
approaches O
and O
early O
interventions O

Thus O
, O
any O
' O
drive O
' O
to O
ovarian B-Disease
rejuvenation O
must O
incorporate O
both O
accelerator O
and O
brake O

Methods O
: O
To O
address O
this O
, O
we O
developed O
a O
more O
accurate O
, O
muscle-specific O
epigenetic O
clock O
based O
on O
the O
genome-wide O
DNA O
methylation O
data O
of O
682 O
skeletal O
muscle O
samples O
from O
12 O
independent O
datasets O
( O
18-89 O
years O
old O
, O
22% O
women O
, O
99% O
Caucasian O
) O
, O
all O

In O
this O
commentary O
, O
we O
propagate O
the O
idea O
of O
a O
widespread O
follow-up O
use O
of O
epigenome O
editing O
technology O
in O
EWAS O
studies O

These O
imprinted O
genes O
play O
an O
important O
role O
in O
embryonic O
and O
extraembryonic O
growth O
and O
development O
, O
as O
well O
as O
in O
a O
variety O
of O
processes O
after O
birth O

787 O
( O
P O
= O
3 O

Over O
600 O
questionnaires O
were O
completed O
, O
with O
391 O
included O
in O
the O
analysis O

A O
deeper O
understanding O
of O
epigenetics O
may O
provide O
an O
answer O
to O
the O
continuing O
strong O
clinical O
impact O
of O
cardiovascular B-Disease
diseases I-Disease
by O
improving O
diagnostic O
capabilities O
, O
personalized O
medical O
approaches O
and O
the O
development O
of O
targeted O
therapeutic O
interventions O

This O
new O
experimental O
approach O
is O
opening O
up O
new O
and O
interesting O
knowledge O
perspectives O

Various O
multifactorial O
diseases O
often O
contain O
changed O
epigenetic O
signatures O
at O
many O
loci O
, O
so O
tools O
for O
simultaneously O
targeting O
different O
loci O
would O
significantly O
facilitate O
the O
understanding O
of O
disease B-Disease
pathogenesis O

Finally O
, O
we O
will O
provide O
some O
examples O
of O
how O
the O
ML O
approach O
to O
epigenetic O
data O
can O
be O
useful O
for O
personalized O
medicine O

220 O
: O
The O
biological O
and O
medical O
importance O
of O
epigenetics O
is O
nowtaken O
for O
granted O
, O
but O
the O
significance O
of O
one O
aspect O
of O
it O
— O
epigenetic O
inheritance O
— O
is O
less O
widely O
recognized O

Accumulating O
evidence O
shows O
that O
epigenetic O
remodeling O
plays O
a O
central O
role O
in O
mediating O
the O
transcriptional O
program O
for O
immune O
cell O
activation O
and O
immunological O
memory O

Furthermore O
, O
the O
constraint O
of O
samples O
size O
, O
inherent O
to O
the O
study O
of O
preimplantation O
embryo O
development O
, O
was O
put O
in O
perspective O
with O
the O
various O
molecular O
platforms O
described O

575 O
: O
Autism O
spectrum O
disorders O
( O
ASD O
) O
have O
been O
increasing O
in O
prevalence O
over O
the O
last O
two O
decades O
, O
primarily O
because O
of O
increased O
awareness O
and O
diagnosis O


368 O
: O
Summary O
: O
We O
created O
bigwig-loader O
, O
a O
data-loader O
for O
epigenetic O
profiles O
from O
BigWig O
files O
that O
decompresses O
and O
processes O
information O
for O
multiple O
intervals O
from O
multiple O
BigWig O
files O
in O
parallel O

Here O
we O
examine O
some O
of O
the O
most O
important O
agronomic O
traits O
known O
to O
be O
controlled O
epigenetically O
and O
review O
the O
best O
studied O
epigenetic O
catalytic O
effectors O
in O
plants O
, O
such O
as O
DNA O
methylases/demethylases O
or O
histone O
acetylases/deacetylases O
and O
their O
associated O
marks O

Research O
has O
shown O
that O
epigenetic O
mechanisms O
provide O
an O
" O
extra O
" O
layer O
of O
transcriptional O
control O
that O
regulates O
how O
genes O
are O
expressed O

Expected O
outcome O
is O
that O
this O
approach O
can O
provide O
insights O
into O
how O
to O
preserve O
health O
and O
reduce O
the O
impact O
of O
ageing O
diseases O
in O
humans O

Our O
recently O
developed O
computational O
framework O
, O
MAPLE O
, O
addresses O
these O
challenges O
using O
supervised O
learning O
models O

The O
conceptual O
MER-Net O
is O
aimed O
at O
linking O
metabolomic O
and O
epigenomic O
networks O
through O
observation O
of O
biological O
processes O
, O
omics O
data O
acquisition O
, O
analysis O
of O
network O
information O
, O
and O
integration O
with O
validated O
database O
knowledge O

Recent O
findings O
: O
Evidence O
suggests O
that O
eating B-Disease
disorders I-Disease
implicate O
alterations O
of O
methylation O
in O
genes O
involved O
in O
the O
mental O
status O
, O
metabolism O
, O
anthropometric O
features O
and O
immunity O

WIREs O
Syst O
Biol O
Med O
2017 O
, O
9 O
: O
e1333 O

minary@cs O

Blood O
cells O
and O
tumor B-Disease
tissue O
were O
the O
most O
commonly O
used O
biospecimens O
in O
these O
studies O
, O
although O
buccal O
cells O
, O
cervical O
cells O
, O
sputum O
, O
and O
stool O
samples O
were O
also O
used O

However O
, O
germ O
cells O
must O
establish O
an O
epigenetic O
program O
that O
supports O
totipotency O
and O
the O
configuration O
of O
parent-specific O
epigenetic O
states O
in O
the O
gametes O

Epigenetic O
age O
is O
believed O
to O
be O
one O
of O
the O
most O
accurate O
metrics O
of O
biological O
age O

and O
M O

The O
article O
further O
provides O
a O
conceptual O
mechanistic O
framework O
on O
how O
stress O
may O
drive O
epigenetic O
changes O
at O
susceptible O
genomic O
sites O
, O
thereby O
exerting O
systems-level O
effects O
on O
the O
aging O
epigenome O
while O
also O
regulating O
the O
expression O
of O
molecules O
implicated O
in O
aging-related O
processes O

g O

663 O
: O
In O
the O
last O
decade O
, O
the O
development O
of O
high-throughput O
sequencing O
methodologies O
has O
significantly O
improved O
the O
gathering O
of O
genomic O
information O
and O
consequent O
under-standing O
of O
the O
genetic O
and O
epigenetic O
background O
of O
complex O
and O
monogenetic O
endocrine O
disorders O
[ O

How O
can O
a O
memory O
persist O
beyond O
the O
lifetimes O
of O
its O
constitutive O
molecular O
building O
blocks O
? O
Epigenetics O
- O
changes O
in O
gene O
expression O
that O
do O
not O
alter O
the O
underlying O
DNA O
sequence O
- O
may O
be O
the O
answer O

These O
processes O
comprise O
abnormal O
methylomes O
, O
transcriptosomes O
, O
genome-wide O
histone O
post-transcriptional O
modifications O
patterns O
, O
histone O
variants O
, O
and O
noncoding O
RNAs O

These O
same O
neurobiological O
processes O
are O
responsible O
for O
determining O
the O
heterogeneous O
features O
of O
complex O
epileptic O
disease B-Disease
states O

We O
also O
show O
that O
epigenetics O
has O
progressively O
focused O
on O
the O
issue O
of O
epigenetic O
inheritance O
within O
the O
Extended O
Evolutionary O
Synthesis O
' O
framework O

Exposure O
to O
airborne O
pollutants O
triggers O
harmful O
mechanisms O
such O
as O
oxidative O
stress O
and O
systemic O
inflammation B-Disease
, O
which O
lead O
to O
increased O
incidence O
of O
myocardial O
infarction O
, O
arterial O
hypertension B-Disease
, O
stroke O
, O
and O
heart B-Disease
failure I-Disease

Yet O
while O
memories O
may O
last O
a O
lifetime O
, O
neurons O
are O
dynamic O
structures O

We O
will O
mention O
the O
drivers O
of O
the O
phenotype O
and O
pattern O
of O
epigenetic O
markers O
set O
down O
during O
the O
reprogramming O
along O
with O
novel O
preventative O
and O
therapeutic O
strategies O

We O
will O
discuss O
four O
overlapping O
but O
distinct O
major O
categories O
under O
ML O
: O
dimensionality O
reduction O
, O
unsupervised O
methods O
, O
supervised O
methods O
, O
and O
deep O
learning O
( O
DL O
) O

In O
this O
study O
, O
we O
applied O
newly O
developed O
lmQCM O
algorithm O
to O
mine O
co-methylation O
clusters O
using O
methylome O
data O
from O
11 O
cancer B-Disease
types O
in O
TCGA O
database O
, O
and O
found O
frequent O
co-methylated O
gene O
clusters O
exist O
in O
these O
cancer B-Disease
types O

Some O
IEIs O
have O
no O
identified O
mutation(s) O
, O
while O
others O
with O
identical O
mutations O
can O
display O
heterogeneous O
presentations O

If O
aging O
is O
not O
a O
stochastic O
process O
of O
attrition O
but O
is O
centrally O
orchestrated O
, O
it O
is O
reasonable O
to O
suspect O
that O
the O
timing O
of O
senescence B-Disease
is O
also O
influenced O
by O
one O
or O
more O
biological O
clocks O

Genome O
sequencing O
, O
chromatin O
immunoprecipitation O
( O
ChIP O
) O
- O
qPCR O
, O
and O
sporulation O
analysis O
provide O
further O
insights O
into O
the O
epigenetic O
and O
genetic O
contributors O
to O
the O
expression O
changes O
observed O

S O

Finally O
, O
we O
would O
like O
to O
emphasize O
that O
research O
on O
human O
infertility O
by O
gene O
knock O
out O
of O
epigenetic O
modifiers O
genes O
must O
be O
relied O
upon O
animal O
models O

642 O
: O
Introduction O
: O
It O
is O
understood O
that O
cancer B-Disease
is O
a O
clonal O
disease B-Disease
initiated O
by O
a O
single O
cell O
, O
and O
that O
metastasis O
, O
which O
is O
the O
spread O
of O
cancer B-Disease
from O
the O
primary O
site O
, O
is O
also O
initiated O
by O
a O
single O
cell O

6 O
years O
across O
datasets O
(vs O

It O
has O
a O
small O
genome O
of O
5243 O
bp O
and O
utilizes O
cellular O
proteins O
for O
its O
molecular O
biology O
, O
with O
the O
exception O
of O
the O
T-antigen O
protein O
, O
which O
is O
coded O
by O
the O
virus B-Disease
and O
is O
involved O
in O
regulating O
transcription O
and O
directing O
replication O

The O
scale O
and O
complexity O
of O
epigenetic O
data O
pose O
significant O
challenges O
for O
biologists O
to O
identify O
the O
regulatory O
events O
controlling O
cell O
differentiation O

DNA O
methylation O
patterns O
are O
susceptible O
to O
change O
in O
response O
to O
environmental O
stimuli O
such O
as O
diet O
or O
toxins O
, O
whereby O
the O
epigenome O
seems O
to O
be O
most O
vulnerable O
during O
early O
life O

By O
adding O
methyl O
groups O
to O
DNA O
and O
histones O
, O
it O
can O
limit O
accessibility O
of O
the O
underlying O
gene O
thereby O
altering O
the O
amount O
of O
gene O
expression O

To O
discover O
co-opted O
TEs O
, O
and O
distinguish O
them O
from O
noisy O
genomic O
elements O
, O
we O
argue O
that O
comparative O
epigenomic O
methods O
will O
also O
be O
important O

However O
, O
autism B-Disease
is O
clearly O
a O
complex O
human O
genetic O
disorder B-Disease
that O
involves O
interactions O
between O
genes O
and O
environment O

Recently O
, O
important O
roles O
of O
various O
epigenetic O
mechanisms O
have O
been O
identified O
in O
the O
pathogenesis O
of O
diabetes B-Disease
and O
its O
complications O

New O
advances O
in O
understanding O
how O
environmentally O
sensitive O
, O
yet O
highly O
heritable O
developmental O
processes O
are O
regulated O
have O
come O
from O
the O
field O
of O
epigenetics O

Studies O
have O
begun O
to O
reveal O
epigenetic O
contributions O
to O
these O
diseases O
, O
primarily O
through O
the O
study O
of O
DNA O
methylation O
, O
but O
chromatin O
and O
non-coding O
RNA O
changes O
are O
also O
emerging O

110 O
: O
The O
American O
Diabetes B-Disease
Association O
convened O
a O
research O
symposium O
, O
" O
Epigenetics O
and O
Epigenomics O
: O
Implications O
for O
Diabetes B-Disease
and O
Obesity O
" O
on O
17-19 O
November O
2017 O

534 O
: O
Purpose O
of O
review O
: O
There O
is O
a O
great O
deal O
of O
interest O
regarding O
the O
biological O
embedding O
of O
childhood O
trauma B-Disease
and O
social O
exposures O
through O
epigenetic O
mechanisms O
, O
including O
DNA O
methylation O
( O
DNAm O
) O
, O
but O
a O
comprehensive O
understanding O
has O
been O
hindered O
by O
issues O
of O
limited O

Environ O

472 O
: O
Epigenetic O
changes O
, O
such O
as O
aberrant O
DNA O
methylation O
, O
contribute O
to O
cancer B-Disease
clonal O
expansion O
and O
disease B-Disease
progression O

06 O
; O
95 O
% O
CI O
= O
1 O

cancer B-Disease
Res O
; O
76 O
( O
7 O
) O
; O
1683-9 O

In O
this O
review O
, O
we O
discuss O
some O
of O
the O
recent O
advances O
in O
cancer B-Disease
genomic O
and O
epigenomic O
research O

e O

Here O
, O
we O
propose O
a O
Monte O
Carlo O
method O
for O
modeling O
the O
Waddington's O
epigenetic O
landscape O
of O
a O
gene O
regulatory O
network O
( O
GRN O
) O

Disorders O
of O
epigenetic O
markers O
, O
such O
as O
histone O
modification O
, O
DNA/RNA O
methylation O
, O
and O
changes O
in O
the O
three-dimensional O
conformation O
of O
chromatin O
, O
can O
interfere O
with O
gene O
expression O
to O
some O
extent O
, O
and O
result O
in O
cancers B-Disease

However O
, O
large O
multicenter O
validation O
studies O
are O
required O
to O
foster O
translation O
to O
the O
clinics O

There O
are O
indeed O
excellent O
biomarker O
candidates O
for O
DNA-methylation-based O
diagnostics O
of O
urothelial O
carcinoma O
, O
whereas O
miRNAs O
are O
well O
investigated O
, O
but O
there O
are O
still O
many O
discrepancies O
between O
studies O
published O
to O
date O

281 O
: O
DNA O
methylation O
is O
an O
epigenetic O
modification O
of O
DNA O
molecule O
that O
plays O
a O
vital O
role O
in O
gene O
expression O
regulation O

We O
present O
emerging O
information O
on O
the O
epigenetic O
control O
of O
the O
polarity O
axis O
, O
a O
central O
feature O
of O
epithelial O
architecture O
created O
by O
the O
orderly O
distribution O
of O
multiprotein O
complexes O
at O
cell-cell O
and O
cell-extracellular O
matrix O
contacts O
and O
altered O
upon O
cancer B-Disease
onset O
( O
with O
apical O
polarity O

This O
article O
will O
discuss O
the O
general O
features O
of O
placental O
DNA O
methylation O
and O
will O
describe O
current O
technologies O
for O
profiling O
genome-wide O
DNA O
methylation O
patterns O
in O
this O
tissue O
, O
the O
approaches O
to O
data O
analysis O
and O
some O
of O
the O
major O
findings O
from O
recent O
studies O

The O
effect O
of O
genetic O
polymorphism O
has O
accrued O
considerable O
interest O
and O
population O
polymorphism O
leading O
to O
variation O
in O
drug O
response O
is O
being O
studied O
extensively O

Genotype O
sets O
the O
substrate O
on O
which O
physiologic O
processes O
, O
which O
communicate O
with O
the O
brain O
, O
mediate O
the O
effects O
of O
life O
experiences O
via O
epigenetics O

Recent O
methodologies O
include O
many O
sequencing O
and O
analytical O
techniques O
to O
extrapolate O
different O
types O
of O
epigenetic O
data O

nih O

Summary O
: O
Genetic O
, O
transcriptomic O
and O
epigenetic O
studies O
have O
offered O
exciting O
clues O
about O
IBD O
pathogenesis O
but O
are O
unlikely O
to O
provide O
all O
answers O

Ultimately O
, O
the O
field O
of O
epigenetics O
has O
the O
potential O
to O
revolutionize O
the O
way O
we O
approach O
cardiovascular O
and O
metabolic B-Disease
diseases I-Disease
, O
paving O
the O
way O
for O
precision O
medicine O
and O
personalized O
health O
care O
, O
and O
improving O
the O
lives O
of O
millions O
of O
individuals O
worldwide O
affected O
by O

Even O
though O
both O
hypo- O
- O
and O
hypermethylation-mediated O
abnormalities O
are O
prevalent O
in O
the O
cancer B-Disease
genome O
, O
the O
field O
of O
cancer B-Disease
epigenetics O
has O
been O
more O
focused O
on O
targeting O
hypermethylation O

in O
J O
Autoimmun O
83:51-61 O
, O
2017 O
) O
, O
providing O
novel O
therapeutic O
potential O
as O
novel O
treatment O
targets O
for O
psoriasis B-Disease

Dr O
Pfeifer O
's O
research O
interests O
are O
cancer B-Disease
etiology O
, O
molecular O
carcinogenesis O
and O
epigenetics O

In O
this O
review O
, O
we O
explain O
briefly O
the O
history O
of O
epigenetics O
and O
we O
propose O
some O
examples O
of O
epigenetic O
and O
transgenerational O
effects O
demonstrated O
in O
humans O
and O
animals O

, O
bacteria O
) O
against O
plasmids O
and O
viruses B-Disease

As O
a O
consequence O
population-level O
differences O
(for O
example O
, O
secular O
trends O
or O
differences O
between O
administrative O
areas O
) O
can O
be O
entirely O
explicable O
by O
causal O
factors O
that O
appear O
to O
account O
for O
only O
a O
small O
proportion O
of O
individual-level O
risk O

However O
, O
despite O
publication O
of O
multiple O
positive O
evaluations O
, O
the O
use O
of O
MBD-seq O
for O
MWAS O
is O
often O
fiercely O
criticized O

DNA O
methyltransferases O
are O
crucial O
in O
disease B-Disease
pathogenesis O
by O
mediating O
methylation O
of O
DNA O
in O
specific O
promoters O
, O
regulating O
expression O
of O
specific O
pathways O

social O
meanings O
, O
beliefs O
, O
norms O
and O
values O
) O
of O
parental O
roles O
in O
DOHaD O
and O
epigenetic O
biomedical O
sciences O
, O
by O
means O
of O
a O
specific O
gendered O
figuration O
of O
paternal O
influences O
: O
the O
' O
father-as-sperm O
' O

Regulation O
exerted O
by O
these O
so-called O
epigenetic O
marks O
is O
vital O
to O
normal O
development O
, O
stability O
of O
cell O
identity O
through O
mitosis O
, O
and O
nongenetic O
transmission O
of O
traits O
between O
generations O
through O
meiosis O

691 O
: O
The O
epigenetic O
landscape O
, O
which O
in O
part O
includes O
DNA O
methylation O
, O
chromatin O
organization O
, O
histone O
modifications O
, O
and O
noncoding O
RNA O
regulation O
, O
greatly O
contributes O
to O
the O
heterogeneity B-Disease
that O
makes O
developing O
effective O
therapies O
for O
lung B-Disease
cancer I-Disease
challenging O

Two O
measures O
of O
performance O
are O
usually O
reported O
, O
the O
R2 O
of O
the O
association O
between O
the O
predicted O
and O
chronological O
age O
, O
and O
the O
mean/median O
absolute O
deviation O
( O
MAD O
) O
of O
estimated O
age O
from O
chronological O
age O
, O
and O
we O
argue O
that O
only O
the O
MAD O
reflects O
accuracy O

Based O
on O
use O
of O
next-generation O
sequencing O
data O
for O
characterizing O
epigenetic O
marks O
and O
transcription O
factor O
binding O
, O
numerous O
peak-calling O
approaches O
have O
been O
developed O
to O
determine O
sites O
of O
genomic O
significance O
in O
these O
data O

7 O
% O
of O
all O
cancer-related O
deaths O

Technical O
challenges O
include O
tissue O
specificity O
issues O
, O
limited O
coverage O
of O
current O
methylation O
arrays O
and O
confounding O
factors O
like O
cell O
composition O
variability O

228 O
: O
Current O
understanding O
of O
environmental O
cross-talk O
with O
genetic O
makeup O
is O
found O
to O
be O
mediated O
through O
an O
epigenetic O
interface O
which O
is O
associated O
with O
prominent O
reversible O
and O
heritable O
changes O
at O
gene O
expression O
level O

Epigenetic O
clocks O
have O
been O
developed O
using O
statistical O
techniques O
to O
identify O
the O
optimal O
combination O
of O
CpG O
sites O
(from O
methylation O
arrays O
) O
to O
correlate O
with O
chronological O
age O

Focusing O
on O
software O
packages O
for O
R O
, O
we O
describe O
methods O
for O
finding O
features O
in O
the O
methylation O
data O
that O
are O
of O
importance O
for O
generating O
and O
testing O
hypotheses O
in O
cancer B-Disease
research O
, O
like O
differentially O
methylated O
positions O
or O
regions O
and O
global O
methylation O
trends O

Furthermore O
, O
the O
efficiencies O
for O
the O
predictions O
are O
above O
80% O
for O
most O
data O
sets O
and O
above O
90% O
for O
four O
data O
sets O
at O
different O
significant O
levels O

Epigenetics O
has O
now O
become O
an O
increasingly O
important O
area O
of O
biomedical O
research O

Epigenomic O
analysis O
has O
quickly O
become O
a O
big O
data O
science O
, O
posing O
tremendous O
challenges O
on O
its O
translation O
into O
knowledge O

Under O
such O
conditions O
, O
the O
two O
types O
of O
variances O
in O
the O
gene O
expression O
levels O
, O
i O

In O
recent O
years O
, O
evidence O
was O
derived O
that O
apart O
from O
5-methylcytosine O
, O
the O
DNA O
methylation/demethylation O
cycle O
includes O
three O
other O
oxidative O
derivatives O
of O
cytosine-5-hydroxymethylcytosine O
( O
5hmC O
) O
, O
5-formylcytosine O
, O
and O
5-carboxylcytosine O

Combined O
, O
our O
genome-wide O
results O
show O
age-related O
differential O
5mC O
and O
5hmC O
, O
as O
well O
as O
some O
evidence O
that O
changes O
in O
5hmC O
may O
drive O
age-related O
DNA O
methylation O
and O
gene O
expression O

We O
propose O
that O
improved O
understanding O
of O
the O
molecular O
mechanisms O
underlying O
human O
health O
and O
disease B-Disease
are O
best O
achieved O
through O
carrying O
out O
studies O
of O
epigenetics O
in O
populations O
as O
a O
part O
of O
an O
integrated O
functional O
genomics O
strategy O

We O
then O
present O
the O
unique O
advantage O
of O
long-read O
sequencing O
in O
detecting O
base O
modifications O
in O
native O
DNA O
and O
highlight O
the O
respective O
strengths O
and O
weaknesses O
of O
PacBio O
and O
Nanopore O
sequencing O
for O
this O
application O

Transcriptional O
mechanisms O
are O
clearly O
critical O
for O
developing O
and O
protecting O
cell O
identities O
, O
because O
a O
mis-expression O
of O
few O
or O
even O
single O
genes O
can O
efficiently O
induce O
inappropriate O
cellular O
programmes O

org O

Next O
, O
we O
evaluated O
the O
contribution O
of O
all O
epigenetic O
features O
in O
two O
successful O
machine/deep O
learning O
models O
which O
predict O
off-target O
activity O

Further O
, O
we O
discuss O
the O
improvement O
in O
the O
development O
of O
natural O
ingredients O
with O
low O
toxicity O
and O
low O
side O
effects O
as O
epi-drugs O

By O
doing O
so O
, O
we O
find O
that O
latent O
cytomegalovirus O
infection B-Disease
drives O
DNA O
methylation O
variation O
and O
provide O
further O
support O
that O
the O
increased O
dispersion O
of O
DNA O
methylation O
with O
aging O
is O
due O
to O
epigenetic O
drift O

A O
selection O
of O
the O
major O
recent O
advances O
in O
this O
area O
will O
be O
reviewed O
, O
focusing O
on O
the O
important O
emerging O
themes O
that O
are O
relevant O
to O
these O
diseases O
including O
inflammatory O
bowel O
disease B-Disease
( O
IBD O
) O

318 O
: O
DNA O
methylation O
( O
DNAme O
) O
is O
a O
major O
epigenetic O
factor O
influencing O
gene O
expression O
with O
alterations O
leading O
to O
cancer B-Disease
and O
immunological O
and O
cardiovascular B-Disease
diseases I-Disease

The O
available O
data O
on O
the O
epigenetic O
marking O
of O
the O
whole O
genome O
in O
different O
contexts O
implies O
that O
no O
biological O
pathway O
or O
process O
in O
the O
mammalian O
system O
is O
free O
of O
epigenetic O
influence O
and O
thus O
, O
drug O
metabolism O
would O
not O
be O
an O
exception O

This O
work O
provides O
a O
mechanistic O
link O
between O
the O
paternal O
age O
effect O
and O
offspring O
neurodevelopmental O
disorders O
leading O
to O
a O
better O
understanding O
of O
causation O
and O
investigation O
into O
potential O
future O
therapy O

Therefore O
, O
elucidating O
the O
dysregulated O
epigenetic O
mechanisms O
in O
the O
immune O
system O
is O
crucial O
for O
understanding O
the O
pathogenesis O
of O
SLE O

The O
emerging O
field O
of O
epigenetics O
is O
beginning O
to O
reveal O
how O
genotypic O
expression O
can O
be O
mediated O
by O
an O
array O
of O
variables O
including O
external O
environmental O
exposure O
, O
inter-individual O
developmental O
variation O
, O
and O
by O
the O
genome O
itself O

Further O
, O
this O
review O
describes O
how O
drug O
therapy O
can O
influence O
, O
and O
be O
influenced O
by O
, O
these O
mechanisms O

Recent O
findings O
: O
A O
growing O
number O
of O
loci O
have O
been O
identified O
, O
which O
are O
good O
candidate O
biomarkers O
for O
atherosclerosis O
and O
provide O
novel O
insights O
into O
the O
molecular O
changes O
taking O
place O
in O
the O
diseased O
vessel O

The O
authors O
describe O
the O
history O
of O
human O
behavioral O
epigenetic O
research O
in O
the O
context O
of O
other O
disciplines O
and O
graphically O
illustrate O
the O
burgeoning O
of O
research O
in O
the O
application O
of O
epigenetic O
methods O
and O
principles O
to O
the O
study O
of O
human O
behavior O

We O
demonstrate O
the O
novelty O
and O
reliability O
of O
our O
method O
by O
plotting O
the O
potential O
landscapes O
of O
a O
few O
published O
models O
of O
GRN O

the O
relationship O
between O
genes O
and O
behavior O
is O
reconsidered O
in O
terms O
of O
epigenetic O
mechanisms O
acting O
after O
birth O
and O
not O
only O
prenatally O
, O
as O
traditionally O
held O

This O
understanding O
provides O
the O
basis O
for O
elucidating O
how O
the O
intricate O
interactions O
of O
the O
genome O
, O
epigenome O
, O
and O
transcriptome O
shape O
immune O
responses O
and O
maintain O
immune O
tolerance O
to O
self-antigens O

ulaval O

An O
increasing O
amount O
of O
evidence O
suggests O
that O
3D O
genome O
folding O
is O
implicated O
in O
diseases O
, O
giving O
us O
a O
clue O
on O
how O
to O
identify O
novel O
therapeutic O
approaches O

Currently O
, O
histone-deacetylase O
and O
DNA-methyltransferase O
inhibitors O
are O
the O
most O
studied O
classes O
of O
chromatin-modifying O
drugs O
( O
so-called O
' O
epidrugs O
' O
) O
within O
cancer B-Disease
radiosensitization O
context O

To O
fast-track O
exploration O
, O
we O
generated O
epidecodeR O
implemented O
in O
R O
, O
which O
allows O
biologists O
to O
quickly O
survey O
whether O
an O
epigenomic O
or O
epitranscriptomic O
status O
of O
their O
interest O
potentially O
influences O
gene O
expression O
responses O

, O
personal O
versus O
public O
responsibilities O
) O

706 O
: O
Background O
: O
High O
surrounding O
greenness O
has O
many O
health O
benefits O
and O
might O
contribute O
to O
slower O
biological O
aging O

The O
DNA O
repair O
mechanisms O
again O
are O
influenced O
by O
the O
chromatin O
structure O

Targeting O
these O
epigenetic O
alterations O
will O
enhance O
our O
understanding O
of O
the O
biological O
basis O
of O
addiction O
and O
might O
even O
yield O
more O
effective O
anti-addiction O
therapies O

Better O
understanding O
of O
DNA O
methylation O
in O
vertebrate O
embryogenesis O
will O
provide O
insights O
for O
new O
treatment O
of O
DNA O
methylation-related O
human O
diseases O

354 O
: O
Variation O
in O
cell-type O
decomposition O
can O
be O
of O
interest O
to O
changes O
in O
biology O
by O
themselves O
, O
or O
a O
confounder O
in O
comparing O
admixed O
samples O
with O
different O
phenotypes O

In O
order O
to O
maximize O
the O
use O
of O
structure-activity O
relationships O
there O
is O
a O
clear O
need O
to O
develop O
robust O
and O
accurate O
models O
to O
understand O
the O
underlying O
structure-activity O
relationship O

, O
[PSI+] O
, O
[URE3] O
, O
[SWI+] O
, O
[MOT3+] O
, O
[MPH1+] O
, O
[LSB+] O
, O
and O
[GAR+] O
) O
, O
which O
have O
the O
capacity O
to O
adopt O
at O
least O
one O
conformation O
that O
self-templates O
over O
long O
biological O
timescales O

Assays O
such O
as O
CUT&RUN O
, O
CUT&Tag O
and O
variations O
thereof O
show O
considerable O
potential O
to O
survey O
multiple O
TFs O
or O
histone O
modifications O
in O
parallel O
from O
a O
single O
experiment O
and O
in O
native O
conditions O

431 O
: O
Epigenomics O
, O
the O
determination O
of O
epigenetic O
landscapes O
on O
a O
genome-wide O
scale O
, O
has O
progressed O
at O
an O
astounding O
rate O
over O
the O
past O
decade O

This O
ultimately O
influences O
disease B-Disease
susceptibility O
and O
health O
in O
an O
individual O

The O
review O
covers O
ethical O
aspects O
such O
as O
how O
epigenetic O
information O
should O
impact O
patient O
autonomy O
and O
the O
ability O
to O
generate O
an O
intentional O
and O
voluntary O
decision O
, O
the O
measures O
of O
data O
protection O
related O
to O
privacy O
and O
confidentiality O
derived O
from O
epigenome O
studies O
( O
e O

667 O
: O
Epigenetics O
, O
the O
study O
of O
functionally O
relevant O
chemical O
modifications O
to O
DNA O
that O
do O
not O
involve O
a O
change O
in O
the O
DNA O
nucleotide O
sequence O
, O
is O
at O
the O
interface O
between O
research O
and O
clinical O
medicine O

e O

265 O
: O
The O
epigenome O
has O
been O
heralded O
as O
a O
key O
'missing O
piece' O
of O
the O
aetiological O
puzzle O
for O
complex O
phenotypes O
across O
the O
biomedical O
sciences O

As O
such O
, O
the O
focus O
for O
DNA O
methylation O
was O
on O
developing O
front-end O
analogue O
circuits O
to O
carry O
out O
Methylation-specific O
PCR O
( O
MSP O
) O
for O
Point-of-Care O
applications O
, O
and O
sequencing O
for O
detailed O
analysis O

Adequate O
nutrition O
is O
particularly O
essential O
during O
critical O
periods O
in O
early O
life O
( O
both O
pre- O
and O
postnatal O
) O

We O
applied O
HopLand O
to O
different O
types O
of O
single-cell O
transcriptomic O
data O

Epigenetics O
could O
explain O
the O
influence O
of O
factors O
such O
as O
the O
nutritional/metabolic O
status O
of O
the O
mother O
or O
the O
artificial O
environment O
of O
assisted O
reproductive O
technologies O

In O
this O
context O
it O
is O
important O
for O
clinicians O
to O
understand O
the O
principles O
of O
epigenetic O
mechanisms O
and O
how O
these O
principles O
relate O
to O
human O
health O
and O
disease B-Disease

Ever O
use O
and O
cumulative O
marijuana-years O
were O
calculated O
from O
the O
baseline O
visit O
to O
Y15 O
and O
Y20 O
, O
and O
recent O
marijuana O
use O
( O
both O
any O
and O
number O
of O
days O
of O
use O
in O
the O
last O
30 O
days O
) O
were O
calculated O
at O
Y15 O
and O
Y20 O

Although O
there O
is O
still O
much O
to O
learn O
about O
the O
relationship O
between O
ageing O
, O
age-related O
diseases O
and O
DNAm O
, O
we O
now O
know O
how O
to O
interpret O
some O
of O
the O
effects O
caused O
by O
age O
in O
the O
form O
of O
changes O
in O
methylation O
marks O
at O
specific O
loci O

Conclusions O
: O
Our O
results O
show O
the O
potential O
of O
large O
serum O
biobank O
collections O
for O
future O
epigenomic O
studies O
and O
biomarker O
discovery O

The O
implication O
of O
epigenetics O
in O
DOHaD O
is O
obvious O
, O
however O
the O
precise O
causal O
chain O
from O
early O
environment O
to O
the O
epigenome O
modifications O
to O
the O
phenotype O
still O
needs O
to O
be O
deciphered O

In O
contrast O
, O
it O
is O
not O
clear O
to O
what O
extent O
population O
structure O
is O
captured O
by O
whole-genome O
DNA O
methylation O
data O

Embodiment O
provides O
a O
basis O
for O
epigenetics O
across O
generations O
and O
for O
epigenetic O
( O
qualitative O
discontinuous O
) O
change O
across O
ontogeny O

Epigenetic O
processes O
thus O
conceived O
generate O
substantial O
subject-specific O
structural O
variation O
, O
for O
instance O
, O
in O
growing O
brain O
networks O

Until O
recently O
our O
understanding O
of O
epigenetic O
mechanisms O
has O
been O
limited O
by O
the O
lack O
of O
tools O
that O
can O
selectively O
manipulate O
the O
epigenome O
with O
genetic O
, O
cellular O
, O
and O
temporal O
precision O
, O
which O
in O
turn O
diminishes O
the O
potential O
impact O
of O
epigenetic O
processes O
as O
therapeutic O
targets O

209 O
: O
Excessive O
production O
of O
microbicidal O
oxidants O
by O
neutrophils O
can O
damage O
host O
tissue O

570 O
: O
The O
rapidly O
emerging O
science O
of O
epigenetics O
and O
epigenomic O
medicine O
promises O
to O
reveal O
novel O
insights O
into O
the O
susceptibility O
to O
and O
the O
onset O
and O
progression O
of O
epileptic O
disorders O

Originally O
prepared O
for O
the O
Organisation O
of O
Economic O
Cooperation O
and O
Development O
( O
OECD O
) O
, O
this O
detailed O
review O
evaluates O
the O
potential O
role O
of O
chemical-induced O
epigenetic O
modifications O
to O
endocrine O
signaling O
pathways O
during O
sensitive O
windows O
of O
exposure O
as O
a O
mechanism O
of O
endocrine O
disruption O
, O
along O
with O

In O
this O
review O
, O
we O
will O
mainly O
consolidate O
the O
applications O
of O
CUT&Tag O
and O
its O
derivatives O
on O
different O
platforms O
, O
give O
a O
detailed O
explanation O
of O
the O
pros O
and O
cons O
of O
this O
technique O
as O
well O
as O
the O
potential O
development O
trends O
and O
applications O
in O
the O
future O

629 O
: O
The O
widespread O
application O
of O
ChIP-seq O
led O
to O
a O
growing O
need O
for O
consistent O
analysis O
of O
multiple O
epigenetics O
profiles O
, O
for O
instance O
, O
in O
human O
studies O
where O
multiple O
replicates O
are O
a O
common O
element O
of O
design O

359 O
: O
Summary O
: O
Epigenetic O
modifications O
reflect O
key O
aspects O
of O
transcriptional O
regulation O
, O
and O
many O
epigenomic O
datasets O
have O
been O
generated O
under O
different O
biological O
contexts O
to O
provide O
insights O
into O
regulatory O
processes O

It O
then O
provides O
a O
series O
of O
easily O
interpretable O
figures O
for O
visualizing O
the O
signal O
and O
epigenetic O
state O
patterns O
of O
the O
cCREs O
clusters O
during O
the O
cell O
differentiation O

Methods O
: O
Pairwise O
correlation O
coefficients O
between O
CpGs O
selected O
in O
two O
published O
EWAS O
, O
the O
top O
hits O
replication O
, O
Bonferroni O
p-values O
, O
Benjamini-Hochberg O
( O
BH O
) O
false O
discovery O
rate O
( O
FDR O
) O
and O
directional O
FDR O
r-values O
were O
calculated O
in O
the O
NINFEA O
cohort O
data O

Mutations O
that O
affect O
epigenetic O
mechanisms O
are O
common O
in O
cancer B-Disease

Members O
of O
the O
International O
Human O
Epigenome O
Consortium O
( O
IHEC O
) O
Bioethics O
Workgroup O
considered O
the O
potential O
ethical O
, O
legal O
, O
and O
social O
issues O
( O
ELSI O
) O
involved O
in O
returning O
epigenetic O
research O
results O
and O
incidental O
findings O
in O
order O
to O
produce O
a O
set O
of O
' O
Points-to-consider O
' O

583 O
: O
Recent O
technological O
advances O
in O
sequencing O
DNA O
and O
RNA O
modifications O
using O
high-throughput O
platforms O
have O
generated O
vast O
epigenomic O
and O
epitranscriptomic O
datasets O
whose O
power O
in O
transforming O
life O
science O
is O
yet O
fully O
unleashed O

Many O
fields O
in O
experimental O
biology O
and O
medicine O
employ O
transgenomic O
or O
otherwise O
genome-manipulated O
cells O
or O
organisms O
without O
considering O
the O
epigenetic O
consequences O
for O
the O
recipient O
genomes O

Here O
we O
review O
some O
of O
these O
techniques O
and O
discuss O
their O
potential O
clinical O
utility O

505 O
: O
Melanoma O
is O
the O
most O
aggressive O
form O
of O
skin O
cancer B-Disease
and O
advanced O
stages O
are O
inevitably O
resistant O
to O
conventional O
therapeutic O
agents O

650 O
: O
Most O
genes O
are O
expressed O
from O
both O
parental O
chromosomes O
; O
however O
, O
a O
small O
number O
of O
genes O
in O
mammals O
are O
imprinted O
and O
expressed O
in O
a O
parent-of-origin O
specific O
manner O

Based O
on O
the O
sequence O
context O
information O
available O
in O
crisprSQL O
, O
we O
also O
computed O
nucleosome B-Disease
occupancy/positioning I-Disease
scores O
for O
off-target O
sites O

283 O
: O
Epigenetic O
regulation O
is O
a O
crucial O
factor O
controlling O
gene O
expression O

jetbrains O

For O
example O
, O
when O
peak O
calling O
is O
done O
independently O
for O
each O
sample O
, O
small O
differences O
in O
signal O
strength/quality O
lead O
to O
a O
very O
different O
number O
of O
peaks O
for O
individual O
samples O
, O
making O
group-level O
analysis O
difficult O

572 O
: O
microRNAs O
( O
miRNAs O
) O
are O
small O
, O
non-coding O
RNAs O
with O
critical O
roles O
in O
fine-tuning O
a O
wide O
array O
of O
biological O
processes O
including O
development O
, O
metabolism O
, O
and O
homeostasis O

316: O
The O
development O
of O
a O
reaction O
for O
the O
detection O
of O
one O
epigenetic O
modification O
in O
a O
long O
DNA O
strand O
is O
a O
chemically O
and O
biologically O
challenging O
research O
subject O

In O
this O
review O
, O
we O
discuss O
general O
aspects O
of O
plant O
responses O
to O
environmental O
stresses O
and O
provide O
an O
overview O
of O
recent O
findings O
on O
the O
role O
of O
transgenerational O
epigenetic O
modifications O
in O
crops O

129 O
: O
ageing O
is O
defined O
by O
the O
decline O
in O
the O
biological O
and O
physiological O
functions O
over O
time O
, O
which O
leads O
to O
health O
problems O
and O
increases O
risks O
of O
diseases O

Increased O
risk O
of O
AD O
is O
associated O
with O
certain O
polymorphic O
variants O
of O
the O
APOE O
gene O
, O
as O
well O
as O
some O
other O
, O
less O
affecting O
genes O

A O
nascent O
area O
of O
research O
focuses O
on O
the O
utility O
of O
epigenetic O
marks O
in O
capturing O
this O
intersection O
of O
genes O
and O
environment O
, O
as O
epigenetic O
mechanisms O
are O
both O
tightly O
linked O
to O
the O
genome O
and O
environmentally O
responsive O

Although O
the O
roles O
of O
5mC O
and O
its O
oxidized O
derivatives O
in O
the O
regulation O
of O
gene O
expression O
are O
relatively O
well O
attested O
and O
extensively O
explored O
, O
a O
number O
of O
recent O
studies O
imply O
that O
noncytosine O
DNA O
modifications O
may O
also O
convey O
specific O
biological O
functions O
and O
act O
as O
" O
epigenetic O

DL O
achieved O
an O
AUC O
( O
95% O
CI O
) O
= O
0 O

In O
the O
current O
study O
, O
we O
have O
developed O
a O
pan O
tissue O
methylation-aging O
clock O
by O
using O
the O
publicly O
available O
illumina O
450k O
and O
EPIC O
array O
methylation O
datasets O

00 O
and O
when O
the O
genetic O
and O
epigenetic O
similarity O
of O
DZ O
twins O
differs O
from O
0 O

This O
analysis O
is O
intended O
to O
assist O
practitioners O
and O
observers O
of O
genetics O
and O
epigenetics O
in O
recognizing O
and O
moving O
beyond O
the O
conceptual O
legacies O
of O
negative O
definition O

Based O
on O
this O
historical O
reconstruction O
, O
in O
§4 O
, O
I O
examine O
what O
modern O
epigenetics O
can O
bring O
to O
the O
picture O
and O
under O
what O
conditions O
epigenetic O
inheritance O
might O
be O
seen O
as O
strengthening O
the O
causal O
relationship O
between O
adaptability O
and O
adaptation O

Here O
, O
we O
will O
first O
summarize O
the O
experimental O
achievements O
over O
the O
last O
7 O
years O
in O
cell O
and O
animal O
rejuvenation O

Understanding O
the O
extent O
of O
epigenetic O
changes O
occurring O
in O
RCC O
and O
the O
mechanisms O
by O
which O
they O
influence O
disease B-Disease
progression O
and O
treatment O
response O
, O
as O
well O
as O
knowledge O
of O
current O
research O
on O
biomarkers O
and O
treatments O
, O
is O
crucial O
to O
successful O
clinical O
translation O
of O
epigenetics O
in O
RCC O

However O
, O
identifying O
subpopulation-level O
changes O
in O
a O
heterogeneous O
sample O
remains O
challenging O

Information O
on O
the O
chronological O
age O
of O
a O
stain O
donor O
(or O
any O
sample O
donor O
) O
is O
elemental O
for O
forensic O
investigations O
in O
a O
number O
of O
aspects O
and O
has O
, O
therefore O
, O
been O
explored O
by O
researchers O
in O
some O
detail O

We O
show O
that O
this O
information O
is O
paving O
the O
way O
towards O
a O
more O
complete O
understanding O
of O
the O
heritable O
basis O
underlying O
population O
epigenomic O
variation O

255 O
: O
The O
human O
genome O
gives O
rise O
to O
different O
epigenomic O
landscapes O
that O
define O
each O
cell O
type O
and O
can O
be O
deregulated O
in O
disease B-Disease

In O
this O
review O
, O
we O
summarize O
different O
computational O
methods O
such O
as O
machine O
learning O
and O
other O
bioinformatics O
tools O
, O
publicly O
available O
databases O
and O
resources O
to O
identify O
key O
modifications O
associated O
with O
epigenetic O
machinery O

In O
Drosophila O
, O
TADs O
are O
biochemically O
defined O
by O
epigenetic O
marks O
, O
this O
suggesting O
that O
the O
3D O
arrangement O
may O
be O
the O
" O
missing O
link O
" O
between O
epigenetics O
and O
gene O
activity O

Biologists O
should O
defend O
science O
against O
ideological O
and O
political O
interferences O

This O
article O
provides O
a O
comprehensive O
review O
of O
the O
nascent O
literature O
at O
the O
crossroads O
of O
epigenetics O
, O
ethics O
, O
law O
and O
society O


To O
date O
, O
these O
studies O
have O
primarily O
focused O
on O
the O
role O
of O
histone O
modification O
, O
nucleosome O
location O
, O
and O
DNA O
methylation O
in O
regulating O
the O
biological O
consequences O
of O
infection B-Disease

Most O
of O
the O
reviewed O
studies O
found O
significant O
epigenetic O
modifications O
linked O
with O
suicidal O
behavior O
rather O
than O
ideation O

Different O
combinations O
of O
these O
genes O
were O
investigated O
using O
Receiver O
Operating O
Characteristic O
analysis O
, O
and O
the O
threshold O
values O
were O
experimentally O
validated O
in O
an O
independent O
cohort O
of O
38 O
control O
and O
45 O
RPL O
spermatozoa O
samples O

200: O
As O
epigenetic O
studies O
become O
more O
common O
and O
lead O
to O
new O
insights O
into O
health O
and O
disease B-Disease
, O
the O
return O
of O
individual O
epigenetic O
results O
to O
research O
participants O
, O
in O
particular O
in O
large-scale O
epigenomic O
studies O
, O
will O
be O
of O
growing O
importance O

Among O
the O
epigenetic O
targets O
are O
the O
writer O
and O
eraser O
enzymes O
that O
are O
, O
respectively O
, O
responsible O
for O
the O
reversible O
introduction O
and O
removal O
of O
structural O
modifications O
in O
the O
nucleosome O

This O
increased O
epigenetic O
stochasticity O
appears O
to O
be O
mediated O
by O
large-scale O
changes O
in O
DNA O
methylation O
and O
chromatin O
in O
domains O
associated O
with O
the O
nuclear O
lamina O

A O
teaching O
session O
on O
epigenetics O
was O
delivered O
either O
as O
a O
traditional O
lecture O
(C-group) O
or O
as O
a O
PRS-including O
Sandwich-based O
session O
(S-group) O

Here O
we O
will O
briefly O
describe O
these O
aspects O
and O
possible O
strategies O
to O
optimize O
the O
search O
for O
new O
diagnostic O
or O
therapeutic O
targets O
for O
cardiovascular B-Disease
diseases I-Disease
in O
the O
post-genomic O
era O

org O
/ O
ewas O

The O
aetiology O
of O
SSc O
is O
unknown O
and O
its O
pathogenesis O
is O
only O
partially O
understood O

392 O
: O
Background O
: O
Diseases O
are O
complex O
phenotypes O
often O
arising O
as O
an O
emergent O
property O
of O
a O
non-linear O
network O
of O
genetic O
and O
epigenetic O
interactions O


It O
was O
concluded O
that O
modern O
epigenetic O
research O
promises O
to O
markedly O
improve O
our O
ability O
to O
diagnose O
, O
prevent O
and O
treat O
these O
and O
other O
pathological O
conditions O
of O
humans O

New O
knowledge O
of O
epigenetic O
alterations O
is O
opening O
a O
gate O
toward O
personalized O
medicine O

The O
aim O
of O
this O
project O
is O
to O
make O
Infinium O
Human O
Methylation O
BeadChip O
analysis O
more O
flexible O
and O
accessible O
to O
everyone O

Further O
studies O
using O
next-generation O
sequencing O
and O
single-cell O
technology O
are O
warranted O
to O
explore O
the O
role O
of O
other O
epigenetic O
mechanisms O
in O
each O
cell O
type O
that O
composes O
the O
endometrium O
throughout O
the O
menstrual O
cycle O

695 O
: O
Despite O
decades O
of O
investigation O
into O
the O
genetics O
of O
autism B-Disease
spectrum O
disorder B-Disease
( O
ASD O
) O
, O
a O
current O
consensus O
in O
the O
field O
persists O
that O
ASD O
risk O
is O
too O
heterogeneous O
to O
be O
diagnosed O
by O
a O
single O
set O
of O
genetic O
variants O

Quantifying O
Waddington's O
epigenetic O
landscape O
by O
mathematical O
modeling O
would O
be O
useful O
for O
understanding O
the O
mechanisms O
of O
cell O
fate O
determination O

To O
examine O
the O
impact O
of O
an O
individual O
's O
sex O
, O
ancestry O
, O
and O
age O
on O
iPSC O
reprogramming O
, O
we O
created O
a O
novel O
sex O
and O
ancestry O
balanced O
cohort O
of O
240 O
iPSC O
lines O
derived O
from O
human O
dermal O
fibroblasts O
( O
DF O
) O
from O
80 O
heathy O
donors O

The O
coming O
of O
the O
epigenetic O
era O
in O
food B-Disease
allergies I-Disease
is O
to O
provide O
better O
understanding O
of O
pathogenesis O
of O
food B-Disease
allergy I-Disease
, O
as O
well O
as O
providing O
therapeutic O
and O
preventive O
strategies O
for O
this O
very O
common O
condition O


Based O
on O
the O
example O
of O
generalized O
anxiety O
disorder B-Disease
( O
GAD O
) O
and O
depressive O
disorder B-Disease
( O
MDD O
) O
, O
we O
shed O
light O
on O
the O
current O
knowledge O
and O
usage O
of O
methodological O
tools O
in O
analyzing O
epigenetics O

They O
expressed O
high O
levels O
of O
concern O
regarding O
non-medical O
applications O
of O
epigenetics O
, O
echoing O
cautionary O
appraisals O
in O
the O
social O
sciences O
and O
humanities O
literature O

Besides O
, O
the O
most O
important O
clinical O
uses O
of O
Epigenetics O
studies O
are O
i O

686 O
years O

The O
modules O
begin O
with O
data O
collection O
and O
preprocessing O
, O
with O
further O
downstream O
analysis O
performed O
in O
a O
Vertex O
AI O
Jupyter O
notebook O
instance O
with O
an O
R O
kernel O

Multistage O
cancer B-Disease
development O
leading O
to O
the O
mutator O
, O
malignant O
cell O
phenotype O
is O
also O
described O

In O
addition O
to O
their O
utility O
in O
estimating O
individual O
age O
, O
differences O
between O
chronological O
and O
predicted O
ages O
arise O
due O
to O
acceleration O
or O
deceleration O
of O
epigenetic O
ageing O
, O
and O
these O
discrepancies O
are O
linked O
to O
disease B-Disease
risk O
and O
multiple O
life O
history O
traits O

Explanation O
of O
the O
interplay O
between O
genomic O
and O
epigenomic O
changes O
will O
contribute O
to O
the O
personalized O
medicine O
approach O

Despite O
successes O
in O
identifying O
causes O
, O
it O
is O
often O
claimed O
that O
there O
are O
missing O
additional O
causes O
for O
even O
reasonably O
well-understood O
conditions O
such O
as O
lung B-Disease
cancer I-Disease
and O
coronary O
heart O
disease B-Disease

455 O
: O
DNA O
modifications O
represent O
an O
integral O
part O
of O
the O
epigenome O
and O
they O
have O
a O
pivotal O
role O
in O
regulation O
of O
genome O
function O

The O
resulting O
large-scale O
data O
sets O
promise O
to O
contribute O
towards O
a O
more O
precise O
and O
complete O
understanding O
of O
gene O
regulation O
and O
to O
yield O
insights O
into O
the O
interplay O
between O
genomes O
and O
the O
environment O

gov/epigenomics O

The O
analysis O
of O
data O
from O
subjects O
influenced O
by O
radiation O
, O
cancer B-Disease
, O
and O
exercise-based O
interventions O
shows O
that O
despite O
being O
good O
predictors O
of O
chronological O
age O
, O
neither O
a O
pathological O
state O
like O
breast B-Disease
cancer I-Disease
, O
a O
hazardous O
environmental O
factor O
( O
radiation O
) O
, O
nor O
exercise O
( O
a O

Findings O
: O
We O
generated O
the O
workflow O
" O
CandiMeth O
" O
( O
Candidate O
methylation O
) O
in O
the O
web-based O
environment O
Galaxy O

We O
focus O
on O
two O
important O
aspects O
: O
marker O
selection O
and O
prediction O
model O
construction O
, O
under O
different O
scenarios O

org O
/ O
10 O

0 O
will O
play O
a O
fundamental O
role O
in O
epigenetic O
studies O
relevant O
to O
biology O
and O
translational O
medicine O

Of O
all O
the O
rheumatic O
diseases O
, O
SSc O
carries O
the O
highest O
all-cause O
mortality O
rate O
and O
represents O
an O
unmet O
medical O
need O

474 O
: O
Schizophrenia B-Disease
is O
a O
debilitating O
psychiatric B-Disease
disorder B-Disease
with O
a O
complex O
genetic O
architecture O
and O
limited O
understanding O
of O
its O
neuropathology O
, O
reflected O
by O
the O
lack O
of O
diagnostic O
measures O
and O
effective O
pharmacological O
treatments O

Two O
additional O
human-elephant O
clocks O
were O
constructed O
by O
combining O
human O
and O
elephant O
samples O

276 O
: O
Polycystic O
ovarian B-Disease
syndrome O
( O
PCOS O
) O
is O
a O
complex O
condition O
of O
ovarian B-Disease
dysfunction O
and O
metabolic O
abnormalities O
with O
widely O
varying O
clinical O
manifestations O
resulting O
from O
interference O
of O
the O
genome O
and O
the O
environment O
through O
integrative O
biological O
mechanisms O
with O
the O
emerging O
field O

540 O
: O
Experiences O
throughout O
the O
life O
course O
lead O
to O
unique O
phenotypes O
even O
among O
those O
with O
the O
same O
genotype O

527 O
: O
To O
assess O
the O
impact O
of O
postnatal O
processing O
on O
placental O
DNA O
methylation O
, O
array O
data O
from O
flash-frozen O
placental O
tissue O
was O
compared O
to O
perfluorocarbon-immersed O
and O
formalin-fixed O
paraffin-embedded O
placental O
tissue O

These O
are O
also O
windows O
of O
opportunity O
for O
interventions O
during O
the O
reproductive O
life O
cycle O
of O
women O
to O
improve O
maternal-child O
health O

However O
, O
the O
mechanism O
governing O
how O
these O
epigenetic O
marks O
accumulate O
at O
discrete O
immune O
gene O
loci O
has O
been O
poorly O
understood O
, O
until O
now O

0 O
million O
children O
under O
18 O
in O
the O
United O
States O
, O
with O
an O
economic O
burden O
that O
is O
estimated O
to O
exceed O
that O
of O
tuberculosis B-Disease
and O
HIV/AIDS O
combined O

The O
SigSeeker O
peak-calling O
ensemble O
uses O
multiple O
tools O
to O
identify O
peaks O
, O
and O
with O
user-defined O
thresholds O
for O
peak O
overlap O
and O
signal O
strength O
it O
retains O
only O
those O
peaks O
that O
are O
concordant O
across O
multiple O
tools O

Epigenetic O
variations O
may O
interplay O
with O
platelet O
functions O
and O
their O
responsiveness O
to O
antiplatelet O
drugs O
, O
and O
they O
may O
also O
exert O
a O
substantial O
contribution O
in O
modulating O
the O
production O
and O
release O
into O
the O
bloodstream O
of O
proteins O
involved O
in O
blood O
coagulation O
and O
fibrinolysis O

Based O
on O
these O
new O
technical O
developments O
, O
we O
discuss O
the O
possibilities O
offered O
by O
epigenetic O
editing O
tools O
in O
plant O
biotechnology O
and O
their O
implications O
in O
crop O
breeding O

DNA O
methylation O
changes O
are O
observed O
in O
both O
hereditary O
and O
sporadic O
forms O
, O
and O
combining O
DNA O
methylation O
analysis O
with O
mutational O
screening O
holds O
the O
potential O
for O
better O
diagnostic O
and O
prognostic O
accuracy O

While O
current O
techniques O
in O
the O
field O
are O
characterizing O
the O
average O
epigenomic O
features O
across O
large O
cell O
ensembles O
, O
the O
increasing O
interest O
in O
the O
epigenetics O
within O
complex O
and O
heterogeneous O
tissues O
is O
driving O
the O
development O
of O
single-cell B-Disease
epigenomics I-Disease

This O
review O
provides O
an O
update O
on O
the O
association O
of O
suboptimal O
nutritional O
environment O
and O
the O
high O
propensity O
to O
produce O
adult-onset O
chronic O
illnesses O
with O
a O
particular O
focus O
on O
modifications O
in O
genome O
functions O
that O
occur O
without O
alterations O
to O
the O
DNA O
sequence O

Alterations O
in O
the O
molecular O
pathways O
that O
drive O
lung B-Disease
cancer I-Disease
, O
which O
include O
epigenetic O
modifications O
, O
may O
provide O
biomarkers O
to O
help O
address O
this O
major O
unmet O
clinical O
need O

358 O
: O
The O
genetic O
and O
epigenetic O
material O
originating O
from O
tumour B-Disease
that O
can O
be O
found O
in O
body O
fluids O
of O
individuals O
with O
cancer B-Disease
harbours O
tumour-specific O
alterations O
and O
represents O
an O
attractive O
target O
for O
biomarker O
discovery O

416 O
: O
Aim O
: O
To O
show O
that O
an O
increased O
correlation O
between O
CpGs O
after O
selection O
through O
an O
epigenome-wide O
association O
studies O
( O
EWAS O
) O
might O
translate O
into O
biased O
replication O
results O

While O
this O
article O
focuses O
on O
current O
literature O
and O
primary O
research O
findings O
in O
lung B-Disease
cancer I-Disease
, O
the O
principles O
we O
describe O
here O
apply O
to O
the O
discovery O
and O
development O
of O
epigenetic O
biomarkers O
for O
other O
types O
of O
cancer B-Disease

DNA O
methylation O
is O
the O
most O
studied O
epigenetic O
mark O
and O
is O
generally O
associated O
with O
the O
regulation O
of O
gene O
expression O
through O
the O
repression O
of O
promoter O
activity O
and O
by O
affecting O
genome O
stability O

I'm O

However O
, O
genetic O
epidemiologic O
research O
into O
FSD O
is O
scarce O
and O
highlights O
the O
need O
for O
more O
in-depth O
exploration O
using O
larger O
samples O
and O
more O
accurate O
phenotypes O

The O
level O
of O
DNA O
methylation O
of O
specific O
genomic O
regions O
correlates O
with O
chromatin O
condensation O
, O
the O
level O
of O
gene O
expression O
, O
and O
in O
some O
cases O
genome O
stability O
and O
the O
frequency O
of O
homologous O
recombination O

We O
emphasize O
that O
an O
integrated O
technological O
approach O
will O
enable O
the O
development O
of O
clinically O
useful O
DNA O
methylation-based O
biomarker O
assays O

By O
tracing O
the O
distribution O
of O
epialleles O
throughout O
the O
tumour B-Disease
we O
can O
infer O
the O
phylogenetic O
history O
of O
the O
tumour B-Disease
, O
identify O
epialleles O
that O
differ O
between O
normal O
and O
cancer B-Disease
tissue O
, O
and O
define O
a O
measure O
of O
global O
epigenetic O
disorder B-Disease

This O
volume O
highlights O
the O
latest O
in O
laboratory O
and O
bioinformatic O
techniques O
used O
for O
the O
investigation O
of O
epigenetic O
phenomena O
in O
plants O

Epigenetics O
is O
strongly O
influenced O
by O
environmental O
factors O
, O
including O
known O
cardiovascular O
risk O
factors O
such O
as O
smoking O
, O
obesity B-Disease
, O
and O
low O
physical O
activity O

Selection O
or O
engineering O
of O
populations O
of O
extracellular O
vesicles O
and O
epigenetic O
editing O
represent O
novel O
tools O
for O
modulation O
of O
the O
cellular O
phenotype O
and O
responses O
, O
although O
further O
technological O
improvements O
are O
required O

New O
method O
: O
Single O
Sample O
Sequencing O
( O
S3EQ O
) O
is O
an O
innovative O
approach O
to O
analyze O
both O
epigenetic O
and O
transcriptomic O
regulation O
within O
a O
single O
neuronal O
sample O

In O
this O
article O
, O
I O
outline O
the O
broad O
scientific O
program O
of O
the O
meeting O
which O
reflected O
the O
wide O
diversity O
in O
epigenetics O
research O

364 O
: O
Epigenetic O
modulations O
underlie O
critical O
developmental O
processes O
and O
contribute O
to O
determining O
adult O
phenotype O

To O
redirect O
future O
novel O
experimental O
or O
theoretical O
efforts O
, O
it O
is O
crucial O
to O
compile O
all O
significant O
issues O
that O
could O
impact O
human O
and O
ecological O
benefit O
in O
the O
most O
precise O
and O
accurate O
manner O

313: O
X-chromosome O
inactivation O
(XCI) O
is O
an O
epigenetic O
phenomenon O
that O
equalizes O
the O
number O
of O
X-linked O
gene O
products O
between O
male O
and O
female O
eutherian O
mammals O
by O
inactivating O
one O
of O
the O
two O
X O
chromosomes O

These O
models O
can O
incorporate O
both O
continuous O
and O
categorical O
phenotypes O
and O
covariates O
, O
as O
well O
as O
fixed O
or O
random O
batch O
or O
chip O
effects O

In O
this O
Review O
, O
we O
discuss O
the O
latest O
insights O
into O
the O
role O
of O
DNA O
methylation O
, O
histone O
modifications O
and O
non-coding O
RNAs O
in O
SSc O
and O
how O
these O
epigenetic O
alterations O
affect O
disease B-Disease
features O

This O
library O
allows O
easy O
integration O
of O
new O
formats O
and O
rapid O
prototyping O
of O
new O
functionalities O
with O
a O
focus O
on O
the O
analysis O
of O
genomic O
regions O
and O
features O

2017 O

ox O

To O
elucidate O
the O
potential O
applications O
of O
these O
recently O
developed O
methods O
in O
transplantation O
research O

In O
the O
last O
few O
years O
, O
epigenetic O
mechanisms O
were O
increasingly O
put O
forward O
in O
this O
context O
because O
of O
their O
pivotal O
role O
in O
gene-environment O
interactions O

DNA O
methylation O
signatures O
associated O
with O
concurrent O
disease B-Disease
and O
with O
the O
development O
of O
asthma O
during O
childhood O
asthma O
have O
been O
identified O
, O
but O
their O
significance O
is O
not O
easily O
interpretable O

Secondary O
analyses O
explored O
the O
effects O
of O
type O
of O
trauma B-Disease
( O
abuse O
and O
neglect O
) O
and O
adult O
chronic B-Disease
stress I-Disease
status O
( O
caregiver O
of O
child O
with O
autism B-Disease
and O
non-caregiver O
) O

This O
review O
surveys O
the O
current O
state O
of O
computational O
tools O
developed O
for O
single-cell O
DNA O
methylome O
data O
analysis O

In O
addition O
, O
the O
dysregulation O
of O
epigenetic O
mechanisms O
commonly O
observed O
in O
cancer B-Disease
may O
alter O
the O
immunogenicity O
of O
tumor B-Disease
cells O
and O
effectiveness O
of O
immunotherapies O

Methods O
: O
In O
the O
German O
birth O
cohort O
KUNO-Kids O
we O
assessed O
when O
information O
for O
such O
scores O
may O
be O
best O
collected O
and O
how O
to O
calculate O
an O
adapted O
FLoSS O


Such O
studies O
are O
particularly O
relevant O
in O
early O
embryonic O
development O
, O
during O
which O
waves O
of O
epigenetic O
reprogramming O
are O
known O
to O
have O
profound O
impacts O

This O
protocol O
chapter O
presents O
a O
unified O
workflow O
to O
explore O
the O
role O
of O
DNA O
methylation O
in O
gene O
expression O
regulation O
in O
breast B-Disease
cancer I-Disease
by O
identifying O
differentially O
expressed O
genes O
whose O
promoter O
or O
gene O
body O
regions O
are O
differentially O
methylated O
using O
various O
Bioconductor O
packages O
in O
R O
environment O

Thus O
, O
for O
the O
first O
time O
, O
we O
can O
identify O
age-associated O
molecular O
changes O
that O
appear O
to O
track O
the O
exponential O
dynamics O
of O
mortality O
risk O

596 O
: O
DNA O
methylation O
at O
cytosine-phosphate-guanine O
( O
CpG O
) O
dinucleotides O
changes O
as O
a O
function O
of O
age O
in O
humans O
and O
animal O
models O
, O
a O
process O
that O
may O
contribute O
to O
chronic O
disease B-Disease
development O

This O
study O
evaluates O
the O
epigenetic O
impact O
of O
preterm O
birth O
in O
isolated O
hematopoietic O
cell O
populations O
, O
reducing O
the O
concern O
of O
cell O
composition O
differences O

Recent O
developments O
start O
to O
exploit O
the O
epigenetic O
information O
on O
cfDNA O
, O
which O
could O
have O
substantially O
wider O
applications O

As O
epigenetic O
modifiers O
are O
relatively O
early O
in O
development O
in O
paediatrics O
, O
there O
is O
a O
clear O
opportunity O
to O
shape O
the O
landscape O
of O
therapies O
targeting O
the O
epigenome O
in O
order O
that O
efficient O
and O
optimum O
plans O
for O
their O
evaluation O
in O
children O
and O
adolescents O
are O
developed O
in O
a O
timely O

Instead O
, O
we O
find O
that O
the O
method O
based O
on O
robust O
partial O
correlations O
is O
generally O
more O
robust O
across O
a O
range O
of O
different O
tissue O
types O
and O
for O
realistic O
noise O
levels O

This O
toolkit O
may O
have O
arisen O
as O
a O
means O
of O
navigating O
the O
genomic O
conflict O
that O
arose O
from O
the O
expansion O
of O
transposable O
elements O
within O
the O
ancestral O
eukaryotic O
genome O

Nevertheless O
, O
the O
success O
of O
modern O
DNA O
fingerprinting O
depends O
on O
the O
availability O
of O
reference O
material O
from O
suspects O

Genetic O
studies O
have O
identified O
a O
limited O
number O
of O
causal O
genes O
from O
a O
marginal O
number O
of O
individuals O
, O
and O
demonstrated O
a O
high O
degree O
of O
discordance O
in O
monozygotic O
twins O

Major O
discoveries O
in O
PPGL O
pathophysiology O
have O
been O
made O
since O
the O
initial O
discovery O
of O
SDHD O
gene O
mutations O
in O
2000 O
, O
improving O
the O
understanding O
of O
their O
biology O
and O
patient O
management O

At O
the O
same O
time O
, O
epigenetic O
changes O
were O
more O
common O
in O
the O
CHG O
( O
C O
= O
cytosine O
, O
H O
= O
cytosine O
, O
adenine O
or O
thymine O
, O
G O
= O
guanine O
) O
and O
CHH O
contexts O
and O
favored O
hypomethylation O

On O
the O
basis O
of O
EWAS1 O

Next O
it O
trains O
a O
soft O
attention O
module O
to O
pick O
out O
which O
epigenetics O
factors O
are O
significant O

A O
number O
of O
chemical O
and O
physical O
factors O
, O
along O
with O
proposed O
infectious O
agents O
or O
aging O
, O
are O
involved O
in O
the O
etiopathogenesis O
of O
autoimmune O
diseases O
through O
epigenetic O
changes O

gov O

To O
meet O
this O
challenge O
, O
comparative O
analysis O
of O
epigenomes O
, O
dubbed O
comparative O
epigenomics O
, O
has O
emerged O
as O
an O
active O
research O
area O

Furthermore O
, O
we O
identify O
significant O
differences O
in O
age-acceleration O
dependent O
on O
the O
lipid O
content O
of O
the O
diet O

The O
types O
of O
analyses O
we O
have O
undertaken O
provide O
insights O
into O
the O
relationships O
between O
immune O
modulation O
and O
cancer B-Disease
etiology O
and O
progression O
, O
offering O
clues O
into O
ways O
of O
therapeutically O
manipulating O
the O
immune O
system O
to O
promote O
immune O
recognition O
and O
immunotherapy O

522 O
: O
Interindividual O
differences O
in O
expression O
of O
ADME O
genes O
are O
controlled O
by O
both O
genetic O
and O
epigenetic O
factors O

A O
second O
research O
axis O
investigates O
novel O
technologies O
for O
the O
analysis O
of O
mutations O
of O
clinical O
relevance O
present O
at O
very O
low O
proportions O
in O
the O
analyzed O
samples O
and O
their O
impact O
on O
treatment O
management O

Although O
still O
a O
developing O
field O
, O
in O
the O
future O
, O
epigenetic O
modifications O
of O
gene O
expression O
may O
provide O
novel O
biomarkers O
to O
predict O
future O
susceptibility O
and/or O
onset O
of O
MDD O
, O
improve O
diagnosis O
, O
and O
aid O
in O
the O
development O
of O
epigenetics-based O
therapies O
for O
depression B-Disease

Biotinylated O
PCR O
products O
were O
then O
analyzed O
using O
pyrosequencing O
to O
generate O
a O
series O
of O
pyrograms O
containing O
18 O
CpG O
sites O

Age O
is O
one O
of O
these O
factors O

In O
fish O
, O
studies O
on O
age-related O
DNA O
methylation O
changes O
are O
scarce O
and O
no O
epigenetic O
clocks O
have O
been O
constructed O

The O
epigenetic O
status O
of O
cells O
plays O
a O
crucial O
role O
in O
determining O
their O
differentiation O
state O
and O
proper O
function O
within O
multicellular O
organisms O

It O
will O
also O
propose O
future O
directions O
to O
fill O
key O
knowledge O
gaps O
and O
to O
test O
whether O
epigenetic O
control O
might O
indeed O
discriminate O
between O
regenerative O
success O
and O
failure O

This O
review O
emphasizes O
the O
significant O
challenges O
for O
epigenetic O
research O
in O
inflammatory O
bowel O
diseases O

In O
contrast O
to O
traditional O
epidemiological O
research O
including O
genome-wide O
association O
studies O
( O
GWAS O
) O
, O
MPE O
is O
founded O
on O
the O
unique O
disease B-Disease
principle O
, O
that O
is O
, O
each O
disease B-Disease
process O
results O
from O
unique O
profiles O
of O
exposomes O
, O
epigenomes O
, O
transcriptomes O
, O
proteomes O
, O
metabolomes O

482 O
: O
There O
is O
mounting O
evidence O
in O
the O
literature O
that O
mesenchymal O
stromal/stem O
cell O
( O
MSC O
) O
like O
populations O
derived O
from O
different O
tissues O
, O
undergo O
epigenetic O
changes O
during O
aging O
, O
leading O
to O
compromised O
connective O
tissue O
integrity O
and O
function O

Further O
, O
multiple O
modulators O
connecting O
epigenetic O
and O
metabolic O
pathways O
help O
dictate O
the O
preferential O
induction O
of O
cytokines O
and O
expression O
of O
lineage-specifying O
genes O
associated O
with O
immunosuppressive O
T-cell O
differentiation O

The O
present O
systematic O
review O
focuses O
on O
the O
potential O
association O
and O
interrelationship O
between O
attachment-related O
dimensions O
and O
DNA O
methylation O
in O
human O
studies O

Conclusions O
: O
Here O
we O
identify O
and O
characterise O
an O
epigenetic O
predictor O
of O
age O
in O
mice O
, O
the O
mouse O
epigenetic O
clock O

Based O
on O
Fisherian O
p-values O
, O
we O
set O
a O
threshold O
for O
methylation O
differences O
" O
worth O
further O
scrutiny O
" O

Epigenetic O
features O
include O
DNA O
methylation O
, O
histone O
modifications O
, O
non-coding O
RNAs O
, O
and O
chromatin O
structure O

Non-genetic O
factors O
, O
including O
diet O
, O
physical O
activity O
, O
health O
habits O
, O
and O
psychosocial O
factors O
contribute O
approximately O
50% O
of O
the O
variability O
in O
human O
lifespan O
with O
another O
25% O
explained O
by O
genetic O
differences O

Here O
, O
we O
discuss O
the O
optimal O
execution O
of O
population-based O
studies O
of O
epigenetic O
variation O
, O
which O
will O
contribute O
to O
the O
emerging O
field O
of O
' O
epigenetic O
epidemiology O
' O
and O
emphasize O
the O
importance O
of O
establishing O
a O
causal O
role O
in O
pathology O
for O
disease-associated O
epigenetic O
changes O

459 O
: O
Personalized O
medicine O
aims O
to O
deliver O
the O
right O
drug O
to O
a O
right O
patient O
at O
the O
right O
time O

Identification O
of O
functionally O
relevant O
epigenetic O
biomarkers O
in O
human O
specimens O
has O
the O
potential O
to O
improve O
prediction O
of O
drug O
responses O
based O
on O
patient O
's O
epigenetic O
profiles O

Genetics O
alone O
cannot O
explain O
sporadic O
cancer B-Disease
and O
cancer B-Disease
development O
in O
individuals O
with O
no O
family O
history O
or O
a O
weak O
family O
history O
of O
cancer B-Disease

We O
apply O
it O
to O
other O
biological O
processes O
, O
including O
symbiopoiesis O

, O
the O
development O
of O
new O
medication O
) O
and O
ultimately O
prevention O

Ninety-four O
of O
the O
96 O
samples O
produced O
satisfactory O
methylation O
calls O
; O
an O
average O
of O
578 O
M O
reads O
per O
sample O
generated O
a O
mean O
coverage O
of O
17× O
and O
mean O
duplication O
level O
of O
35% O

It O
can O
be O
transient O
, O
intergenerational O
, O
or O
transgenerational O

As O
expected O
, O
we O
found O
that O
DNA O
methylomes O
are O
strongly O
associated O
with O
age O
, O
enabling O
the O
construction O
of O
epigenetic O
clocks O

Presented O
here O
is O
the O
" O
polyamine O
hypothesis O
" O
in O
which O
increased O
polyamine O
synthesis O
competes O
with O
cellular O
methylation O
( O
epigenetic O
control O
) O
for O
SAM O

First O
, O
I O
assess O
the O
view O
that O
epigenetic O
inheritance O
could O
be O
seen O
as O
vindicating O
a O
revival O
of O
( O
neo O
) O
Lamarckism O

There O
might O
be O
transgenerational O
effects O
associated O
with O
epigenetic O
modifications O
of O
gametes O
and O
studies O
suggest O
the O
importance O
of O
alterations O
in O
epigenetic O
modification O
at O
early O
and O
late O
stages O
of O
gametogenesis O

Thus O
, O
development O
of O
molecularly O
guided O
diagnostic O
strategies O
has O
emerged O
to O
complement O
traditional O
procedures O
, O
thereby O
improving O
the O
clinical O
management O
of O
patients O
with O
CUP O

Recent O
technological O
advances O
in O
methods O
for O
detecting O
epigenetic O
marks O
at O
a O
whole-genome O
scale O
have O
launched O
new O
opportunities O
for O
studying O
epigenomics O
in O
ecologically O
relevant O
non-model O
systems O

Adverse O
environmental O
exposure O
can O
induce O
aberrant O
DNA O
methylation O
changes O
conducive O
to O
genetic O
dysfunction O
and O
, O
eventually O
, O
various O
pathologies O

299 O
: O
Advances O
in O
our O
understanding O
of O
the O
epigenetic O
mechanisms O
that O
control O
gene O
expression O
in O
the O
central O
nervous B-Disease
system I-Disease
( O
CNS O
) O
and O
their O
role O
in O
neuropsychiatric O
disorders O
are O
paving O
the O
way O
for O
a O
potential O
new O
therapeutic O
approach O
that O
is O
focused O
on O
reversing O

Epigenetic O
regulation O
provides O
a O
plausible O
explanation O
for O
the O
nongenetic O
paternal O
transmission O
of O
disease B-Disease
susceptibility O

Advances O
in O
epigenetics O
and O
epigenomics O
have O
influenced O
pharmacology O
, O
leading O
to O
the O
development O
of O
a O
new O
specialty O
, O
pharmacoepigenetics O
, O
the O
study O
of O
the O
epigenetic O
basis O
for O
the O
individual O
variation O
in O
drug O
response O

We O
further O
used O
epidecodeR O
to O
explore O
the O
effectiveness O
of O
demethylase O
FTO O
inhibitors O
and O
histone-associated O
modifications O
in O
drug O
abuse O
in O
animals O

Recent O
proteomic O
technologies O
have O
enabled O
the O
study O
of O
epigenetic O
mechanisms O
in O
a O
high-throughput O
manner O

Interactions O
of O
epigenetic O
molecular O
functions O
and O
drugs O
are O
mutual O

In O
this O
review O
, O
we O
will O
consider O
the O
current O
evidence O
that O
early-life O
environmental O
signals O
can O
have O
long-term O
effects O
on O
the O
epigenome O

Based O
on O
recent O
research O
on O
the O
model O
plant O
Arabidopsis O
thaliana O
, O
its O
is O
clear O
that O
Lysenkoism O
has O
nothing O
to O
do O
with O
heritable O
'epigenetic' O
modifications O

We O
anticipate O
the O
development O
of O
DNA O
methylome O
association O
study O
designs O
and O
new O
analytical O
methods O
, O
together O
with O
integration O
of O
data O
from O
other O
molecular O
species O
and O
other O
studies O
, O
which O
will O
boost O
statistical O
power O
and O
tackle O
causality O

The O
evaluation O
is O
based O
on O
the O
cumulative O
distribution O
function O
and O
the O
statistical O
significance O
in O
differential O
expression O
of O
genes O
grouped O
by O
the O
number O
of O
'epi-marks' O

749 O
: O
Tumor O
heterogeneity B-Disease
poses O
one O
of O
the O
greatest O
challenges O
to O
a O
successful O
treatment O
of O
cancer B-Disease

We O
also O
highlight O
important O
conceptual O
challenges O
when O
interpreting O
results O
from O
these O
genetic O
studies O
, O
particularly O
in O
plants O
, O
in O
which O
epigenomic O
variation O
can O
be O
determined O
both O
by O
genetic O
and O
epigenetic O
inheritance O

Future O
research O
should O
focus O
on O
the O
identification O
of O
further O
relevant O
confounding O
factors O
and O
the O
development O
of O
models O
that O
are O
"robust" O
against O
the O
influence O
of O
such O
biological O
factors O
by O
systematic O
investigations O
under O
targeted O
inclusion O
of O
diverse O
and O
defined O
cohorts O

EZH2 O
and O
EED O
) O
and O
exploration O
of O
the O
optimum O
combination O
( O
s O
) O
should O
be O
supported O
by O
preclinical O
research O
and O
, O
where O
possible O
, O
molecular O
biomarker O
validation O
in O
advance O
of O
clinical O
translation O

There O
is O
evidence O
that O
histone O
deacetylases O
confer O
effects O
of O
environmental O
triggers O
such O
as O
smoking O
, O
diet O
or O
therapy O
on O
expression O
levels O
of O
target O
genes O

The O
other O
4 O
existing O
scores O
are O
experimental O
features O
( O
CTCF O
, O
DNase O
I O
, O
H3K4me3 O
, O
RRBS O
) O
commonly O
used O
in O
deep O
learning O
models O
for O
off-target O
activity O
prediction O

These O
molecular O
alterations O
include O
multiple O
cancer-driving O
mutations O
, O
gene O
fusions O
, O
amplification O
, O
deletion O
, O
and O
post-translational O
modifications O
, O
among O
others O

Basic O
Protocol O
1 O
: O
ChIPseeker O
and O
epigenomic O
dataset O
preparation O
Basic O
Protocol O
2 O
: O
Annotation O
of O
epigenomic O
datasets O
Basic O
Protocol O
3 O
: O
Comparison O
of O
epigenomic O
datasets O
Basic O
Protocol O
4 O
: O
Visualization O
of O
annotated O
results O
Basic O
Protocol O
5 O
: O
Functional O
analysis O
of O
epigenomic O
datasets O
Basic O
Protocol O
6 O
: O

We O
demonstrate O
EpiExplorer O
's O
utility O
by O
describing O
a O
hypothesis-generating O
analysis O
of O
DNA O
hydroxymethylation O
in O
relation O
to O
public O
reference O
maps O
of O
the O
human O
epigenome O

We O
emphasize O
opportunities O
for O
small-molecule O
inhibitors O
of O
epigenetic O
regulators O
to O
enhance O
antitumour O
immune O
responses O
, O
and O
discuss O
the O
challenges O
of O
exploiting O
the O
complex O
interplay O
between O
cancer B-Disease
epigenetics O
and O
cancer B-Disease
immunology O
to O
develop O
treatment O
regimens O
combining O
epigenetic O
therapies O
with O
immunotherapies O

To O
bolster O
the O
review O
of O
these O
topics O
, O
we O
include O
novel O
analyses O
to O
assess O
the O
effect O
of O
gbM O
on O
transcripts O

410 O
: O
Background O
: O
Genetic O
and O
epigenetic O
dysregulation O
of O
Wnt O
signaling O
pathway O
is O
widely O
linked O
up O
with O
abnormal O
proliferation O
and/or O
epithelial-to-mesenchymal O
transition O
, O
in O
different O
cancer B-Disease
cell O
types O

However O
, O
it O
is O
of O
equal O
importance O
to O
understand O
how O
epigenetic O
machinery O
works O

Through O
clustering O
of O
methylation-based O
latent O
space O
features O
, O
we O
demonstrate O
that O
the O
VAEs O
can O
capture O
differential O
methylation O
patterns O
about O
subtypes O
of O
lung B-Disease
cancer I-Disease

The O
epigenetic O
profile O
captures O
the O
unique O
regulatory O
landscape O
and O
the O
exposure O
to O
environmental O
stimuli O
of O
an O
individual O

Approximately O
70 O
% O
of O
all O
CpG O
dinucleotides O
are O
affected O
by O
DNA O
methylation O
, O
which O
serve O
to O
" O
lock O
in O
" O
chromatin O
states O
and O
thus O
transcriptional O
programs O

The O
projects O
concern O
the O
effects O
of O
exposures O
such O
as O
endocrine O
disrupting O
chemicals O
, O
flame O
retardants O
, O
pesticides O
, O
metals O
and O
particulate O
air O
pollution O
, O
as O
well O
as O
drugs O
, O
psycho-social O
stressors O
and O
ethnical O

Epigenetic O
mechanisms O
such O
as O
DNA O
methylation O
and O
histone O
modifications O
influence O
gene O
expression O
by O
modulating O
the O
packaging O
of O
DNA O
in O
the O
nucleus O

edu O
or O
gcyuan@jimmy O

We O
conclude O
that O
MBD-seq O
represents O
an O
excellent O
approach O
for O
large-scale O
MWAS O
and O
that O
increased O
utilization O
is O
likely O
to O
result O
in O
more O
discoveries O
, O
advance O
biological O
knowledge O
, O
and O
expedite O
the O
clinical O
translation O
of O
methylome-wide O
research O
findings O

Methods O
: O
A O
systematic O
review O
was O
conducted O
in O
accordance O
with O
the O
PRISMA O
guidelines O

Although O
the O
role O
of O
epigenetic O
mechanisms O
in O
Alzheimer's B-Disease
disease I-Disease
is O
still O
little O
understood O
, O
recent O
findings O
clearly O
show O
that O
such O
mechanisms O
are O
dysregulated O
during O
disease B-Disease
progression O
, O
already O
in O
its O
early O
stages O

Most O
existing O
approaches O
perform O
diagnosis O
based O
on O
the O
detection O
of O
sequence O
variants O
on O
cfDNA O
; O
thus O
, O
their O
applications O
are O
limited O
to O
diseases O
associated O
with O
high O
mutation O
rate O
such O
as O
cancer B-Disease

Hybrids O
had O
predominantly O
intermediate O
methylation O
patterns O
( O
88 O

Recent O
findings O
: O
The O
ultra-high O
dimensionality O
and O
high O
correlations O
that O
characterize O
omics O
data O
have O
hindered O
the O
precise O
quantification O
of O
mediated O
effects O

Loss O
of O
Dnmt O
genes O
in O
zebrafish O
and O
mice O
caused O
defects O
in O
organogenesis O
and O
tissue O
terminal O
differentiation O

Recent O
intriguing O
empirical O
observations O
also O
suggest O
that O
inherited O
epigenetic O
effects O
could O
influence O
lifespan/longevity O
in O
a O
variety O
of O
organisms O

237 O
: O
Axonal O
regeneration O
relies O
on O
the O
expression O
of O
regenerative O
associated O
genes O
within O
a O
coordinated O
transcriptional O
programme O
, O
which O
is O
finely O
tuned O
as O
a O
result O
of O
the O
activation O
of O
several O
regenerative O
signalling O
pathways O

Conclusion O
: O
In O
order O
to O
make O
full O
use O
of O
machine O
learning O
algorithms O
, O
one O
should O
get O
familiar O
with O
the O
pros O
and O
cons O
of O
them O
, O
which O
will O
benefit O
from O
big O
data O
by O
choosing O
the O
most O
suitable O
method O
( O
s O
) O

The O
aim O
of O
this O
article O
was O
to O
provide O
the O
comprehension O
about O
current O
research O
trends O
from O
ENCODE O
project O
and O
establish O
the O
link O
between O
epigenetics O
and O
periodontal O
diseases O
based O
on O
epigenome O
studies O
and O
seek O
the O
future O
direction O

644 O
: O
This O
review O
highlights O
emerging O
areas O
of O
interest O
in O
public O
health O
genomics O

395 O
: O
Epigenetic O
modifications O
are O
gene O
regulatory O
mechanisms O
that O
allow O
rapid O
adaptation O
to O
the O
environment O

Summary O
: O
Epigenetics O
continues O
to O
represent O
a O
promising O
area O
of O
research O
in O
atherosclerosis O

We O
discuss O
one O
approach O
for O
methylation-based O
biomarker O
assay O
development O
that O
describes O
the O
discovery O
at O
a O
genome-scale O
level O
, O
which O
addresses O
some O
of O
the O
practical O
considerations O
for O
design O
of O
assays O
that O
can O
be O
implemented O
in O
the O
clinic O

Epigenetics O
provides O
a O
molecular O
mechanism O
for O
environment O
to O
influence O
development O
, O
program O
cellular O
differentiation O
, O
and O
alter O
the O
genetic O
regulation O
of O
development O

It O
has O
become O
increasingly O
clear O
, O
however O
, O
that O
different O
investigators O
ascribe O
different O
definitions O
to O
the O
term O

The O
relevance O
of O
aberrant O
epigenetic O
patterns O
in O
human O
neoplasms B-Disease
has O
surfaced O
over O
the O
last O
decade O
, O
placing O
epigenetics O
at O
the O
forefront O
of O
cancer B-Disease
research O

Knowledge O
gained O
from O
genetic O
studies O
also O
highlights O
the O
importance O
of O
environmental O
factors O
and O
gene-environment O
interactions O
in O
disease B-Disease
development O
and O
maintenance O

The O
only O
SDR O
gene O
to O
show O
a O
marked O
pattern O
of O
gender-specific O
methylation O
is O
PbRR9 O
, O
a O
member O
of O
the O
two O
component O
response O
regulator O
( O
type-A O
) O
gene O
family O
, O
involved O
in O
cytokinin O
signalling O

Furthermore O
, O
integration O
of O
multiple O
genome-wide O
assays O
allows O
for O
different O
genomic O
features O
to O
be O
combined O
, O
and O
can O
improve O
predictive O
performance O

Finally O
, O
we O
tuned O
, O
trained O
, O
and O
evaluated O
both O
random O
forest O
and O
neural O
network O
classifiers O
on O
the O
resulting O
dataset O

Epigenetic O
landscapes O
are O
influenced O
by O
age O
, O
genetics O
, O
toxins O
and O
other O
environmental O
factors O
, O
including O
dietary O
exposures O
and O
nutritional O
status O

05 O
, O
0 O

We O
found O
that O
the O
methylation O
status O
of O
2 O
consecutive O
CpG O
sites O
showed O
deviation O
from O
equilibrium O
frequency O
toward O
concordant O
linkage O
(both O
methylated O
or O
both O
unmethylated O
) O
in O
germline O
cells O

0 O
to O
execute O
chi-square O
test O
, O
t-test O
, O
linear O
regression O
analysis O
, O
logistic O
regression O
analysis O
, O
identify O
the O
association O
between O
epi-alleles O
, O
identify O
the O
methylation O
disequilibrium O
( O
MD O
) O
blocks O
, O
calculate O
the O
MD O
coefficient O
, O
the O
frequency O
of O
meplotype O
and O
Pearson's O
correlation O

Given O
the O
potential O
and O
variety O
of O
computational O
implementations O
(epigenetic O
clocks O
), O
we O
here O
present O
a O
systematic O
review O
of O
such O
clocks O

The O
current O
state O
of O
knowledge O
of O
epigenetics O
has O
evolved O
as O
our O
understanding O
of O
DNA O
methylation O
, O
chromatin B-Disease
modifications I-Disease
, O
and O
noncoding O
RNA O
, O
and O
their O
effects O
on O
gene O
expression O
increased O

I'm O

We O
present O
an O
R O
package O
called O
MammalMethylClock O
for O
the O
construction O
, O
assessment O
, O
and O
application O
of O
epigenetic O
clocks O
in O
different O
mammalian O
species O

However O
, O
to O
our O
knowledge O
, O
the O
two O
methods O
have O
not O
yet O
been O
compared O

Previous O
studies O
have O
linked O
physiological O
features O
to O
coding O
DNA O
sequence O
, O
regulatory O
DNA O
sequence O
, O
and O
epigenetic O
state O
, O
but O
few O
have O
disentangled O
their O
relative O
contributions O
or O
unambiguously O
distinguished O
causative O
effects O
(' O
drivers O
') O
from O
correlations O

Recent O
work O
has O
convincingly O
linked O
the O
accumulation O
of O
senescent O
cells O
in O
aged O
tissues O
to O
a O
decline O
in O
health O
and O
a O
limit O
of O
lifespan O
, O
primarily O
through O
" O
inflammaging O
" O

This O
short O
report O
has O
2 O
main O
components O

Our O
results O
demonstrate O
that O
sperm O
epigenetic O
factors O
can O
contribute O
to O
intergenerational O
inheritance O
of O
behavioral O
changes O
after O
pathogenic O
infection B-Disease
, O
which O
could O
have O
major O
public O
health O
implications O

Despite O
the O
well-known O
deleterious O
health O
effects O
of O
arsenic O
exposure O
, O
the O
molecular O
mechanisms O
in O
arsenic-mediated O
carcinogenesis O
are O
not O
fully O
understood O

Proper O
epigenetic O
regulation O
is O
essential O
for O
normal O
differentiation O
in O
embryogenesis O
and O
development O

Density O
curves O
comparing O
these O
studies O
indicated O
these O
heritability O
estimates O
were O
similar O

Computational O
predictions O
indicate O
that O
one-twentieth O
of O
all O
drugs O
might O
potentially O
interact O
with O
human O
histone O
deacetylase O
, O
which O
was O
prospectively O
experimentally O
verified O
for O
the O
compound O
with O
the O
highest O
predicted O
interaction O
probability O

Innovative O
epigenetic O
therapy O
could O
be O
targeted O
to O
treat O
the O
disease B-Disease
in O
a O
precision O
epigenetics O
approach O

We O
next O
discuss O
how O
this O
trajectory O
may O
be O
affected O
by O
prenatal O
environmental O
exposures O

Many O
more O
fascinating O
examples O
of O
epigenetic O
plasticity O
lie O
outside O
the O
realm O
of O
model O
organisms O
and O
have O
so O
far O
been O
only O
sporadically O
investigated O
at O
a O
molecular O
level O
; O
however O
, O
recent O
progress O
on O
sequencing O
technology O
and O
genome O
editing O
tools O
have O
begun O
to O
blur O
the O
lines O
between O
model O

588 O
: O
Purpose O
of O
review O
: O
To O
give O
an O
overview O
of O
recently O
published O
articles O
addressing O
the O
role O
of O
epigenetic O
modifications O
in O
rheumatoid B-Disease
arthritis I-Disease
( O
RA O
) O


In O
this O
article O
, O
we O
illustrate O
increasing O
contribution O
of O
modern O
pathology O
to O
broader O
public O
health O
sciences O
, O
which O
attests O
pivotal O
roles O
of O
pathologists O
in O
the O
new O
integrated O
MPE O
science O
towards O
our O
ultimate O
goal O
of O
personalized O
medicine O
and O
prevention O

7 O
and O
several O
freely O
available O
Python O
packages O

461 O
: O
In O
this O
article O
, O
we O
outline O
the O
two O
dominant O
concepts O
of O
personalized O
medicine O
put O
forward O
by O
epigenetics O
in O
the O
field O
of O
oncology O

We O
provide O
an O
overview O
of O
cardiovascular O
epigenomics O
, O
discussing O
the O
challenges O
of O
data O
sovereignty O
, O
data O
analysis O
, O
doctor-patient O
ethics O
and O
innovations O
necessary O
to O
implement O
precision O
health O

, O
" O
the O
epigenetics O
of O
cancer B-Disease
" O
) O

ca O

To O
improve O
performance O
further O
, O
additional O
focus O
on O
improving O
discrimination O
of O
current O
from O
former O
smokers O
is O
necessary O


Expert O
opinion O
: O
Despite O
significant O
interests O
in O
targeting O
epigenetic O
modifiers O
as O
a O
therapeutic O
route O
, O
certain O
classes O
of O
target O
proteins O
are O
heavily O
studied O
while O
some O
are O
less O
characterized O

Moreover O
, O
SDHx O
mutations O
induce O
cell O
metabolic O
reprogramming O
and O
redox O
imbalance O

194 O
: O
Growing O
cancer B-Disease
incidence O
and O
mortality O
worldwide O
demands O
development O
of O
accurate O
biomarkers O
to O
perfect O
detection O
, O
diagnosis O
, O
prognostication O
and O
monitoring O

This O
review O
first O
describes O
an O
overview O
of O
the O
pathophysiology O
and O
then O
focuses O
on O
clinical O
implications O
of O
the O
epigenetic O
and O
metabolic O
reprogramming O
of O
SDH-deficient O
PPGL O

The O
intricate O
interplay O
between O
these O
factors O
offers O
insights O
into O
genetic O
and O
epigenetic O
mechanisms O
in O
IEIs O

This O
converted O
DNA O
was O
then O
amplified O
via O
multiplex O
PCR O
with O
reverse O
primers O
containing O
a O
biotin O
molecule O

Methods O
: O
The O
study O
comprised O
of O
80 O
samples O
of O
University O
paramedicine O
students O
including O
40 O
individuals O
at O
two O
time O
points O
- O
t0 O
( O
baseline O
) O
and O
t1 O
( O
post-trauma B-Disease
exposure I-Disease
) O

For O
quantifying O
miRNAs O
, O
digital O
back-end O
processing O
circuits O
were O
considered O
toward O
a O
fully O
portable O
platform O
that O
can O
carry O
out O
real-time O
monitoring O
of O
DNA O
amplification O
reactions O

42 O
: O
Neuroimaging O
epigenetics O
is O
an O
interdisciplinary O
application O
of O
epigenetics O
to O
cognitive O
neuroscience O
that O
seeks O
to O
identify O
molecular O
and O
neural O
predictors O
of O
human O
behavior O

It O
was O
found O
that O
all O
derived O
models O
, O
for O
every O
HDAC O
endpoint O
and O
all O
three O
significance O
levels O
, O
are O
valid O
with O
respect O
to O
predictions O
for O
the O
external O
test O
sets O
as O
well O
as O
the O
internal O
validation O
of O
the O
corresponding O
training O
sets O

Here O
, O
we O
focus O
on O
four O
prominent O
genome-wide O
approaches O
: O
whole-genome O
bisulfite O
sequencing O
( O
WGBS O
) O
; O
methyl-binding O
domain O
capture O
sequencing O
( O
MBDCap-Seq O
) O
; O
reduced-representation-bisulfite-sequencing O
( O
RRBS O
) O
; O
and O
Infinium O
Methylation450 O
BeadChips O
( O
450 O
K O
, O

We O
also O
discuss O
the O
advantages O
and O
challenges O
of O
using O
epigenetic O
biomarkers O
as O
an O
indicator O
of O
toxicant O
exposure O
, O
using O
measures O
that O
can O
be O
taken O
to O
improve O
risk O
assessment O
, O
and O
our O
perspectives O
on O
the O
future O
role O
of O
epigenetics O
in O
toxicology O

Osteoporosis O
, O
followed O
by O
osteopetrosis O
, O
was O
the O
most O
commonly O
evaluated O
disorder B-Disease

We O
hypothesized O
that O
the O
use O
of O
a O
newly O
developed O
, O
highly O
sensitive O
, O
and O
specific O
epigenetic O
test O
, O
PrecisionCHD O
, O
could O
decrease O
the O
costs O
of O
secondary O
prevention O

Applying O
PRISM O
for O
two O
AML O
samples O
, O
we O
demonstrate O
that O
PRISM O
could O
infer O
the O
evolutionary O
history O
of O
malignant O
samples O
from O
an O
epigenetic O
point O
of O
view O

Epigenetic O
changes O
can O
be O
seen O
from O
the O
very O
early O
stages O
in O
tumorigenesis B-Disease
and O
dysregulation O
of O
the O
epigenome O
has O
an O
increasingly O
acknowledged O
pathogenic O
role O

Gene-environment O
complementary O
contributions O
to O
the O
molecular O
mechanisms O
involved O
in O
psychiatric B-Disease
disorders I-Disease
have O
emphasized O
the O
need O
to O
analyze O
epigenetic O
marks O
such O
as O
DNA O
methylation O
(DNAm) O
and O
non-coding O
RNAs O

While O
the O
field O
is O
still O
in O
its O
infancy O
, O
epigenetics O
holds O
promise O
as O
a O
predictive O
tool O
by O
examining O
individual O
patients O
' O
epigenetic O
profiles O
in O
conjunction O
with O
other O
indicators O

Methylated O
DNA O
can O
also O
be O
sequenced O
by O
either O
methylated O
DNA O
immunoprecipitation O
followed O
by O
sequencing O
( O
MeDIP-seq O
) O
or O
single-molecule O
real-time O
sequencing O
( O
SMRTseq O
) O
for O
identifying O
genomic O
locations O
of O
DNA O
methylation O

To O
this O
day O
, O
quantifying O
the O
importance O
of O
stochasticity O
in O
epigenetic O
variability O
remains O
a O
challenge O

Improvements O
in O
diagnostics O
and O
therapy O
of O
this O
common O
tumor B-Disease
are O
urgently O
required O
and O
need O
to O
be O
based O
on O
a O
better O
understanding O
of O
its O
biology O

Epigenetic O
mechanisms O
are O
crucial O
in O
the O
fine-tuning O
of O
gene O
expression O
to O
generate O
such O
transcriptional O
networks O

MicroRNA O
(miRNA) O
, O
a O
member O
of O
noncoding O
RNAs O
superfamily O
, O
participates O
in O
RNA O
interference O
through O
a O
unique O
mechanism O

Prenatal O
stress-associated O
epigenetic O
changes O
have O
also O
been O
linked O
to O
child O
health O
including O
internalizing O
problems O
, O
neurobehavioral O
outcomes O
and O
stress O
reactivity O

In O
this O
review O
, O
we O
discuss O
how O
studying O
the O
genetic O
predisposition O
to O
IBD O
has O
increased O
our O
understanding O
about O
IBD O
pathogenesis O
and O
how O
epigenetics O
is O
becoming O
more O
and O
more O
important O

In O
addition O
, O
the O
authors O
present O
expert O
consensus O
on O
knowledge O
gaps O
and O
research O
recommendations O
for O
the O
field O

Loss O
of O
this O
regulation O
contributes O
to O
many O
diseases O

When O
assayed O
for O
metal O
ion O
stress O
, O
a O
combination O
of O
Mn O
deficiency O
with O
excess O
Cu O
or O
Zn O
stress O
was O
shown O
to O
induce O
gene O
silencing O
in O
Chlamydomonas O

158 O
: O
Epigenetics O
represents O
a O
widely O
accepted O
set O
of O
mechanisms O
by O
which O
organisms O
respond O
to O
the O
environment O
by O
regulating O
phenotypic O
plasticity O
and O
life O
history O
transitions O

To O
overcome O
this O
hurdle O
, O
we O
designed O
a O
split-TET2 O
enzyme O
to O
enable O
temporal O
control O
of O
5-methylcytosine O
( O
5mC O
) O
oxidation O
and O
subsequent O
remodeling O
of O
epigenetic O
states O
in O
mammalian O
cells O
by O
simply O
adding O
chemicals O

Several O
polymorphisms O
that O
mediate O
the O
HPA O
axis O
, O
neurotransmission O
, O
immune O
response O
, O
brain O
development O
, O
serotonin O
synthesis O
, O
and O
other O
processes O
were O
found O

identification O
of O
disease B-Disease
biomarkers O
and O
ii O

661 O
: O
Waddington O
's O
epigenetic O
landscape O
is O
a O
classic O
metaphor O
for O
describing O
the O
cellular O
dynamics O
during O
the O
development O
modulated O
by O
gene O
regulation O

CUT&RUN O
is O
now O
being O
widely O
used O
for O
characterizing O
the O
epigenetic O
landscape O
in O
many O
cell O
types O
as O
it O
utilizes O
far O
less O
cell O
numbers O
when O
compared O
to O
Chromatin O
Immunoprecipitation-sequencing O
( O
ChIP-seq O
) O
, O
thereby O
making O
it O
a O
powerful O
tool O
for O
researchers O
working O
with O
limited O

Nevertheless O
, O
many O
questions O
still O
remain O
with O
respect O
to O
the O
specific O
mechanisms O
underlying O
epigenetic O
regulation O
of O
the O
viruses B-Disease
and O
transformation O

We O
performed O
a O
literature O
review O
using O
electronic O
databases O
such O
as O
PubMed O
, O
Scopus O
, O
Web O
of O
Science O
, O
and O
EBSCOhost O

The O
substantial O
overlap O
in O
genetically O
identified O
pathogenic O
pathways O
has O
been O
demonstrated O
between O
these O
diseases O

The O
fundamental O
functions O
of O
ChIPseeker O
, O
including O
data O
preparation O
, O
annotation O
, O
comparison O
, O
and O
visualization O
, O
are O
explained O
in O
this O
article O

Recent O
advances O
in O
single-cell O
DNA O
methylome O
profiling O
have O
presented O
opportunities O
to O
resolve O
this O
heterogeneity B-Disease
at O
the O
maximum O
resolution O

Here O
we O
highlight O
how O
the O
changes O
in O
genome O
architecture O
in O
diverse O
eukaryotes O
are O
regulated O
by O
epigenetic O
processes O
, O
such O
as O
DNA O
elimination O
, O
genome O
rearrangements O
, O
and O
adaptive O
changes O
to O
genome O
architecture O

138 O
: O
Discoveries O
from O
the O
Human O
Genome O
Project O
have O
invigorated O
discussions O
of O
epigenetic O
effects-modifiable O
chemical O
processes O
that O
influence O
DNA O
's O
ability O
to O
give O
instructions O
to O
turn O
gene O
expression O
on O
or O
off O
- O
on O
health O
outcomes O

The O
covalent O
modifications O
of O
chromatin O
, O
which O
include O
methylation O
and O
acetylation O
, O
on O
DNA O
nucleotide O
bases O
, O
histone O
proteins O
and O
RNA O
are O
derived O
from O
intermediates O
of O
one-carbon O
metabolism O
and O
central O
metabolism O

This O
article O
is O
part O
of O
the O
theme O
issue O
'How O
does O
epigenetics O
influence O
the O
course O
of O
evolution?'304:A O
better O
understanding O
of O
normal O
and O
diseased O
brain O
aging O
and O
cognition O
will O
have O
a O
significant O
public O
health O
impact O
, O
given O
that O
the O
oldest-old O
persons O
older O
than O
85 O
years O
of O
age O

This O
short O
review O
aims O
at O
summarizing O
the O
role O
of O
epigenetics O
in O
multiple O
aspects O
of O
biology O
and O
medicine O
, O
including O
development O
, O
cancer B-Disease
, O
non-tumoral O
diseases O
, O
environmentally O
induced O
phenotypic O
changes O
, O
and O
also O
in O
inheritance O
and O
evolution O

Indeed O
, O
improved O
methods O
to O
study O
DNA O
methylation O
patterning O
and O
dynamics O
at O
base O
pair O
resolution O
and O
across O
individual O
DNA O
molecules O
on O
a O
genome-wide O
scale O
has O
highlighted O
the O
scope O
of O
change O
to O
the O
DNA O
methylation O
landscape O
in O
disease B-Disease
states O
, O
particularly O
during O
tumorigenesis B-Disease

Methylation O
values O
for O
cytosine O
guanine O
dinucleotide O
(CpG) O
sites O
at O
each O
locus O
were O
then O
measured O
across O
the O
four O
markers O

Although O
research O
in O
this O
area O
is O
still O
under O
investigation O
, O
available O
results O
suggest O
that O
DNA O
methylation O
associated O
with O
attachment-related O
dimensions O
might O
affect O
the O
development O
of O
stress O
regulation O
system O
and O
social-emotional O
capacities O
, O
thus O
contributing O
to O
the O
emerging O
phenotypic O
outcomes O

Contact O
: O
elior O

Furthermore O
, O
if O
the O
objective O
is O
the O
detection O
of O
DNA O
methylation O
in O
subclonal O
tumor B-Disease
cell O
populations O
or O
in O
circulating O
tumor B-Disease
DNA O
or O
in O
any O
case O
of O
mosaicism O
, O
the O
importance O
of O
accuracy O
becomes O
critical O

the O
emerging O
field O
of O
epigenetics O
as O
related O
to O
psychology O
is O
reviewed O

533 O
: O
DNA O
enrichment O
followed O
by O
sequencing O
( O
DNA-IP O
seq O
) O
is O
a O
versatile O
tool O
in O
molecular O
biology O
with O
a O
wide O
variety O
of O
applications O

The O
objectives O
of O
this O
conference O
were O
to O
showcase O
the O
breadth O
of O
epigenetic O
research O
on O
environment O
and O
health O
across O
Canada O
and O
to O
provide O
the O
catalyst O
to O
develop O
collaborative O
Canadian O
epigenetic O
research O
opportunities O
, O
similar O
to O
existing O
international O
epigenetic O
initiatives O
in O
the O
US O
and O
Europe O

For O
example O
, O
adverse O
exposures O
, O
such O
as O
precarious O
social O
and O
living O
conditions O
and O
related O
psychosocial O
stress O
among O
others O
, O
have O
been O
linked O
to O
specific O
genes O
being O
switched O
" O
on O
and O
off O
" O
through O
epigenetic O
mechanisms O

296 O
: O
Purpose O
of O
review O
: O
Genome-wide O
association O
studies O
( O
GWAS O
) O
have O
helped O
to O
understand O
the O
genetic O
basis O
and O
pathogenesis O
of O
inflammatory O
bowel O
disease B-Disease
( O
IBD O
) O

He O
earned O
his O
B O

g O

Given O
its O
medical O
utility O
, O
in O
recent O
years O
it O
has O
become O
apparent O
that O
there O
is O
a O
need O
to O
develop O
methods O
for O
the O
analysis O
of O
DNA O
methylation O
using O
different O
approaches O
: O
global O
, O
locus-specific O
, O
or O
genome-wide O

The O
use O
of O
epiNet O
should O
help O
to O
design O
or O
complement O
biological O
experiments O
in O
epigenetics O
studies O

We O
consolidate O
evidence O
suggesting O
that O
although O
DNA O
methylation O
is O
likely O
present O
in O
some O
flatworm O
lineages O
, O
it O
does O
not O
regulate O
neoblast O
function O
in O
Schmidtea O
mediterranea O

Some O
questions O
may O
instead O
be O
addressable O
via O
epigenomics O
, O
as O
the O
epigenome O
acts O
as O
an O
interphase O
between O
the O
fixed O
genome O
and O
the O
dynamic O
environment O

934 O
for O
the O
prior O
model O
and O
0 O

463 O
: O
Within O
the O
past O
two O
decades O
, O
seven O
epigenetic O
drugs O
have O
received O
regulatory O
approval O
and O
numerous O
other O
candidates O
are O
currently O
in O
clinical O
trials O

Nowadays O
, O
the O
complex O
milieu O
of O
epigenomic O
marks O
can O
be O
studied O
at O
the O
genome-wide O
level O
thanks O
to O
massive O
, O
high-throughput O
technologies O

Epigenetic O
processes O
, O
such O
as O
DNA O
methylation O
and O
histone O
posttranslational O
modifications O
, O
instruct O
the O
cell/tissue O
to O
correctly O
interpret O
external O
signals O
and O
adjust O
its O
functions O
accordingly O

If O
confirming O
the O
hypothesis O
, O
such O
studies O
challenge O
our O
fundamental O
understanding O
of O
evolution O
by O
natural O
selection O
; O
therefore O
they O
require O
particular O
rigor O
in O
design O
and O
great O
care O
in O
data O
analysis O

This O
article O
demonstrates O
that O
this O
emphasis O
on O
the O
environment O
and O
on O
so-called O
Lamarckian O
inheritance O
, O
in O
addition O
to O
other O
factors O
, O
reflects O
an O
interdisciplinary O
power O
struggle O
with O
genetics O
, O
in O
which O
epigenetics O
appears O
to O
grant O
the O
social O
sciences O
a O
higher O
epistemic O
status O

Specifically O
, O
we O
observed O
enriched O
binding O
of O
transcription O
factors O
associated O
with O
chromatin O
structure O
around O
methyl-valleys O

Yet O
the O
inherited O
genome O
determines O
only O
part O
of O
an O
individual's O
risk O
profile O

Stem O
Cells O
Translational O
Medicine O
2019 O
; O
8 O
: O
75 O
- O
81 O

84 O
: O
Ovarian O
platelet-rich O
plasma O
( O
PRP O
) O
is O
claimed O
to O
restore O
the O
fertility O
potential O
by O
improving O
reserve O
, O
an O
effect O
perhaps O
mediated O
epigenetically O
by O
platelet-discharged O
regulatory O
elements O
rather O
than O
gonadotropin-activated O
G-protein O
coupled O
receptors O
, O
as O
with O
stimulated O
in O
vitro O

Recently O
concerns O
have O
been O
raised O
about O
the O
accuracy O
of O
twin O
studies O
in O
light O
of O
findings O
of O
genetic O
and O
epigenetic O
changes O
in O
twins O

Referring O
to O
huge O
amounts O
of O
epigenetic O
data O
coming O
from O
biological O
experiments O
and O
clinic O
, O
machine O
learning O
can O
help O
in O
detecting O
epigenetic O
features O
in O
genome O
, O
finding O
correlations O
between O
phenotypes O
and O
modifications O
in O
histone O
or O
genes O
, O
accelerating O
the O
screen O
of O
lead O
compounds O
targeting O
epigenetics O

Could O
the O
same O
be O
true O
for O
RNA O
? O
Joseph O
Martin O
discusses O

Epigenetic O
changes O
are O
believed O
to O
be O
a O
result O
of O
changes O
in O
an O
organism's O
environment O
that O
result O
in O
fixed O
and O
permanent O
changes O
in O
most O
differentiated O
cells O

Pro O
- O
angiogenic O
factors O
that O
are O
secreted O
by O
tumors B-Disease
will O
trigger O
the O
sprouting O
of O
nearby O
existing O
blood O
vessels O
towards O
themselves O
and O
therefore O
researchers O
have O
developed O
targeted O
therapy O
towards O
these O
pro-angiogenic O
proteins O
to O
inhibit O
angiogenesis O

137 O
: O
Our O
paper O
aims O
at O
bringing O
to O
the O
fore O
the O
crucial O
role O
that O
habits O
play O
in O
Charles O
Darwin O
's O
theory O
of O
evolution O
by O
means O
of O
natural O
selection O

These O
ambiguities O
can O
be O
eliminated O
by O
robust O
methods O
that O
directly O
characterize O
the O
existence O
and O
genomic O
locations O
of O
combinations O
of O
chromatin O
features O
in O
very O
small O
inputs O
of O
cells O
or O
ideally O
, O
single O
cells O

Alterations O
to O
the O
epigenome O
are O
thought O
to O
capture O
and O
mediate O
the O
effects O
of O
genetic O
and O
environmental O
risk O
factors O
on O
complex O
disease B-Disease

Herein O
, O
we O
report O
and O
discuss O
the O
formation O
of O
5-methylcytosine-osmium O
complexes O
that O
are O
used O
as O
the O
basis O
for O
a O
bisulfite-free O
chemical O
assay O
for O
DNA O
methylation O
analysis O

The O
model O
reported O
the O
lowest O
epigenetic O
age O
acceleration O
in O
normal O
populations O
, O
as O
well O
as O
the O
lowest O
variation O
across O
technical O
replicates O
and O
repeated O
samples O
from O
the O
same O
subjects O

One O
study O
identified O
accelerated O
epigenetic O
aging O
associated O
with O
discrimination O
using O
Hannum's O
clock O
; O
33% O
of O
studies O
evaluating O
life O
trauma B-Disease
reported O
epigenetic O
age O
acceleration O
using O
GrimAge O
or O
Horvath's O
clock O
; O
25% O
of O
studies O
evaluating O
childhood O
trauma B-Disease
reported O
epigenetic O
age O
acceleration O
using O
Horvath O

Epigenetic O
clock O
(eAge) O
algorithms O
utilize O
DNA O
methylation O
to O
estimate O
the O
age O
and O
risk O
factors O
for O
diseases O
as O
well O
as O
analyze O
the O
impact O
of O
various O
interventions O

This O
review O
, O
therefore O
, O
aims O
to O
acquaint O
the O
cardiovascular O
community O
with O
the O
rapidly O
advancing O
and O
evolving O
field O
of O
epigenetics O
and O
its O
implications O
in O
cardiovascular O
precision O
medicine O

Mouse O
blood O
showed O
a O
general O
pattern O
of O
epigenome-wide O
hypermethylation O
and O
hypo-hydroxymethylation O
with O
age O

In O
this O
brief O
commentary O
, O
I O
will O
attempt O
to O
address O
and O
delineate O
some O
of O
the O
open O
questions O
and O
areas O
of O
opportunity O
that O
discoveries O
in O
epigenetics O
are O
providing O
to O
the O
discipline O
of O
neuroscience O

Here O
, O
we O
provide O
a O
critical O
overview O
of O
different O
analytical O
methods O
that O
are O
suitable O
for O
biomarker O
validation O
, O
including O
general O
study O
design O
considerations O
, O
which O
might O
help O
to O
streamline O
epigenetic O
marker O
development O

In O
this O
review O
, O
we O
center O
on O
epigenetic O
regulatory O
mechanisms O
and O
their O
aging-associated O
changes O
, O
highlighting O
their O
inferences O
in O
age-associated O
diseases O

This O
review O
will O
discuss O
epigenetic O
studies O
in O
both O
suicidal B-Disease
ideation I-Disease
and O
behavior O

Results O
: O
Haystack O
is O
a O
bioinformatics O
pipeline O
to O
identify O
hotspots O
of O
epigenetic O
variability O
across O
different O
cell-types O
, O
cell-type O
specific O
cis-regulatory O
elements O
, O
and O
associated O
transcription O
factors O

Epigenetic O
modifications O
influence O
drug O
response O
, O
but O
they O
can O
also O
be O
modulated O
by O
drugs O

Horvath O
clock O
has O
been O
adopted O
in O
various O
aging O
studies O
as O
a O
DNA O
methylation O
age O
predicting O
clock O
due O
to O
its O
higher O
accuracy O
and O
multi O
tissue O
prediction O
potential O

The O
adaptation O
of O
the O
different O
schemes O
for O
processing O
variations O
is O
quantified O
for O
a O
range O
of O
fluctuating O
environments O
, O
following O
an O
approach O
that O
links O
quantitative O
genetics O
with O
stochastic O
control O
theory O

The O
differential O
DNA O
methylation O
status O
of O
specific O
gene O
regions O
has O
been O
used O
in O
the O
past O
to O
differentiate O
breast B-Disease
cancer I-Disease
cells O
from O
normal O
tissue O

However O
, O
the O
complex O
heritability O
pattern O
of O
' O
epigenetic O
syndromes' O
also O
introduces O
unique O
legal O
and O
ethical O
issues O
that O
were O
discussed O
at O
the O
end O
of O
this O
outstanding O
meeting O

Availability O
and O
implementation O
: O
PRISM O
is O
freely O
available O
on O
GitHub O
( O
https O
: O
/ O
/ O
github O

The O
findings O
of O
several O
studies O
have O
shown O
that O
instituting O
tight O
glycemic O
control O
in O
diabetic B-Disease
patients O
does O
not O
immediately O
benefit O
the O
progression O
of O
retinopathy O
, O
and O
the O
benefits O
of O
good O
control O
persist O
beyond O
the O
period O
of O
good O
glycemic O
control O

If O
molecular O
or O
pharmacological O
interventions O
could O
be O
discovered O
that O
rejuvenate O
aging O
HSCs O
, O
it O
could O
reduce O
the O
burden O
of O
age O
related O
immune O
system O
compromise O
as O
well O
as O
open O
up O
new O
opportunities O
for O
treatment O
of O
hematological O
disorders O
with O
regenerative O
therapy O

This O
review O
discusses O
the O
progress O
achieved O
in O
the O
design O
and O
development O
of O
inhibitors O
against O
the O
key O
writer O
and O
eraser O
pairs O
: O
DNA O
methyltransferases O
and O
Tet O
demethylases O
; O
lysine/arginine B-Disease
methyltransferases I-Disease
and O
lysine B-Disease
demethylases I-Disease
; O
and O
histone O
acetyltransferases O
and O
histone O
deacetylases O


O O
to O
their O
involvement O
in O
these O
pathways O
and O
frequent O
occurrence O
in O
RCC O
, O
epigenetic O
alterations O
are O
regarded O
as O
potential O
biomarkers O
for O
the O
early O
detection O
of O
disease B-Disease
and O
for O
prediction O
of O
prognosis O
and O
treatment O
response O

g O

Survival O
advantages O
may O
be O
induced O
by O
cancer B-Disease
therapies O
and O
also O
occur O
as O
a O
result O
of O
inherent O
cell O
and O
microenvironmental O
factors O

Thompson O
has O
established O
a O
landmark O
for O
mathematical O
biology O
, O
introducing O
new O
perspectives O
of O
study O
and O
research O
in O
biology O
, O
providing O
mathematical O
methods O
to O
morphology O
of O
biological O
systems O

Aberrant O
epigenetic O
alterations O
play O
an O
important O
role O
in O
the O
pathogenesis O
and O
development O
of O
specific O
types O
of O
peripheral O
T-cell O
lymphoma B-Disease
, O
including O
the O
regulation O
of O
the O
expression O
of O
genes O
and O
signal O
transduction O

This O
is O
the O
case O
in O
epigenome-wide O
association O
studies O
used O
as O
genome-wide O
screening O
of O
methylation O
changes O
to O
detect O
new O
candidate O
genes O
and O
regions O
associated O
with O
a O
specific O
disease B-Disease
or O
condition O

262 O
: O
Age-associated O
DNA-methylation O
profiles O
have O
been O
used O
successfully O
to O
develop O
highly O
accurate O
biomarkers O
of O
age O
( O
" O
epigenetic O
clocks O
" O
) O
in O
humans O
, O
mice O
, O
dogs O
, O
and O
other O
species O

Subsequently O
, O
based O
on O
this O
background O
, O
we O
critically O
examine O
some O
recent O
findings O
of O
studies O
investigating O
transgenerational O
inheritance O

53 O
: O
Interest O
in O
the O
field O
of O
epigenetics O
has O
increased O
rapidly O
over O
the O
last O
decade O
, O
with O
the O
term O
becoming O
more O
identifiable O
in O
biomedical O
research O
, O
scientific O
fields O
outside O
of O
the O
molecular O
sciences O
, O
such O
as O
ecology O
and O
physiology O
, O
and O
even O
mainstream O
culture O

420 O
: O
Introduction O
: O
The O
cost O
of O
secondary O
prevention O
of O
coronary O
heart O
disease B-Disease
( O
CHD O
) O
is O
continuing O
to O
increase O
, O
with O
a O
substantial O
portion O
of O
this O
acceleration O
being O
driven O
by O
the O
expense O
of O
confirmatory O
diagnostic O
testing O


Examining O
the O
epigenome O
by O
age O
, O
we O
identified O
28,196 O
unique O
differentially O
methylated O
CpGs O
( O
DMCs O
) O
and O
8,613 O
differentially O
hydroxymethylated O
regions O
( O
DHMRs O
) O

Yet O
, O
the O
dynamicity O
of O
epigenetic O
age O
after O
exposure O
to O
trauma B-Disease
and O
the O
factors O
that O
influence O
epigenetic O
age O
are O
not O
fully O
understood O

We O
base O
our O
hypothesis O
on O
theoretical O
and O
experimental O
studies O
showing O
quantum O
phenomena O
to O
be O
active O
in O
double-stranded O
DNA O
, O
even O
under O
ambient O
conditions O

By O
including O
environmental O
exposures O
as O
random O
effects O
, O
the O
authors O
found O
heritability O
estimates O
became O
more O
stable O
but O
not O
significantly O
different O

Here O
, O
we O
review O
recent O
developments O
in O
basic O
and O
translational O
research O
that O
have O
provided O
tantalizing O
clues O
that O
may O
be O
used O
to O
unlock O
the O
therapeutic O
potential O
of O
the O
epigenome O
in O
heart B-Disease
failure I-Disease

541 O
: O
Epigenetic O
clocks O
, O
developed O
using O
DNA O
methylation O
data O
, O
have O
been O
widely O
used O
to O
quantify O
biological O
aging O
in O
multiple O
tissues/cells O

Already O
, O
there O
is O
evidence O
to O
suggest O
that O
, O
in O
people O
with O
eating B-Disease
disorders I-Disease
, O
epigenetically O
informed O
interventions O
help O
reduce O
stigma O
and O
shame O
, O
and O
increase O
self-acceptance O
and O
hopes O
of O
recovery O

Oskar O
Karlsson O
, O
is O
an O
associate O
professor O
at O
the O
Science O
for O
Life O
Laboratory O
( O
SciLifeLab O
) O
, O
Department O
of O
Environmental O
Science O
, O
Stockholm O
University O
, O
Sweden O

nlm O

Recent O
studies O
have O
shown O
that O
epigenetic O
mechanisms O
, O
such O
as O
DNA O
methylation O
, O
play O
a O
key O
role O
in O
adapting O
plants O
to O
stress O
conditions O

We O
discovered O
increased O
frequency O
of O
hypomethylation O
across O
the O
genome O
after O
reloading O
( O
18,816 O
CpGs O
) O
versus O
earlier O
loading O
( O
9,153 O
CpG O
sites O
) O

The O
authors O
discuss O
the O
current O
evidence O
for O
transgenerational O
epigenetic O
inheritance O
and O
summarize O
the O
data O
linking O
epigenetics O
to O
cardiovascular O
disease B-Disease

Epigenetics O
refers O
to O
the O
study O
of O
heritable O
changes O
in O
gene O
expression O
without O
alterations O
in O
DNA O
sequences O

Then O
, O
methodological O
considerations O
for O
implementing O
social O
epigenomics O
into O
oral B-Disease
health I-Disease
research O
are O
highlighted O
, O
with O
emphasis O
on O
the O
implications O
for O
study O
design O
and O
interpretation O

The O
development O
of O
genome-wide O
methods O
capable O
of O
distinguishing O
5-methylcytosine O
( O
5mC O
) O
from O
5hmC O
has O
revealed O
that O
a O
growing O
number O
of O
behaviors O
are O
linked O
to O
independent O
disruptions O
of O
5mC O
and O
5hmC O
levels O
, O
further O
emphasizing O
the O
unique O
importance O
of O
both O
of O

Some O
basic O
approaches O
to O
the O
study O
of O
epigenetics O
are O
reviewed O

No O
doubt O
, O
this O
important O
goal O
has O
been O
successfully O
achieved O
owing O
to O
the O
high O
quality O
of O
presented O
epidemiological O
and O
experimental O
studies O
and O
engaging O
discussions O
of O
many O
yet O
to O
be O
published O
results O

Main O
body O
: O
Here O
we O
review O
evidence O
suggesting O
that O
epigenetic O
therapeutics O
can O
deactivate O
immunosuppressive O
gene O
expression O
or O
reprogram O
tumor B-Disease
cells O
to O
activate O
antigen O
presentation O
mechanisms O

Apart O
from O
this O
, O
the O
involvement O
of O
novel O
cellular O
and O
molecular O
mechanisms O
including O
the O
role O
of O
endothelin-receptor O
antagonists O
, O
Wnt O
signaling O
pathway O
, O
epigenetics O
and O
micro O
RNA O
is O
also O
discussed O
so O
that O
key O
molecular O
switches O
involved O
in O
the O
pathogenesis O
of O
diabetic B-Disease

All O
of O
these O
studies O
specifically O
surveyed O
human O
DNA O
methylation O
and O
involved O
a O
genome-wide O
component O

234 O
: O
Epigenetics O
, O
defined O
as O
inheritable O
and O
reversible O
phenomena O
that O
affect O
gene O
expression O
without O
altering O
the O
underlying O
base O
pair O
sequence O
has O
been O
shown O
to O
play O
an O
important O
role O
in O
the O
etiopathogenesis O
of O
obesity B-Disease

516 O
: O
Amr O
H O
Sawalha O
is O
Professor O
of O
Internal O
Medicine O
and O
Marvin O
and O
Betty O
Danto O
Research O
Professor O
of O
Connective O
Tissue O
Research O
at O
the O
University O
of O
Michigan O
, O
Department O
of O
Internal O
Medicine O
, O
Division O
of O
Rheumatology O

ngsplusplus O

These O
approaches O
include O
the O
use O
of O
novel O
small O
molecule O
inhibitors O
of O
epigenetic O
processes O
specifically O
deregulated O
in O
cancer B-Disease
cells O
and O
the O
design O
of O
engineered O
proteins O
able O
to O
stably O
reprogram O
the O
epigenetic O
code O
in O
cancer B-Disease
cells O
in O
a O
way O
that O
is O
similar O
to O
normal O
cells O

Importantly O
, O
as O
the O
clinical O
pattern O
of O
PCa O
ranges O
from O
an O
indolent O
tumor B-Disease
to O
an O
aggressive O
disease B-Disease
, O
discovering O
specific O
targetable O
epigenetic O
molecules O
able O
to O
overcome O
and O
predict O
PCa O
radioresistance O
is O
urgently O
needed O

In O
this O
article O
, O
we O
discuss O
the O
link O
between O
the O
environment O
, O
DNA O
methylation O
and O
allergic B-Disease
disease I-Disease
, O
as O
well O
as O
questions O
of O
causality O
inherent O
to O
analyses O
of O
DNA O
methylation O

690 O
: O
There O
is O
robust O
evidence O
of O
genetic O
susceptibility O
to O
Attention-Deficit O
Hyperactivity O
Disorder O
( O
ADHD O
) O
; O
however O
, O
there O
still O
remains O
significant O
variability O
that O
is O
not O
attributable O
to O
genetic O
factors O

Investigative O
use O
of O
CCSs O
in O
biological O
and O
medical O
research O
shows O
promise O
in O
identifying O
the O
likelihood O
that O
a O
disease B-Disease
state O
is O
present O
or O
absent O
, O
as O
well O
as O
an O
ability O
to O
prospectively O
stratify O
individuals O
according O
to O
their O
likely O
response O
to O
medical O
intervention O

502 O
: O
Motivation O
: O
With O
the O
development O
of O
biotechnology O
, O
DNA O
methylation O
data O
showed O
exponential O
growth O

277 O
: O
Genome-wide O
analysis O
of O
transcription O
factors O
and O
epigenomic O
features O
is O
instrumental O
to O
shed O
light O
on O
DNA-templated O
regulatory O
processes O
such O
as O
transcription O
, O
cellular O
differentiation O
or O
to O
monitor O
cellular O
responses O
to O
environmental O
cues O

We O
believe O
that O
knowledge O
accumulated O
in O
this O
review O
together O
with O
further O
studies O
will O
provide O
a O
solid O
basis O
for O
new O
approaches O
to O
epigenetic O
therapy O
and O
chemoprevention O
of O
environmentally O
induced O
epigenetic O
toxicity O
involving O
5hmC O
patterns O

g O

Findings O
revealed O
significant O
epigenetic O
effects O
in O
an O
assortment O
of O
genes O
that O
are O
implicated O
in O
the O
etiology O
of O
depression B-Disease
, O
suicidality O
, O
callous-unemotional O
traits O
, O
and O
chronic O
and O
intergenerational O
aggressive O
behavior O

Comparative O
integrative O
biologists O
also O
recognize O
epigenetics O
as O
a O
potentially O
confounding O
source O
of O
variation O
in O
their O
data O

We O
discuss O
the O
influences O
of O
the O
operon O
model O
and O
its O
broader O
theoretical O
framework O
on O
the O
first O
generation O
of O
synthetic O
biological O
circuits O
, O
which O
were O
predominantly O
transcriptional O
and O
posttranscriptional O
circuits O

However O
, O
the O
complexity O
of O
the O
neuroepigenetic O
landscape O
makes O
it O
difficult O
to O
determine O
which O
drug-induced O
epigenetic O
changes O
causally O
contribute O
to O
the O
pathogenic O
mechanisms O
of O
drug O
addiction O

e O

712 O
: O
Motivation O
: O
The O
development O
of O
computational O
tools O
to O
enable O
testing O
and O
analysis O
of O
high-throughput-sequencing O
data O
is O
essential O
to O
modern O
genomics O
research O

e O

In O
this O
review O
, O
we O
aim O
to O
present O
the O
recent O
developments O
and O
applications O
of O
the O
CRISPR-Cas O
systems O

Future O
epigenomic O
studies O
will O
no O
doubt O
continue O
to O
widen O
our O
understanding O
of O
extraarticular O
tissues O
and O
OA O
pathogenesis O
, O
and O
studies O
in O
animal O
models O
may O
offer O
glimpses O
into O
epigenome O
alterations O
in O
the O
earliest O
stages O
of O
OA O

Epigenetic O
mechanisms O
, O
including O
DNA O
methylation O
, O
chromatin O
remodeling O
, O
and O
non-coding O
RNA O
, O
are O
the O
link O
between O
environmental O
stimuli O
and O
disease B-Disease
onset O
on O
a O
permissive O
genetic O
background O
in O
autoimmune O
and O
chronic O
inflammatory O
diseases O

Interactions O
between O
genetics O
and O
epigenetics O
are O
multifaceted O
and O
epigenetic O
variation O
stands O
at O
the O
crossroad O
between O
genetic O
and O
environmental O
variance O
, O
which O
make O
these O
mechanisms O
prominent O
in O
the O
processes O
of O
adaptive O
evolution O

These O
observed O
associations O
may O
be O
modified O
by O
alcohol O
consumption O

539 O
: O
Epigenetics O
is O
one O
of O
the O
most O
rapidly O
expanding O
fields O
in O
biology O
, O
which O
plays O
important O
roles O
in O
environmental O
pollutant-induced O
neurotoxicity O

Deep O
learning O
has O
brought O
success O
in O
many O
domains O
in O
recent O
years O


510 O
: O
Our O
social O
environment O
, O
from O
the O
microscopic O
to O
the O
macro-social O
, O
affects O
us O
for O
the O
entirety O
of O
our O
lives O

207 O
: O
The O
genome O
is O
almost O
identical O
in O
all O
the O
cells O
of O
the O
body O

Conclusions O
: O
We O
have O
developed O
a O
muscle-specific O
epigenetic O
clock O
that O
predicts O
age O
with O
better O
accuracy O
than O
the O
pan-tissue O
clock O

Although O
DNA O
methylation O
is O
involved O
in O
normal O
development O
, O
aging O
and O
gene O
regulation O
, O
altered O
methylation O
patterns O
have O
been O
associated O
with O
disease B-Disease

It O
has O
been O
suggested O
that O
epigenetics O
may O
underlie O
the O
observation O
that O
some O
individuals O
appear O
to O
age O
faster O
than O
others O

A O
deep O
understanding O
of O
these O
mechanisms O
will O
help O
in O
properly O
coordinating O
future O
individual O
treatments O
of O
osteoporosis B-Disease
and O
OVF O

183 O
: O
Polygenic O
approaches O
often O
access O
more O
variance O
of O
complex O
traits O
than O
is O
possible O
by O
single O
variant O
approaches O


Here O
, O
we O
review O
the O
recent O
links O
that O
indicate O
DNA O
methylation O
( O
both O
5mC O
and O
5hmC O
) O
is O
highly O
dynamic O
and O
that O
perturbations O
in O
this O
modification O
may O
contribute O
to O
behaviors O
related O
to O
psychiatric B-Disease
disorders I-Disease
and O
hold O
clinical O
relevance O

18 O
], O
P O
= O
0 O

The O
genome-wide O
analyses O
of O
synonymous O
and O
nonsynonymous O
substitutions O
at O
protein-coding O
regions O
show O
prevalence O
of O
very O
weak O
selection O

651 O
: O
Alzheimer's B-Disease
disease I-Disease
( O
AD O
) O
is O
one O
of O
the O
most O
important O
economic O
, O
medical O
and O
social O
problems O
in O
modern O
society O

Recent O
advances O
in O
sequencing O
technologies O
and O
the O
development O
of O
techniques O
that O
profile O
epigenetic O
marks O
and O
chromatin O
accessibility O
using O
reagents O
that O
can O
be O
used O
in O
any O
species O
has O
catapulted O
epigenomic O
studies O
in O
diverse O
animal O
species O
, O
shedding O
light O
on O
the O
multitude O
of O
epigenomic O
mechanisms O
util O

The O
prevalence O
of O
combined O
genetic O
and O
epigenetic O
susceptibility O
toward O
UC O
and O
CD O
is O
calculated O
herein O
to O
be O
as O
high O
as O
2% O
, O
and O
approximately O
1% O
for O
UC O
and O
CD O
in O
highly O
developed O
countries O
, O
respectively O

Here O
, O
we O
review O
emerging O
evidence O
that O
epigenetics O
contributes O
to O
the O
machinery O
that O
can O
alter O
DNA O
structure O
, O
gene O
expression O
, O
and O
cellular O
differentiation O
during O
physiological O
and O
pathological O
bone O
remodeling O

Epigenetic O
changes O
(DNA O
methylation O
, O
histone O
modifications O
and O
non-coding O
RNAs O
) O
are O
present O
ubiquitously O
in O
virtually O
all O
types O
of O
human O
malignancies B-Disease
and O
may O
appear O
in O
early O
cancer B-Disease
development O
, O
and O
thus O
they O
provide O
particularly O
attractive O
markers O
with O
broad O
applications O
in O
diagnostics O

Polyamines O
are O
essential O
for O
many O
cellular O
functions O
and O
polyamine O
activity O
is O
increased O
in O
many O
autoimmune O
diseases O

In O
doing O
that O
, O
we O
developed O
a O
highly O
accurate O
epigenetic O
clock O
, O
which O
predicts O
the O
age O
of O
multiple O
tissues O
with O
higher O
accuracy O

Recently O
, O
RNA O
modifications O
(epitranscriptomics) O
have O
been O
shown O
to O
hold O
enormous O
potential O
in O
shaping O
cellular O
transcriptomes O

The O
opinions O
expressed O
here O
are O
those O
of O
Dr O

189: O
Epidemiologists O
aim O
to O
identify O
modifiable O
causes O
of O
disease B-Disease
, O
this O
often O
being O
a O
prerequisite O
for O
the O
application O
of O
epidemiological O
findings O
in O
public O
health O
programmes O
, O
health O
service O
planning O
and O
clinical O
medicine O


Then O
, O
we O
show O
that O
the O
evo-devo O
research O
field O
is O
where O
some O
particular O
uses O
of O
epigenetics O
have O
started O
shifting O
from O
developmental O
issues O
to O
evolutionary O
problems O

We O
developed O
MeDeCom O
as O
a O
novel O
reference-free O
computational O
framework O
that O
allows O
the O
decomposition O
of O
complex O
DNA O
methylomes O
into O
latent O
methylation O
components O
and O
their O
proportions O
in O
each O
sample O


Elucidating O
new O
molecular O
pathways O
will O
help O
in O
the O
development O
of O
novel O
therapeutics O
for O
the O
prevention O
and O
treatment O
of O
diabetic B-Disease
nephropathy O

But O
as O
the O
genetic O
and O
epigenetic O
mechanisms O
of O
aging O
came O
to O
be O
elucidated O
in O
many O
species O
, O
the O
signature O
of O
an O
adaptation O
became O
clear O

, O
BDNF O
) O
, O
extracellular O
matrix O
proteins O
( O
e O

While O
the O
pioneers O
of O
epigenetic O
research O
were O
met O
with O
disbelief O
when O
they O
described O
phenomena O
that O
did O
not O
follow O
the O
normal O
Mendelian O
laws O
of O
inheritance O
, O
the O
popular O
media O
today O
praises O
the O
modulation O
of O
epigenetics O
through O
behavioral O
changes O
as O
a O
cure O
for O
diseases O

A O
wide O
range O
of O
tools O
have O
been O
integrated O
in O
dbEM O
e O

Array O
-based O
methods O
, O
such O
as O
the O
popular O
Illumina O
GoldenGate O
and O
Infinium O
platforms O
, O
estimate O
the O
proportion O
of O
DNA O
methylated O
at O
single-base O
resolution O
for O
thousands O
of O
CpG O
sites O
across O
the O
genome O

This O
project O
is O
an O
interdisciplinary O
, O
cross-organizational O
effort O
to O
provide O
a O
guided O
learning O
module O
for O
integrating O
transcriptomics O
and O
epigenetics O
data O
analysis O
protocols O
into O
a O
comprehensive O
analysis O
pipeline O
for O
users O
to O
implement O
in O
their O
own O
work O
, O
utilizing O
the O
cloud O
computing O
infrastructure O
on O
Google O
Cloud O

ViCAR O
is O
a O
practical O
and O
powerful O
tool O
to O
explore O
epigenetic O
marks O
and O
3D O
genome O
interactomes O

We O
applied O
uCoTarget O
to O
the O
in O
vitro O
generation O
of O
hematopoietic B-Disease
stem/progenitor I-Disease
cells I-Disease
( O
HSPCs O
) O
from O
human O
embryonic O
stem O
cells O
, O
presenting O
multimodal O
epigenomic O
profiles O
in O
26,418 O
single O
cells O

This O
paper O
reviews O
recent O
researches O
that O
highlight O
the O
links O
between O
CTCF O
, O
epigenetics O
and O
diseases O

Based O
on O
epigenomic O
information O
, O
biomarkers O
have O
been O
identified O
that O
may O
serve O
as O
diagnostic O
tools O
; O
some O
such O
biomarkers O
also O
may O
be O
useful O
in O
identifying O
individuals O
who O
will O
respond O
to O
therapy O
and O
survive O
longer O

In O
this O
review O
, O
we O
focus O
on O
metabolic O
remodeling O
of O
epigenetics O
in O
cancer B-Disease
and O
examine O
potential O
mechanisms O
by O
which O
cancer B-Disease
cells O
integrate O
nutritional O
inputs O
into O
epigenetic O
modification O

509 O
: O
Background O
: O
Characterization O
of O
robustness O
and O
plasticity O
of O
phenotypes O
is O
a O
basic O
issue O
in O
evolutionary O
and O
developmental O
biology O

295 O
: O
Individuals O
with O
a O
history O
of O
child O
abuse O
are O
at O
high O
risk O
for O
depression B-Disease
, O
anxiety O
disorders O
, O
aggressive O
behavior O
, O
and O
substance O
use O
problems O

Altering O
the O
structure O
of O
the O
chromatin O
, O
DNA O
methylation O
has O
the O
potential O
to O
down-regulate O
gene O
expression O

Availability O
and O
implementation O
: O
EpiSAFARI O
is O
publicly O
available O
at O
https O
: O
/ O
/ O
github O

Our O
EWAS O
identified O
570 O
CpG O
sites O
where O
methylation O
variability O
was O
significantly O
associated O
with O
age O
( O
P O
< O
1 O

One O
estimated O
drug-associated O
methylation O
effects O
on O
triglyceride O
levels O
as O
the O
response O
, O
and O
identified O
11 O
significant O
cytosine-phosphate-guanine O
( O
CpG O
) O
sites O
with O
or O
without O
adjusting O
for O
high-density O
lipoprotein O

Many O
voices O
are O
already O
proclaiming O
the O
post-genomics O
era O
, O
in O
which O
phenomena O
other O
than O
sequence O
polymorphism O
influence O
gene O
expression O
and O
also O
explain O
complex O
phenotypes O

com O
/ O
pinellolab O
/ O
haystack_bio O

The O
direction O
of O
DNAm O
change O
with O
gestational O
age O
at O
these O
prematurity-DM O
sites O
followed O
known O
patterns O
of O
hematopoietic O
differentiation O
, O
suggesting O
that O
term O
hematopoietic O
cell O
populations O
are O
more O
epigenetically O
mature O
than O
their O
preterm O
counterparts O

A O
data O
science O
approach O
is O
used O
to O
synthesize O
current O
knowledge O
on O
the O
pharmacological O
implications O
of O
epigenetic O
regulation O
of O
gene O
expression O

Measures O
of O
DNAmAgeAC O
acceleration O
( O
DNAmAgeAC O
) O
were O
derived O
from O
the O
residuals O
after O
regressing O
each O
DNAmAgeAC O
metric O
on O
chronological O
age O

Importantly O
, O
SV40 O
exists O
as O
chromatin O
in O
both O
the O
virus B-Disease
particle O
and O
intracellular O
minichromosomes O

203 O
: O
Epigenomics O
refers O
to O
the O
study O
of O
genome-wide O
changes O
in O
epigenetic O
mechanisms O
including O
DNA O
methylation O
, O
histone O
modifications O
and O
non-coding O
RNAs O
expression O

We O
also O
highlight O
current O
challenges O
and O
future O
potential O
for O
epigenetics-based O
therapies O

This O
work O
involves O
the O
use O
of O
an O
epidemiologic O
approach O
to O
characterize O
epigenetic O
and O
genetic O
alteration O
of O
genes O
in O
the O
causal O
pathway O
for O
malignancy O

com O
/ O
sjthursby O
/ O
CandiMeth O

In O
particular O
, O
environmental B-Disease
epigenomics I-Disease
, O
which O
addresses O
the O
effect O
of O
the O
environment O
on O
the O
epigenome O
and O
human O
health O
, O
is O
becoming O
an O
area O
of O
great O
interest O
for O
many O
researchers O
working O
in O
different O
scientific O
fields O

Unlike O
the O
DNA O
sequence O
, O
epigenetic O
patterns O
vary O
not O
only O
between O
individuals O
, O
but O
also O
between O
different O
cell O
types O
within O
an O
individual O

The O
epigenetic O
studies O
in O
dental O
field O
have O
been O
mainly O
conducted O
in O
periodontology O
and O
have O
focused O
on O
DNA O
methylation O
analysis O

In O
this O
chapter O
we O
describe O
the O
backbone O
procedures O
behind O
targeted O
methylation O
analyses O
: O
bisulfite O
conversion O
and O
downstream O
PCR-based O
techniques O
, O
including O
real-time O
quantitative O
methylation-specific O
PCR O
( O
qMSP O
) O
and O
high-resolution O
melting O
( O
HRM O
) O
methylation-sensitive O
analyses O

490 O
: O
Identifying O
and O
annotating O
distal O
regulatory O
enhancers O
is O
critical O
to O
understand O
the O
mechanisms O
that O
control O
gene O
expression O
and O
cell-type-specific O
activities O

's O

Despite O
the O
striking O
lack O
of O
overlap O
in O
CpGs O
, O
multi-omics O
analysis O
suggested O
five O
clocks O
( O
Horvath1 O
, O
Horvath2 O
, O
Levine O
, O
Hannum O
, O
and O
Lin O
) O
share O
transcriptional O
associations O
conserved O
across O
purified O
CD14+ O
monocytes O
and O
dorsolateral O
prefrontal O
cortex O

These O
social O
differences O
become O
embodied O
as O
physiological O
and O
health O
differences O

The O
current O
special O
section O
includes O
contributions O
from O
behavioral O
genetic O
, O
molecular O
genetic O
, O
and O
epigenetic O
perspectives O
, O
reflecting O
the O
diversity O
of O
methodologies O
that O
are O
currently O
being O
applied O
to O
the O
study O
of O
genetic O
contributions O
to O
family O
processes O
and O
outcomes O

In O
combination O
, O
their O
results O
broaden O
our O
understanding O
of O
asthma O
pathogenesis O
and O
the O
role O
the O
methylome O
plays O
in O
this O
process O

Methods O
: O
In O
a O
subsets O
( O
ASSET O
) O
meta-analytic O
approach O
, O
we O
investigated O
associations O
of O
genetic O
variants O
related O
to O
epigenetic O
mechanisms O
with O
risks O
of O
breast O
, O
lung O
, O
colorectal O
, O
ovarian B-Disease
and O
prostate O
carcinomas O
using O
51,724 O
cases O
and O
52, O

Additionally O
, O
this O
paper O
outlines O
the O
future O
trends O
of O
these O
technologies O
and O
their O
current O
technical O
limitations O

Specifically O
, O
aging O
is O
associated O
with O
profound O
epigenetic O
changes O
, O
resulting O
in O
alterations O
of O
gene O
expression O
and O
disturbances O
in O
broad O
genome O
architecture O
and O
the O
epigenomic O
landscape O

620 O
: O
It O
is O
important O
for O
large-scale O
epigenomic O
studies O
to O
determine O
and O
explore O
the O
nature O
of O
hidden O
confounding O
variation O
, O
most O
importantly O
cell O
composition O


This O
has O
resulted O
in O
an O
exponential O
increase O
of O
450k O
data O
in O
recent O
years O
and O
triggered O
the O
development O
of O
numerous O
integrated O
analysis O
pipelines O
and O
stand-alone O
packages O

Nanomedicine O
, O
the O
application O
of O
nanotechnology O
in O
medicine O
, O
has O
a O
potential O
to O
advance O
the O
identification O
of O
diagnostic O
and O
prognostic O
biomarkers O
and O
the O
delivery O
of O
right O
drug O
to O
disease B-Disease
sites O

Insects O
offer O
a O
number O
of O
advantages O
over O
mammalian O
models O
including O
ethical O
acceptability O
, O
short O
generation O
times O
and O
the O
potential O
to O
investigate O
complex O
interacting O
parameters O
such O
as O
fecundity O
, O
longevity O
, O
gender O
ratio O
, O
and O
resistance O
to O
pathogens O
, O
parasites O
and O
environmental O
stress O

Recently O
, O
it O
has O
become O
apparent O
that O
epigenetic O
mechanisms O
play O
an O
important O
role O
in O
gene O
regulation O

The O
strongest O
predictor O
is O
the O
region O
coincident O
with O
PbRR9 O
, O
showing O
that O
this O
gene O
stands O
out O
against O
all O
genes O
in O
the O
genome O
in O
having O
the O
strongest O
sex-specific O
methylation O
pattern O

It O
also O
contains O
information O
of O
54 O
drug O
molecules O
against O
different O
epigenetic O
proteins O

To O
mitigate O
batch O
and O
array O
differences O
, O
we O
also O
provide O
a O
modified O
RCP O
method O
( O
ref-RCP O
) O
that O
normalize O
input O
DNA O
methylation O
data O
to O
reference O
data O
prior O
to O
estimation O

641 O
: O
Unlike O
genomes O
, O
which O
are O
static O
throughout O
the O
lifespan O
of O
an O
organism O
, O
DNA O
methylomes O
are O
dynamic O

Finally O
, O
we O
discuss O
clinical O
implications O
, O
unanswered O
questions O
, O
and O
future O
directions O
for O
human O
development O
in O
epigenetics O
research O

Heterogeneity O
in O
gene O
expression O
responses O
among O
cells O
and O
individuals O
involves O
epigenetic O
mechanisms O

8 O
: O
Why O
do O
we O
grow O
up O
to O
have O
the O
traits O
we O
do O
? O
Most O
20th O
century O
scientists O
answered O
this O
question O
by O
referring O
only O
to O
our O
genes O
and O
our O
environments O

399 O
: O
( O
1 O
) O
Background O
: O
Obesity O
and O
mood B-Disease
disorders I-Disease
are O
considered O
as O
the O
most O
prevalent O
morbidities O
in O
many O
countries O

400 O
: O
We O
examined O
the O
usefulness O
of O
commercially O
available O
DNA O
methylation O
arrays O
designed O
for O
the O
human O
genome O
( O
Illumina O
HumanMethylation450 O
and O
MethylationEPIC O
) O
for O
high-throughput O
epigenome O
analysis O
of O
the O
common O
marmoset O
, O
a O
nonhuman O
primate O
suitable O
for O
research O
on O
neuropsychiatric O

Conclusion O
: O
Here O
, O
we O
review O
the O
recent O
trends O
in O
CRISPR-based O
biotechnologies O
, O
encompassing O
genome O
editing O
, O
epigenome O
regulation O
and O
direct O
RNA O
targeting O
and O
provide O
an O
overview O
of O
methods O
employed O
for O
CRISPR O
delivery O
with O
an O
emphasis O
on O
the O
most O
recent O
nanotechnology-based O
delivery O
strategies O

Nevertheless O
, O
there O
are O
still O
no O
biomarkers O
in O
routine O
clinical O
use O
in O
RCC O

735 O
: O
The O
benefits O
of O
diploidy O
are O
considered O
to O
involve O
masking O
partially O
recessive O
mutations O
and O
increasing O
genetic O
diversity O

657 O
, O
and O
an O
area O
under O
the O
ROC O
curve O
of O
0 O

DPF1 O
rs12611084 O
was O
inversely O
associated O
with O
ER-negative O
breast O
, O
endometrioid B-Disease
ovarian I-Disease
, O
and O
overall O
and O
aggressive O
prostate B-Disease
cancer I-Disease
risk O
( O
OR O
= O
0 O

However O
, O
the O
demand O
for O
its O
accurate O
quantification O
might O
vary O
across O
studies O

Relapse O
after O
treatment O
has O
been O
previously O
explained O
using O
the O
cancer B-Disease
stem O
cell O
model O
and O
the O
clonal O
evolution O
model O

com O
/ O
guanjue O
/ O
Snapshot O

Surveying O
epigenomic-environment O
of O
cancer B-Disease
stem-like O
cells O
( O
CSC O
) O
is O
vital O
for O
developing O
novel O
diagnostic O
methods O
and O
improving O
current O
therapies O
since O
CSCs O
are O
among O
the O
most O
challenging O
clinical O
hurdles O

We O
further O
investigated O
psychological O
and O
social O
risk O
( O
psychological B-Disease
distress I-Disease
, O
posttraumatic O
stress O
disorder/PTSD O
symptom O
severity O
, O
professional O
quality O
of O
life O
) O
and O
protective O
factors O
( O
social O
support O
and O
organisational O
membership O
) O
that O
drive O
epigenetic O
aging O
at O
both O
time O
points O

A O
recent O
study O
by O
Takahashi O
et O
al O

238 O
: O
Epigenetics O
studies O
heritable O
genomic O
modifications O
that O
occur O
with O
the O
participation O
of O
epigenetic O
modifying O
enzymes O
but O
without O
alterations O
of O
the O
nucleotide O
structure O

289 O
: O
Human O
health O
tends O
to O
mirror O
gradients O
in O
social O
standing O
related O
to O
class O
, O
ethnicity O
and O
race O

112 O
: O
The O
field O
described O
as O
' O
epigenetics O
' O
has O
captured O
the O
imagination O
of O
scientists O
and O
the O
lay O
public O

Yet O
many O
epigenetic O
traits O
are O
instead O
linked O
to O
self-perpetuating O
changes O
in O
the O
individual O
or O
collective O
activity O
of O
proteins O

This O
leads O
to O
high O
demands O
on O
bioinformaticians O
, O
who O
may O
lack O
insight O
into O
the O
specific O
biological O
problem O

In O
this O
review O
we O
provide O
an O
overview O
of O
the O
epigenetic O
landscape O
and O
discuss O
the O
potential O
for O
redox O
regulation O

Epigenetics O
is O
able O
to O
provide O
answers O
to O
previously O
unanswered O
health-related O
questions O
and O
can O
explain O
differences O
in O
level O
of O
complexity O
between O
organisms O

While O
his O
late O
allusion O
clearly O
reveals O
that O
Waddington O
readily O
associated O
the O
notion O
of O
epigenetics O
with O
the O
developmental O
process O
, O
in O
the O
contemporary O
uses O
of O
the O
notion O
this O
developmental O
connotation O
seems O
to O
have O
disappeared O

Psychiatry O
has O
learned O
that O
diseases O
with O
strong O
genetic O
predisposition O
, O
such O
as O
schizophrenia B-Disease
, O
show O
a O
concordance O
of O
around O
50% O
between O
monozygotic O
twins O
, O
thus O
evidencing O
the O
importance O
of O
the O
genetic O
background O
and O
the O
presence O
of O
environmental O
variables O
that O
stimulate O
or O
block O
phen O

Recently O
, O
there O
has O
been O
marked O
progress O
in O
the O
field O
on O
a O
new O
generation O
of O
epigenomic O
therapies O
which O
address O
these O
challenges O
directly O
by O
targeting O
defined O
loci O
with O
highly O
precise O
, O
durable O
, O
and O
tunable O
approaches O

The O
cumulative O
DNA O
damage O
model O
of O
aging O
fails O
to O
explain O
the O
resetting O
of O
the O
aging O
clock O
at O
the O
time O
of O
conception O
as O
well O
as O
the O
continued O
vitality O
of O
species O
as O
millenia O
go O
by O

Nevertheless O
, O
DNA O
methylation O
in O
prokaryotes O
plays O
a O
pivotal O
role O
in O
many O
cellular O
processes O
such O
as O
defense O
systems O
against O
exogenous O
DNA O
, O
cell O
cycle O
dynamics O
, O
and O
gene O
expression O
, O
including O
virulence O

512 O
: O
Liquid O
chromatography-tandem O
mass O
spectrometry O
( O
LC-MS/MS O
) O
is O
a O
widely O
used O
technique O
in O
the O
global O
analysis O
of O
epigenetic O
DNA O
modifications O

Pharmaco-epigenomics O
is O
a O
research O
area O
, O
which O
refers O
to O
the O
study O
of O
epigenome O
changes O
in O
cancer B-Disease
development O
and O
how O
chemotherapeutic O
agents O
can O
reverse O
these O
aberrant O
epigenetic O
marks O
by O
targeting O
the O
epigenetic O
machinery O

We O
also O
discuss O
future O
needs O
in O
this O
area O
including O
exploration O
of O
epigenomic O
variation O
between O
individuals O
, O
single-cell B-Disease
epigenomics I-Disease
, O
environmental B-Disease
epigenomics I-Disease
, O
exploration O
of O
the O
use O
of O
surrogate O
tissues O
, O
and O
improved O
technologies O
for O
epigenome O
manipulation O

Summary O
: O
Structured O
investigation O
of O
epigenetic O
events O
, O
their O
causes O
and O
effects O
on O
immune O
phenotypes O
in O
autoimmune/inflammatory B-Disease
, O
will O
improve O
our O
understanding O
of O
disease B-Disease
, O
deliver O
new O
diagnostic O
tools O
and O
treatment O
options O

The O
gold O
standard O
for O
assaying O
genome-wide O
DNA O
methylation O
at O
single-base O
resolution O
is O
whole-genome O
bisulfite O
sequencing O
( O
WGBS O
) O

19 O
: O
Epigenetics O
, O
a O
term O
conventionally O
used O
to O
explain O
the O
intricate O
interplay O
between O
genes O
and O
the O
environment O
, O
is O
now O
regarded O
as O
the O
fundament O
of O
developmental O
biology O

Considerable O
work O
is O
being O
devoted O
to O
understanding O
the O
mechanisms O
of O
action O
of O
both O
asbestos O
and O
arsenic O
including O
their O
ability O
to O
affect O
promoter O
methylation O
and O
gene O
silencing O
in O
carcinogenesis O

The O
selected O
"more O
fit" O
clones O
outmatch O
their O
competition O
and O
then O
become O
dominant O
in O
the O
tumor B-Disease
via O
propagation O
of O
progeny O

Currently O
, O
fibromyalgia O
diagnosis O
is O
based O
exclusively O
on O
a O
comprehensive O
clinical O
assessment O
, O
according O
to O
2016 O
ACR O
criteria O
, O
but O
validated O
biological O
biomarkers O
associated O
with O
fibromyalgia O
have O
not O
yet O
been O
identified O

Baseline O
epigenetic O
age O
and O
follow-up O
epigenetic O
age O
were O
significantly O
associated O
with O
risk O
factors O
of O
psychological B-Disease
distress I-Disease
and O
PTSD O
symptom O
severity O

Here O
we O
will O
discuss O
the O
relationship O
between O
canonical O
and O
non-canonical O
epigenetic O
mechanisms O
that O
govern O
gene O
expression O
and O
offer O
our O
perspective O
on O
whether O
( O
or O
not O
) O
epitranscriptomic O
modifications O
can O
be O
classified O
as O
epigenetic O
mechanisms O

Thus O
, O
we O
highlight O
recent O
evidence O
that O
is O
beginning O
to O
elucidate O
the O
specific O
roles O
played O
by O
epigenetic O
mechanisms O
, O
including O
DNA O
methylation O
, O
histone O
code O
modifications O
and O
chromatin O
remodeling O
, O
noncoding O
RNAs O
and O
RNA O
editing O
, O
in O
human O
epilepsy B-Disease
syndromes I-Disease
and O
in O
the O
process O

These O
approaches O
offer O
the O
possibility O
to O
identify O
disease B-Disease
mechanisms O
, O
discover O
novel O
diagnostic O
biomarkers O
, O
and O
develop O
new O
therapeutic O
strategies O

However O
, O
the O
discovery O
of O
sequence-independent O
heritable O
DNA O
changes O
( O
epigenetics O
) O
have O
helped O
us O
to O
explain O
the O
link O
between O
genes O
and O
the O
environment O

Besides O
, O
the O
effects O
of O
genome-wide O
polymorphisms O
in O
populations O
leading O
to O
variations O
in O
drug O
response O
are O
also O
study O
subject O
of O
pharmaco-epigenomics O
and O
are O
being O
studied O
extensively O
in O
cancer B-Disease

Additionally O
, O
results O
demonstrate O
that O
different O
risk O
and O
protective O
factors O
influence O
epigenetic O
aging O
at O
different O
times O

119 O
: O
Epigenetic O
modifications O
are O
dynamic O
mechanisms O
involved O
in O
the O
regulation O
of O
gene O
expression O

This O
new O
approach O
, O
named O
iCloneViz O
( O
integrated O
CloneViz O
) O
employs O
visualization O
and O
quantitative O
methods O
, O
revealing O
an O
integrative O
genomic O
mutational O
dissection O
and O
traceability O
( O
DNA O
, O
RNA O
, O
epigenetics O
) O
thru O
the O
different O
layers O
of O
molecular O
structures O

In O
terms O
of O
novel O
features O
, O
15 O
of O
the O
epigenetic O
scores O
are O
newly O
considered O

The O
dbHiMo O
provides O
users O
with O
web-based O
personalized O
data O
browsing O
and O
analysis O
tools O
, O
supporting O
comparative O
and O
evolutionary O
genomics O

We O
have O
performed O
extensive O
user O
testing O
throughout O
the O
development O
of O
this O
resource O
, O
and O
new O
features O
and O
improvements O
are O
continuously O
being O
implemented O
based O
on O
the O
results O

Although O
estimates O
of O
genetic O
and O
nonshared O
environmental O
influences O
from O
the O
standard O
biometric O
model O
were O
found O
to O
deviate O
from O
" O
true O
" O
values O
, O
the O
bias O
was O
usually O
smaller O
than O
10 O
% O
points O
indicating O
that O
the O
interpretations O
of O
findings O
from O
previous O
twin O
studies O
are O
mostly O
correct O

Conclusions O
: O
EPISTRUCTURE O
can O
be O
used O
to O
infer O
ancestry O
information O
of O
individuals O
based O
on O
their O
methylation O
data O
in O
the O
absence O
of O
corresponding O
genetic O
data O

For O
example O
, O
each O
interquartile O
range O
increase O
in O
NDVI O
within O
1,000m O
was O
associated O
with O
a O
0 O

The O
principles O
together O
with O
pros O
and O
cons O
are O
discussed O

Chance O
events O
- O
such O
as O
a O
particular O
lifelong O
smoker O
living O
unharmed O
to O
100 O
years O
- O
are O
averaged O
out O
at O
the O
group O
level O

Epigenetic O
mechanisms O
, O
especially O
DNA O
methylation O
( O
DNAm O
) O
, O
are O
a O
possible O
process O
how O
these O
adverse O
environmental O
events O
could O
be O
biologically O
embedded O

654 O
: O
Neuropsychiatric O
disorders O
affect O
a O
large O
segment O
of O
the O
human O
population O
and O
result O
in O
large O
costs O
to O
society O

Despite O
identification O
of O
multiple O
gene O
loci O
associated O
with O
AF O
, O
thus O
far O
none O
has O
led O
to O
a O
therapy O
, O
indicating O
additional O
contributors O
to O
pathology O

We O
also O
highlight O
unique O
aspects O
of O
single-cell O
DNA O
methylome O
data O
analysis O
and O
discuss O
how O
techniques O
common O
to O
other O
single-cell O
omics O
data O
analyses O
can O
be O
adapted O
to O
analyze O
DNA O
methylomes O

Such O
divergent O
research O
foci O
can O
occasionally O
render O
the O
umbrella O
term O
" O
epigenetics O
" O
ambiguous O

The O
development O
of O
accurate O
computational O
approaches O
for O
analyzing O
complex O
epigenetic O
profiles O
is O
essential O
for O
disentangling O
the O
mechanisms O
underlying O
cellular O
development O
, O
and O
the O
intricate O
interaction O
networks O
determining O
and O
sensing O
chromatin B-Disease
modifications I-Disease
and O
DNA O
methylation O
to O
control O
gene O
expression O

Considerable O
epidemiological O
, O
experimental O
and O
clinical O
data O
have O
been O
amassed O
showing O
that O
the O
risk O
of O
developing O
disease B-Disease
in O
later O
life O
is O
dependent O
on O
early O
life O
conditions O
, O
mainly O
operating O
within O
the O
normative O
range O
of O
developmental O
exposures O

For O
example O
, O
gene O
imprinting O
, O
a O
mechanism O
of O
parental O
allele-specific O
gene O
expression O
, O
was O
firstly O
observed O
in O
maize O
; O
evidence O
of O
paramutation O
, O
an O
epigenetic O
phenomenon O
that O
one O
allele O
acts O
in O
a O
single O
locus O
to O
induce O
a O
heritable O
change O
in O
the O
other O
allele O

STAR O
and O
the O
Haplotype O
Caller O
were O
used O
for O
RNA-seq O
processing O

Recent O
discoveries O
of O
5-methylcytosine O
( O
5mC O
) O
oxidation O
derivatives O
including O
5-hydroxymethylcytosine O
( O
5hmC O
) O
, O
5-formylcytsine O
( O
5fC O
) O
and O
5-carboxycytosine O
( O
5caC O
) O
in O
mammalian O
genome O
further O
expand O
our O
understanding O
of O
the O
epigenetic O
regulation O

The O
5th O
session O
focused O
on O
epigenetic O
end O
points O
in O
biology O
, O
toxicity O
, O
and O
carcinogenicity O
, O
and O
how O
those O
end O
points O
are O
relevant O
to O
human O
exposures O

Therefore O
, O
we O
are O
now O
looking O
closer O
at O
epigenetics O
, O
an O
interface O
between O
genetics O
and O
environmental O
factors O

528 O
: O
Motivation O
: O
Epigenetic O
data O
are O
invaluable O
when O
determining O
the O
regulatory O
programs O
governing O
a O
cell O

In O
contrast O
to O
genetic O
changes O
, O
which O
are O
difficult O
to O
reverse O
, O
epigenetic O
aberrations O
can O
be O
pharmaceutically O
reversible O

In O
addition O
to O
genes O
and O
promoters O
, O
CandiMeth O
can O
analyse O
methylation O
differences O
at O
long O
and O
short O
interspersed O
nuclear O
elements O

Communicated O
by O
Ramaswamy O
H O

Most O
of O
existing O
machine O
learning-based O
methods O
suffer O
defects O
in O
prediction O
accuracy O
, O
interpretability O
or O
training O
speed O

Many O
of O
these O
genomic O
and O
epigenetic O
events O
function O
in O
tandem O
to O
drive O
tumor B-Disease
development O
and O
metastasis O

Integration O
with O
transcriptional O
datasets O
enabled O
us O
to O
determine O
that O
the O
ncRNA O
promoter O
methylation O
events O
were O
associated O
with O
transcriptional O
changes O

435 O
: O
Delivery O
of O
engineered O
zinc-finger O
proteins O
( O
ZFPs O
) O
for O
targeted O
epigenetic O
remodeling O
in O
rodent O
brain O
can O
be O
facilitated O
by O
the O
use O
of O
viral O
vector-mediated O
gene O
transfer O
coupled O
with O
stereotaxic O
surgery O
techniques O

Here O
, O
we O
attempt O
to O
provide O
a O
broad O
overview O
of O
chromatin O
regulation O
, O
as O
it O
relates O
to O
central O
nervous B-Disease
system I-Disease
( O
CNS O
) O
function O
, O
with O
specific O
emphasis O
on O
the O
modes O
of O
histone O
posttranslational O
modifications O
, O
chromatin O
remodeling O
, O
and O
histone O
variant O
exchange O

A O
thoroughly O
epigenetic O
model O
of O
development O
and O
evolution O
was O
Waddington's O
aim O
when O
he O
introduced O
the O
term O
'epigenetics' O
in O
the O
1940s O
, O
but O
it O
has O
taken O
the O
modern O
development O
of O
molecular O
epigenetics O
to O
realize O
this O
aim O

In O
addition O
to O
acquisition O
of O
resistance-conferring O
genetic O
mutations O
, O
accumulating O
evidence O
suggests O
an O
intimate O
involvement O
of O
the O
epigenetic O
machinery O
in O
this O
process O
as O
well O

This O
clock O
may O
prove O
valuable O
in O
assessing O
the O
impact O
of O
environmental O
factors O
, O
such O
as O
exercise O
and O
diet O
, O
on O
muscle-specific O
biological O
ageing O
processes O

We O
found O
that O
both O
the O
epi(genetic) O
status O
of O
the O
explant O
and O
the O
regeneration O
protocol O
employed O
play O
critical O
roles O
in O
shaping O
the O
molecular O
and O
phenotypic O
landscape O
of O
clonal O
plants O

Gene O
-specific O
methylation O
analysis O
by O
sequencing O
of O
bisulfite-treated O
genomic O
DNA O
has O
been O
instrumental O
in O
understanding O
how O
DNA O
methylation O
affects O
gene O
transcription O

701 O
: O
Most O
psychiatric B-Disease
disorders I-Disease
are O
associated O
with O
an O
elevated O
risk O
of O
suicide O

The O
perturbations O
are O
either O
genetic O
, O
i O

e O

Additionally O
, O
disturbed O
methylation O
patterns O
and O
cell-type O
specific O
histone O
methylation O
marks O
were O
identified O
as O
potential O
mediators O
of O
genetic O
risk O
in O
RA O


Our O
commentary O
rises O
six O
question O
relating O
to O
key O
issues O
that O
need O
to O
be O
addressed O
as O
we O
search O
for O
definitive O
evidence O
from O
human O
studies O
that O
such O
mechanisms O
actually O
do O
make O
an O
important O
causal O
contribution O
to O
abnormal O
trajectories O
of O
development O
to O
disorder B-Disease

1 O
in O
this O
issue O
of O
Cell O
, O
now O
allows O
researchers O
to O
study O
the O
epigenomic O
regulation O
of O
gene O
expression O
in O
a O
tissue-region O
specific O
manner O

670 O
: O
Tumor-derived O
DNA O
, O
found O
in O
body O
fluids O
( O
liquid O
biopsy O
) O
of O
cancer B-Disease
patients O
as O
part O
of O
cell-free O
DNA O
( O
cfDNA O
) O
, O
lends O
itself O
for O
noninvasive O
cancer B-Disease
detection O
and O
monitoring O

First O
, O
2 O
studies O
are O
summarized O
, O
one O
a O
candidate O
gene O
study O
and O
the O
other O
an O
epigenome-wide O
association O
study O
in O
which O
DNAm O
was O
reported O
to O
( O
partially O
) O
mediate O
the O
link O
between O
adversity O
and O
child O
development O

This O
further O
demonstrates O
the O
ability O
of O
our O
strategy O
to O
take O
full O
advantage O
of O
molecular-level O
information O
as O
well O
as O
protein-level O
information O
in O
molecular O
activity O
prediction O

Patients O
& O
methods O
: O
Data O
were O
based O
on O
a O
German O
population-based O
cohort O
of O
older O
adults O
( O
n O
= O
9631 O
) O

We O
apply O
our O
method O
to O
reduced O
representation O
bisulfite O
sequencing O
( O
RRBS O
) O
data O
from O
multiple O
regions O
of O
one O
lung B-Disease
cancer I-Disease
tumour B-Disease
and O
a O
matched O
normal O
sample O

It O
achieved O
high O
accuracies O
of O
pseudotime O
prediction O
compared O
with O
existing O
methods O

Here O
we O
review O
single O
molecule O
epigenomic O
methods O
under O
development O
to O
overcome O
these O
limitations O
, O
the O
technical O
challenges O
associated O
with O
single O
molecule O
methods O
and O
their O
potential O
application O
to O
single O
cells O

sg O

Here O
, O
we O
present O
this O
approach O
's O
implementation O
, O
centered O
around O
the O
JBR O
genome O
browser O
, O
a O
stand-alone O
tool O
that O
allows O
for O
accessible O
and O
streamlined O
annotation O
, O
analysis O
and O
visualization O

We O
demonstrated O
that O
nuclear O
localization O
signals O
( O
NLS O
) O
at O
both O
termini O
of O
fusion O
constructs O
is O
crucial O
for O
both O
proper O
nuclear O
import O
of O
such O
large O
constructs O
as O
well O
as O
for O
maximization O
of O
targeted O
DNA O
methylation O
activity O

Existing O
therapeutic O
strategies O
have O
had O
limited O
success O
; O
they O
have O
poor O
effects O
on O
core O
cognitive O
impairment O
and O
long-term O
disability O

Thus O
, O
the O
dysregulation O
of O
zinc O
homeostasis O
can O
lead O
to O
epigenetic O
alterations O

547 O
: O
Motivation O
: O
The O
interpretation O
of O
transcriptional O
dynamics O
in O
single-cell O
data O
, O
especially O
pseudotime O
estimation O
, O
could O
help O
understand O
the O
transition O
of O
gene O
expression O
profiles O

The O
canonical O
epigenetic O
mark O
is O
5-methylcytosine O
(5mC) O
, O
but O
oxidized O
versions O
of O
5mC O
, O
including O
5-hydroxymethylcytosine O
(5hmC) O
, O
are O
now O
known O
to O
be O
important O
players O
in O
epigenomic O
dynamics O

10-1 O

This O
epigenetic O
toolkit O
can O
be O
easily O
altered O
with O
a O
large O
variety O
of O
epigenetic O
effectors O
and O
is O
a O
useful O
tool O
for O
researchers O
to O
use O
in O
understanding O
gene-specific O
epigenetic O
changes O
and O
their O
relation O
to O
gene O
expression O

385 O
: O
Epigenetics O
is O
a O
major O
field O
of O
biomedical O
research O
, O
and O
epigenetic O
drug O
discovery O
shows O
great O
promise O
for O
new O
drugs O

All O
EpiExplorer O
analyses O
are O
performed O
dynamically O
within O
seconds O
, O
using O
an O
efficient O
and O
versatile O
text O
indexing O
scheme O
that O
we O
introduce O
to O
bioinformatics O

This O
presupposes O
, O
however O
, O
that O
gbM O
has O
a O
function O
that O
affects O
phenotype O
, O
which O
has O
been O
a O
topic O
of O
debate O
in O
the O
literature O

Epigenetics O
has O
a O
broad O
impact O
on O
development O
, O
by O
controlling O
pluripotent O
and O
differentiated O
states O

107 O
: O
Epigenetics O
is O
the O
term O
that O
has O
been O
classically O
used O
to O
describe O
inheritable O
nongenetic O
factors O
that O
regulate O
genes O

Here O
, O
we O
focus O
on O
recent O
advances O
in O
our O
understanding O
of O
the O
genetics O
and O
epigenetics O
of O
RCC O
, O
and O
the O
potential O
for O
such O
knowledge O
to O
provide O
novel O
markers O
and O
therapeutic O
targets O

573 O
: O
Background O
: O
The O
CRISPR-Cas O
systems O
have O
emerged O
as O
a O
robust O
genome O
editing O
tool O
useful O
in O
various O
fields O
of O
research O

Conclusion O
: O
Bonferroni O
and O
Benjamini-Hochberg O
FDR O
are O
inappropriate O
for O
the O
EWAS O
replication O
phase O
, O
and O
methods O
that O
account O
for O
the O
underlying O
correlation O
need O
to O
be O
used O

The O
use O
of O
MSP O
prompted O
the O
design O
of O
an O
ISFET O
weak O
inversion O
current O
mirror O
topology O
for O
differential O
sensing O
and O
reduction O
of O
drift O
and O
temperature O
sensitivities O

This O
review O
will O
critically O
evaluate O
inherited O
epigenetic O
effects O
from O
an O
evolutionary O
perspective O

Epigenetic O
alterations O
comprise O
DNA O
methylation O
, O
histone O
modification O
, O
and O
microRNAs O
dysregulated O
expression O
and O
they O
play O
a O
significant O
role O
in O
the O
differentiation O
and O
proliferation O
properties O
of O
TC O

This O
tool O
proves O
useful O
in O
predicting O
the O
role O
of O
H3K9ac O
and O
H3K27ac O
in O
associated O
gene O
expression O
after O
knocking O
down O
deacetylases O
FAM60A O
and O
SDS3 O
and O
N6-methyl-adenosine-associated O
gene O
expression O
after O
knocking O
out O
the O
reader O
proteins O

There O
are O
different O
types O
of O
epigenetic O
mechanisms O
: O
histone O
modification O
, O
non-coding O
RNAs O
and O
DNA O
methylation O

41 O
% O
and O
sensitivity O
of O
70 O
% O

Main O
body O
: O
Global O
epigenome O
research O
projects O
have O
emphasized O
the O
importance O
of O
epigenetic O
research O
for O
understanding O
human O
health O
and O
disease B-Disease
, O
and O
current O
international O
consortia O
show O
an O
improved O
interest O
in O
the O
importance O
of O
oral B-Disease
health I-Disease
with O
systemic O
health O

63 O
: O
Epigenetic O
events O
like O
DNA O
methylation O
and O
histone O
modification O
can O
alter O
heritable O
phenotypes O

In O
this O
article O
, O
we O
trace O
strategies O
of O
" O
refusal O
" O
( O
Simpson O
, O
2014 O
) O
in O
response O
to O
epigenetics O
in O
Indigenous O
contexts O

The O
role O
of O
epigenetics O
in O
these O
and O
other O
CVDs O
is O
currently O
under O
intense O
scrutiny O
, O
and O
we O
can O
expect O
important O
insights O
to O
emerge O
, O
including O
novel O
biomarkers O
and O
new O
approaches O
to O
enable O
precision O
medicine O

ca O
or O
arnaud O

This O
updated O
manuscript O
highlights O
these O
changes O
and O
improvements O

Furthermore O
, O
recent O
research O
has O
provided O
evidence O
for O
an O
altered O
epigenomic O
landscape O
in O
disease-relevant O
cell O
populations O

Some O
suggestions O
regarding O
the O
state-of-the-art O
methods O
and O
databases O
have O
been O
made O
, O
including O
examining O
patterns O
of O
epigenetic O
changes O
that O
are O
important O
in O
epigenotypes O
detection O

Investigations O
using O
genetic O
and O
pharmacologic O
gain- O
and O
loss-of-function O
approaches O
have O
interrogated O
the O
function O
of O
distinct O
epigenetic O
regulators O
, O
while O
the O
increased O
deployment O
of O
the O
suite O
of O
next-generation O
sequencing O
technologies O
have O
fundamentally O
altered O
our O
understanding O
of O
the O
genomic O
targets O
of O
these O
chromatin O
modifiers O

Gene O
overlapping O
with O
other O
mental B-Disease
disorders I-Disease
represents O
another O
problem O
in O
identifying O
potential O
susceptibility O
genes O
in O
bipolar O
disorder B-Disease

We O
introduce O
the O
term O
bio-ethnography O
to O
refer O
to O
research O
designs O
that O
integrate O
both O
of O
these O
methodologies O
into O
a O
single O
research O
project O

The O
heritability O
of O
these O
modifications O
provides O
a O
memory O
of O
cell O
identity O
and O
function O

The O
newly O
developed O
clock O
uses O
200 O
cytosine-phosphate-guanine O
dinucleotides O
to O
estimate O
chronological O
age O
in O
skeletal O
muscle O
, O
16 O
of O
which O
are O
in O
common O
with O
the O
353 O
cytosine-phosphate-guanine O
dinucleotides O
of O
the O
pan-tissue O
clock O

Finally O
, O
we O
review O
the O
CRISPR O
delivery O
systems O
highlighting O
recent O
attempts O
to O
integrate O
nanotechnology O
to O
develop O
novel O
CRISPR O
delivery O
modalities O

The O
focus O
of O
this O
review O
will O
be O
to O
discuss O
the O
chemical O
methodologies O
that O
have O
been O
developed O
to O
detect O
the O
cytosine O
derivatives O
in O
the O
genomic O
DNA O

Genome O
- O
wide O
profiling O
revealed O
differential O
methylation O
in O
3791 O
of O
> O
480,000 O
CpG's O
examined O
in O
transgenomic O
versus O
nontransgenomic O
clones O

This O
mini-review O
puts O
recent O
developments O
in O
age O
estimation O
via O
(epi)genetic O
methods O
in O
the O
context O
of O
the O
requirements O
and O
goals O
of O
forensic O
genetics O
and O
highlights O
paths O
to O
follow O
in O
the O
future O
of O
forensic O
genomics O

Analyses O
of O
subpathways O
did O
not O
reveal O
gene O
subsets O
that O
contributed O
disproportionately O
to O
susceptibility O

We O
identified O
BRG1 O
, O
BAF155 O
, O
and O
BAF60a O
expression O
as O
strongly O
correlating O
with O
iPSC O
reprogramming O
efficiency O

Advances O
in O
genomics O
, O
transcriptomics O
, O
and O
epigenomics O
are O
generating O
multidimensional O
structures O
of O
biomarkers O
of O
effect O
and O
susceptibility O
, O
increasingly O
important O
for O
the O
understanding O
of O
molecular O
mechanisms O
and O
the O
emergence O
of O
personalized O
medicine O

674 O
: O
Purpose O
of O
review O
: O
Epigenomics O
has O
emerged O
as O
a O
key O
player O
in O
our O
rapidly O
evolving O
understanding O
of O
osteoarthritis O

Recent O
studies O
have O
investigated O
the O
role O
of O
an O
oxidized O
form O
of O
DNA O
methylation O
- O
5-hydroxymethylcytosine O
( O
5hmC O
) O
- O
in O
the O
epigenome O
, O
but O
its O
contribution O
to O
age-related O
DNA O
methylation O
remains O
unclear O

737 O
: O
Availability O
and O
implementation O
: O
The O
code O
together O
with O
examples O
and O
tutorials O
are O
available O
from O
http://www O

Methods O
: O
To O
test O
this O
hypothesis O
, O
we O
constructed O
a O
budget O
impact O
analysis O
using O
a O
cost O
calculation O
model O
that O
examined O
the O
effects O
of O
substituting O
PrecisionCHD O
for O
conventional O
CHD O
diagnostic O
tests O
on O
the O
expenses O
of O
the O
initial O
evaluation O
and O
first O
year O
of O
care O
of O
stable O
CHD O

A O
recent O
case-control O
study O
in O
Koreans O
reported O
that O
nitrogen O
dioxide O
(NO2) O
may O
be O
a O
risk O
factor O
for O
LCNS O

As O
most O
mutations O
in O
paediatric O
malignancies B-Disease
influence O
chromatin-associated O
proteins O
or O
transcription O
and O
paediatric O
cancers B-Disease
are O
driven O
by O
developmental O
gene O
expression O
programs O
, O
targeting O
epigenetic O
mechanisms O
is O
predicted O
to O
be O
a O
very O
important O
therapeutic O
approach O
in O
paediatric O
cancer B-Disease


From O
among O
the O
probes O
on O
the O
methylation O
arrays O
, O
we O
selected O
those O
available O
for O
the O
common O
marmoset O

It O
is O
in O
this O
intersection O
where O
the O
science O
of O
epigenetics O
plays O
a O
crucial O
role O

( O
3 O
) O
Results O
: O
After O
deduplication O
, O
we O
identified O
198 O
potentially O
related O
citations O

The O
R O
package O
includes O
the O
utility O
for O
implementing O
pre-existing O
mammalian O
clocks O
from O
the O
Mammalian O
Methylation O
Consortium O

Epigenetic O
modifications O
provide O
a O
potential O
association O
with O
the O
environmental O
factors O
and O
altered O
gene O
expression O
that O
might O
cause O
disease B-Disease
phenotypes O

Our O
objective O
was O
to O
determine O
whether O
significant O
epigenetic O
changes O
occur O
in O
isolated O
, O
non-syndromic O
CoA O

However O
, O
much O
like O
the O
GWAS O
studies O
, O
EWAS O
are O
likely O
to O
require O
large O
international O
consortium-based O
approaches O
to O
reach O
the O
numbers O
of O
subjects O
, O
and O
statistical O
and O
scientific O
rigor O
, O
required O
for O
robust O
findings O

We O
propose O
a O
set O
of O
parameters O
to O
be O
collected O
in O
disaster O
settings O
to O
assess O
the O
long-term O
outcomes O
of O
famine O
: O
PALTEM O
( O
parameters O
to O
assess O
long-term O
effects O
of O
malnutrition O
) O

A O
precise O
therapeutic O
strategy O
is O
complicated O
by O
poor O
understanding O
of O
the O
pathological O
changes O
in O
epilepsy O
thus O
, O
30% O
of O
TLE O
patients O
are O
resistant O
to O
drug O
therapy O

This O
is O
likely O
to O
happen O
because O
of O
the O
current O
biopolitical O
context O
in O
which O
scientific O
findings O
are O
translated O

Here O
, O
we O
review O
the O
development O
of O
epigenome O
editing O
tools O
, O
summarize O
proof O
of O
concept O
applications O
focusing O
on O
brain O
disease-associated O
genes O
, O
and O
discuss O
the O
promising O
application O
and O
challenges O
of O
epigenome O
editing O
to O
tackle O
brain O
disorders O


Traditional O
methods O
used O
to O
identify O
functional O
DNA O
have O
relied O
on O
comparative O
genomics O
, O
conservation O
analysis O
and O
low O
throughput O
validation O
assays O

SigSeeker O
has O
been O
validated O
using O
established O
benchmarks O
for O
transcription O
factor O
binding O
and O
histone O
modification O
ChIP-Seq O
data O

Furthermore O
, O
we O
summarize O
other O
potential O
sources O
of O
epigenetic O
variability O
, O
such O
as O
epigenetic O
drift O
and O
the O
epigenetic O
clock O
, O
as O
well O
as O
the O
current O
ongoing O
direction O
of O
the O
field O

He O
is O
Chair O
of O
the O
Lupus O
Foundation O
of O
America O
research O
subcommittee O
and O
is O
a O
member O
of O
the O
Vasculitis O
Foundation O
Medical O
and O
Scientific O
Advisory O
Board O

Additionally O
, O
with O
the O
help O
of O
improved O
computational O
resources O
and O
data O
mining O
, O
researchers O
are O
able O
to O
integrate O
data O
from O
different O
multi-omics O
regimes O
to O
identify O
new O
prognostic O
, O
diagnostic O
, O
or O
predictive O
biomarkers O
, O
uncover O
novel O
therapeutic O
targets O
, O
and O
develop O
more O
personalized O
treatment O

However O
, O
the O
direction O
of O
causation O
for O
these O
associations O
is O
not O
always O
clear O
, O
and O
investigations O
to-date O
have O
often O
failed O
to O
replicate O
at O
the O
level O
of O
individual O
loci O

CG O
methylation O
is O
transmitted O
transgenerationally O
in O
plants O
, O
opening O
the O
possibility O
that O
gbM O
may O
be O
shaped O
by O
adaptation O

Several O
studies O
identified O
putative O
epigenetic O
cancer B-Disease
biomarkers O
, O
some O
of O
which O
have O
been O
commercialized O

548 O
: O
Advances O
in O
high-throughput O
technologies O
and O
the O
generation O
of O
multiomics O
, O
such O
as O
genomic O
, O
epigenomic O
, O
transcriptomic O
, O
and O
metabolomic O
data O
, O
are O
paving O
the O
way O
for O
the O
biological O
risk O
stratification O
and O
prediction O
of O
oral O
diseases O

The O
current O
objective O
is O
to O
review O
relevant O
studies O
of O
interest O
to O
behavioral O
scientists O
who O
study O
crime O
, O
and O
to O
translate O
admittedly O
challenging O
scientific O
information O
into O
text O
that O
is O
digestible O
to O
the O
average O
criminologist O

09 O
, O
0 O

Besides O
a O
detailed O
protocol O
of O
sample O
preparation O
for O
the O
ChIP O
assay O
from O
primary O
human O
monocyte-derived O
macrophages O
( O
MDM O
) O
[ O
an O
acceptable O
in O
vitro O
model O
for O
primary O
, O
human O
macrophage O
cells O
] O
, O
we O
show O
that O
differences O
between O
various O
types O
of O
cells O
exist O

99 O
) O

Here O
we O
report O
a O
robust O
, O
high-throughput O
targeted O
, O
quantitative O
mass O
spectrometry O
( O
MS O
) O
method O
to O
rapidly O
profile O
modifications O
of O
the O
core O
histones O
of O
chromatin O
that O
compose O
the O
epigenetic O
landscape O
, O
enabling O
comparisons O
among O
cells O
with O
differing O
genetic O
backgrounds O
, O
genomic O
perturbations O

In O
so O
doing O
, O
the O
paper O
considers O
the O
appearance O
and O
functions O
of O
epigenetics O
in O
evolutionary O
history-sketching O
a O
pathway O
by O
which O
epigenetic O
processes O
might O
have O
evolved O
via O
exaptation O
and O
then O
contributed O
to O
the O
later O
development O
and O
evolution O
of O
phenotypes O

While O
drug O
response O
can O
be O
modulated O
by O
the O
epigenome O
, O
the O
therapeutic O
intervention O
by O
drugs O
can O
also O
be O
considered O
as O
an O
environmental O
cue O
for O
epigenetic O
alterations O

606 O
: O
Dynamically O
regulated O
changes O
in O
chromatin O
states O
are O
vital O
for O
normal O
development O
and O
can O
produce O
disease B-Disease
when O
they O
go O
awry O

Annual O
citations O
increased O
to O
a O
plateau O
in O
2000 O
and O
show O
a O
downward O
trend O
since O
2008 O

Current O
clinical O
trials O
are O
testing O
this O
combination O
therapy O
as O
a O
potent O
new O
cancer B-Disease
management O
strategy O

625 O
: O
Histone O
posttranslational O
modifications O
( O
hPTMs O
) O
play O
a O
key O
role O
in O
regulating O
chromatin O
dynamics O
and O
fine-tuning O
DNA-based O
processes O

This O
implies O
that O
biological O
pathways O
and O
cellular O
processes O
are O
under O
the O
impact O
of O
epigenome O
status O

Therefore O
, O
the O
ability O
of O
the O
cell O
to O
interpret O
correct O
methylation O
marks O
and/or O
the O
correct O
interpretation O
of O
methylation O
plays O
a O
role O
in O
many O
diseases O

We O
identified O
SpCas9 O
, O
SaCas9 O
and O
CjCas9 O
as O
potential O
candidates O
for O
the O
fusion O
constructs O

nih O

Here O
, O
we O
review O
new O
studies O
showing O
evidence O
for O
diverse O
allele-specific O
expression O
and O
epigenetic O
states O
in O
mammalian O
brain O
cells O
, O
which O
suggest O
that O
diploidy O
expands O
the O
landscape O
of O
gene O
regulatory O
and O
expression O
programs O
in O
cells O

The O
third O
part O
will O
apply O
both O
models O
to O
two O
natural O
processes O
, O
namely O
, O
the O
setting O
of O
the O
aging O
clock O
in O
the O
mammalian O
zygote O
and O
the O
changes O
in O
the O
aging O
clock O
along O
successive O
generations O
in O
mammals O

Here O
, O
we O
review O
the O
predictive O
biomarkers O
of O
12 O
epi-drugs O
as O
well O
as O
the O
progress O
of O
combination O
therapy O
with O
chemotherapeutic O
drugs O
or O
immunotherapy O

Recent O
advances O
revealed O
that O
ZIPs O
modulate O
epigenetics O

Here O
we O
will O
review O
how O
dietary O
factors O
modulate O
the O
establishment O
and O
maintenance O
of O
epigenetic O
marks O
, O
thereby O
influencing O
gene O
expression O
and O
, O
hence O
, O
disease B-Disease
risk O
and O
health O

687 O
: O
Background O
: O
Marijuana O
is O
the O
third O
most O
commonly O
used O
drug O
in O
the O
USA O
and O
efforts O
to O
legalize O
it O
for O
medical O
and O
recreational O
use O
are O
growing O

We O
present O
a O
summary O
of O
the O
epidemiologic O
studies O
in O
NCI O
's O
grant O
portfolio O
( O
from O
January O
2005 O
through O
December O
2012 O
) O
and O
in O
the O
scientific O
literature O
published O
during O
the O
same O
period O
, O
irrespective O
of O
support O
from O
the O
NCI O

Thus O
, O
nutrition O
represents O
a O
promising O
tool O
to O
be O
used O
not O
only O
in O
cancer B-Disease
prevention O
, O
but O
hopefully O
also O
in O
cancer B-Disease
treatment O

We O
tested O
these O
genes O
for O
differential O
methylation O
using O
whole O
methylome O
sequencing O
of O
xylem O
tissue O
of O
multiple O
individuals O
grown O
under O
field O
conditions O
in O
two O
common O
gardens O

To O
address O
these O
problems O
, O
in O
this O
paper O
, O
we O
propose O
a O
Multiple O
Self-Attention O
model O
for O
predicting O
DEGs O
on O
Epigenetic O
data O
( O
Epi-MSA O
) O

Compared O
with O
existing O
methods O
, O
EpiMix O
showed O
higher O
sensitivity O
in O
detecting O
abnormal O
DNAme O
that O
was O
present O
in O
only O
small O
patient O
subsets O

While O
epigenetic O
marks O
can O
be O
inherited O
independently O
of O
genetic O
sequences O
in O
some O
species O
, O
there O
is O
little O
evidence O
that O
such O
" O
transgenerational O
inheritance O
" O
is O
a O
general O
phenomenon O

On O
the O
other O
hand O
, O
DNA O
methylation O
can O
influence O
the O
genetic O
mutation O
rate O
and O
directly O
affect O
the O
evolutionary O
potential O
of O
a O
population O

Long O
thought O
to O
be O
an O
inexorable O
road O
toward O
decline O
and O
diseases O
, O
aging O
is O
in O
fact O
remarkably O
plastic O

We O
suggest O
three O
domains O
in O
which O
new O
understandings O
of O
epigenetics O
could O
inform O
innovations O
in O
health O
promotion O
research O
: O
( O
1 O
) O
increase O
the O
motivational O
potency O
of O
health O
communications O
( O

626 O
: O
Is O
a O
theory O
of O
identity O
necessary O
for O
bioethics O
? O
In O
this O
paper O
I O
investigate O
that O
question O
starting O
from O
an O
empirical O
explication O
of O
identity O
based O
on O
post-genomics O
, O
in O
particular O
on O
epigenetics O

Piscine O
epigenetic O
clocks O
should O
be O
of O
great O
utility O
for O
fisheries O
management O
and O
conservation O
purposes O
, O
where O
age O
determination O
is O
of O
crucial O
importance O

Epigenetic O
changes O
are O
fundamental O
for O
the O
regulatory O
physiological O
processes O
that O
regulate O
gene O
activity O
; O
therefore O
, O
these O
changes O
are O
altered O
in O
response O
to O
environmental O
factors O
or O
disease B-Disease
states O
, O
but O
, O
in O
many O
circumstances O
, O
they O
are O
also O
believed O
to O
contribute O
to O
disease B-Disease
occurrence O

Cu O
stress O
resulted O
in O
the O
accumulation O
of O
intracellular O
ROS O
, O
while O
Zn O
stress O
elevated O
the O
sensitivity O
to O
ROS O

We O
examine O
the O
current O
state O
of O
DNA O
methylation O
studies O
in O
AS O
, O
IBD O
and O
psoriasis B-Disease
; O
the O
limitations O
of O
previous O
studies O
; O
and O
the O
best O
practices O
for O
DNA O
methylation O
studies O

We O
get O
strong O
indications O
that O
epigenetically O
induced O
changes O
in O
nucleosome-nucleosome O
interaction O
can O
cause O
chromatin O
to O
shift O
between O
different O
activity O
states O

Second O
, O
there O
is O
a O
discussion O
of O
( O
1 O
) O
the O
" O
tissue O
issue O
, O
" O
( O
2 O
) O
maximizing O
the O
interpretability O
of O
candidate O
gene O
and O
epigenome-wide O
approaches O
, O
and O
( O
3 O
) O
the O
need O
for O
examining O
DNAm O
as O
a O
potential O
biomarker O
for O
mental O
health O

Conclusion O
and O
perspectives O
: O
Epigenetic O
mechanisms O
are O
emerging O
as O
key O
players O
in O
regulating O
transcriptional O
networks O
associated O
with O
key O
processes O
and O
functions O
of O
the O
cyclical O
endometrium O

Here O
, O
we O
review O
our O
current O
knowledge O
of O
gbM O
in O
plants O

668 O
: O
Animals O
and O
plants O
have O
biological O
clocks O
that O
help O
to O
regulate O
circadian O
cycles O
, O
seasonal O
rhythms O
, O
growth O
, O
development O
and O
sexual O
maturity O

335 O
: O
Epigenetic O
mechanisms O
are O
highly O
dynamic O
events O
that O
modulate O
gene O
expression O

EpiSAFARI O
employs O
a O
novel O
smoothing O
method O
for O
decreasing O
noise O
in O
signal O
profiles O
and O
accounts O
for O
technical O
factors O
such O
as O
sparse O
signals O
, O
mappability O
and O
nucleotide O
content O

Applying O
MPTR O
to O
dermal O
fibroblasts O
from O
middle-aged O
donors O
, O
we O
found O
that O
cells O
temporarily O
lose O
and O
then O
reacquire O
their O
fibroblast O
identity O
, O
possibly O
as O
a O
result O
of O
epigenetic O
memory O
at O
enhancers O
and/or O
persistent O
expression O
of O
some O
fibroblast O
genes O

We O
describe O
how O
the O
chapters O
in O
this O
two-volume O
set O
present O
theory O
and O
research O
pertinent O
to O
the O
roles O
of O
evolutionary O
and O
ontogenetic O
processes O
in O
cognitive O
, O
emotional O
, O
and O
behavioral O
development O
across O
the O
life O
span O

Our O
tool O
is O
integrated O
into O
Galaxy O
( O
http://galaxyproject O

g O

DNA O
methylation O
array O
data O
are O
commonly O
used O
in O
the O
prediction O
of O
methylation O
age O

Consistent O
shifts O
in O
DNAm O
between O
preterm O
and O
term O
cells O
were O
observed O
at O
25 O
CpG O
sites O
, O
with O
many O
of O
these O
sites O
located O
in O
genes O
involved O
in O
growth O
and O
proliferation O
, O
hematopoietic O
lineage O
commitment O
, O
and O
the O
cytoskeleton O

Emerging O
scientific O
advances O
in O
recent O
years O
have O
made O
high-throughput O
genome-wide O
sequencing O
a O
central O
focus O
in O
molecular O
research O
by O
allowing O
for O
the O
collective O
analysis O
of O
various O
kinds O
of O
molecular O
biological O
data O
from O
different O
types O
of O
specimens O
in O
a O
single O
tissue O
or O
even O
at O
the O
level O
of O

Nonetheless O
, O
the O
lack O
of O
reliable O
validation O
trials O
is O
a O
foremost O
drawback O

edu O

346 O
: O
The O
abundance O
of O
the O
biological O
data O
and O
the O
rapid O
evolution O
of O
the O
newer O
machine O
learning O
technologies O
have O
increased O
the O
epigenetics O
research O
in O
the O
last O
decade O

These O
studies O
not O
only O
confirm O
the O
importance O
of O
epigenetic O
marks O
in O
developmental O
processes O
, O
but O
also O
highlight O
the O
significant O
diversity O
in O
epigenetic O
regulatory O
mechanisms O
across O
taxa O

We O
also O
discuss O
current O
treatment O
regimens O
targeting O
these O
factors O
and O
other O
promising O
inhibitors O
in O
clinical O
trials O

Given O
these O
assumptions O
, O
we O
propose O
a O
Bayesian O
mixed O
model O
methodology O
that O
allows O
the O
estimation O
of O
epigenetic O
variance O
from O
a O
genealogical O
and O
phenotypic O
database O

Among O
these O
, O
Cleavage O
Under O
Targets O
and O
Tagmentation O
( O
CUT&Tag O
) O
is O
a O
relatively O
novel O
chromatin O
profiling O
method O
that O
has O
rapidly O
gained O
popularity O
in O
the O
field O
of O
epigenetics O
since O
2019 O

244 O
: O
This O
paper O
gives O
an O
overview O
of O
how O
CMOS O
design O
methods O
can O
be O
applied O
to O
ion-sensitive O
field O
effect O
transistor O
( O
ISFETs O
) O
for O
pH-based O
DNA O
methylation O
and O
miRNA O
detection O

Data O
holdings O
have O
also O
increased O
dramatically O
since O
the O
initial O
publication O
describing O
the O
NCBI O
Epigenomics O
resource O
and O
currently O
consist O
of O
>3700 O
viewable O
and O
downloadable O
data O
tracks O
from O
955 O
biological O
sources O
encompassing O
five O
well-studied O
species O

, O
extrinsic O
and O
intrinsic O
epigenetic O
age O
acceleration O

Indeed O
, O
with O
the O
exception O
of O
rare O
mutations O
, O
the O
human O
genome-sequence O
has O
remained O
remarkably O
stable O
over O
the O
past O
centuries O

With O
new O
advances O
in O
technique O
, O
epigenome-wide O
DNA O
methylation O
data O
( O
EWAS O
) O
have O
become O
the O
new O
standard O
for O
epigenetic O
studies O
in O
human O
populations O

For O
data O
curation O
, O
MNase O
was O
aggregated O
from O
existing O
experimental O
nucleosome O
occupancy O
data O

Historical O
studies O
implicated O
epigenetic O
alterations O
, O
particularly O
DNA O
methylation O
, O
in O
OA O
pathogenesis O
; O
however O
, O
recent O
technological O
advances O
have O
resulted O
in O
numerous O
epigenome-wide O
studies O
examining O
in O
detail O
epigenetic O
modifications O
in O
OA O

, O
CREB O
, O
c-fos O
, O
and O
c-jun O
) O

We O
found O
that O
the O
most O
efficient O
fixation O
time O
for O
MDM O
is O
10min O

Next O
we O
describe O
chromatin O
immunoprecipitation-based O
techniques O
( O
ChIP O
) O
for O
study O
of O
the O
epigenome O

201 O
: O
Epigenetics O
studies O
the O
emergence O
of O
different O
phenotypes O
from O
a O
single O
genotype O

However O
, O
although O
multiple O
frameworks O
have O
been O
developed O
to O
facilitate O
access O
to O
these O
tools O
, O
comparatively O
little O
effort O
has O
been O
made O
at O
implementing O
low-level O
programming O
libraries O
to O
increase O
the O
speed O
and O
ease O
of O
their O
development O

Taken O
together O
incorporating O
epigenetic O
studies O
in O
ecotoxicology O
context O
presents O
a O
promising O
tool O
for O
development O
of O
sensitive O
biomarkers O
for O
environmental O
stress O
assessment O

Indeed O
, O
medications O
previously O
used O
to O
treat O
autoimmune O
diseases O
have O
later O
been O
discovered O
to O
exert O
their O
action O
via O
epigenetic O
mechanisms O

In O
adulthood O
, O
changes O
in O
the O
epigenome O
are O
crucial O
for O
higher O
cognitive O
functions O
such O
as O
learning O
and O
memory O

Areas O
of O
agreement O
: O
Epigenetic O
mechanisms O
are O
important O
in O
predisposing O
ageing O
tendon O
to O
injury O

com O
or O
ehalperin@cs O

The O
advent O
of O
commercial O
, O
array-based O
methods O
to O
interrogate O
DNA O
methylation O
has O
led O
to O
a O
profusion O
of O
epigenetic O
studies O
in O
the O
literature O

It O
can O
be O
applied O
to O
both O
live O
and O
fixed O
cells O
, O
easily O
compatible O
with O
high-throughput O
screening O
, O
and O
provide O
access O
to O
rich O
spatial O
information O
down O
to O
the O
single O
cell O
level O

To O
maximize O
their O
utility O
and O
impact O
, O
new O
tools O
are O
needed O
that O
facilitate O
interactive O
analysis O
of O
epigenome O
datasets O

Methods O
: O
Genome-wide O
DNA O
methylation O
analysis O
of O
newborn O
blood O
DNA O
was O
performed O
in O
24 O
isolated O
, O
non-syndromic O
CoA O
cases O
and O
16 O
controls O
using O
the O
Illumina O
HumanMethylation450 O
BeadChip O
arrays O

Baylin O
attended O
Duke O
University O
, O
where O
he O
earned O
his O
medical O
degree O
and O
completed O
his O
internship O
and O
first O
year O
residency O
in O
internal O
medicine O

179 O
: O
Purpose O
of O
review O
: O
Epigenetic O
mechanisms O
of O
transcriptional O
regulation O
in O
atherosclerosis O
have O
gained O
an O
increasing O
interest O
in O
recent O
years O

These O
epiblast O
cells O
carry O
epigenetic O
information O
from O
both O
parents O
that O
is O
required O
for O
development O
and O
cell O
function O
in O
the O
fetus O
and O
during O
post-natal O
life O

748 O
: O
LINE-1 O
hypomethylation O
of O
cell-free O
DNA O
has O
been O
described O
as O
an O
epigenetic O
biomarker O
of O
human O
aging O

ChIP O
has O
been O
widely O
applied O
to O
assess O
the O
abundance O
of O
various O
epigenetic O
regulators O
, O
including O
modified O
histones O
, O
in O
various O
regions O
of O
cellular O
and O
viral O
chromatin O

However O
, O
further O
studies O
in O
larger O
cohorts O
with O
well-defined O
phenotypes O
in O
specific O
cell O
populations O
need O
to O
be O
performed O
before O
their O
implementation O

However O
, O
to O
date O
most O
epigenetic O
studies O
of O
mediation O
effects O
only O
involve O
selected O
( O
gene-specific O
) O
candidate O
methylation O
markers O

We O
therefore O
tested O
the O
DNA O
methylation O
profiles O
of O
these O
cells O
via O
epigenome-wide O
bisulphite O
sequencing O
and O
found O
vast O
epigenetic O
changes O
in O
hundreds O
of O
loci O
, O
remarkably O
after O
a O
very O
short O
exposure O
to O
particles O
; O
ELISA O
assay O
for O
methylcytosine O
levels O
determined O
the O
particles O
induced O

Moreover O
, O
besides O
the O
genetic O
causes O
of O
IEMs O
, O
it O
is O
increasingly O
recognized O
that O
their O
clinical O
phenotypes O
are O
associated O
with O
epigenetic O
changes O

However O
, O
the O
essential O
challenge O
to O
link O
specific O
' O
epi-marks O
' O
to O
gene O
expression O
in O
the O
particular O
context O
of O
cellular O
and O
biological O
processes O
is O
unmet O

The O
results O
showed O
that O
the O
majority O
of O
CpGs O
on O
Illumina O
HumanMethylation450 O
BeadChip O
probe O
set O
were O
longitudinally O
stable O
over O
the O
time O
period O
of O
three O
months O

As O
molecular O
epigenetic O
mechanisms O
often O
control O
gene O
expression O
, O
even O
across O
generations O
, O
they O
may O
impact O
many O
evolutionary O
processes O

Post-translational O
histone O
modifications O
are O
mainly O
studied O
by O
immunoprecipitation O
with O
high-throughput O
sequencing O
( O
ChIP-Seq O
) O

005 O

A O
major O
challenge O
for O
the O
clinical O
management O
of O
cancer B-Disease
is O
the O
heterogeneous O
nature O
of O
this O
disease B-Disease

In O
this O
paper O
, O
we O
review O
the O
important O
roles O
of O
epigenetic O
disorders O
in O
the O
pathogenesis O
of O
SLE O

Szyf O
was O
the O
founder O
of O
the O
first O
pharma O
to O
develop O
epigenetic O
pharmacology O
, O
Methylgene O
Inc O

Such O
effects O
on O
cellular O
and O
physiological O
phenotypic O
traits O
may O
result O
from O
external O
or O
environmental O
factors O
or O
be O
part O
of O
normal O
developmental O
program O

Unlike O
epigenetic O
clocks O
that O
constrain O
the O
functional O
form O
of O
methylation O
changes O
with O
time O
, O
pseudotime O
analysis O
orders O
samples O
along O
a O
path O
, O
based O
on O
similarities O
in O
a O
latent O
dimension O
, O
to O
provide O
an O
unbiased O
trajectory O

He O
trained O
for O
his O
PhD O
with O
Dr O
Piet O
Borst O
, O
The O
Netherlands O
Cancer B-Disease
Institute O
, O
and O
as O
a O
postdoc O
with O
Dr O
Anton O
Berns O
, O
The O
Netherlands O
Cancer B-Disease
Institute O
, O
and O
with O
Dr O
Rudolf O
Jaenisch O
, O
at O
the O
Whitehead O
Institute O
for O
Biomedical O
Research O
in O
Cam O

Moreover O
, O
we O
summarized O
five O
patterns O
of O
aberrant O
ncRNA O
promoter O
methylation O
in O
the O
context O
of O
genomic O
CpG O
islands O
( O
CGIs O
) O
, O
in O
which O
aberrant O
methylation O
occurred O
not O
only O
on O
CGIs O
, O
but O
also O
in O
regions O
flanking O
CGI O
and O
in O
CGI-lacking O
promoters O

We O
outline O
experimental O
protocols O
and O
best O
practices O
for O
the O
cellular O
characterization O
and O
use O
of O
"chemical O
probes" O
that O
selectively O
inhibit O
protein O
methyltransferases O
, O
many O
of O
which O
methylate O
histones O
to O
regulate O
heritable O
gene O
expression O
patterns O

Studies O
put O
major O
importance O
on O
candidate O
genes O
associated O
with O
the O
formation O
of O
connective O
tissue O
( O
COL1A1 O
) O
, O
osteogenesis O
( O
PAPPA2 O
, O
GDF5 O
) O
, O
chondrogenesis O
( O
UQCC1 O
, O
ASPN O
) O
and O
cell O
growth O
, O
proliferation O
and O
differentiation O
( O
TGFB1 O
) O

As O
a O
practical O
research O
contribution O
, O
we O
make O
the O
off-target O
dataset O
containing O
all O
19 O
epigenetic O
features O
available O
to O
the O
research O
community O

Real O
- O
world O
pilots O
to O
test O
the O
reliability O
of O
these O
analyses O
are O
indicated O

MethLAB O
tests O
for O
association O
between O
methylation O
and O
relevant O
phenotypes O
by O
fitting O
a O
separate O
linear O
model O
for O
each O
CpG O
site O

Hence O
, O
epigenetic O
changes O
can O
both O
impact O
on O
and O
be O
induced O
by O
lipids O

The O
recent O
contribution O
of O
epigenetic O
modifications O
in O
defining O
the O
molecular O
basis O
of O
IBD O
and O
how O
such O
changes O
may O
act O
as O
fine-tuners O
of O
gene O
expression O
in O
these O
intestinal O
disorders O
are O
also O
discussed O

Currently O
, O
DNA O
methylation O
is O
the O
only O
epigenetic O
mark O
that O
can O
be O
measured O
reliably O
and O
genome-wide O
in O
large O
numbers O
of O
samples O

In O
juvenile O
fish O
, O
accelerated O
growth O
due O
to O
elevated O
temperatures O
had O
no O
effect O
on O
age O
prediction O
, O
indicating O
that O
the O
clock O
is O
able O
to O
predict O
the O
chronological O
age O
independently O
of O
environmentally-driven O
perturbations O


Two O
contributions O
addressed O
QC O
and O
identified O
large O
statistical O
differences O
with O
pretreatment O
and O
posttreatment O
DNA O
methylation O
, O
possibly O
a O
result O
of O
batch O
effects O

We O
conclude O
by O
discussing O
the O
potential O
adaptive O
character O
of O
gbM O
and O
its O
implications O
for O
an O
updated O
view O
of O
the O
mechanisms O
of O
adaptation O
in O
plants O

It O
enables O
an O
accurate O
profiling O
of O
target O
modifications O
along O
the O
genome O
, O
but O
suffers O
from O
the O
high O
cost O
of O
analysis O
and O
the O
inability O
to O
work O
with O
living O
cells O

In O
this O
review O
, O
we O
will O
identify O
and O
discuss O
current O
ethical O
, O
legal O
and O
social O
issues O
of O
epigenetics O
research O
in O
the O
context O
of O
personalized O
medicine O

H O

Finally O
, O
we O
discuss O
existing O
challenges O
and O
opportunities O
for O
future O
development O

Here O
we O
present O
an O
overview O
of O
methodologies O
available O
for O
DNA O
methylation O
analysis O
with O
special O
focus O
on O
recent O
developments O
in O
genome-wide O
and O
high-throughput O
methods O

In O
this O
review O
, O
we O
make O
a O
brief O
summary O
of O
important O
progress O
achieved O
in O
plant O
epigenetics O
field O
in O
China O
over O
the O
past O
several O
decades O
and O
give O
a O
brief O
outlook O
on O
future O
research O
prospects O

Recently O
, O
epigenetics O
has O
become O
one O
of O
the O
fastest-growing O
areas O
of O
science O
and O
has O
now O
become O
a O
central O
issue O
in O
biologic O
studies O
of O
development O
and O
disease B-Disease
pathogenesis O

ERK O
signalling O
is O
known O
to O
be O
essential O
for O
EMT O
, O
however O
its O
influence O
on O
the O
epigenetic O
and O
transcriptional O
programme O
underlying O
EMT O
is O
poorly O
understood O

The O
protocol O
outlined O
herein O
could O
be O
applied O
for O
delivery O
of O
adeno-associated B-Disease
viruses I-Disease
( O
AAV O
) O
or O
lentiviruses O
in O
both O
mice O
and O
rats O

538 O
: O
Cancer B-Disease
is O
a O
disease B-Disease
of O
global O
epigenetic O
dysregulation O

91-0 O

One O
of O
these O
modules O
was O
enriched O
for O
development-related O
processes O
and O
overlaps O
strongly O
with O
epigenetic O
aging O
sites O

It O
has O
recently O
been O
found O
that O
some O
of O
the O
chromatin O
modulatory O
machinery O
essential O
for O
proper O
development O
plays O
a O
previously O
unappreciated O
role O
in O
the O
pathogenesis O
of O
cardiac O
disease B-Disease
in O
adults O

DNA O
methylation O
, O
an O
epigenetic O
factor O
, O
is O
used O
for O
model O
training O
in O
many O
studies O

The O
epigenome O
may O
also O
harbour O
useful O
information O
about O
life-time O
exposures O
(measured O
or O
unmeasured O
) O
irrespective O
of O
their O
influence O
on O
health O
or O
disease B-Disease
, O
creating O
the O
potential O
for O
a O
person-specific O
biosocial O
archive O

(Ecker O
S O
, O
Chen O
L O
, O
Pancaldi O
V O
, O
Bagger O
FO O
, O
et O
al O

In O
turn O
, O
environmental O
factors O
influence O
epigenetic O
mechanisms O
, O
such O
that O
an O
epigenetic-environmental O
link O
may O
contribute O
to O
the O
accumulation O
of O
cellular O
damage O
, O
susceptibility O
or O
resilience O
to O
stressors O
, O
and O
variability O
in O
the O
trajectory O
of O
age-related O
cognitive O
decline O

self O
- O
report O
) O
and O
could O
potentially O
translate O
to O
clinical O
settings O

Advances O
in O
-omics O
have O
provided O
new O
insights O
into O
the O
sources O
and O
inheritance O
of O
epigenetic O
variation O
and O
enabled O
the O
efficient O
introduction O
of O
epi-traits O
from O
CWR O
into O
crops O
using O
epigenetic O
molecular O
markers O
, O
such O
as O
epiQTLs O

In O
1940 O
, O
Waddington O
coined O
the O
term O
" O
epigenetic O
landscape O
" O
as O
a O
metaphor O
for O
pluripotency O
and O
differentiation O
, O
but O
methylation O
landscapes O
have O
not O
yet O
been O
rigorously O
computed O

Here O
, O
we O
introduce O
HopLand O
, O
a O
pseudotime O
recovery O
method O
using O
continuous O
Hopfield O
network O
to O
map O
cells O
to O
a O
Waddington's O
epigenetic O
landscape O

EpiProfile O
is O
freely O
available O
at O
https://github O

e O

Advancements O
in O
high-throughput O
sequencing O
technologies O
have O
provided O
the O
opportunity O
to O
study O
the O
epigenetic O
mechanisms O
at O
genome-wide O
levels O

The O
power O
of O
this O
novel O
ML O
approach O
and O
our O
ability O
to O
predict O
epigenetic O
phenomena O
and O
associated O
disease B-Disease
is O
suggested O

To O
avoid O
an O
unwarranted O
backlash O
against O
this O
promising O
research O
field O
, O
we O
encourage O
a O
more O
balanced O
ELSI O
discussion O
conveying O
the O
full O
spectrum O
of O
issues O
faced O
by O
stakeholders O

407 O
: O
The O
Great O
Irish O
Famine O
( O
1845-52 O
) O
saw O
the O
Irish O
population O
fall O
by O
20% O
as O
one O
million O
people O
died O
and O
another O
million O
emigrated O

However O
, O
research O
in O
human O
subjects O
is O
still O
limited O

This O
article O
is O
part O
of O
the O
theme O
issue O
' O
Developing O
differences O
: O
early-life O
effects O
and O
evolutionary O
medicine O
' O


MPE O
may O
represent O
a O
logical O
evolution O
of O
GWAS O
, O
termed O
' O
GWAS-MPE O
approach O
' O

Analysis O
of O
the O
gene O
ontology O
enrichment O
and O
regulatory O
pathways O
showed O
that O
genes O
characterized O
by O
differential O
DNA O
methylation O
are O
mainly O
associated O
with O
stress O
response O
, O
including O
heat O
stress O

169 O
: O
At O
the O
Epigenetics O
Europe O
conference O
in O
Munich O
, O
Germany O
, O
held O
on O
8-9 O
September O
2011 O
, O
19 O
speakers O
from O
different O
European O
countries O
were O
presenting O
novel O
data O
and O
concepts O
on O
molecular O
epigenetics O

However O
, O
recent O
research O
has O
shed O
light O
on O
the O
crucial O
role O
of O
epigenomic O
alterations O
in O
various O
cell O
types O
present O
within O
the O
tumor B-Disease
microenvironment O
, O
suggesting O
their O
potential O
contribution O
to O
tumor B-Disease
formation O
and O
progression O

Although O
epigenetic O
abnormalities O
are O
thought O
to O
be O
a O
symptom O
of O
cell O
tumorigenesis B-Disease
and O
malignant O
events O
that O
impact O
tumor B-Disease
growth O
and O
drug O
resistance O
, O
physicians O
believe O
that O
related O
processes O
might O
be O
a O
key O
therapeutic O
target O
for O
cancer B-Disease
treatment O
and O
prevention O
due O
to O
the O
reversible O
nature O

Examples O
of O
such O
modifications O
include O
DNA O
methylation O
, O
histone O
modifications O
, O
noncoding O
RNAs O
, O
and O
chromatin O
architecture O

682 O
: O
Biochemical O
, O
epigenetic O
, O
genetic O
, O
and O
imaging O
biomarkers O
are O
used O
to O
identify O
people O
at O
high O
risk O
for O
developing O
cancer B-Disease

Finally O
, O
we O
summarize O
the O
current O
technologies O
best O
suited O
to O
capturing O
mtDNA O
methylation O
, O
and O
how O
a O
move O
towards O
whole O
epigenome O
sequencing O
of O
mtDNA O
may O
help O
to O
advance O
our O
current O
understanding O
of O
the O
field O

However O
, O
the O
construction O
of O
the O
original O
pan-tissue O
epigenetic O
clock O
did O
not O
include O
skeletal O
muscle O
samples O
and O
hence O
exhibited O
a O
strong O
deviation O
between O
DNA O
methylation O
and O
chronological O
age O
in O
this O
tissue O

4 O
%) O

This O
has O
limited O
precise O
correlation O
of O
epigenetic O
changes O
in O
gene O
expression O


The O
methylation O
level O
of O
five O
studied O
CpG O
sites O
demonstrated O
significant O
correlations O
with O
chronological O
age O
and O
an O
acceptable O
convergence O
of O
data O
obtained O
by O
the O
iPlex O
MassARRAY O
and O
Illumina O
EPIC O
array O

bioapp O

We O
implemented O
the O
muscle O
clock O
in O
an O
r O
package O
called O
Muscle O
Epigenetic O
Age O
Test O
available O
on O
Bioconductor O
to O
estimate O
epigenetic O
age O
in O
skeletal O
muscle O
samples O

As O
the O
Environmental O
Mutagenesis O
and O
Genomics O
Society O
( O
EMGS O
) O
celebrates O
its O
50th O
Anniversary O
this O
year O
, O
we O
have O
come O
together O
to O
review O
and O
summarize O
the O
seminal O
advances O
in O
the O
field O
of O
environmental B-Disease
epigenomics I-Disease

Defined O
as O
multivariate O
regression O
models O
, O
these O
DNA O
methylation-based O
biomarkers O
of O
age O
or O
mortality O
risk O
are O
useful O
in O
species O
conservation O
efforts O
and O
in O
preclinical O
studies O

Results O
: O
Childhood O
exposure O
to O
hunger O
was O
associated O
with O
CVD O
and O
depressive B-Disease
symptoms I-Disease
in O
later O
life O

To O
address O
this O
gap O
in O
our O
knowledge O
, O
we O
compared O
clonally O
propagated O
Arabidopsis O
thaliana O
plants O
derived O
from O
somatic O
embryogenesis O
using O
two O
different O
embryonic O
transcription O
factors O
- O
RWP-RK O
DOMAIN-CONTAINING O
4 O
( O
RKD4 O
) O
or O
LEAFY O
COTYLEDON2 O
( O
LEC2 O
) O
and O
from O

530 O
: O
In O
the O
past O
few O
years O
, O
thorough O
investigation O
of O
chemical O
modifications O
operated O
in O
the O
cells O
on O
ribonucleic O
acid O
( O
RNA O
) O
molecules O
is O
gaining O
momentum O

e O

Such O
variability O
poses O
a O
challenge O
in O
successfully O
targeting O
all O
tumor B-Disease
subpopulations O
at O
the O
same O
time O

A O
set O
of O
statistics O
collected O
from O
each O
genomic O
region O
is O
modeled O
with O
a O
beta-binomial O
mixture O

280 O
: O
Epigenetic O
alterations O
are O
a O
common O
hallmark O
of O
human O
cancer B-Disease

Multiple O
diverse O
epigenetic O
processes O
, O
including O
DNA O
methylation O
, O
histone O
modification O
, O
and O
the O
expression O
of O
non-coding O
RNA O
molecules O
affect O
the O
expression O
of O
genes O
that O
produce O
important O
changes O
in O
cellular O
differentiation O
and O
function O
, O
influencing O
the O
health O
and O
adaptability O
of O
the O

The O
Famine O
occurred O
at O
a O
time O
when O
the O
Irish O
asylums O
were O
growing O
rapidly O
anyway O
, O
so O
its O
precise O
effects O
on O
mental O
health O
are O
difficult O
although O
not O
impossible O
to O
study O

This O
feature O
has O
stimulated O
intensive O
research O
to O
identify O
predictive O
biomarkers O
of O
response O
and O
disentangle O
the O
molecular O
bases O
of O
their O
clinical O
efficacy O

This O
software O
is O
accompanied O
by O
a O
set O
of O
precomputed O
tracks O
, O
which O
may O
be O
used O
as O
a O
valuable O
resource O
for O
functional O
annotation O
of O
the O
human O
genome O

Consequently O
, O
the O
article O
calls O
for O
abandoning O
analysis O
of O
these O
research O
practices O
using O
clear-cut O
dichotomies O
of O
reductionism O
vs O

Single O
epigenetic O
markers O
are O
starting O
to O
be O
incorporated O
into O
clinical O
practice O
; O
however O
, O
the O
translational O
use O
of O
these O
biomarkers O
has O
not O
been O
validated O
at O
the O
'omics O
' O
level O

Here O
, O
we O
review O
the O
current O
knowledge O
on O
epitranscriptomic O
marks O
and O
propose O
a O
categorization O
method O
based O
on O
the O
reference O
ribonucleotide O
and O
its O
rounds O
of O
modifications O
( O
" O
stages O
" O
) O
until O
reaching O
the O
given O
modified O
form O

The O
high-resolution O
chromatographic O
separation O
along O
with O
sensitive O
MS O
detection O
permits O
the O
identification O
and O
quantification O
of O
deoxyribonucleosides O
with O
precision O
and O
reliability O

The O
number O
of O
such O
biomedical O
resources O
is O
increasing O
constantly O
and O
mining O
these O
large O
and O
diverse O
data O
sets O
continues O
to O
present O
real O
challenges O

e O

In O
the O
present O
review O
, O
we O
aim O
to O
discuss O
the O
clinical O
opportunities O
and O
challenges O
arising O
from O
the O
epigenetic O
research O
in O
psychiatry O

Jirtle O
was O
presented O
the O
Linus O
Pauling O
Award O
from O
the O
Institute O
of O
Functional O
Medicine O
in O
2014 O

JBR O
was O
designed O
for O
efficient O
data O
processing O
, O
resulting O
in O
fast O
viewing O
and O
analysis O
of O
multiple O
replicates O
, O
up O
to O
thousands O
of O
tracks O

Using O
evolutionary O
principles O
, O
it O
is O
also O
possible O
to O
interpret O
" O
sunsetting O
" O
of O
modified O
phenotypes O
when O
environmental O
conditions O
result O
in O
a O
disappearance O
of O
the O
epigenetic O
modification O
of O
gene O
regulation O

While O
these O
advances O
enable O
us O
to O
explore O
frontiers O
of O
chromatin O
biology O
and O
better O
understand O
cell O
lineage O
relationships O
, O
they O
pose O
new O
challenges O
in O
data O
processing O
and O
interpretation O

However O
, O
clear O
and O
unequivocal O
guidelines O
on O
how O
to O
approach O
this O
in O
the O
clinical O
setting O
have O
not O
been O
developed O

Methods O
: O
Participants O
were O
premenopausal O
women O
( O
N O
= O
183 O
) O

Many O
other O
non-canonical O
players O
, O
such O
as O
chromatin O
regulators O
and O
noncoding O
RNAs O
, O
are O
also O
involved O
in O
regulating O
gene O
expression O

In O
this O
Review O
, O
we O
present O
the O
latest O
data O
on O
strategies O
using O
epigenetics O
and O
other O
molecular O
biomarkers O
to O
guide O
therapeutic O
decisions O
involving O
patients O
with O
CUP O
, O
and O
we O
highlight O
areas O
warranting O
further O
research O
to O
engage O
the O
medical O
community O
in O
this O
unmet O
need O

680 O
: O
The O
series O
of O
events O
that O
allow O
the O
conversion O
from O
adherent O
epithelial O
cells O
into O
migratory O
cells O
is O
collectively O
known O
as O
epithelial-mesenchymal O
transition O
( O
EMT O
) O

g O

development O
of O
their O
therapeutics O

Epigenetic O
pathways O
mediate O
cellular O
adaptation O
, O
and O
are O
therefore O
a O
potential O
target O
of O
oxidative O
stress O

While O
nutritional O
intakes O
from O
foods O
cannot O
be O
adequately O
controlled O
for O
dosage O
, O
the O
role O
of O
nutrients O
in O
the O
epigenetics O
of O
cancer B-Disease
has O
led O
to O
more O
research O
aimed O
at O
developing O
nutriceuticals O
and O
drugs O
as O
cancer B-Disease
therapies O

Conclusions O
: O
In O
sum O
, O
we O
present O
several O
epigenetic O
associations O
with O
incident O
CVD O
which O
reveal O
disease B-Disease
mechanisms O
related O
to O
development O
and O
monocyte O
biology O

In O
contrast O
, O
social O
epigeneticists O
, O
e O

To O
achieve O
this O
, O
the O
epigenetic O
information O
inherited O
by O
the O
primordial O
germ O
cells O
at O
specification O
is O
erased O
and O
new O
epigenetic O
states O
are O
established O
during O
development O
of O
the O
male O
and O
female O
germ-lines O

In O
addition O
to O
the O
analysis O
of O
transcription O
factor O
binding O
, O
ChIP O
has O
proved O
to O
be O
a O
reliable O
method O
to O
map O
histone O
modifications O
across O
cellular O
and O
viral O
epigenomes O

A O

Summary O
: O
Epigenetic O
factors O
represent O
a O
promising O
area O
to O
link O
genetics O
, O
regulation O
of O
gene O
expression O
and O
environmental O
risk O
factors O

, O
RELN O
) O
, O
and O
diverse O
transcriptional O
regulators O
( O
e O

In O
this O
work O
, O
Reduced O
Representation O
Bisulphite O
Sequencing O
( O
RRBS O
) O
profiling O
of O
the O
taurine O
Angus O
( O
A O
) O
and O
indicine O
Nellore O
( O
N O
) O
cattle O
breeds O
was O
applied O
to O
identify O
methylation O
differences O
between O
the O
two O
subspecies O

In O
this O
report O
, O
we O
demonstrate O
a O
simple O
microfluidic O
device O
that O
integrates O
sonication O
and O
immunoprecipitation O
( O
IP O
) O
for O
epigenetic O
assays O
, O
such O
as O
chromatin O
immunoprecipitation O
( O
ChIP O
) O
and O
methylated O
DNA O
immunoprecipitation O
( O
MeDIP O

To O
support O
this O
claim O
, O
we O
reanalysed O
GEO O
datasets O
with O
an O
improved O
QC O
pipeline O
that O
reduced O
test-statistic O
inflation O
parameter O
lambda O
from O
the O
original O
mean/median O
of O
20 O

This O
study O
particularly O
focuses O
on O
the O
role O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
and O
nitric O
oxide O
( O
NO O
) O
in O
modulating O
metabolic O
pathways O
and O
gene O
activities O
that O
are O
involved O
in O
these O
chromatin B-Disease
modifications I-Disease

185 O
: O
The O
availability O
of O
reference O
genome O
sequences O
for O
virtually O
all O
species O
under O
active O
research O
has O
revolutionized O
biology O

300 O
: O
Background O
: O
DNA O
methylation O
( O
DNAm O
) O
performs O
excellently O
in O
the O
discrimination O
of O
current O
and O
former O
smokers O
from O
never O
smokers O
, O
where O
AUCs O
> O
0 O

This O
technology O
could O
be O
a O
potential O
research O
tool O
for O
displaying O
the O
systematic O
associations O
of O
genetic O
and O
epigenetic O
variations O
, O
especially O
in O
terms O
of O
cytosine B-Disease
methylation I-Disease
onto O
the O
genomic O
region O
in O
a O
specific O
cell O
or O
tissue O

Interrogating O
the O
interaction O
of O
genetic O
and O
environmental O
influences O
raised O
new O
challenges O
of O
statistical O
power O
, O
which O
were O
not O
easily O
bested O
by O
the O
addition O
of O
subjects O

Conclusion O
: O
This O
discovery O
provides O
new O
insight O
on O
the O
epigenetic O
regulation O
in O
cancers B-Disease
and O
leads O
to O
potential O
new O
direction O
for O
epigenetic O
biomarker O
and O
cancer B-Disease
drug O
discovery O

Despite O
significant O
technological O
advances O
for O
epigenetic O
profiling O
, O
there O
is O
still O
a O
need O
for O
a O
systematic O
understanding O
of O
how O
epigenetics O
shapes O
cellular O
circuitry O
, O
and O
disease B-Disease
pathogenesis O

In O
particular O
, O
we O
emphasize O
the O
need O
to O
understand O
the O
presence O
and O
role O
of O
transgenerational O
inheritance O
, O
as O
well O
as O
the O
impact O
of O
epigenomic O
signatures O
on O
adaptation O
and O
genome O
evolution O

5281/zenodo O

Two O
key O
lines O
of O
investigation O
have O
been O
pursued O
that O
aim O
to O
unravel O
endogenous O
epigenetic O
events O
at O
particular O
genes O
( O
probing O
) O
and O
artificially O
manipulate O
the O
epigenetic O
landscape O
( O
editing O
) O

This O
would O
underlie O
an O
essential O
paradigm O
shift O
, O
and O
power O
the O
search O
for O
links O
between O
genomic O
and O
epigenomic O
features O
and O
physiology O

Social O
scientists O
' O
understanding O
of O
epigenetics O
, O
thus O
, O
appears O
in O
part O
to O
be O
socially O
constructed O
, O
i O

386 O
: O
Over O
the O
last O
years O
, O
it O
has O
become O
increasingly O
clear O
that O
environmental O
influences O
can O
affect O
the O
epigenomic O
landscape O
and O
that O
some O
epigenetic O
variants O
can O
have O
heritable O
, O
phenotypic O
effects O

g O

677 O
: O
Evidence O
suggests O
that O
nutritional O
status O
during O
fetal O
development O
and O
early O
life O
leaves O
an O
imprint O
on O
the O
genome O
, O
which O
leads O
to O
health O
outcomes O
not O
only O
on O
a O
person O
as O
an O
adult O
but O
also O
on O
his O
offspring O

However O
, O
since O
methylation O
data O
is O
more O
sensitive O
to O
confounding O
, O
e O

With O
the O
advent O
of O
new O
technologies O
we O
are O
just O
starting O
to O
unravel O
the O
cancer B-Disease
epigenome O
and O
latest O
mechanistic O
findings O
provide O
the O
first O
clue O
as O
to O
how O
altered O
epigenetic O
patterns O
might O
occur O
in O
different O
cancers B-Disease

229 O
: O
Genome-wide O
association O
studies O
had O
a O
troublesome O
adolescence O
, O
while O
researchers O
increased O
statistical O
power O
, O
in O
part O
by O
increasing O
subject O
numbers O

In O
this O
review O
, O
the O
three O
major O
epigenetic O
mechanisms O
are O
described O
: O
covalent O
DNA O
modification O
, O
histone O
protein O
modification O
, O
and O
regulation O
by O
noncoding O
RNA O

4 O
: O
Epigenetic O
modifications O
of O
histones O
( O
methylation O
, O
acetylation O
, O
phosphorylation O
, O
etc O

69 O
nm O
which O
helped O
us O
achieve O
two O
critical O
parameters O
for O
epigenomics O
monitoring O
: O
efficient O
nuclear O
uptake O
( O
98 O
% O
) O
without O
complex O
functionalization O
and O
no O
conformational O
nuclear O
changes O

The O
first O
part O
of O
this O
chapter O
is O
dedicated O
to O
histone O
enrichment O
methods O
that O
allow O
the O
study O
of O
histones O
using O
techniques O
such O
as O
immunoblot O
or O
mass O
spectrometry O
for O
the O
mapping O
of O
the O
histone O
PTM O
network O

We O
found O
several O
cases O
of O
Parkinson's B-Disease
disease I-Disease
with O
epigenetic O
abnormality O
in O
SNCA O
gene O

While O
such O
methods O
adjust O
for O
differences O
in O
sequencing O
depths O
, O
they O
do O
not O
address O
differences O
in O
the O
signal-to-noise O
ratios O
across O
different O
experiments O

306 O
: O
Systemic B-Disease
lupus I-Disease
erythematosus I-Disease
( O
SLE O
) O
is O
an O
autoimmune O
disease B-Disease
with O
multiple O
organ O
involvement O

Epigenetic O
alterations O
can O
significantly O
impact O
the O
expression O
and O
function O
of O
these O
critical O
genes O
, O
contributing O
to O
the O
initiation O
and O
progression O
of O
cancer B-Disease

We O
show O
that O
Conway's O
organization O
of O
rules O
reflects O
the O
epigenetic O
principle O
, O
that O
genetic O
action O
and O
developmental O
processes O
are O
inseparable O
dimensions O
of O
a O
single O
biological O
system O
, O
analogous O
to O
the O
integration O
processes O
in O
symbiopoiesis O

However O
, O
before O
this O
can O
be O
undertaken O
, O
an O
understanding O
of O
epigenetic O
mechanisms O
is O
required O
, O
and O
this O
can O
be O
obtained O
only O
by O
precise O
and O
accurate O
analysis O
of O
epigenetic O
patterns O

The O
association O
of O
CCSs O
with O
gene O
expression O
patterns O
suggests O
that O
there O
are O
likely O
to O
be O
CCSs O
that O
respond O
, O
or O
regulate O
the O
response O
, O
to O
exercise O
and O
related O
stimuli O

We O
also O
identified O
AXIN1 O
, O
GRIK2 O
, O
CAMK4 O
, O
TRAF1 O
as O
hypomethylated O
genes O
with O
enhanced O
expression O
after O
loading O
that O
maintained O
their O
hypomethylated O
status O
even O
during O
unloading O
where O
muscle O
mass O
returned O
to O
control O
levels O
, O
indicating O
a O
memory O
of O
these O
genes O
methylation O
signatures O
following O

Epigenetic O
instability O
may O
arise O
due O
to O
the O
genetic O
mutations O
or O
transcriptional O
deregulation O
of O
the O
proteins O
implicated O
in O
epigenetic O
signaling O

376 O
: O
How O
evolution O
can O
be O
facilitated O
by O
epigenetic O
mechanisms O
has O
received O
refreshed O
attention O
recently O

ChIPseeker O
is O
a O
Bioconductor O
package O
for O
performing O
these O
analyses O
among O
variable O
epigenomic O
datasets O

A O
better O
understanding O
of O
these O
mechanisms O
has O
implications O
for O
treatment O
of O
memory O
disorders O
caused O
by O
normal O
aging O
or O
diseases O
including O
schizophrenia B-Disease
, O
Alzheimer's O
, O
depression B-Disease
, O
and O
drug O
addiction O

In O
this O
review O
, O
recent O
studies O
on O
the O
biological O
role O
and O
regulation O
of O
class O
IIa O
HDACs O
as O
well O
as O
their O
contribution O
in O
neurodegenerative B-Disease
diseases I-Disease
, O
immune O
disorders O
and O
cancer B-Disease
will O
be O
presented O

253 O
: O
Biological O
phenomena O
defined O
as O
having O
an O
" O
epigenetic O
" O
component O
( O
according O
to O
various O
definitions O
) O
have O
been O
extensively O
studied O
in O
plant O
systems O
and O
illuminated O
many O
mechanisms O
by O
which O
gene O
expression O
is O
regulated O
and O
patterns O
of O
expression O
inherited O
through O
cell O
divisions O

434 O
: O
Human O
pluripotent O
stem O
cell O
( O
PSC O
) O
technology O
and O
direct O
somatic O
cell O
reprogramming O
have O
opened O
up O
a O
promising O
new O
avenue O
in O
the O
field O
of O
neuroscience O

230 O
: O
Cancer B-Disease
immune O
evasion O
is O
one O
of O
the O
hallmarks O
of O
carcinogenesis O

Targeting O
epigenetic O
modulators O
associated O
with O
cancer B-Disease
stem O
cell O
survival O
can O
unlock O
a O
promising O
therapeutic O
approach O
in O
completely O
eradicating O
cancer B-Disease

We O
, O
first O
( O
I O
) O
, O
make O
the O
case O
that O
a O
broader O
ethical O
debate O
on O
EE O
is O
due O
, O
provide O
scientific O
background O
on O
EE O
, O
compile O
potential O
use-cases O
and O
recap O
previous O
debates O

Therefore O
, O
our O
results O
were O
implemented O
as O
a O
freely O
accessible O
web O
application O

kr/) O
aimed O
at O
facilitating O
functional O
and O
comparative O
analysis O
of O
histone-modifying O
enzymes O
(HMEs) O

In O
performance O
comparisons O
, O
EpiSAFARI O
performs O
favorably O
in O
terms O
of O
accuracy O

The O
term O
epigenetics O
refers O
to O
changes O
in O
gene O
expression O
that O
are O
not O
encoded O
in O
the O
DNA O
sequence O
, O
leading O
to O
remodeling O
of O
the O
chromatin O
and O
activation O
or O
inactivation O
of O
gene O
expression O

The O
present O
review O
aims O
to O
shed O
some O
light O
on O
the O
key O
mechanisms O
governing O
the O
epigenetic O
characteristics O
of O
the O
human O
genome O
and O
how O
epigenetic O
patterns O
can O
be O
analysed O
on O
whole O
genome O
scale O

293 O
: O
Cancer B-Disease
initiation O
and O
progression O
is O
an O
accumulation O
of O
genetic O
and O
epigenetic O
modifications O

This O
module O
delivers O
learning O
materials O
on O
the O
analysis O
of O
bulk O
and O
single-cell O
ATAC-seq O
data O
in O
an O
interactive O
format O
that O
uses O
appropriate O
cloud O
resources O
for O
data O
access O
and O
analyses O

We O
find O
that O
the O
local O
chromatin O
environment O
of O
the O
reporter O
has O
a O
significant O
effect O
on O
the O
observed O
phenotype O

R O
code O
is O
available O
at O
github O

50 O

610 O
: O
Several O
environmental O
risk O
factors O
such O
as O
early O
adverse O
childhood O
experiences O
, O
stress O
, O
and O
stressful O
life O
events O
are O
associated O
with O
anxiety O
disorders O

, O
replace O
or O
augment O
self-reported O
adherence O
) O

634 O
: O
Current O
trends O
in O
Higher O
Education O
Pedagogies O
include O
an O
ongoing O
discussion O
about O
active O
learning O
strategies O

Vitamin O
C O
deficiency O
is O
rare O
in O
the O
general O
population O
, O
but O
is O
frequently O
observed O
in O
patients O
with O
cancer B-Disease

The O
methylation O
levels O
of O
selected O
imprinted O
genes O
in O
spermatozoa O
, O
which O
were O
previously O
found O
to O
be O
differentially O
methylated O
, O
were O
combined O
into O
a O
probability O
score O
( O
between O
0-1 O
) O
using O
multiple O
logistic O
regression O

While O
it O
is O
known O
that O
intergenerational O
trauma B-Disease
can O
be O
transmitted O
through O
attachment O
relationships O
, O
a O
new O
branch O
of O
genetics O
( O
epigenetics O
) O
has O
emerged O
to O
study O
the O
interaction O
between O
human O
behavior O
and O
changes O
in O
DNA O
expression O

Amongst O
all O
, O
bioinformatics O
plays O
a O
pivotal O
role O
in O
achieving O
epigenetics-related O
computational O
studies O

Cellular O
senescence B-Disease
, O
mediated O
by O
telomere B-Disease
attrition I-Disease
, O
is O
in O
a O
class O
by O
itself O
, O
having O
recently O
been O
validated O
as O
a O
primary O
regulator O
of O
aging O

Our O
work O
highlights O
the O
contribution O
of O
machine O
learning O
in O
the O
identification O
of O
potential O
epigenetic O
targets O
and O
offers O
a O
novel O
approach O
for O
epigenetic O
drug O
discovery O
and O
development O

These O
reversible O
modifications O
include O
DNA O
methylation O
, O
histone O
acetylation O
and O
RNA O
interference O

Advancements O
towards O
high-dimensional O
molecular O
profiles O
and O
functional O
follow-up O
studies O
have O
started O
to O
uncover O
the O
complexity O
of O
these O
interacting O
networks O
of O
control O

Urologic O
( O
prostate O
, O
bladder O
, O
kidney O
) O
, O
lung O
, O
breast O
and O
colorectal B-Disease
cancers I-Disease
are O
the O
most O
common O
and O
despite O
major O
advances O
in O
their O
characterization O
, O
this O
has O
seldom O
translated O
into O
biomarkers O
amenable O
for O
clinical O
practice O

Conclusions O
: O
In O
general O
, O
it O
can O
be O
stated O
that O
behavior O
and O
environment O
will O
finally O
take O
on O
a O
leading O
role O
in O
human O
development O
through O
epigenetic O
mechanisms O

Co O
- O
existing O
parental O
species O
displayed O
highly O
distinct O
genetic O
( O
SNPs O
) O
and O
methylation O
patterns O
( O
37,000 O
differentially O
methylated O
cytosines O
) O

Drug O
discovery O
undertakings O
have O
focused O
mainly O
on O
the O
role O
of O
genomics O
in O
carcinogenesis O
, O
with O
the O
focus O
turning O
to O
the O
epigenome O
recently O

369 O
: O
Epigenetic O
concepts O
are O
fundamentally O
shaped O
by O
a O
legacy O
of O
negative O
definition O
, O
often O
understood O
by O
what O
they O
are O
not O

As O
a O
result O
, O
advances O
in O
pharmacogenetics O
and O
pharmacoepigenomics O
now O
allow O
for O
personalized O
treatments O
based O
on O
the O
profile O
of O
each O
patient O
and O
the O
specific O
genetic O
and O
epigenetic O
mechanisms O
involved O

372 O
: O
DNA O
methylation O
microarrays O
have O
been O
the O
platform O
of O
choice O
for O
epigenome-wide O
association O
studies O
in O
epidemiology O
, O
but O
declining O
costs O
have O
rendered O
targeted O
bisulphite O
sequencing O
a O
feasible O
alternative O

The O
alterations O
in O
normal O
DNA O
methylation O
and O
histone O
acetylation/deacetylation O
patterns O
lead O
to O
deregulated O
transcription O
and O
chromatin O
organization O
resulting O
in O
altered O
gene O
expression O
profiles O
that O
facilitates O
tumor B-Disease
development O
and O
progression O

Several O
studies O
have O
linked O
epigenetic O
modifications O
induced O
during O
regeneration O
with O
this O
newly O
acquired O
phenotypic O
variation O

Using O
a O
new O
codec O
, O
the O
decompression O
can O
be O
done O
on O
a O
graphical O
processing O
unit O
( O
GPU O
) O
making O
it O
fast O
enough O
to O
create O
the O
training O
batches O
during O
training O
, O
mitigating O
the O
need O
for O
saving O
preprocessed O
training O
examples O
to O
disk O

No O
CpG O
reached O
epigenome-wide O
significance O
after O
multiple O
testing O
correction O

310 O
: O
The O
universality O
of O
DNA O
methylation O
as O
an O
epigenetic O
regulatory O
mechanism O
belongs O
to O
all O
biological O
kingdoms O

To O
overcome O
this O
limitation O
, O
it O
would O
be O
useful O
to O
acquire O
reliable O
signals O
from O
multiple O
epigenetic O
marks O
in O
the O
same O
single O
cell O

Recent O
strides O
in O
this O
field O
encompass O
identifying O
specific O
epigenetic O
markers O
associated O
with O
stress O
resilience O
, O
developing O
tools O
for O
editing O
the O
epigenome O
, O
and O
integrating O
epigenetic O
data O
into O
breeding O
programs O
for O
stress-resistant O
crops O

riken O

When O
integrated O
with O
electronic O
health O
records O
, O
survey O
, O
census O
, O
and/or O
epidemiologic O
data O
, O
multiomics O
are O
anticipated O
to O
facilitate O
data-driven O
precision O
oral B-Disease
health I-Disease
, O
or O
the O
delivery O
of O
the O
right O
oral B-Disease
health I-Disease
intervention O
to O
the O
right O
individuals/populations O
at O
the O
right O
time O

741 O
: O
Aging O
is O
an O
inevitable O
outcome O
of O
life O
, O
characterized O
by O
a O
progressive O
decline O
in O
tissue O
and O
organ O
function O

The O
attention O
mechanism O
makes O
the O
model O
interpretable O
, O
and O
the O
pure O
matrix O
operation O
of O
self-attention O
enables O
the O
model O
to O
be O
parallel O
calculated O
and O
speeds O
up O
the O
training O

Additional O
advantages O
of O
this O
method O
over O
other O
methods O
for O
DNA O
methylation O
analysis O
are O
that O
it O
requires O
very O
less O
amount O
of O
DNA O
and O
can O
screen O
DNA O
methylation O
changes O
globally O
at O
genome-wide O
level O
with O
high O
sensitivity O

430 O
: O
Atrial O
fibrillation O
( O
AF O
) O
is O
the O
most O
common O
cardiac O
arrhythmia O
and O
an O
important O
cause O
of O
morbidity O
and O
mortality O
globally O

This O
study O
generates O
the O
first O
published O
reference O
epigenomes O
for O
human O
thyroid O
from O
four O
individuals O
using O
ChIP-seq O
and O
RNA-seq O

Our O
new O
model O
translates O
the O
capabilities O
of O
state-of-the-art O
epigenetic O
clocks O
to O
the O
EPICv2 O
platform O
and O
is O
cross-compatible O
with O
older O
microarrays O

However O
, O
the O
extent O
to O
which O
epigenetic O
factors O
( O
primarily O
methylation O
at O
promoter O
regions O
) O
affect O
transcription O
of O
immune-related O
genes O
may O
vary O
across O
cancer B-Disease
types O

https O
: O
/ O
/ O
doi O

Our O
analysis O
offers O
both O
a O
state-of-the-art O
overview O
of O
the O
computational O
techniques O
developed O
so O
far O
and O
a O
heterogeneous O
picture O
of O
performances O
, O
which O
can O
be O
helpful O
in O
orienting O
future O
research O

Genome O
- O
wide O
association O
studies O
have O
made O
it O
possible O
to O
link O
psoriasis B-Disease
to O
genes O
and O
therefore O
to O
epigenetics O

Our O
results O
demonstrate O
that O
AERNs O
are O
more O
adept O
at O
controlling O
multiple O
opposing O
trajectories O
when O
applied O
to O
a O
chaos O
control O
task O
within O
a O
conservative O
dynamical O
system O
, O
suggesting O
that O
AERNs O
are O
an O
interesting O
area O
for O
further O
investigation O

This O
study O
of O
complexity O
work O
and O
complexification O
shows O
that O
biosocial O
complexity O
is O
hardly O
a O
univocal O
enterprise O
in O
epigenetics O

Currently O
, O
available O
therapies O
provide O
only O
symptomatic O
relief O
and O
unable O
to O
treat O
the O
underlying O
pathophysiology O
of O
diabetic B-Disease
nephropathy O

This O
article O
reviews O
several O
examples O
that O
illustrate O
well O
how O
different O
environmental O
pressures O
, O
particularly O
those O
imposed O
by O
pathogens O
and O
infectious B-Disease
diseases I-Disease
, O
have O
shaped O
the O
patterns O
of O
genetic O
and O
epigenetic O
variability O
currently O
observed O
in O
human O
populations O

In O
this O
article O
, O
we O
propose O
a O
graph O
neural O
network-based O
model O
for O
the O
extraction O
of O
molecular O
features O
, O
thus O
reducing O
the O
computational O
requirements O

Four O
EAA O
estimates O
( O
intrinsic O
epigenetic O
age O
acceleration O
, O
extrinsic O
epigenetic O
age O
acceleration O
, O
PhenoAge O
acceleration O
, O
and O
GrimAge O
acceleration O
) O
were O
calculated O
from O
DNA O
methylation O
levels O
measured O
at O
Y15 O
and O
Y20 O

XCI O
is O
essential O
for O
female O
mammalian O
development O
, O
and O
its O
failure O
can O
lead O
to O
embryonic O
death B-Disease
in O
mutant O
mice O

7 O
% O
of O
the O
28 O

The O
most O
common O
epigenetic O
alterations O
are O
DNA O
methylation O
and O
histone O
modification O

These O
considerations O
suggest O
that O
epidemiological O
approaches O
will O
remain O
fruitful O
as O
we O
enter O
the O
decade O
of O
the O
epigenome O

106 O
: O
Peripheral O
T-cell O
lymphoma B-Disease
( O
PTCL O
) O
is O
a O
rare O
and O
heterogeneous O
group O
of O
clinically O
aggressive O
diseases O
associated O
with O
poor O
prognosis O

Any O
summary O
and O
selection O
of O
resources O
is O
inherently O
limited O
, O
given O
the O
spectrum O
available O
, O
but O
the O
aim O
is O
to O
provide O
a O
guideline O
for O
the O
assessment O
and O
comparison O
of O
currently O
available O
provision O
, O
particularly O
as O
this O
relates O
to O
epigenetics/epigenomics O

Concerning O
development O
, O
it O
cements O
the O
vision O
of O
a O
reactive O
genome O
strongly O
coupled O
to O
its O
environment O

We O
show O
that O
pseudotime O
analysis O
can O
be O
applied O
to O
DNA O
methylation O
in O
human O
blood O
and O
brain O
tissue O
and O
find O
that O
it O
is O
highly O
correlated O
with O
the O
epigenetic O
states O
described O
by O
the O
Epigenetic O
Pacemaker O

Tumor O
cell O
populations O
consist O
of O
different O
subpopulations O
that O
have O
distinct O
phenotypic O
and O
genotypic O
profiles O

The O
aim O
of O
the O
study O
was O
to O
present O
selected O
epigenetic O
pathways O
, O
their O
significance O
in O
cardiovascular B-Disease
diseases I-Disease
, O
and O
their O
potential O
as O
a O
therapeutic O
target O
in O
specific O
medical O
conditions O

Recent O
findings O
: O
New O
studies O
have O
further O
strengthened O
the O
evidence O
that O
joint O
tissue O
cells O
highly O
dependent O
on O
epigenetic O
control O
mechanisms O
, O
such O
as O
methylation O
at O
CpG-sites O
, O
noncoding O
RNAs O
and O
histone O
modifications O
to O
assure O
phenotypic O
plasticity O
and O
respective O
tissue O
homeostasis O

460 O
: O
Finding O
correlations O
across O
multiple O
data O
sets O
in O
imaging O
and O
( O
epi O
) O
genomics O
is O
a O
common O
challenge O

This O
chapter O
provides O
a O
broad O
overview O
of O
the O
major O
genomic O
databases O
and O
browsers O
, O
and O
describes O
various O
approaches O
and O
the O
latest O
resources O
for O
searching O
them O

Artificial O
Intelligence O
, O
and O
in O
particular O
Machine O
Learning O
, O
are O
emerging O
as O
powerful O
resources O
to O
decipher O
epigenomic O
data O

Gene O
ontology O
( O
GO O
) O
analysis O
yielded O
epigenetic O
alterations O
in O
important O
cardiovascular O
developmental O
genes O
and O
biological O
processes O
: O
abnormal B-Disease
morphology I-Disease
of I-Disease
cardiovascular I-Disease
system I-Disease
, O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
, O
heart O
conduction O
disorder B-Disease
, O
thrombus B-Disease
formation I-Disease
, O
and O
coronary O
artery O
disease B-Disease

Hence O
, O
adequate O
emphasis O
should O
be O
given O
to O
such O
factors O
in O
an O
individual O
's O
nutrition O
, O
especially O
early O
in O
life O

Recent O
findings O
showed O
that O
drug O
response O
could O
be O
largely O
influenced O
by O
the O
presence O
of O
aberrant O
epigenetic O
marks O
of O
the O
whole O
genome O

This O
is O
a O
very O
brief O
review O
of O
some O
early O
discoveries O
, O
and O
by O
no O
means O
is O
a O
complete O
account O
of O
the O
history O
of O
epigenetics O

Stem O
Cells O
2018 O
; O
36 O
: O
1697-1708 O

The O
recovery O
of O
pseudotime O
increases O
the O
temporal O
resolution O
of O
single-cell O
transcriptional O
data O
, O
but O
is O
challenging O
due O
to O
the O
high O
variability O
in O
gene O
expression O
between O
individual O
cells O

Thus O
, O
this O
review O
focuses O
on O
the O
emerging O
area O
of O
pharmaco(epi)genomics O
, O
specifically O
highlighting O
epigenetic O
reprogramming O
during O
tumorigenesis B-Disease
and O
how O
epigenetic O
markers O
are O
targeted O
as O
a O
therapy O
( O
epidrugs O
) O
and O
the O
clinical O
implications O
of O
this O
for O
cancer B-Disease
treatment O

g O

Conclusion O
: O
The O
S3EQ O
method O
can O
be O
applied O
to O
improve O
the O
correlative O
power O
of O
transcriptomic O
and O
epigenomic O
studies O
in O
neuronal O
tissue O

I'm O

After O
, O
we O
improved O
the O
selection O
with O
a O
data-driven O
procedure O
, O
based O
on O
Boruta O

Epigenetics O
is O
more O
and O
more O
emerging O
as O
a O
basis O
for O
cardiac O
malformations O

They O
find O
substantial O
epigenetic O
variation O
among O
plant O
individuals O

Recent O
establishment O
of O
large-scale O
genome O
sequencing O
projects O
will O
result O
in O
a O
significant O
increase O
in O
genome O
availability O
that O
will O
lead O
to O
new O
demands O
for O
data O
analysis O
including O
new O
predictive O
bioinformatics O
approaches O
that O
can O
be O
verified O
with O
traditional O
scientific O
rigor O

The O
emerging O
tools O
of O
epigenetics O
can O
be O
used O
as O
preventive O
, O
diagnostic O
, O
and O
therapeutic O
markers O

Social O
epigenetics O
is O
an O
emerging O
area O
of O
research O
that O
aims O
to O
uncover O
biological O
pathways O
through O
which O
social O
experiences O
affect O
health O
outcomes O

Similarly O
, O
accurate O
models O
should O
be O
able O
to O
guide O
the O
rational O
screening O
of O
compound O
libraries O

Then O
we O
discuss O
the O
potential O
of O
using O
targeted O
epigenetic O
pharmacotherapy O
, O
combined O
with O
psychosocial O
interventions O
, O
for O
future O
personalized O
medicine O
for O
patients O

Due O
to O
their O
intimacy O
with O
DNA O
, O
histones O
have O
a O
central O
role O
in O
chromatin O
structure O
and O
epigenetic O
regulation O

They O
mainly O
arise O
from O
heterogeneity B-Disease
at O
the O
individual O
and O
tissue O
level O
and O
require O
future O
strategies O
in O
order O
to O
reinforce O
the O
biological O
relevance O
of O
epigenetic O
data O
and O
its O
translational O
use O
in O
psychiatry O

This O
review O
will O
focus O
on O
the O
potential O
of O
vitamin O
C O
to O
optimize O
the O
outcome O
of O
epigenetic O
therapy O
in O
cancer B-Disease
patients O
and O
alternatively O
to O
act O
as O
a O
therapeutic O
at O
high O
doses O

This O
review O
discusses O
cancer B-Disease
biomarkers O
, O
the O
characteristics O
of O
an O
ideal O
biomarker O
for O
cancer B-Disease
, O
and O
technologies O
for O
biomarker O
detection O

To O
accomplish O
an O
era O
of O
gene-environment-wide O
interaction O
studies O
, O
it O
is O
necessary O
to O
launch O
a O
national O
human O
epigenome O
project O

The O
metabolism-induced O
recoding O
of O
epigenetics O
in O
cancer B-Disease
depends O
strongly O
on O
nutrient O
availability O
for O
tumor B-Disease
cells O

Recommendations O
for O
safeguards O
and O
guidelines O
on O
the O
use O
of O
epigenetics O
with O
children O
and O
adolescents O
are O
outlined O
based O
on O
the O
identified O
issues O

Further O
, O
they O
describe O
the O
implications O
of O
epigenetic O
mechanisms O
in O
the O
etiopathogenesis O
of O
the O
disease B-Disease
and O
the O
effects O
of O
current O
antipsychotic O
drugs O
on O
epigenetic O
processes O

J O
Biomed O
Mater O
Res O
Part O
B O
: O
Appl O
Biomater O
, O
106B O
: O
2065-2071 O
, O
2018 O

Advantages O
of O
the O
described O
method O
include O
amplification-insensitive O
detection O
, O
5-hydroxymethylcytosine O
complexation O
, O
and O
visualization O
through O
methylation-specific O
in O
situ O
hybridization O

Here O
, O
the O
evidence O
of O
the O
epigenetic O
correlates O
of O
prenatal O
adversities O
, O
NICU-related O
environment O
and O
development O
of O
preterm O
infants O
is O
systematically O
reviewed O

Behavioural O
genomics O
is O
beginning O
to O
demonstrate O
links O
to O
biological O
mechanisms O
through O
regulation O
of O
gene O
expression O
, O
which O
directs O
the O
proteome O
and O
influences O
the O
personal O
phenotype O

It O
offers O
unique O
opportunities O
to O
integrate O
new O
technologies O
and O
concepts O
to O
disease B-Disease
prognosis O
, O
diagnosis O
and O
therapeutics O

Our O
results O
indicate O
that O
the O
models O
reported O
herein O
have O
considerable O
potential O
to O
identify O
small O
molecules O
with O
epigenetic O
activity O

Epigenetics O
is O
the O
study O
of O
biochemical O
modifications O
to O
DNA O
and O
to O
histones O
, O
the O
proteins O
that O
provide O
stability O
to O
DNA O

Scaled O
MAD O
tended O
to O
be O
lower O
among O
individuals O
in O
captive O
populations O
, O
and O
decreased O
with O
an O
increasing O
number O
of O
CpG O
sites O

International O
experts O
in O
genetics O
, O
epigenetics O
, O
computational O
biology O
, O
and O
physiology O
discussed O
the O
current O
state O
of O
understanding O
of O
the O
relationships O
between O
genetics O
, O
epigenetics O
, O
and O
environment O
in O
diabetes B-Disease
and O
examined O
existing O
evidence O
for O
the O
role O
of O
epigenetic O
factors O
in O
regulating O
metabolism O

Consequently O
, O
this O
cohort O
can O
be O
a O
vital O
tool O
for O
researchers O
seeking O
to O
validate O
observational O
results O
from O
human O
population O
studies O
and O
perform O
detailed O
mechanistic O
studies O
in O
a O
controlled O
cell O
culture O
environment O

In O
summary O
, O
the O
conference O
highlighted O
the O
functional O
implication O
of O
epigenetics O
in O
chromatin O
compaction O
, O
transcription O
regulation O
, O
replication O
control O
and O
DNA O
repair O

We O
also O
assessed O
their O
level O
of O
concern O
regarding O
four O
emerging O
non-medical O
applications O
of O
epigenetic O
testing-i O

It O
therefore O
allows O
the O
identification O
of O
susceptibility O
loci O
that O
may O
be O
sensitive O
to O
modification O
by O
the O
environment O

Lastly O
, O
we O
identified O
180 O
differentially O
methylated O
regions O
with O
age O
in O
skeletal O
muscle O
at O
a O
false O
discovery O
rate O
< O
0 O

However O
, O
further O
research O
is O
needed O
, O
including O
additional O
studies O
, O
replication O
, O
validation O
, O
and O
application O
beyond O
clinical O
settings O

Annotation O
, O
comparison O
, O
visualization O
, O
and O
interpretation O
of O
epigenomic O
datasets O
remain O
key O
aspects O
of O
computational O
biology O

The O
preclinical O
evidence O
for O
efficacy O
of O
pharmacological O
approaches O
that O
target O
epigenetics O
in O
the O
CNS O
and O
the O
particular O
challenges O
of O
this O
approach O
are O
also O
examined O

He O
received O
the O
2018 O
Northern O
Communities O
Health O
Foundation O
Visiting O
Professorship O
Award O
at O
the O
University O
of O
Adelaide O
, O
Australia O

We O
extended O
the O
model-based O
analyses O
of O
EpiMix O
to O
cis-regulatory O
elements O
within O
protein-coding O
genes O
, O
distal O
enhancers O
, O
and O
genes O
encoding O
microRNAs O
and O
long O
non-coding O
RNAs O
( O
lncRNAs O
) O

The O
epigenome O
provides O
a O
mechanistic O
link O
between O
environmental O
exposures O
and O
gene O
expression O
profiles O
ultimately O
leading O
to O
disease B-Disease

The O
potential O
reversibility O
of O
these O
epigenetic O
changes O
that O
occur O
as O
a O
hallmark O
of O
aging O
offers O
exciting O
opportunities O
to O
alter O
the O
trajectory O
of O
age-related O
diseases O

In O
the O
last O
decade O
, O
an O
exciting O
boom O
of O
experimental O
research O
has O
brought O
to O
light O
the O
pivotal O
biological O
functions O
of O
long O
non-coding O
RNAs O
( O
lncRNAs O
) O
, O
representing O
more O
than O
the O
half O
of O
the O
whole O
non-coding O
transcriptome O
, O
along O
with O
their O
dysregulation O
in O
many O

Summary O
: O
Recent O
conceptual O
advances O
in O
the O
field O
of O
DNA O
methylation O
and O
the O
advent O
and O
rapid O
development O
of O
new O
technologies O
in O
epigenomics O
have O
started O
to O
unravel O
the O
mechanisms O
underlying O
aberrant O
DNA O
methylation O
in O
cancer B-Disease
cells O
and O
identify O
novel O
targets O
for O
diagnosis O
, O
risk O

Assay O
miniaturization O
increases O
screening O
throughput O
and O
reduces O
operating O
costs O

DNA O
methylation O
is O
an O
epigenetic O
mark O
and O
is O
involved O
in O
plants O
' O
biological O
processes O
, O
including O
development O
, O
stress O
adaptation O
, O
and O
genome O
evolution O

However O
, O
how O
transcriptional O
activities O
are O
molecularly O
controlled O
and O
which O
of O
the O
many O
known O
epigenomic O
features O
have O
causal O
roles O
remains O
unclear O

At O
the O
cellular O
level O
, O
ageing O
is O
associated O
with O
reduced O
function O
, O
altered O
gene O
expression O
and O
a O
perturbed O
epigenome O

html O
) O

Summary O
: O
Technical O
advancements O
in O
genomics O
, O
particularly O
epigenomics O
, O
shed O
light O
on O
the O
role O
of O
epigenetics O
and O
recently O
epitranscriptomics O
in O
different O
fields O

Meanwhile O
, O
STR O
multiplexes O
have O
been O
developed O
and O
made O
commercially O
available O
which O
simultaneously O
amplify O
up O
to O
30 O
STR O
loci O
from O
as O
little O
as O
15 O
cells O
or O
fewer O

Increasing O
evidence O
also O
implicates O
activity-dependent O
regulation O
of O
epigenetic O
mechanisms O
to O
alter O
chromatin O
architecture O

127 O
: O
This O
paper O
provides O
a O
summary O
of O
literature O
on O
epigenetic O
effects O
and O
infant O
health O
outcomes O
of O
maternal O
psychosocial O
stress O
during O
pregnancy O

Following O
that O
, O
we O
will O
point O
out O
some O
challenges O
in O
which O
an O
epigenetic O
viewpoint O
may O
be O
essential O
for O
the O
evaluation O
of O
chemical O
safety O
, O
and O
we O
will O
show O
some O
current O
approaches O

Dr O
Jirtle O
was O
also O
given O
the O
Alexander O
Hollaender O
Award O
in O
2019 O
at O
the O
50th O
annual O
meeting O
of O
the O
Environmental O
Mutagenesis O
and O
Genomics O
Society O

515 O
: O
Health O
problems O
associated O
with O
aging O
are O
a O
major O
public O
health O
concern O
for O
the O
future O

Thanks O
to O
the O
recently O
introduced O
bisulfite-sequencing-based O
methods O
, O
it O
is O
possible O
to O
profile O
the O
entire O
methylome O
at O
single-cell O
resolution O

125 O
: O
Epigenetics O
is O
defined O
as O
the O
modulation O
of O
gene O
expression O
without O
changes O
to O
the O
underlying O
DNA O
sequence O

In O
this O
review O
, O
we O
discuss O
current O
findings O
in O
mitochondrial O
epigenetics O
as O
well O
as O
its O
potential O
role O
as O
a O
regulator O
of O
mitochondria O
within O
the O
brain O

The O
technique O
does O
not O
require O
special O
equipment O
and O
is O
independent O
of O
prior O
knowledge O
about O
the O
genome O

Thereafter O
, O
using O
specific O
antibody O
directed O
against O
the O
protein O
of O
interest O
the O
covalently O
cross-linked O
DNA O
is O
pulled O
down O
together O
with O
Protein O
A O
or O
G O
carrying O
beads O
that O
bind O
the O
Fc O
fragment O
of O
the O
antibody O

Scientists O
and O
physicians O
in O
each O
of O
those O
silos O
have O
not O
often O
paid O
attention O
to O
the O
brain-body O
communication O
that O
leads O
to O
multi-morbidity O
of O
systemic O
and O
brain-related O
disorders O
[eg O

We O
describe O
biomarker O
assays O
to O
validate O
the O
probes O
in O
specific O
cellular O
systems O
, O
and O
provide O
guidelines O
for O
their O
use O
in O
functional O
characterization O
of O
methyltransferases O
including O
detailed O
protocols O
, O
examples O
, O
and O
controls O

In O
this O
review O
, O
we O
provide O
an O
overview O
of O
epigenetics O
, O
DOHaD O
, O
NCDs O
, O
and O
the O
links O
between O
them O

All O
three O
techniques O
provide O
absolute O
measurements O
of O
methylation O
and O
hydroxymethylation O
levels O
at O
single-base O
resolution O

Substantial O
challenges O
exist O
in O
determining O
DNA O
methylation O
to O
situation-specific O
phenotypic O
traits O

They O
can O
be O
used O
as O
biomarkers O
in O
risk O
calculation O
, O
early O
diagnosis O
, O
and O
evaluation O
of O
prognosis O
of O
GC O
, O
as O
well O
as O
treatment O
targets O

g O

Additionally O
, O
it O
also O
facilitates O
' O
Viral O
EpiGenome O
Browser' O
for O
user-affable O
browsing O
experience O
using O
JavaScript-based O
JBrowse O

However O
, O
current O
technologies O
in O
DPI O
profiling O
still O
suffer O
from O
high O
cell O
demands O
, O
low O
detection O
sensitivity O
, O
and O
large O
reagent O
consumption O

Several O
methods O
have O
been O
proposed O
to O
deal O
with O
mediation O
in O
high-dimensional O
settings O
, O
including O
methods O
that O
incorporate O
dimensionality O
reduction O
techniques O
to O
the O
mediation O
algorithm O

47 O
: O
The O
past O
decade O
has O
seen O
an O
explosion O
of O
articles O
in O
scientific O
journals O
involving O
non-genetic O
influences O
on O
phenotype O
through O
modulation O
of O
gene O
function O
without O
changes O
in O
gene O
sequence O

We O
also O
highlight O
the O
knowledge O
gaps O
that O
need O
to O
be O
investigated O
for O
understanding O
the O
entire O
role O
of O
DNA O
methylation O
in O
plant O
pathogen O
interactions O

These O
readily O
available O
epigenetic O
clocks O
can O
be O
used O
for O
elephant O
conservation O
efforts O
where O
accurate O
estimates O
of O
age O
are O
needed O
to O
predict O
demographic O
trends O

Given O
that O
epigenetic O
modifications O
are O
sensitive O
to O
environment O
, O
stable O
, O
and O
reversible O
, O
epigenetic O
studies O
in O
psychiatry O
could O
represent O
a O
promising O
approach O
to O
better O
understanding O
and O
treating O
disease B-Disease

The O
first O
epigenetic O
inhibitors O
are O
already O
approved O
for O
human O
treatment O

80 O
: O
Epigenetics O
can O
be O
defined O
as O
stable O
, O
potentially O
heritable O
changes O
in O
the O
cellular O
phenotype O
caused O
by O
mechanisms O
other O
than O
alterations O
to O
the O
underlying O
DNA O
sequence O

Altogether O
, O
these O
resources O
make O
the O
epigenetic O
study O
of O
marine O
organisms O
( O
and O
more O
specifically O
marine O
invertebrates O
) O
a O
reality O

The O
quality O
of O
age O
predictions O
might O
particularly O
be O
influenced O
by O
lifetime O
adversities O
( O
chronic B-Disease
stress I-Disease
, O
trauma/post-traumatic O
stress O
disorder B-Disease
( O
PTSD O
) O
, O
violence O
, O
low O
socioeconomic O
status/education O
) O
, O
cancer B-Disease
, O
obesity B-Disease
and O
related O
diseases O
, O
infectious O

g O

Availability O
and O
implementation O
: O
SPAN O
and O
JBR O
run O
on O
Linux O
, O
Mac O
OS O
and O
Windows O
, O
and O
is O
freely O
available O
at O
https://research O

It O
is O
noted O
that O
family O
researchers O
are O
incorporating O
genetic O
factors O
in O
their O
research O
with O
increasing O
frequency O

We O
estimated O
technical O
noise O
and O
intra-subject O
variation O
using O
two O
datasets O
with O
repeated O
sampling O

B O
and O
T O
lymphocyte O
abnormalities O
, O
dysregulation O
of O
apoptosis O
, O
defects O
in O
the O
clearance O
of O
apoptotic O
materials O
, O
and O
various O
genetic O
and O
epigenetic O
factors O
are O
believed O
to O
contribute O
to O
the O
initiation O
and O
development O
of O
SLE O

Nutrients O
such O
as O
L-methylfolate O
and O
S-adenosylmethionine O
may O
also O
be O
useful O
in O
nutritional O
therapy O
of O
these O
disorders O

Genes O
differentially O
methylated O
among O
these O
racially O
and O
ethnically O
diverse O
populations O
were O
involved O
in O
important O
cellular O
functions O
, O
such O
as O
tumor B-Disease
growth O
, O
tumor B-Disease
suppression O
, O
hormone O
receptors O
, O
and O
genes O
involved O
in O
tumor B-Disease
metastasis O

The O
origin O
of O
epigenetic O
variance O
can O
be O
attributed O
to O
genetic O
, O
environmental O
, O
or O
stochastic O
factors O


We O
review O
the O
current O
literature O
of O
epigenetic O
studies O
on O
PCOS O
from O
disease B-Disease
development O
to O
the O
association O
analysis O
of O
the O
DNA O
methylome O
and O
to O
exploratory O
studies O
on O
the O
molecular O
mechanisms O
of O
disease B-Disease
heterogeneity B-Disease
and O
comorbidity O

Epigenetic O
therapy O
using O
DAC O
should O
be O
an O
attractive O
strategy O
for O
lung B-Disease
cancer I-Disease
therapy O

Current O
technologies O
that O
not O
only O
read O
out O
the O
DNA O
sequence O
, O
but O
also O
determine O
how O
the O
DNA O
is O
modified O
in O
response O
to O
the O
environment O
, O
promise O
new O
insight O
into O
how O
puberty O
is O
regulated O
, O
including O
the O
identification O
and O
understanding O
of O
gene O
regulatory O
networks O
that O
control O
the O
biological O

In O
this O
review O
, O
we O
will O
discuss O
and O
summarize O
recent O
advances O
in O
PROTAC O
discovery O
with O
focus O
on O
epigenetic O
targets O

Source O
code O
, O
tests O
, O
code O
examples O
and O
documentation O
are O
available O
via O
the O
website O
at O
http://www O

Rapidly O
evolving O
methodologies O
of O
exposure O
assessment O
and O
the O
conceptual O
framework O
of O
the O
Exposome O
, O
first O
introduced O
in O
2005 O
, O
are O
new O
frontiers O
of O
environmental O
research O

Associations O
were O
also O
evident O
for O
three O
individual O
components O
of O
GrimAge O
, O
but O
were O
inconsistent O
for O
other O
measures O
of O
biological O
aging O

The O
recent O
identification O
of O
5-hydroxymethylcytosine O
( O
5hmC O
) O
, O
which O
is O
enriched O
in O
the O
brain O
( O
tenfold O
over O
peripheral O
tissues O
) O
, O
raises O
new O
questions O
as O
to O
the O
role O
of O
this O
base O
in O
mediating O
epigenetic O
effects O
in O
the O
brain O

Reflecting O
these O
age-related O
epigenetic O
changes O
, O
Nfic O
RNA O
expression O
in O
blood O
decreased O
with O
age O
, O
suggesting O
that O
age-related O
regulation O
of O
this O
gene O
may O
be O
driven O
by O
5hmC O
, O
not O
canonical O
DNA O
methylation O

Ten O
articles O
met O
inclusion O
criteria O

Epigenetic O
modification O
plays O
a O
central O
role O
in O
neurobiological O
and O
developmental O
processes O
, O
and O
disturbances O
to O
these O
processes O
can O
have O
implications O
for O
a O
range O
of O
mental O
health O
problems O

Although O
the O
advent O
of O
genome-wide O
DNA O
methylation O
profiling O
in O
primary O
disease B-Disease
tissue O
has O
provided O
a O
manifold O
resource O
for O
biomarker O
development O
, O
only O
a O
tiny O
fraction O
of O
DNA O
methylation-based O
assays O
have O
reached O
clinical O
testing O

10 O
years O
old O

Here O
we O
present O
a O
new O
methodological O
strategy O
to O
properly O
and O
unambiguously O
extract O
DNA O
methylation O
patterns O
of O
repetitive O
, O
as O
well O
as O
single O
genetic O
loci O
from O
pure O
cell-free O
DNA O
from O
peripheral O
blood O

We O
have O
developed O
a O
pipeline O
for O
the O
Galaxy O
platform O
for O
those O
without O
experience O
aimed O
at O
DNA O
methylation O
analysis O
using O
the O
Infinium O
Human O
methylation O
BeadChip O

595 O
: O
Bladder O
cancer B-Disease
is O
a O
heterogeneous O
disease B-Disease
, O
both O
clinically O
and O
pathologically O

The O
three O
major O
classes O
of O
epigenetic O
effectors O
are O
DNA O
methylation O
, O
histone O
post-translational O
modifications O
( O
such O
as O
acetylation O
, O
methylation O
or O
phosphorylation O
) O
and O
small O
noncoding O
RNAs O
( O
most O
notably O
microRNAs O
) O

However O
, O
there O
is O
a O
paucity O
of O
DNAm O
models O
which O
attempt O
to O
distinguish O
current O
, O
former O
and O
never O
smokers O
as O
individual O
classes O

PU O

For O
example O
, O
pathways O
related O
to O
activation O
and O
proliferation O
of O
helper O
and O
cytotoxic O
T O
cells O
appear O
to O
be O
more O
highly O
enriched O
in O
kidney O
, O
skin O
, O
head O
and O
neck O
, O
and O
esophageal O
cancers B-Disease
compared O
to O
those O
of O
lung O
, O
colorectal O
, O
and O
liver O
or O
bile O

In O
this O
issue O
of O
Molecular O
Ecology O
, O
Herrera O
& O
Bazaga O
( O
2011 O
) O
provide O
one O
of O
the O
first O
attempts O
to O
truly O
address O
this O
question O
in O
an O
ecological O
setting O

Recently O
, O
in O
the O
context O
of O
expanding O
knowledge O
of O
the O
epigenome O
( O
DNA O
methylation O
, O
histone O
modifications O
, O
and O
noncoding O
RNAs O
) O
, O
its O
potential O
involvement O
in O
the O
onset O
and O
progression O
of O
AF O
pathophysiology O
has O
started O
to O
emerge O

153 O
: O
Background O
: O
Advances O
in O
omics O
and O
computational O
Artificial O
Intelligence O
( O
AI O
) O
have O
been O
said O
to O
be O
key O
to O
meeting O
the O
objectives O
of O
precision O
cardiovascular O
medicine O

DNA O
methylation O
, O
cause O
cancer B-Disease

Methods O
: O
Participants O
were O
248 O
members O
of O
the O
Lothian O
Birth O
Cohort O
1936 O

348 O
: O
After O
sequencing O
the O
human O
genome O
, O
it O
has O
become O
clear O
that O
genetic O
information O
alone O
is O
not O
sufficient O
to O
understand O
phenotypic O
manifestations O

Conclusion O
: O
In O
an O
exploratory O
study O
we O
report O
the O
use O
of O
AI O
and O
epigenomics O
to O
achieve O
important O
objectives O
of O
precision O
cardiovascular O
medicine O

The O
articles O
also O
demonstrate O
that O
, O
in O
addition O
to O
genetic O
polymorphisms O
, O
epigenetics O
may O
also O
contribute O
to O
wide O
interindividual O
variations O
in O
drug O
metabolism O
and O
transport O

001 O

These O
altered O
epigenetic O
patterns O
are O
potential O
useful O
biomarkers O
to O
detect O
cancer B-Disease
cells O
and O
to O
classify O
tumor B-Disease
types O

Some O
transcriptomic O
and O
epigenomic O
changes O
were O
shared O
between O
talc O
and O
titanium O
dioxide O
, O
however O
, O
it O
is O
especially O
interesting O
that O
each O
of O
the O
two O
particles O
of O
similar O
size O
and O
insoluble O
nature O
has O
also O
induced O
a O
specific O
pattern O
of O
gene O
expression O
and O
DNA O
methylation O
changes O
which O
we O

Tumor O
plasticity O
is O
controlled O
by O
genetic O
and O
epigenetic O
changes O
of O
crucial O
genes O
involved O
in O
cancer B-Disease
cell O
survival O
, O
growth O
and O
metastasis O

491 O
: O
Epigenetic O
inheritance O
occurs O
due O
to O
different O
mechanisms O
such O
as O
chromatin O
and O
histone O
modifications O
, O
DNA O
methylation O
and O
processes O
mediated O
by O
non-coding O
RNAs O

We O
then O
will O
recapitulate O
some O
of O
the O
recent O
applications O
of O
ML O
to O
epigenomic O
analysis O

243 O
: O
Acupuncture O
has O
been O
widely O
used O
for O
treating O
diseases O
since O
the O
ancient O
days O
in O
China O
, O
but O
the O
mechanism O
by O
which O
acupuncture O
exerts O
such O
powerful O
roles O
is O
unclear O

Results O
: O
Among O
162,887 O
imputed O
or O
genotyped O
variants O
in O
555 O
candidate O
genes O
, O
SNPs O
in O
eight O
genes O
were O
associated O
with O
risk O
of O
more O
than O
one O
cancer B-Disease
type O

We O
used O
targeted O
bisulfite O
sequencing O
to O
amplify O
48 O
CpGs O
from O
four O
genes O
in O
muscle O
samples O
and O
applied O
penalized O
regressions O
to O
predict O
age O

Charge O
transfer O
via O
quantum O
tunneling O
mediated O
by O
overlapping O
orbitals O
results O
in O
charge O
delocalization O
along O
several O
neighboring O
bases O
, O
which O
can O
even O
be O
extended O
by O
classical O
( O
non-quantum O
) O
electron O
hopping O

In O
order O
to O
do O
so O
, O
we O
first O
describe O
the O
place O
of O
questions O
regarding O
the O
relative O
weight O
of O
paternal O
and O
maternal O
influences O
on O
the O
health O
of O
the O
offspring O
in O
the O
discursive O
formalisation O
of O
this O
research O
in O
scientific O
publications O

Importantly O
, O
interventions O
that O
clear O
senescent O
cells O
have O
achieved O
marked O
improvements O
in O
healthspan O
and O
lifespan O
in O
mice O

New O
data O
suggest O
that O
epigenetic O
influences O
might O
be O
involved O
in O
the O
regulation O
of O
fetal O
development O
and O
the O
pathophysiology O
of O
adult O
diseases O
such O
as O
cancer B-Disease
, O
diabetes B-Disease
, O
obesity B-Disease
, O
and O
neurodevelopmental O
disorders O

1 O
: O
Neuromuscular B-Disease
disorders I-Disease
are O
a O
heterogeneous O
group O
of O
conditions O
affecting O
the O
neuromuscular O
system O

Recent O
emergence O
of O
epigenetic O
modulation O
in O
shaping O
the O
genetic O
information O
has O
become O
a O
key O
regulatory O
factor O
in O
answering O
the O
underlying O
complexities O
associated O
with O
several O
mental B-Disease
disorders I-Disease

556 O
: O
Epigenetic O
mechanisms O
, O
which O
include O
DNA O
methylation O
, O
histone O
modification O
, O
and O
microRNA O
( O
miRNA O
) O
, O
can O
produce O
heritable O
phenotypic O
changes O
without O
a O
change O
in O
DNA O
sequence O

, O
sociologists O
, O
scholars O
of O
STS O
, O
and O
behavioural O
scientists O
, O
share O
a O
focus O
and O
definition O
of O
epigenetics O
that O
is O
environmentally O
caused O
and O
trans-generationally O
inherited O

360 O
: O
It O
is O
unknown O
if O
adult O
human O
skeletal O
muscle O
has O
an O
epigenetic O
memory O
of O
earlier O
encounters O
with O
growth O

DNA O
methylation O
is O
a O
major O
epigenetic O
mechanism O
that O
is O
most O
intensively O
studied O
in O
the O
context O
of O
gene O
regulation O
and O
unscheduled O
silencing O
in O
cancer B-Disease
cells O


275 O
: O
Epigenetics O
is O
a O
new O
branch O
of O
genetics O
which O
studies O
reversible O
and O
heritable O
changes O
of O
gene O
function O
that O
do O
not O
involve O
alterations O
in O
DNA O
sequence O
of O
nucleus O

We O
assess O
the O
historical O
forces O
structuring O
the O
use O
of O
epimutation O
and O
like O
terms O
such O
as O
paramutation O

Large-scale O
multiomics O
studies O
will O
facilitate O
the O
prioritization O
of O
putative O
causal O
risk O
variants O
and O
gene O
networks O
that O
contribute O
to O
schizophrenia B-Disease
etiology O
, O
informing O
clinical O
diagnostics O
and O
treatment O
downstream O

178 O
: O
Genetics O
and O
environmental O
factors O
have O
important O
roles O
in O
autoimmune O
diseases O
but O
neither O
has O
given O
us O
sufficient O
understanding O
of O
these O
mysterious O
diseases O

To O
explore O
the O
role O
epigenetic O
inheritance O
plays O
in O
evolution O
, O
we O
subject O
isogenic O
wild-type O
yeast O
cells O
expressing O
PGAL1-YFP O
( O
yellow O
fluorescent O
protein O
) O
to O
selection O
by O
daily O
sorting O
based O
on O
reporter O
expression O

366 O
: O
Cancer B-Disease
genome O
analyses O
have O
revealed O
that O
the O
enzymes O
involved O
in O
epigenetic O
gene O
regulation O
are O
frequently O
deregulated O
in O
cancer B-Disease

Dysregulation O
of O
these O
epigenetic O
mechanisms O
as O
well O
as O
genomic O
mutations O
at O
imprinted O
gene O
clusters O
can O
lead O
to O
human O
disease B-Disease

328 O
: O
The O
growing O
interest O
in O
epigenetic O
probes O
and O
drug O
discovery O
, O
as O
revealed O
by O
several O
epigenetic O
drugs O
in O
clinical O
use O
or O
in O
the O
lineup O
of O
the O
drug O
development O
pipeline O
, O
is O
boosting O
the O
generation O
of O
screening O
data O

This O
review O
will O
provide O
an O
overview O
of O
the O
major O
epigenetic O
pathways O
and O
modern O
techniques O
for O
their O
study O
, O
before O
focusing O
on O
experimental O
evidence O
supporting O
a O
strong O
role O
for O
epigenetics O
in O
selected O
psychiatric B-Disease
disorders I-Disease
such O
as O
depression B-Disease
, O
schizophrenia B-Disease
, O
and O
drug O
addiction O

Recently O
, O
studies O
have O
demonstrated O
that O
these O
modifications O
are O
influenced O
not O
only O
by O
biological O
cues O
but O
also O
by O
mechanical O
and O
topographical O
signals O

Although O
these O
disorders O
differ O
in O
their O
underlying O
causes O
and O
pathophysiologies O
, O
many O
involve O
the O
dysregulation O
of O
restrictive O
element O
1-silencing O
transcription O
factor O
( O
REST O
) O
, O
which O
acts O
via O
epigenetic O
mechanisms O
to O
regulate O
gene O
expression O

Nevertheless O
, O
the O
lack O
of O
epigenetic O
knowledge O
in O
other O
ecologically O
and O
environmentally O
relevant O
organisms O
has O
hampered O
the O
application O
of O
these O
tools O
in O
a O
broader O
range O
of O
ecosystems O
, O
most O
notably O
in O
the O
marine O
environment O

Epigenetics O
is O
having O
an O
increasing O
impact O
on O
several O
areas O
of O
pharmacology O

Furthermore O
such O
data O
may O
prove O
of O
use O
in O
providing O
identifying O
information O
, O
providing O
the O
possibility O
of O
a O
future O
forensic O
epigenome O

Methods O
: O
First O
, O
we O
introduce O
how O
the O
advancements O
of O
CRISPR O
technology O
enabled O
genome O
editing O
to O
single O
base O
precision O

In O
multicellular O
organisms O
, O
a O
single O
genome O
can O
give O
rise O
to O
tremendous O
variability O
across O
tissues O
at O
the O
single-cell O
level O
due O
to O
epigenetic O
differences O
in O
the O
genes O
that O
are O
expressed O

It O
constitutes O
a O
mechanism O
by O
which O
cell O
genome O
is O
regulated O
, O
allowing O
from O
a O
common O
genome O
of O
an O
individual O
to O
obtain O
all O
the O
different O
cell O
types O
that O
constitute O
the O
individual O

Overall O
, O
we O
demonstrate O
that O
it O
is O
possible O
to O
separate O
rejuvenation O
from O
complete O
pluripotency O
reprogramming O
, O
which O
should O
facilitate O
the O
discovery O
of O
novel O
anti-ageing O
genes O
and O
therapies O

© O
2022 O
Wiley O
Periodicals O
LLC O

The O
appropriate O
transition O
of O
immune O
cells O
into O
diverse O
functional O
states O
, O
which O
is O
crucial O
for O
immunity O
, O
involves O
complex O
and O
well-regulated O
changes O
in O
transcriptional O
program O

It O
has O
also O
not O
been O
shown O
whether O
this O
epigenetic O
clock O
is O
unique O
to O
humans O
or O
conserved O
in O
the O
more O
experimentally O
tractable O
mouse O

The O
meeting O
was O
centered O
on O
the O
contribution O
of O
epigenetics O
to O
gene O
expression O
, O
DNA O
damage O
and O
repair O
, O
and O
the O
role O
of O
environmental O
factors O

006 O
( O
0 O
) O

Although O
whole O
genome O
microarray O
techniques O
will O
remain O
complementary O
to O
NGS O
for O
some O
time O
in O
domestic O
species O
, O
research O
will O
transition O
to O
sequencing-based O
methods O
due O
to O
cost-effectiveness O
and O
the O
extra O
information O
that O
such O
methods O
provide O

Also O
, O
the O
diversity O
of O
interactions O
between O
DNA O
, O
histones O
, O
and O
transcriptional O
regulators O
is O
much O
bigger O
than O
previously O
considered O

g O

604 O
: O
At O
present O
, O
after O
extensive O
studies O
in O
the O
field O
of O
cancer B-Disease
, O
cancer B-Disease
stem O
cells O
( O
CSCs O
) O
have O
been O
proposed O
as O
a O
major O
factor O
in O
tumor B-Disease
initiation O
, O
progression O
, O
metastasis O
, O
and O
recurrence O

However O
, O
the O
exact O
etiology O
is O
largely O
unknown O

The O
opposition O
to O
all O
forms O
of O
non-genetic O
inheritance O
that O
prevailed O
at O
the O
time O
of O
the O
rise O
of O
the O
Modern O
Synthesis O
helps O
to O
explain O
why O
the O
Baldwin O
effect O
was O
understood O
as O
an O
insignificant O
mechanism O
during O
the O
second O
half O
of O
the O
twentieth O
century O

Indeed O
, O
there O
is O
evidence O
that O
many O
proteins O
and O
metabolites O
involved O
in O
epigenetic O
pathways O
are O
redox O
sensitive O

For O
example O
, O
the O
lifespan O
of O
erythrocytes O
is O
about O
100 O
days O
and O
adults O
make O
about O
two O
million O
new O
erythrocytes O
every O
second O

ncbi O

166 O
: O
Over O
the O
past O
25 O
years O
, O
the O
broad O
field O
of O
epigenetics O
and O
, O
over O
the O
past O
decade O
in O
particular O
, O
the O
emerging O
field O
of O
neuroepigenetics O
have O
begun O
to O
have O
tremendous O
impact O
in O
the O
areas O
of O
learned O
behavior O
, O
neurotoxicology O
, O
CNS O
development O

Molecular O
profiling O
of O
AML O
through O
targeted O
sequencing O
panels O
and O
cytogenetics O
has O
become O
a O
mainstay O
in O
risk-stratifying O
AML O
patients O
and O
guiding O
clinicians O
toward O
optimal O
therapies O
for O
their O
patients O

This O
review O
covers O
the O
latest O
applications O
of O
epigenetic O
therapies O
for O
treatment O
of O
B O
cell O
, O
T O
cell O
, O
and O
Hodgkin O
lymphomas B-Disease
, O
highlighting O
key O
clinical O
trial O
results O
with O
monotherapies O
and O
combination O
therapies O
from O
the O
main O
classes O
of O
epigenetic O
therapies O
, O
including O
inhibitors O

Epigenetic O
research O
with O
the O
advancement O
in O
technology O
has O
helped O
identify O
biomarkers O
, O
therapeutic O
targets O
, O
and O
understand O
cancer B-Disease
causation O
in O
the O
general O
population O

We O
also O
consider O
future O
applications O
of O
epigenetics O
in O
ASD O
research O
and O
clinical O
practice O
, O
focusing O
on O
substratification O
, O
biomarker O
development O
, O
and O
experimental O
preclinical O
models O
of O
ASD O
that O
test O
causality O

The O
findings O
suggest O
that O
in O
the O
standard O
biometric O
model O
when O
MZ O
or O
DZ O
twin O
similarity O
differs O
from O
1 O

These O
are O
consisted O
of O
aggregated O
conformationally O
abnormal O
proteins O

This O
led O
to O
the O
conduct O
of O
epigenome-wide O
association O
studies O
(EWAS) O

This O
heterogeneity B-Disease
confounds O
decisions O
regarding O
treatment O
and O
promotes O
disease B-Disease
relapse O

361 O
: O
Our O
paper O
explores O
the O
value-laden O
and O
epistemic O
resources O
that O
scientists O
working O
in O
epigenetics O
and O
developmental O
programming O
of O
health O
and O
disease B-Disease
( O
DOHaD O
) O
mobilise O
to O
produce O
scientific O
representations O
of O
pregnancy O
and O
parenthood O
, O
which O
in O
turn O
imagine O
norms O
, O
values O
, O

This O
reductionism O
about O
biosocial O
dynamics O
of O
disease B-Disease
, O
we O
argue O
, O
hampers O
the O
pursuit O
of O
the O
goals O
epigenetics O
has O
given O
itself O
( O
in O
cardiology O
and O
beyond O
) O

33 O
) O

In O
this O
review O
we O
discuss O
the O
application O
of O
epigenomics O
as O
a O
tool O
for O
biomarker O
research O
, O
with O
the O
focus O
on O
the O
analysis O
of O
DNA O
methylation O
in O
biofluids O

The O
authors O
conclude O
with O
a O
discussion O
of O
challenges O
and O
opportunities O
, O
including O
intervention O
, O
as O
the O
field O
of O
human O
behavioral O
epigenetics O
continue O
to O
grow O

205 O
: O
Single-cell O
multi-omics O
has O
recently O
emerged O
as O
a O
powerful O
technology O
by O
which O
different O
layers O
of O
genomic O
output-and O
hence O
cell O
identity O
and O
function-can O
be O
recorded O
simultaneously O

Relevance O
: O
Nursing O
scholars O
and O
other O
health O
scientists O
who O
utilize O
epigenetic O
age O
acceleration O
to O
assess O
health O
risks O
may O
need O
to O
consider O
including O
psychosocial O
stressors O
in O
their O
studies O
as O
covariates O

On O
the O
other O
hand O
, O
the O
characterization O
of O
early O
epigenetic O
predictors O
of O
asthma O
points O
to O
a O
potential O
role O
of O
epigenetic O
mechanisms O
in O
regulating O
the O
inception O
of O
, O
and O
the O
susceptibility O
to O
, O
this O
disease B-Disease

g O

Our O
consideration O
on O
near-neutrality O
expands O
in O
relation O
to O
the O
progress O
on O
molecular O
understanding O
of O
robustness O
and O
epigenetics O

The O
goal O
of O
this O
minireview O
is O
to O
summarize O
pharmacological O
strategies O
to O
modify O
the O
epigenetic O
landscape O
of O
cancer B-Disease
cells O

Results O
: O
Nucleated O
red O
blood O
cells O
( O
nRBCs O
) O
showed O
the O
most O
extensive O
changes O
in O
DNAm O
, O
with O
9258 O
differentially O
methylated O
( O
DM O
) O
sites O
( O
FDR O
< O
5% O
, O
|Δβ| O
> O
0 O

Genetic O
predisposition O
, O
as O
well O
as O
aging O
, O
contribute O
to O
epigenetic O
variability O
, O
and O
several O
environmental O
factors O
, O
including O
exercise O
and O
diet O
, O
further O
interact O
with O
the O
human O
epigenome O

Stem O
Cells O
2019 O
; O
37 O
: O
1267 O
- O
1272 O

There O
is O
growing O
literature O
discussing O
the O
most O
promising O
opportunities O
, O
as O
well O
as O
arising O
ethical O
, O
legal O
and O
social O
issues O
( O
ELSI O
) O

684 O
: O
Over O
the O
past O
two O
decades O
, O
epigenetics O
has O
evolved O
into O
a O
key O
concept O
for O
understanding O
regulation O
of O
gene O
expression O

e O

We O
call O
the O
combined O
algorithm O
which O
uses O
DHS O
data O
and O
robust O
partial O
correlations O
for O
inference O
, O
EpiDISH O
( O
Epigenetic O
Dissection O
of O
Intra-Sample O
Heterogeneity O
) O

Here O
, O
we O
describe O
the O
combined O
bisulfite O
restriction O
analysis O
( O
COBRA O
) O
assay O
that O
allows O
analyzing O
the O
methylation O
status O
at O
a O
specific O
locus O

This O
data O
represents O
many O
structure-activity O
relationships O
that O
have O
not O
been O
exploited O
thus O
far O
to O
develop O
predictive O
models O
to O
support O
medicinal O
chemistry O
efforts O

, O
CD3D O
, O
CD3E O
) O
, O
CTLA4 O
, O
and O
GZMA O

It O
is O
hoped O
that O
an O
understanding O
of O
this O
area O
will O
lead O
to O
interventions O
that O
might O
prevent O
or O
reduce O
rates O
of O
musculoskeletal O
ageing O
in O
later O
life O

Epigenetic O
mechanisms O
provide O
new O
directions O
and O
therapeutic O
strategies O
for O
the O
research O
and O
treatment O
of O
peripheral O
T-cell O
lymphoma B-Disease

730 O
: O
Systemic B-Disease
lupus I-Disease
erythematosus I-Disease
( O
SLE O
) O
is O
a O
multisystem O
autoimmune O
disease B-Disease
in O
which O
immune O
disorders O
lead O
to O
autoreactive O
immune O
responses O
and O
cause O
inflammation B-Disease
and O
tissue O
damage O

Here O
I O
discuss O
several O
areas O
of O
contemporary O
epigenetics O
research O
in O
the O
context O
of O
evolutionary O
biology O
, O
aiming O
to O
provide O
balanced O
views O
across O
timescales O
and O
molecular O
mechanisms O

174 O
: O
This O
paper O
addresses O
historical O
dimensions O
of O
epigenetic O
studies O
on O
human O
populations O

g O

Epigenetic O
alterations O
, O
as O
a O
consequence O
of O
in O
utero O
malnutrition O
, O
may O
play O
a O
role O
in O
susceptibility O
to O
develop O
adulthood O
diseases O
and O
inheritance O

614 O
: O
Anne O
Ferguson-Smith O
and O
Marisa O
Bartolomei O
look O
back O
at O
the O
life O
and O
science O
of O
Denise O
Barlow O
, O
a O
pioneer O
in O
genomic O
imprinting O
and O
epigenetics O

Finally O
, O
we O
directly O
compared O
RNA-seq O
by O
cellular O
compartments O
, O
addressing O
a O
limitation O
of O
RNA-seq O
studies O
limited O
to O
neuronal O
nuclei O

Furthermore O
, O
we O
highlight O
some O
of O
the O
recent O
marker O
validation O
studies O
and O
established O
markers O
that O
are O
currently O
commercially O
available O
for O
assisting O
in O
clinical O
management O
of O
different O
cancers B-Disease

Although O
the O
study O
by O
Herrera O
& O
Bazaga O
( O
2011 O
) O
raises O
at O
least O
as O
many O
new O
questions O
as O
it O
answers O
, O
it O
is O
a O
pioneering O
example O
of O
how O
epigenetics O
can O
be O
incorporated O
into O
ecological O
field O
studies O
, O
and O
it O
illustrates O
the O
value O
and O
potential O
novel O
insights O

Sites O
of O
lineage-specific O
hypomethylation O
were O
associated O
with O
distinct O
combinations O
of O
transcription O
factors O
in O
each O
cell O
type O

Advances O
in O
Machine O
Learning O
(ML) O
are O
critical O
to O
realize O
this O
promise O

It O
is O
important O
to O
recognise O
that O
epigenetic O
changes O
, O
in O
contrast O
to O
genetic O
changes O
, O
can O
vary O
according O
to O
different O
cell O
types O
and O
therefore O
can O
demonstrate O
significant O
tissue-specificity O

However O
, O
the O
study O
of O
Kammerer's O
original O
publications O
reveals O
that O
there O
are O
substantial O
misunderstandings O
in O
Vargas O
' O
treatment O
of O
the O
subject O

e O

org O
/ O
packages O
/ O
release O
/ O
bioc O
/ O
html O
/ O
ENmix O

Multiple O
lines O
of O
evidence O
indicate O
that O
early O
life O
exposure O
to O
environmental O
chemicals O
at O
relatively O
low O
concentrations O
could O
have O
lasting O
effects O
on O
individual O
and O
population O
health O

The O
results O
suggest O
the O
relevance O
of O
genetic O
and O
epigenetic O
processes O
for O
future O
theorizing O
regarding O
marital O
and O
family O
precursors O
of O
several O
forms O
of O
adult O
psychopathology O

A O
number O
of O
different O
approaches O
have O
been O
established O
to O
map O
the O
DNA O
epigenomes O
with O
single-base O
resolution O
, O
as O
represented O
by O
the O
bisulfite-based O
methods O
, O
such O
as O
classical O
bisulfite O
sequencing O
( O
BS-seq O
) O
, O
TAB-seq O
( O
TET-assisted O
bisulfite O
sequencing O
) O
, O
oxBS-seq O
( O

``` O
458 O
: O
The O
deeper O
understanding O
of O
non-coding O
RNAs O
has O
recently O
changed O
the O
dogma O
of O
molecular O
biology O
assuming O
protein-coding O
genes O
as O
unique O
functional O
biological O
effectors O
, O
while O
non-coding O
genes O
as O
junk O
material O
of O
doubtful O
significance O
``` O

We O
discovered O
two O
modules O
whose O
activation O
correlated O
with O
CVD O
risk O
and O
replicated O
across O
cohorts O

The O
pathogenesis O
of O
most O
neurodegenerative B-Disease
diseases I-Disease
is O
associated O
with O
a O
myriad O
of O
genetic O
defects O
, O
epigenetic O
alterations O
( O
DNA O
methylation O
, O
histone/chromatin O
remodeling O
, O
miRNA O
dysregulation O
) O
, O
and O
environmental O
factors O

A O
number O
of O
phenotypic O
studies O
have O
documented O
the O
role O
of O
histone O
modification O
and O
chromatin O
remodelling O
complexes O
in O
regulating O
distinct O
neoblast O
processes O
, O
and O
we O
focus O
on O
four O
important O
examples O
of O
planarian O
epigenetic O
regulators O
: O
Nucleosome O
Remodeling O
Deacetylase O
( O
NuRD O
) O
complex O
, O

, O
and O
the O
journal O
Epigenetics O

While O
the O
application O
focus O
relates O
to O
cancer B-Disease
research O
, O
the O
methods O
are O
equally O
relevant O
to O
broader O
issues O
of O
epigenetics O
and O
redox O
science O
in O
this O
special O
forum O

411 O
: O
Epigenetic O
mechanisms O
such O
as O
DNA O
methylation O
modulate O
gene O
expression O
in O
a O
complex O
fashion O
are O
consequently O
recognized O
as O
among O
the O
most O
important O
contributors O
to O
phenotypic O
variation O
in O
natural O
populations O
of O
plants O
, O
animals O
, O
and O
microorganisms O

Recent O
research O
activities O
on O
the O
discovery O
and O
development O
of O
novel O
epigenetic O
therapeutics O
have O
passed O
successfully O
, O
whereas O
epigenetic O
effects O
of O
non-epigenetic O
drugs O
or O
epigenetically O
induced O
changes O
in O
the O
targets O
of O
common O
drugs O
have O
not O
yet O
received O
the O
necessary O
systematic O
attention O
in O
the O
context O

They O
are O
also O
burdened O
by O
relevant O
side O
effects O

As O
epigenome O
editing O
tools O
have O
continued O
to O
develop O
, O
researchers O
have O
applied O
them O
in O
new O
ways O
to O
explore O
the O
function O
of O
the O
epigenome O
in O
human O
health O
and O
disease B-Disease

77 O
: O
Epigenetics O
refers O
to O
the O
study O
of O
heritable O
changes O
in O
gene O
function O
that O
do O
not O
involve O
changes O
in O
the O
DNA O
sequence O

Recent O
efforts O
by O
ENCODE O
, O
the O
NIH O
Roadmap O
and O
the O
International O
Human O
Epigenome O
Consortium O
( O
IHEC O
) O
have O
made O
significant O
advances O
towards O
assembling O
reference O
epigenomic O
maps O
of O
various O
tissues O

Areas O
covered O
: O
In O
this O
review O
, O
we O
summarize O
the O
role O
of O
methylation O
changes O
, O
histone O
modifications O
, O
and O
non-coding O
RNAs O
in O
the O
pathogenesis O
of O
GC O
and O
how O
these O
signatures O
can O
be O
used O
as O
diagnostic O
and O
therapeutic O
targets O
in O
clinical O
management O

These O
results O
suggest O
that O
the O
new O
method O
provides O
mechanistic O
insights O
for O
cellular O
phenotypes O
through O
multilayered O
epigenome O
analysis O
in O
the O
same O
single O
cells O

In O
this O
review O
, O
we O
perform O
a O
critical O
analysis O
of O
methods O
with O
the O
explicit O
aim O
of O
harmonizing O
data O
, O
as O
opposed O
to O
case-specific O
integration O

However O
, O
the O
individual O
methylation O
profile O
within O
each O
allele O
has O
not O
yet O
been O
examined O
at O
the O
whole-genome O
level O

Here O
we O
have O
developed O
the O
first O
" O
maturation O
phase O
transient O
reprogramming O
" O
( O
MPTR O
) O
method O
, O
where O
reprogramming O
factors O
are O
selectively O
expressed O
until O
this O
rejuvenation O
point O
then O
withdrawn O

Epigenetic O
studies O
further O
report O
encouraging O
findings O
about O
the O
use O
of O
methylation O
changes O
as O
diagnostic O
markers O
of O
disease B-Disease
phenotype O
and O
predictive O
tools O
of O
progression O
and O
response O
to O
treatment O

By O
the O
hypothesis O
put O
forward O
here O
, O
we O
would O
like O
to O
foster O
research O
on O
"Quantum O
Epigenetics" O
at O
the O
interface O
of O
medicine O
, O
biology O
, O
biochemistry O
, O
and O
physics O
to O
investigate O
the O
potential O
epigenetic O
impact O
of O
quantum O
physical O
principles O
on O
( O
human O
) O
life O

Overall O
, O
we O
review O
the O
bright O
( O
health-related O
) O
and O
dark O
( O
disease-related O
) O
side O
of O
DNA O
methylation O
changes O
, O
outlining O
how O
bulk O
and O
single-cell O
genomic O
analyses O
are O
moving O
toward O
the O
identification O
of O
new O
molecular O
targets O
and O
driving O
the O
development O
of O
more O
specific O
and O
less O
toxic O

``` O
Supplementary O
information O
: O
Supplementary O
data O
are O
available O
at O
Bioinformatics O
online O
``` O

Here O
, O
we O
describe O
methods O
for O
introducing O
a O
chemical-inducible O
epigenome O
remodeling O
tool O
( O
CiDER O
) O
, O
based O
on O
an O
engineered O
split-TET2 O
enzyme O
, O
into O
mammalian O
cells O
and O
quantifying O
the O
chemical O
inducible O
production O
of O
5-hydroxymethylcytosine O
( O
5hmC O
) O
with O
immunostaining O
, O

Conclusions O
: O
Early O
trauma B-Disease
and O
early O
menarche O
appear O
to O
exert O
independent O
effects O
on O
DNAm O
GrimAge O
, O
which O
has O
been O
shown O
to O
be O
the O
strongest O
epigenetic O
predictor O
of O
mortality O
risk O


This O
article O
is O
part O
of O
a O
discussion O
meeting O
issue O
' O
Frontiers O
in O
epigenetic O
chemical O
biology O
' O

This O
is O
the O
human O
self-domestication O
hypothesis O

97 O
: O
Individual O
cells O
are O
the O
fundamental O
unit O
of O
life O
with O
diverse O
functions O
from O
metabolism O
to O
motility O

MicroRNAs O
are O
critical O
in O
the O
maintenance O
of O
glomerular O
homeostasis O
and O
hence O
RNA O
interference O
may O
be O
important O
in O
the O
progression O
of O
renal O
disease B-Disease

Cross O
- O
comparison O
to O
other O
open-resource O
genomic O
data O
at O
UCSC O
facilitates O
interpretation O
of O
the O
biological O
significance O
of O
the O
data O
and O
the O
design O
of O
wet-lab O
assays O
to O
further O
explore O
methylation O
changes O
and O
their O
consequences O
for O
the O
candidate O
genes O

In O
this O
article O
, O
we O
first O
analyse O
the O
transformations O
of O
the O
concept O
of O
epigenetics O
, O
from O
Waddington O
to O
contemporary O
accounts O
, O
in O
order O
to O
identify O
its O
different O
meanings O
and O
traditions O
, O
and O
to O
come O
up O
with O
a O
typology O
of O
epigenetics O
throughout O
its O
history O

Genome O
- O
wide O
analyses O
such O
as O
arrays O
and O
next-generation O
sequencing O
( O
NGS O
) O
technologies O
have O
been O
used O
to O
assess O
large O
fractions O
of O
the O
methylome O
at O
a O
single-base-pair O
resolution O

pylori B-Disease
infection I-Disease
is O
an O
independent O
predictive O
indicator O
of O
gene O
methylation O

Following O
this O
wrapping-up O
of O
current O
evidence O
, O
we O
particularly O
focused O
on O
bringing O
together O
the O
most O
promising O
future O
research O
avenues O
towards O
a O
better O
understanding O
of O
the O
effects O
of O
climate O
change O
on O
freshwater O
biodiversity O
, O
specifically O
highlighting O
potential O
molecular O
targets O
and O
the O
most O
suitable O
freshwater O
species O
for O

Our O
model O
, O
inspired O
from O
evolutionary O
models O
, O
is O
able O
to O
account O
for O
acceleration/deceleration O
in O
epigenetic O
changes O
by O
fitting O
an O
individual O
's O
model O
age O
, O
the O
epigenetic O
age O
, O
which O
is O
related O
to O
chronological O
age O
in O
a O
non-linear O
fashion O

It O
closely O
interacts O
with O
histone O
modifications O
and O
chromatin O
remodeling O
complexes O
to O
form O
the O
local O
genomic O
and O
higher-order O
chromatin O
landscape O

In O
recent O
years O
, O
there O
has O
been O
a O
great O
deal O
of O
research O
on O
the O
epigenomic O
profile O
of O
GC O
, O
and O
epigenetic O
alterations O
seem O
to O
play O
a O
more O
important O
role O
than O
genetic O
factors O

It O
is O
largely O
attributed O
to O
genetic O
, O
as O
well O
as O
epigenetic O
variations O
between O
individuals O
, O
which O
may O
be O
inherited O
or O
acquired O

e O

117: O
Environmental O
epigenetics O
investigates O
the O
cause-effect O
relationships O
between O
specific O
environmental O
factors O
and O
the O
subsequent O
epigenetic O
modifications O
triggering O
adaptive O
responses O
in O
the O
cell O

With O
the O
recent O
advances O
in O
genomics O
, O
the O
original O
classification O
of O
CMPs O
on O
the O
basis O
of O
morphological O
and O
functional O
criteria O
( O
dilated O
( O
DCM O
) O
, O
hypertrophic O
( O
HCM O
) O
, O
restrictive O
( O
RCM O
) O
, O
and O
arrhythmogenic O
ventricular O
cardiomyopathy O
( O
AVC O
) O

It O
is O
well-known O
that O
during O
carcinogenesis O
, O
a O
site-specific O
DNA O
hypermethylation O
and O
a O
global O
DNA O
hypomethylation O
take O
place O

242 O
: O
DNA O
methylation O
is O
a O
stable O
covalent O
epigenetic O
modification O
of O
primarily O
CpG O
dinucleotides O
that O
has O
recently O
gained O
considerable O
attention O
for O
its O
use O
as O
a O
biomarker O
in O
different O
clinical O
settings O
, O
including O
disease B-Disease
diagnosis O
, O
prognosis O
and O
therapeutic O
response O
prediction O

672 O
: O
Epigenetic O
sex O
differences O
and O
their O
resulting O
implications O
for O
human O
health O
have O
been O
studied O
for O
about O
a O
decade O

Mechanistically O
, O
treatment O
of O
lung B-Disease
cancer I-Disease
cells O
or O
lung B-Disease
cancer I-Disease
xenografts O
with O
DAC O
induced O
the O
conversion O
of O
the O
FBW7 O
gene O
from O
a O
methylated O
form O
to O
an O
unmethylated O
form O
, O
which O
was O
associated O
with O
the O
increased O
expression O
of O
FBW7 O
and O
decreased O
expression O

636 O
: O
Epigenetic O
mechanisms O
may O
contribute O
to O
the O
pathogenesis O
of O
complex O
diseases O

Prenatal O
and O
early O
life O
exposure O
to O
famine O
was O
associated O
with O
metabolic O
, O
cardiovascular O
, O
respiratory O
, O
reproductive O
, O
neuropsychiatric O
and O
oncologic O
diseases O

Third O
, O
we O
claim O
that O
the O
classical O
opposition O
between O
epigenesis O
and O
preformationism O
as O
ways O
of O
thinking O
about O
the O
developmental O
process O
is O
part O
of O
the O
history O
of O
epigenetics O
and O
has O
contributed O
to O
its O
current O
various O
meanings O

Drawing O
on O
ethnographic O
fieldwork O
conducted O
in O
Australia O
with O
researchers O
and O
clinicians O
in O
Indigenous O
health O
, O
we O
explore O
how O
some O
construct O
epigenetics O
as O
useless O
knowledge O
and O
a O
distraction O
from O
implementing O
anti-colonial O
change O
, O
rather O
than O
a O
tool O
with O
which O
to O
enact O
change O

The O
approaches O
presented O
here O
constitute O
the O
forefront O
of O
epigenetics O
research O
at O
the O
single-cell O
level O
using O
classic O
and O
innovative O
methods O
to O
dissect O
epigenetics O
mechanisms O
from O
the O
limited O
material O
available O
in O
a O
single O
cell O

Frequencies O
of O
such O
two O
patterns O
form O
a O
sufficient O
statistic O
for O
subclonal O
abundance O

The O
current O
review O
is O
an O
update O
of O
the O
previously O
published O
paper O
, O
describing O
the O
most O
recent O
advances O
in O
the O
epigenetics O
of O
diabetes B-Disease

498 O
: O
In O
this O
interview O
, O
Professor O
Karl O
Kelsey O
speaks O
with O
Storm O
Johnson O
, O
Commissioning O
Editor O
for O
Epigenomics O
, O
on O
his O
work O
to O
date O
in O
the O
field O
of O
environmental B-Disease
epigenomics I-Disease
and O
epidemiology O

The O
methyl O
group O
is O
derived O
from O
an O
essential O
molecule O
in O
the O
cell O
, O
S-adenosylmethionine O
( O
SAM O
) O

As O
a O
stable O
nucleic O
acid-based O
modification O
that O
is O
technically O
easy O
to O
handle O
and O
which O
can O
be O
analyzed O
with O
great O
reproducibility O
and O
accuracy O
by O
different O
laboratories O
, O
DNA O
methylation O
is O
a O
promising O
biomarker O
for O
many O
applications O

19 O
; O
q O
= O
6 O

55 O
: O
Epigenetic O
modifications O
offer O
compelling O
evidence O
of O
the O
environmental O
etiology O
of O
complex O
diseases O

To O
understand O
current O
progress O
and O
trends O
in O
the O
inclusion O
of O
epigenetics O
in O
cancer B-Disease
epidemiology O
, O
we O
evaluated O
the O
published O
literature O
and O
the O
National O
Cancer B-Disease
Institute O
( O
NCI O
) O
- O
supported O
research O
grant O
awards O
in O
this O
field O
to O
identify O
trends O
in O
epigenetics O
research O

645 O
: O
Epigenetic O
modifications O
such O
as O
DNA O
methylation O
, O
post-translational O
chromatin B-Disease
modifications I-Disease
and O
non-coding O
RNA-mediated O
mechanisms O
are O
responsible O
for O
epigenetic O
inheritance O

This O
chapter O
describes O
epigenetic O
biomarkers O
as O
they O
are O
expressed O
during O
cancer B-Disease
development O
and O
their O
potential O
use O
in O
cancer B-Disease
diagnosis O
and O
prognosis O

34 O
: O
Epigenetic O
mechanisms O
inducing O
phenotypic O
changes O
without O
altering O
the O
DNA O
genome O
are O
increasingly O
recognized O
as O
key O
factors O
modulating O
gene O
expression O
and O
, O
consequently O
, O
cell O
functions O
[ O

We O
also O
discuss O
the O
systems O
biology O
approaches O
that O
enabled O
these O
discoveries O

For O
example O
, O
DNA O
hypermethylation O
of O
E-cadherin O
( O
CDH1 O
) O
, O
upstream O
transcription O
factor O
1/2 O
( O
USF1/2 O
) O
, O
WW O
domain O
containing O
oxidoreductase O
( O
WWOX O
) O
, O
and O
mutL O
homolog O
1 O
( O
MLH1 O
) O
genes O
in O
gastric B-Disease
mucosa I-Disease
is O
correlated O

Recent O
evidence O
has O
also O
demonstrated O
that O
epigenetic O
factors O
contribute O
to O
the O
pathogenesis O
of O
SLE O

Follow-up O
studies O
should O
include O
both O
an O
epigenetic O
as O
well O
as O
a O
genomic O
component O
to O
differentiate O
between O
the O
contributions O
of O
potentially O
compensatory O
mechanisms O

Additional O
molecular O
functions O
modulated O
by O
these O
drugs O
included O
other O
enzyme O
interactions O
, O
whereas O
modulation O
of O
ion O
channels O
or O
G-protein-coupled O
receptors O
were O
underrepresented O

A O
common O
theme O
for O
the O
successful O
inhibition O
of O
these O
enzymes O
in O
a O
potent O
and O
selective O
manner O
is O
the O
targeting O
of O
the O
cofactors O
present O
in O
the O
active O
site O
, O
namely O
zinc O
and O
iron O
cations O
, O
S-adenosylmethione O
, O
nicotinamide O
adenine O
dinucleotide O
, O
flavin O
adenine O

DXM O
does O
not O
require O
prior O
knowledge O
of O
the O
number O
of O
subpopulations O
or O
types O
of O
cells O
to O
expect O


Second O
, O
I O
show O
that O
Waddington O
's O
own O
view O
of O
epigenetics O
has O
changed O
over O
time O
and O
I O
analyze O
how O
these O
changes O
appear O
through O
his O
many O
representations O
( O
both O
schematic O
or O
metaphorical O
images O
) O
of O
the O
relationships O
between O
genetic O
signals O
and O
developmental O
processes O

A O
series O
of O
genetic O
loci O
capable O
of O
discerning O
the O
origin O
of O
DNA O
as O
coming O
from O
saliva O
, O
blood O
, O
vaginal B-Disease
epithelia I-Disease
, O
or O
semen O
were O
used O
for O
this O
application O

3 O
: O
Fibromyalgia B-Disease
is O
a O
disease B-Disease
characterized O
by O
chronic O
widespread O
pain O
with O
additional O
symptoms O
, O
such O
as O
joint O
stiffness O
, O
fatigue O
, O
sleep O
disturbance O
, O
cognitive O
dysfunction O
, O
and O
depression B-Disease

Because O
epigenetic O
modifications O
are O
reversible O
many O
anticancer O
strategies O
targeting O
these O
mechanisms O
are O
currently O
under O
development O
and O
in O
clinical O
trials O

The O
conference O
provided O
a O
unique O
venue O
for O
a O
significant O
cross-section O
of O
Canadian O
epigenetic O
researchers O
from O
diverse O
disciplines O
to O
meet O
, O
interact O
, O
collaborate O
and O
strategize O
at O
the O
national O
level O

In O
vitro O
plant O
cell O
and O
tissue O
culture O
methodologies O
are O
important O
for O
many O
ongoing O
plant O
propagation O
and O
breeding O
programmes O
as O
well O
as O
for O
cutting-edge O
research O
in O
several O
plant O
model O
species O

Additional O
studies O
are O
needed O
to O
confirm O
our O
results O

First O
described O
as O
a O
conceptual O
model O
of O
how O
genes O
might O
interact O
with O
their O
surroundings O
to O
produce O
a O
phenotype O
, O
epigenomic O
research O
currently O
investigates O
mechanisms O
of O
nongenetic O
modification O
contributing O
to O
gene O
regulation O
and O
examines O
the O
impact O
of O
these O
changes O
on O
human O
health O
and O
behavior O

Altogether O
, O
our O
work O
shows O
that O
the O
Sandwich O
Model O
is O
a O
powerful O
pedagogical O
approach O
that O
exerts O
a O
positive O
impact O
on O
student O
perceptions O
for O
learning O
and O
satisfaction O
and O
that O
can O
support O
the O
teaching O
of O
challenging O
biomedical O
concepts O
, O
such O
as O
epigenetics O

Some O
employ O
epigenetics O
to O
explain O
changes O
in O
gene O
expression O
, O
others O
use O
it O
to O
refer O
to O
transgenerational O
effects O
and/or O
inherited O
expression O
states O

Epigenetics O
is O
a O
process O
involved O
in O
gene O
regulation O
, O
mediated O
via O
DNA O
methylation O
, O
histone O
modification O
, O
chromatin O
remodeling O
, O
and O
functional O
noncoding O
RNAs O
, O
which O
influences O
the O
accessibility O
of O
the O
underlying O
DNA O
to O
transcriptional O
regulatory O
factors O
that O
activate O
or O
repress O
expression O

Standard O
output O
includes O
a O
spreadsheet-ready O
text O
file O
and O
an O
array O
of O
publication-quality O
figures O

This O
review O
discusses O
our O
current O
understanding O
of O
the O
role O
epigenetic O
processes O
play O
in O
asthma O
pathogenesis O
, O
focusing O
on O
genome-wide O
, O
population-based O
studies O

Having O
a O
similar O
conceptual O
framework O
to O
systems O
biology O
, O
the O
holistic O
MPE O
approach O
enables O
us O
to O
link O
potential O
etiological O
factors O
to O
specific O
molecular O
pathology O
, O
and O
gain O
novel O
pathogenic O
insights O
on O
causality O

On O
the O
other O
hand O
, O
there O
are O
a O
lot O
of O
promising O
studies O
showing O
that O
these O
new O
techniques O
can O
be O
adapted O
to O
study O
the O
molecular O
biology O
of O
transplant-related O
problems O

In O
this O
issue O
of O
Cancer B-Disease
Cell O
, O
Loukas O
et O
al O

These O
approaches O
have O
the O
potential O
to O
increase O
resolution O
of O
epigenetic O
changes O
to O
the O
single O
base O
level O
in O
multiple O
disease B-Disease
states O
or O
across O
a O
population O
of O
individuals O

The O
many O
attributes O
of O
marine O
fish O
species O
, O
including O
their O
high O
diversity O
, O
variable O
life O
histories O
, O
high O
fecundity O
, O
impressive O
plasticity O
, O
and O
economic O
value O
provide O
unique O
opportunities O
for O
studying O
epigenetic O
mechanisms O
in O
an O
environmental O
context O

It O
may O
caused O
by O
specific O
or O
multiple O
physical O
and O
physiological O
factors O
, O
including O
abnormalities O
in O
homeostasis O
, O
hormonal O
imbalances O
and O
genetic O
alterations O


Recent O
advances O
in O
epigenome O
engineering O
technologies O
allow O
now O
for O
the O
large-scale O
assessment O
of O
the O
functional O
relevance O
of O
DNA O
methylation O

EpiProfile O
2 O

NCCN O
Clinical O
Practice O
Guidelines O
also O
recommended O
epigenetic O
drugs O
for O
PTCL O
subtypes O
as O
second-line O
therapy O

In O
conclusion O
, O
the O
research O
identified O
risk O
and O
protective O
factors O
associated O
with O
epigenetic O
aging O
pre- O
and O
post-trauma B-Disease
exposure I-Disease
, O
with O
implications O
for O
health O
and O
well-being O
among O
individuals O
exposed O
to O
trauma B-Disease

57 O
: O
Gene O
expression O
is O
an O
intricate O
biological O
process O
that O
bridges O
gap O
between O
the O
genotype O
and O
the O
phenotype O

Still O
, O
in O
most O
cases O
, O
the O
mechanisms O
involved O
are O
poorly O
understood O

551 O
: O
Biological O
ageing O
is O
connected O
to O
life O
history O
variation O
across O
ecological O
scales O
and O
informs O
a O
basic O
understanding O
of O
age-related O
declines O
in O
organismal O
function O

221 O
: O
Epigenetics O
plays O
a O
key O
role O
in O
cellular O
development O
and O
function O

[BMB O
Reports O
2024 O
; O
57 O
( O
5 O
) O
: O
216 O
- O
231 O
] O

In O
this O
paper O
, O
the O
reader O
can O
find O
one O
of O
the O
widest O
compilations O
of O
the O
landmarks O
and O
epistemic O
considerations O
of O
the O
knowledge O
of O
epigenetics O
across O
the O
history O
of O
biology O
from O
the O
earliest O
epigenetic O
formulation O
to O
genetic O
determinism O
until O
the O
present O

703 O
: O
Motivation O
: O
Functional O
genomics O
experiments O
generate O
genomewide O
signal O
profiles O
that O
are O
dense O
information O
sources O
for O
annotating O
the O
regulatory O
elements O

io O

These O
findings O
pave O
the O
way O
for O
future O
studies O
using O
fish O
species O
as O
models O
to O
investigate O
epigenetic O
changes O
as O
drivers O
of O
human O
self-domestication O
and O
as O
triggers O
of O
cognitive O
disorders O

Practice O
implications O
: O
Advanced O
practice O
psychiatric B-Disease
nurses O
will O
benefit O
from O
an O
expanded O
knowledge O
base O
in O
neuroscience O
and O
epigenetics O
that O
informs O
and O
explains O
the O
scientific O
rationale O
for O
our O
integrated O
practice O

0 O
software O
was O
developed O
based O
on O
our O
'population O
epigenetic O
framework' O
and O
can O
perform O
: O
( O
i O
) O
epigenome-wide O
single O
marker O
association O
study O
; O
( O
ii O
) O
epigenome-wide O
methylation O
haplotype O
( O
meplotype O
) O
association O
study O
and O
( O
iii O
) O
epigenome-wide O
association O
meta-analysis O

Conclusions O
: O
Our O
findings O
provide O
insight O
into O
the O
epigenetic O
crosstalk O
regulating O
the O
CG O
methylation O
pattern O
in O
mammalian O
oocytes O
and O
other O
cells O

Approved O
and O
investigational O
drugs O
in O
the O
DrugBank O
database O
included O
122 O
compounds O
that O
interacted O
with O
68 O
unique O
epigenetic O
enzymes O

In O
hibition O
of O
DNA O
methyltransferases O
by O
decitabine O
( O
DAC O
) O
can O
demethylate O
and O
activate O
epigenetically O
silenced O
tumor B-Disease
suppressor O
genes O

Adapted O
FLoSS O
≥7 O
as O
a O
marker O
of O
exceptional O
longevity O
occurred O
in O
3 O

With O
the O
advances O
in O
multi-omics O
technologies O
, O
innovative O
ideas O
regarding O
disease B-Disease
prevention O
and O
drug O
responsiveness O
in O
anxiety O
disorders O
require O
further O
research O
in O
epigenetics O
and O
gene-environment O
interactions O


By O
exploring O
these O
challenges O
, O
among O
others O
, O
the O
field O
of O
epigenetic O
chemical O
biology O
will O
increase O
its O
potential O
for O
clinical O
benefit O
, O
and O
more O
effective O
strategies O
targeting O
the O
aberrant O
epigenome O
in O
cancer B-Disease
are O
likely O
to O
be O
developed O
both O
in O
haematological O
and O
solid O
tumours O

13 O
/ O
bioc O
/ O
html O
/ O
epidecodeR O

Further O
, O
we O
develop O
a O
DNAm O
classifier O
which O
performs O
well O
in O
discriminating O
current O
from O
former O
smokers O
( O
agnostic O
LASSO O
model O
AUC O
in O
external O
validation O
data O
: O
0 O

Herein O
, O
we O
highlight O
emerging O
paradigms O
for O
linking O
epigenetic O
machinery O
and O
processes O
with O
neurological O
disease B-Disease
states O
, O
including O
how O
( O
1 O
) O
mutations O
in O
genes O
encoding O
epigenetic O
factors O
cause O
disease B-Disease
, O
( O
2 O
) O
genetic O
variation O
in O
genes O
encoding O
epigenetic O
factors O

g O

These O
clocks O
were O
developed O
using O
novel O
DNA O
methylation O
profiles O
of O
140 O
elephant O
blood O
samples O
of O
known O
age O
, O
at O
loci O
that O
are O
highly O
conserved O
between O
mammalian O
species O
, O
using O
a O
custom O
Infinium O
array O
( O
HorvathMammalMethylChip40 O
) O

The O
extensive O
high-resolution O
genomic O
data O
generated O
to O
characterize O
AML O
have O
been O
instrumental O
in O
revealing O
the O
tremendous O
biological O
complexity O
of O
the O
disease B-Disease
, O
dictated O
in O
part O
by O
mutational O
, O
clonal O
, O
and O
epigenetic O
heterogeneity B-Disease

Here O
, O
an O
overview O
of O
recent O
findings O
related O
to O
developmental O
switches O
occurring O
during O
in O
vitro O
culture O
is O
presented O

Results O
: O
Reported O
are O
major O
enhancements O
to O
CloneViz O
, O
which O
now O
provides O
capabilities O
enabling O
a O
formal O
tumor B-Disease
multi-dimensional O
clonality O
analysis O
by O
integrating O
: O
i O
) O
DNA O
mutations O
, O
ii O
) O
RNA O
expressed O
mutations O
, O
and O
iii O
) O
DNA O
methylation O
data O

Although O
these O
processes O
are O
essential O
to O
cellular O
differentiation O
and O
transcriptional O
memory O
, O
they O
are O
also O
widely O
used O
in O
all O
branches O
of O
the O
tree O
of O
life O
by O
organisms O
that O
require O
plastic O
but O
stable O
adaptation O
to O
their O
physical O
and O
social O
environment O

38 O
: O
The O
field O
of O
tissue O
engineering O
and O
regenerative O
medicine O
( O
TE/RM O
) O
involves O
regeneration O
of O
tissues O
and O
organs O
using O
implantable O
biomaterials O

Overall O
, O
we O
suggest O
that O
epigenetics O
could O
provide O
new O
insights O
into O
a O
more O
comprehensive O
interpretation O
of O
mental O
illness B-Disease
and O
might O
eventually O
improve O
the O
nosology O
, O
treatment O
, O
and O
prevention O
of O
psychiatric B-Disease
disorders I-Disease

This O
review O
specifically O
focuses O
on O
these O
techniques O
, O
such O
as O
EM-seq O
to O
study O
DNA O
methylation O
, O
CUT&RUN O
, O
and O
CUT&Tag O
to O
study O
histone/transcription O
factor--DNA O
interactions O
, O
ATAC-seq O
to O
study O
chromatin O
accessibility O
, O
Hi-C O
to O
explore O
3D O
genome O
architecture O
and O
several O
methods O

These O
disparities O
are O
thought O
to O
be O
due O
to O
socioeconomic O
status O
, O
culture O
, O
diet O
, O
stress O
, O
the O
environment O
, O
and O
biology O

Although O
evidence O
suggests O
that O
patterns O
of O
DNA O
methylation O
can O
describe O
ageing O
in O
plants O
, O
predictions O
with O
epigenetic O
clocks O
have O
yet O
to O
be O
performed O

Twin O
studies O
have O
played O
an O
essential O
role O
in O
estimating O
phenotypic O
heritability O
, O
and O
these O
now O
offer O
an O
opportunity O
to O
study O
epigenetic O
variation O
as O
a O
dynamic O
quantitative O
trait O

336 O
: O
Mutations O
in O
epigenetic O
regulators O
are O
prevalent O
in O
cancer B-Disease
, O
but O
their O
functional O
impact O
is O
poorly O
delineated O
aside O
from O
disrupting O
differentiation O

Cancer B-Disease
Epidemiol O
Biomarkers O
Prev O
; O
26(6) O
; O
816-25 O

609 O
: O
The O
aging O
process O
is O
associated O
with O
the O
accumulation O
of O
epigenetic O
alterations O
in O
immune O
cells O
, O
although O
the O
origin O
of O
these O
changes O
is O
not O
clear O

Here O
, O
we O
review O
the O
promise O
and O
pitfalls O
of O
epigenetic O
drug O
development O
to O
date O
and O
provide O
an O
outlook O
on O
recent O
advances O
and O
their O
promise O
for O
future O
therapeutic O
applications O

However O
, O
the O
scales O
of O
different O
pairwise O
covariances O
could O
be O
quite O
different O
and O
the O
direct O
combination O
of O
pairwise O
covariances O
in O
SMCCA O
is O
unfair O

It O
outperforms O
other O
methods O
in O
terms O
of O
interpreting O
and O
reproducing O
the O
identified O
cCREs O
clusters O

Therefore O
, O
it O
is O
of O
interest O
to O
consider O
the O
evolution O
of O
epigenetic O
processes O

This O
chapter O
addresses O
epigenetics O
in O
the O
context O
of O
sex O
differences O
, O
discussing O
the O
intersection O
between O
genetics O
and O
gonadal O
hormones O
and O
their O
effect O
in O
the O
brain O
at O
discrete O
developmental O
periods O

We O
performed O
gene O
chip O
microarray O
profiling O
and O
found O
that O
talc O
alone O
, O
and O
especially O
with O
oestrogen O
, O
has O
induced O
a O
substantially O
more O
prominent O
gene O
expression O
change O
than O
titanium O
dioxide O
; O
the O
affected O
genes O
were O
involved O
in O
pathways O
of O
cell O
proliferation O
, O
immune O
response O
and O
reg O

Altogether O
, O
these O
epigenomes O
represent O
a O
powerful O
resource O
to O
develop O
a O
deeper O
understanding O
of O
the O
underlying O
molecular O
biology O
of O
thyroid O
function O
and O
provide O
contextual O
information O
of O
thyroid O
and O
human O
epigenomic O
data O
for O
comparison O
and O
integration O
into O
future O
studies O

However O
, O
all O
these O
epigenetic O
biomarkers O
should O
be O
validated O
in O
larger O
clinical O
studies O

Focusing O
on O
dynamic O
and O
stable O
CpGs O
extracted O
from O
datasets O
, O
dynamic O
CpGs O
were O
more O
likely O
to O
be O
reported O
as O
epigenome-wide O
association O
study O
( O
EWAS O
) O
markers O
of O
various O
traits O
, O
especially O
those O
of O
immune- O
and O
inflammatory-related O
traits O
; O
meanwhile O
, O
the O
stable O
CpGs O
were O
enriched O

In O
our O
study O
, O
the O
TabNet O
architecture O
( O
deep O
tabular O
data O
learning O
architecture O
) O
exhibited O
the O
best O
performance O
( O
best O
MAE O
= O
5 O

Second O
, O
and O
drawing O
from O
a O
set O
of O
interviews O
( O
N O
= O
15 O
) O
, O
we O
describe O
a O
tension O
between O
this O
dominant O
, O
objectifying O
molecular O
discourse O
and O
the O
perspective O
of O
individual O
scientists O

droit@crchuq O

Finally O
we O
discuss O
the O
crucial O
areas O
requiring O
a O
greater O
understanding O
of O
these O
processes O
, O
in O
order O
to O
piece O
together O
a O
global O
picture O
of O
the O
changing O
epigenetic O
landscape O
in O
MSC O
during O
aging O

Methylation O
of O
DNA O
, O
modification O
of O
histone O
and O
silencing O
of O
micro-RNA O
(miRNA)-associated O
gene O
are O
currently O
considered O
to O
initiate O
and O
sustain O
epigenetic O
changes O

0 O
to O
become O
a O
popular O
software O
and O
be O
widely O
used O
in O
epigenome-wide O
associated O
studies O
in O
the O
future O

DNA O
methylation O
, O
an O
enzymatic O
covalent O
modification O
of O
DNA O
, O
has O
been O
one O
of O
the O
principal O
epigenetic O
mechanisms O
investigated O

Then O
, O
we O
summarize O
the O
current O
knowledge O
of O
the O
impact O
of O
epigenetics O
on O
cardiac O
cell O
fate O
decision O

In O
the O
present O
article O
, O
we O
have O
described O
and O
advocated O
the O
epigenetic O
role O
in O
Aging O
and O
associated O
diseases O

Vargas O
( O
2009 O

The O
potential O
landscapes O
show O
that O
not O
only O
attractors O
represent O
stability O
, O
but O
the O
paths O
between O
attractors O
are O
also O
part O
of O
the O
stability O
or O
robustness O
of O
biological O
systems O

Prenatal O
or O
infant O
exposure O
was O
strongly O
associated O
with O
depressive B-Disease
symptoms I-Disease

Canonical O
and O
hereditable O
epigenetic O
mechanisms O
, O
such O
as O
histone O
and O
DNA O
modifications O
, O
regulate O
the O
release O
of O
genetic O
information O
encoded O
in O
DNA O
without O
altering O
the O
underlying O
sequence O

In O
the O
penultimate O
section O
, O
consideration O
is O
given O
to O
how O
advances O
in O
molecular O
techniques O
are O
opening O
the O
doors O
to O
a O
more O
comprehensive O
understanding O
of O
epigenetic O
phenomena O
in O
plants O

EMT O
is O
employed O
during O
embryonic O
development O
such O
as O
for O
gastrulation O
and O
neural O
crest O
migration O
and O
is O
misused O
in O
diseases O
, O
such O
as O
cancer B-Disease
metastasis O

Here O
we O
present O
EpiProfile O
2 O

Contact O
: O
zhengjie@ntu O

Finally O
, O
epigenetic O
change O
partially O
mediated O
the O
effect O
of O
CSA O
on O
antisocial O
characteristics O

Micronutrients O
such O
as O
betaine O
, O
choline O
, O
folate O
, O
and O
methionine O
serve O
as O
cofactors O
or O
methyl O
donors O
for O
one-carbon O
metabolism O
and O
other O
DNA O
methylation O
reactions O

We O
show O
that O
the O
chemical O
inhibition O
of O
Erk O
signalling O
during O
EMT O
prevents O
the O
loss O
and O
gain O
of O
the O
H3K27ac O
mark O
at O
regulatory O
regions O
of O
epithelial O
and O
mesenchymal O
genes O
, O
respectively O
, O
and O
results O
in O
a O
transcriptome O
and O
epigenome O
closer O
to O
those O
of O
epithelial O

The O
method O
can O
acquire O
at O
least O
five O
epigenetic O
marks O
: O
H3K27ac O
, O
H3K27me3 O
, O
mediator O
complex O
subunit O
1 O
, O
a O
DNA O
modification O
, O
and O
a O
DNA-interacting O
protein O

It O
describes O
nine O
emerging O
areas O
of O
discussion O
, O
relating O
to O
( O
1 O
) O
the O
impact O
of O
epigenetics O
on O
the O
nature O
versus O
nurture O
dualism O
, O
( O
2 O
) O
the O
potential O
resulting O
biologization O
of O
the O
social O
, O
( O
3 O
) O
the O
meaning O
of O
epigenetics O
for O
public O
health O
, O

The O
analysis O
of O
the O
orthogonal O
dimension O
of O
the O
chromatin O
space O
identify O
32,662 O
chromatin O
determinant O
regions O
( O
CDRs O
) O
, O
genomic O
regions O
with O
different O
epigenetic O
characteristics O
between O
the O
cell O
types O

GrimAge O
acceleration O
at O
follow-up O
was O
significantly O
associated O
with O
increased O
PTSD O
symptom O
severity O
at O
baseline O
and O
follow-up O

Because O
of O
these O
reasons O
, O
many O
of O
the O
global O
DNA O
methylation O
analysis O
methods O
are O
mainly O
performed O
at O
core O
facility O
, O
and O
laboratories O
with O
limited O
resources O
and O
expertise O
are O
not O
able O
to O
use O
these O
methods O

Thus O
, O
future O
research O
should O
go O
beyond O
the O
study O
of O
epigenetic O
mechanisms O
at O
the O
level O
of O
the O
gene O
and O
devote O
additional O
investigation O
of O
epigenetic O
outcomes O
at O
the O
level O
of O
both O
the O
individual O
organism O
and O
how O
it O
affects O
the O
evolution O
of O
populations O

5hmC O
is O
a O
predominantly O
stable O
form O
and O
serves O
as O
both O
an O
intermediate O
product O
of O
active O
DNA O
demethylation O
and O
an O
essential O
hallmark O
of O
epigenetic O
gene O
regulation O

It O
is O
not O
clear O
, O
however O
, O
if O
this O
is O
a O
causal O
relationship O

Among O
different O
methodological O
approaches O
tested O
to O
date O
, O
the O
methylation-sensitive O
analysis O
of O
carefully O
selected O
DNA O
markers O
( O
CpG O
sites O
) O
has O
brought O
the O
most O
promising O
results O
by O
providing O
prediction O
accuracies O
of O
±3-4 O
years O
, O
which O
can O
be O
comparable O
to O
, O
or O
even O
surpass O
those O
from O

Interdisciplinary O
collaboration O
and O
good O
public O
communication O
regarding O
epigenetic O
risk O
will O
be O
important O
to O
advance O
the O
return O
of O
results O
framework O
for O
epigenetic O
science O

In O
recent O
years O
, O
techniques O
have O
been O
developed O
for O
genome-wide O
5mC O
detection O
, O
and O
complete O
methylome O
at O
single O
base O
resolution O
has O
been O
reported O
for O
several O
organisms O
, O
providing O
unprecedented O
details O
on O
the O
dynamic O
nature O
of O
DNA O
methylation O
during O
development O

Finally O
, O
we O
discuss O
possible O
mechanisms O
that O
may O
explain O
transgenerational O
inheritance O
, O
including O
transmission O
of O
an O
epigenetic O
blueprint O
, O
which O
may O
predispose O
offspring O
to O
specific O
epigenetic O
patterning O

Identification O
of O
genetic O
polymorphisms O
due O
to O
single O
nucleotide O
polymorphisms O
is O
the O
most O
common O
approach O
, O
but O
this O
does O
not O
take O
into O
account O
the O
potential O
relevance O
of O
copy O
number O
variants O
, O
noncoding O
RNA O
gene O
regulation O
, O
gene-gene O
and O
gene-interactions O
, O
and O
epigenetic O
modifications O
, O
which O

Experimental O
evidences O
for O
the O
proportionality O
of O
the O
variances O
over O
genes O
are O
also O
discussed O

These O
are O
in O
the O
path O
to O
become O
the O
dominant O
assays O
for O
genome-wide O
analysis O
of O
TFs O
and O
chromatin B-Disease
modifications I-Disease
in O
bulk O
, O
single-cell O
, O
and O
spatial O
genomic O
applications O

The O
present O
review O
is O
focused O
on O
recent O
developments O
in O
the O
area O
and O
a O
brief O
discussion O
of O
the O
future O
prospects O
and O
challenges O

Other O
cell O
rejuvenation O
studies O
in O
old O
humans O
and O
rodents O
published O
afterwards O
will O
be O
very O
briefly O
mentioned O

Furthermore O
, O
small O
non-coding O
RNA O
, O
termed O
microRNA O
( O
miRNA O
) O
bind O
to O
messenger O
RNA O
( O
mRNA O
) O
to O
regulate O
translation O

Finally O
, O
to O
perform O
multiple O
analytical O
assays O
, O
we O
showed O
that O
even O
with O
thorough O
methodology O
, O
the O
yield O
of O
material O
obtained O
from O
primary O
cells O
is O
the O
major O
challenge O

What O
is O
new O
and O
conclusion O
: O
Epigenetics O
plays O
a O
key O
role O
in O
the O
pathogenesis O
of O
the O
idiopathic O
mental B-Disease
disorders I-Disease

Based O
on O
its O
position O
of O
integration O
, O
the O
PmR O
gene O
expression O
hinged O
on O
two O
epigenetic O
hallmarks O
: O
the O
spreading O
of O
heterochromatin O
, O
and O
the O
transmissible O
memory O
of O
epigenetic O
states O
across O
generations O

Aging O
, O
in O
fact O
, O
is O
one O
of O
the O
most O
relevant O
risk O
factors O
for O
a O
wide O
range O
of O
maladies B-Disease
, O
and O
molecular O
surrogates O
of O
this O
phenotype O
could O
enable O
better O
patients O
stratification O

However O
, O
when O
devoid O
of O
its O
nuclease O
activity O
, O
the O
underlying O
DNA-binding O
activity O
of O
SSNs O
can O
be O
used O
to O
bring O
other O
protein O
functional O
domains O
close O
to O
specific O
genomic O
sites O
, O
thus O
expanding O
further O
the O
range O
of O
applications O
of O
the O
technology O

192 O
: O
Aging O
has O
become O
one O
of O
the O
fastest-growing O
research O
topics O
in O
biology O

In O
1971 O
, O
he O
joined O
the O
departments O
of O
oncology O
and O
medicine O
at O
Johns O
Hopkins O
University O
School O
of O
Medicine O

Here O
, O
we O
introduce O
CFEA O
( O
http://www O

Microfluidics O
and O
microfabrication O
have O
played O
a O
central O
role O
in O
the O
range O
of O
new O
techniques O
, O
and O
will O
likely O
continue O
to O
impact O
their O
further O
development O
towards O
routine O
single-cell O
epigenetic O
analysis O

- O
and O
they O
will O
be O
the O
subject O
of O
this O
comprehensive O
review O

Here O
, O
we O
provide O
an O
overview O
of O
our O
method O
and O
detailed O
guidance O
on O
how O
to O
use O
it O
for O
the O
integration O
of O
methylome O
and O
transcriptome O
data O

315 O
: O
Artificial O
gene O
regulatory O
networks O
are O
computational O
models O
that O
draw O
inspiration O
from O
biological O
networks O
of O
gene O
regulation O

e O

In O
contrast O
to O
genetic O
studies O
, O
which O
estimate O
the O
effects O
of O
structural O
changes O
in O
DNA O
, O
and O
transcriptomic O
studies O
, O
which O
measure O
genomic O
outputs O
, O
epigenetic O
studies O
can O
access O
states O
of O
regulation O
of O
genome O
function O
in O
particular O
cells O
and O
in O
response O
to O
specific O
stimuli O

Another O
contribution O
used O
a O
variance-component O
LME O
to O
depict O
the O
proportion O
of O
heritability O
resulting O
from O
a O
genetic O
and O
shared O
environment O

Disruption O
of O
these O
processes O
is O
now O
understood O
to O
be O
a O
major O
contributor O
to O
cancer B-Disease
development O
and O
progression O
, O
and O
recent O
efforts O
have O
attempted O
to O
pharmacologically O
reverse O
such O
altered O
epigenetics O

We O
demonstrate O
COCOA O
's O
utility O
by O
analyzing O
DNA O
methylation O
, O
ATAC-seq O
, O
and O
multi-omic O
data O
in O
supervised O
and O
unsupervised O
analyses O
, O
showing O
that O
COCOA O
provides O
new O
understanding O
of O
inter-sample O
epigenetic O
variation O

175 O
: O
Quantifying O
the O
relative O
importance O
of O
genomic O
and O
epigenomic O
modulators O
of O
phenotype O
is O
a O
focal O
challenge O
in O
comparative O
physiology O
, O
but O
progress O
is O
constrained O
by O
availability O
of O
data O
and O
analytic O
methods O

They O
are O
associated O
with O
DNA O
but O
without O
altering O
the O
DNA O
sequence O

Biologically O
, O
these O
changes O
manifest O
as O
blunted O
immune O
responses O
, O
decreased O
bone O
marrow O
cellularity O
, O
and O
increased O
risk O
of O
myeloid O
diseases O

Although O
long O
thought O
to O
be O
rare O
, O
protein-based O
epigenetic O
inheritance O
has O
now O
been O
uncovered O
in O
all O
domains O
of O
life O

This O
epigenetic O
heterogeneity B-Disease
is O
of O
biological O
importance O
in O
normal O
functions O
such O
as O
tissue O
morphogenesis O
and O
can O
contribute O
to O
development O
or O
resistance O
of O
cancer B-Disease
, O
or O
other O
disease B-Disease
states O

In O
both O
cases O
, O
deviation O
to O
the O
concordant-linked O
alleles O
was O
conspicuous O
, O
indicating O
that O
the O
methylation O
pattern O
is O
not O
random O
but O
rather O
concordant O
within O
each O
allele O

While O
Vargas O
' O
general O
idea-invoking O
epigenetic O
effects O
as O
an O
explanation O
of O
Kammerer O
's O
findings O
- O
remains O
attractive O
, O
at O
least O
two O
key O
aspects O
of O
his O
model O
need O
to O
be O
revised O

Several O
cost-effective O
reduced O
representation O
bisulfite O
sequencing O
approaches O
(RRBS) O
have O
been O
recently O
developed O
and O
applied O
to O
different O
organisms O
that O
lack O
a O
well O
annotated O
reference O
genome O

Indeed O
, O
this O
tendency O
to O
always O
look O
forward O
, O
with O
minimal O
concern O
or O
regard O
of O
what O
has O
gone O
before O
, O
has O
led O
to O
the O
present O
situation O
in O
which O
" O
true O
" O
epigenetic O
studies O
are O
believed O
to O
consist O
of O
one O
of O
two O
schools O

In O
addition O
, O
by O
using O
an O
expanded O
dataset O
from O
both O
sample O
types O
, O
we O
confirmed O
our O
previous O
finding O
that O
age O
has O
strong O
, O
non-linear O
negative O
correlation O
with O
epithelial O
cell O
proportion O
in O
both O
sample O
types O

The O
focus O
of O
precision O
medicine O
includes O
a O
better O
assessment O
of O
disease B-Disease
risk O
and O
understanding O
of O
disease B-Disease
mechanisms O

We O
then O
detailed O
the O
importance O
of O
epigenetics O
and O
the O
need O
for O
intensive O
research O

We O
conclude O
by O
highlighting O
the O
potential O
for O
ongoing O
research O
on O
the O
epigenomics O
of O
marine O
fishes O
to O
reveal O
critical O
aspects O
of O
the O
interaction O
between O
organisms O
and O
their O
environments O

Conclusion O
: O
In O
this O
cross-sectional O
study O
of O
79-year-olds O
, O
we O
found O
no O
convincing O
evidence O
that O
biological O
age O
, O
as O
indexed O
by O
extrinsic O
or O
intrinsic O
epigenetic O
age O
acceleration O
, O
was O
associated O
with O
objectively O
measured O
sedentary O
or O
walking O
behavior O

Moreover O
, O
studies O
of O
other O
epigenetic O
mechanisms O
in O
various O
invertebrate O
species O
, O
apart O
from O
DNA O
methylation O
would O
provide O
better O
understanding O
of O
interconnected O
cross-talk O
between O
epigenetic O
marks O

506 O
: O
Methylation O
has O
frequently O
been O
implicated O
in O
gender O
determination O
in O
plants O

The O
epigenetic O
mechanism O
includes O
DNA O
methylation O
, O
post-translational O
histone O
modification O
, O
chromatin O
remodeling O
, O
microRNA O
regulation O
and O
so O
on O

In O
the O
limiting O
case O
of O
fully O
stable O
epialleles O
our O
approach O
reduces O
to O
the O
classical O
theory O
of O
experimental O
line O
crosses O
and O
thus O
illustrates O
a O
fundamental O
continuity O
between O
genetic O
and O
epigenetic O
inheritance O


Understanding O
the O
genetic O
basis O
and O
therefore O
physiologic O
key O
mechanisms O
of O
sexual O
function O
and O
dysfunction O
has O
the O
potential O
for O
improved O
treatments O
( O
i O

Despite O
much O
research O
, O
the O
natural O
history O
of O
asthma O
and O
its O
pathogenesis O
are O
still O
in O
many O
ways O
elusive O

The O
role O
of O
5mC O
in O
transcriptional O
repression O
is O
well O
established O
for O
a O
few O
hundred O
genes O
through O
methylation O
of O
their O
promoters O

This O
review O
provides O
a O
brief O
overview O
of O
epigenetics O
, O
focusing O
on O
their O
association O
with O
the O
genesis O
of O
cancers B-Disease
, O
and O
we O
look O
forward O
to O
the O
application O
of O
epigenetics O
in O
cancer B-Disease
clinical O
diagnosis O
and O
treatment O

0001 O
) O
and O
an O
average O
correlation O
of O
ρ O
= O
0 O

The O
first O
challenge O
is O
to O
clarify O
how O
perimenopausal O
ovarian B-Disease
function O
is O
reset O
to O
levels O
consistent O
with O
ovulation O

Based O
on O
recent O
studies O
, O
methodological O
developments O
are O
necessary O
to O
improve O
epigenetic O
research O

Leveraging O
closed O
submicroliter O
reaction O
volumes O
and O
a O
superhydrophobic O
interface O
, O
DMF-ChIP-seq O
presented O
higher O
sensitivity O
in O
peak O
enrichment O
than O
other O
current O
methods O
, O
with O
high O
accuracy O
( O
Pearson O
Correlation O
Coefficient O
( O
PCC O
) O
> O
0 O

We O
envision O
future O
forensic O
applications O
of O
DNA O
methylation O
analysis O
that O
will O
broaden O
DNA-based O
forensic O
intelligence O

Objectives O
: O
We O
aimed O
to O
evaluate O
the O
association O
between O
surrounding O
greenness O
and O
biological O
aging O
based O
on O
DNA O
methylation O

Mol O

There O
is O
increasing O
evidence O
that O
transcriptional O
reprogramming O
caused O
by O
epigenetic O
modifications O
can O
be O
passed O
from O
parents O
to O
offspring O

As O
this O
new O
strategy O
of O
chemically O
induced O
protein O
degradation O
can O
serve O
as O
a O
biological O
tool O
and O
provides O
new O
possibilities O
for O
drug O
discovery O
, O
it O
has O
been O
applied O
to O
a O
variety O
of O
targets O
including O
( O
nuclear O
) O
receptors O
, O
kinases O
, O
and O
epigenetic O
proteins O

The O
model O
is O
achieved O
by O
using O
the O
combination O
of O
pairwise O
covariances O
between O
any O
two O
data O
sets O


232 O
: O
DNA O
methylation O
controls O
several O
cellular O
processes O
, O
from O
early O
development O
to O
old O
age O
, O
including O
biological O
responses O
to O
endogenous O
or O
exogenous O
stimuli O
contributing O
to O
disease B-Disease
transition O

In O
order O
to O
summarize O
current O
knowledge O
and O
to O
facilitate O
the O
potential O
coordination O
of O
future O
research O
activities O
, O
the O
first O
international O
workshop O
on O
the O
epigenetics O
of O
OA O
was O
held O
in O
Amsterdam O
in O
October O
2015 O

The O
results O
of O
an O
application O
of O
iFACE O
to O
multilead O
EEG O
obtained O
with O
a O
single O
dizygotic O
twin O
pair O
is O
presented O

Research O
suggests O
that O
epigenetic O
processes O
can O
be O
manipulated O
in O
the O
future O
to O
treat O
or O
prevent O
epilepsy O
as O
epigenetics O
has O
been O
shown O
to O
have O
a O
profound O
influence O
on O
how O
genes O
are O
expressed O
in O
epilepsy O

There O
is O
an O
opportunity O
for O
deep O
learning O
methods O
to O
analyze O
the O
lung B-Disease
cancer I-Disease
epigenetic O
data O
to O
determine O
their O
subtypes O
for O
appropriate O
treatment O

In O
the O
review O
, O
recent O
studies O
demonstrating O
the O
role O
of O
genetic O
and O
epigenetic O
factors O
in O
the O
etiology O
and O
pathogenesis O
of O
AD O
are O
discussed O

This O
review O
is O
the O
first O
of O
seven O
in O
this O
special O
issue O
of O
Integrative O
and O
Comparative O
Biology O
that O
addresses O
in O
detail O
these O
and O
other O
key O
topics O
in O
the O
study O
of O
epigenetics O

The O
widespread O
application O
of O
epigenome O
( O
eg O
, O
methylome O
) O
analyses O
will O
enhance O
our O
understanding O
of O
disease B-Disease
heterogeneity B-Disease
, O
epigenotypes O
( O
CpG O
island O
methylator O
phenotype O
, O
LINE-1 O
( O
long O
interspersed O
nucleotide O
element-1 O
; O
also O
called O
long O
interspersed O
nuclear O
element-1 O
; O

Over O
the O
recent O
years O
, O
mass O
spectrometry O
( O
MS O
) O
has O
become O
an O
indispensable O
tool O
in O
epigenetics O
research O

Following O
PRISMA O
guidelines O
, O
two O
independent O
authors O
conducted O
a O
search O
within O
PubMed O
and O
Web O
of O
Science O
and O
identified O
18 O
journal O
articles O
and O
conference O
abstracts O
addressing O
anorexia O
nervosa O
( O
n O
= O
13 O
) O
, O
bulimia B-Disease
nervosa I-Disease
( O
n O
= O
6 O
) O
, O
and O
b O

This O
article O
gives O
an O
account O
of O
a O
journey O
that O
started O
with O
the O
analysis O
of O
transgene-related O
silencing O
events O
and O
that O
led O
to O
the O
discovery O
of O
a O
new O
molecular O
world O
of O
small O
RNAs O
and O
epigenetic O
marks O
that O
regulate O
plant O
gene O
expression O
and O
adaptation O
to O
environmental O
changes O

501 O
: O
Background O
: O
Genetic O
data O
are O
known O
to O
harbor O
information O
about O
human O
demographics O
, O
and O
genotyping O
data O
are O
commonly O
used O
for O
capturing O
ancestry O
information O
by O
leveraging O
genome-wide O
differences O
between O
populations O

For O
scientists O
whose O
primary O
training O
is O
in O
a O
field O
other O
than O
epigenetics O
, O
the O
choices O
can O
be O
confusing O
, O
and O
it O
can O
be O
challenging O
to O
determine O
which O
technology O
is O
best O
for O
the O
task O
at O
hand O

Using O
principles O
from O
statistical O
physics O
and O
information O
theory O
, O
we O
derive O
epigenetic O
energy O
landscapes O
from O
whole-genome O
bisulfite O
sequencing O
( O
WGBS O
) O
data O
that O
enable O
us O
to O
quantify O
methylation O
stochasticity O
genome-wide O
using O
Shannon O
's O
entropy O
, O
associating O
it O
with O
chromatin O
structure O

This O
knowledge O
constantly O
accumulates O
and O
is O
provided O
openly O
in O
the O
expanding O
hubs O
of O
information O
such O
as O
the O
USCS O
Genome O
Browser O

While O
it O
is O
now O
possible O
to O
draw O
direct O
connections O
between O
specific O
DNA O
sequences O
and O
specific O
physical O
features O
and O
to O
predict O
disease B-Disease
risk O
, O
the O
effects O
of O
certain O
genes O
can O
be O
masked O
by O
a O
process O
called O
" O
epigenetics O

However O
, O
differences O
in O
sequencing O
depth O
and O
signal-to-noise O
ratios O
in O
the O
data O
from O
different O
experiments O
can O
hinder O
our O
ability O
to O
identify O
real O
biological O
variation O
from O
raw O
epigenomic O
data O

Our O
analysis O
suggests O
that O
epigenetic O
models O
of O
stress O
, O
trauma B-Disease
, O
and O
adversity O
therefore O
situate O
histories O
of O
oppression O
, O
inequality O
, O
and O
subjugation O
in O
discrete O
and O
gendered O
family O
relations O
, O
resulting O
in O
the O
temporal O
embedding O
of O
adversity O
during O
early O
life O

We O
present O
a O
novel O
approach O
named O
JMnorm O
that O
simultaneously O
normalizes O
multiple O
epigenetic O
features O
across O
cell O
types O
, O
species O
, O
and O
experimental O
conditions O
by O
leveraging O
information O
from O
partially O
correlated O
epigenetic O
features O

Multiple O
studies O
have O
demonstrated O
the O
involvement O
of O
certain O
noncoding O
RNAs O
, O
particularly O
miR-140 O
, O
in O
OA O
development O
via O
modulation O
of O
key O
catabolic O
factors O

This O
review O
considers O
patent O
applications O
for O
small-molecule O
inhibitors O
of O
selected O
epigenetic O
targets O
from O
2010 O
to O
2014 O

Finally O
, O
a O
selected O
group O
of O
transgenic O
clones O
responsive O
to O
HDACi O
sodium O
butyrate O
, O
when O
tested O
in O
a O
gradient O
plate O
format O
showed O
similarity O
in O
phenotype O
to O
the O
plant-derived O
compound O
cinnamic O
acid O

Finally O
, O
they O
provide O
their O
perspective O
of O
using O
epigenetic O
drugs O
for O
treating O
schizophrenia B-Disease

15: O
Given O
the O
increasing O
research O
activity O
on O
epigenetics O
to O
monitor O
human O
diseases O
and O
its O
connection O
with O
lifestyle O
and O
environmental O
expositions O
, O
the O
field O
of O
epigenetics O
has O
attracted O
a O
great O
deal O
of O
interest O
also O
at O
the O
ethical O
and O
societal O
level O

Based O
on O
the O
proposed O
model O
, O
we O
provided O
a O
method O
to O
stratify O
glioma O
patients O
according O
to O
their O
epigenomic O
state O

43 O
: O
Psychiatric B-Disease
disorders I-Disease
are O
clinically O
heterogeneous O
and O
debilitating O
chronic O
diseases O
resulting O
from O
a O
complex O
interplay O
between O
gene O
variants O
and O
environmental O
factors O

While O
there O
has O
been O
some O
research O
exploring O
the O
public's O
understanding O
of O
genetic O
and O
environmental O
susceptibility O
to O
disease B-Disease
, O
limited O
research O
exists O
on O
public O
opinion O
and O
understanding O
of O
epigenetics O
and O
epigenetic O
concepts O

Supplementary O
information O
: O
Supplementary O
data O
are O
available O
at O
Bioinformatics O
online O

164 O
: O
Phenotypic O
variation O
arises O
from O
interactions O
between O
environmental O
and O
genetic O
variation O
, O
and O
the O
emergence O
of O
such O
variation O
is O
, O
in O
part O
, O
mediated O
by O
epigenetic O
mechanisms O
: O
factors O
that O
modify O
gene O
expression O
but O
do O
not O
change O
the O
gene O
sequence O
, O
per O
se O


341 O
: O
Epigenomic O
profiling O
, O
by O
revealing O
genome-wide O
distributions O
of O
epigenetic O
modifications O
, O
generated O
a O
large O
amount O
of O
structural O
information O
about O
the O
chromosomes O

Integrating O
various O
components O
of O
the O
epigenome O
into O
multi-omics O
measurements O
allows O
for O
studying O
cellular O
heterogeneity B-Disease
at O
different O
time O
scales O
and O
for O
discovering O
new O
layers O
of O
molecular O
connectivity O
between O
the O
genome O
and O
its O
functional O
output O

Computer-aided O
knowledge O
discovery O
for O
epigenetic O
implications O
of O
current O
approved O
or O
investigational O
drugs O
was O
performed O
by O
querying O
information O
from O
multiple O
publicly O
available O
gold-standard O
sources O
to O
(i) O
identify O
enzymes O
involved O
in O
classical O
epigenetic O
processes O
, O
(ii) O
screen O
original O
biomedical O
scientific O
publications O
including O
bibliometric O
analyses O

To O
our O
understanding O
, O
the O
concept O
of O
epigenetics O
needs O
to O
be O
revisited O
, O
as O
it O
is O
one O
of O
the O
most O
relevant O
and O
multifaceted O
terms O
in O
human O
knowledge O

We O
then O
discuss O
the O
emerging O
field O
of O
locus-specific O
neuroepigenetic O
editing O
, O
which O
is O
a O
promising O
method O
for O
determining O
the O
causal O
epigenetic O
molecular O
mechanisms O
that O
drive O
an O
addicted O
state O

This O
may O
be O
a O
way O
of O
understanding O
the O
successes O
to O
date O
of O
plasma-based O
rejuvenation O

5 O
% O
of O
the O
sites O
) O
suggesting O
additive O
effects O
, O
as O
expected O
from O
hybridization O
between O
genetically O
distant O
species O

Current O
methods O
for O
estimating O
humpback O
age O
cannot O
be O
applied O
to O
all O
individuals O
and O
populations O

We O
summarise O
this O
progress O
and O
highlight O
resulting O
key O
findings O
about O
the O
complexity O
of O
eukaryotic O
DNA O
methylation O
, O
its O
role O
in O
metazoan O
genome O
evolution O
, O
epigenetic O
reprogramming O
, O
and O
its O
close O
ties O
with O
histone O
modifications O
in O
the O
context O
of O
transcription O

10 O
: O
Epigenetic O
alterations O
such O
as O
DNA O
methylation O
defects O
and O
aberrant O
covalent O
histone O
modifications O
occur O
within O
all O
cancers B-Disease
and O
are O
selected O
for O
throughout O
the O
natural O
history O
of O
tumor B-Disease
formation O
, O
with O
changes O
being O
detectable O
in O
early O
onset O
, O
progression O
, O
and O
ultimately O
recurrence O
and O

The O
Inheritance O
of O
Acquired O
Characteristics O
) O

This O
method O
is O
cost-effective O
, O
requires O
simple O
and O
basic O
instrumentation O
, O
and O
therefore O
can O
easily O
be O
performed O
in O
any O
laboratory O
with O
basic O
setup O
having O
a O
regular O
DNA O
thermal O
cycler O
and O
DNA O
gel O
electrophoresis O
system O

Although O
hypermethylation O
of O
gene O
promoters O
is O
in O
turn O
associated O
with O
gene O
inactivation O
, O
the O
precise O
consequences O
of O
genome-wide O
hypomethylation O
are O
still O
debated O

Taken O
together O
, O
we O
conclude O
that O
presently O
, O
the O
evidence O
suggesting O
that O
acquired O
epigenetic O
marks O
are O
passed O
to O
the O
subsequent O
generation O
remains O
limited O

This O
conference O
represented O
the O
current O
state O
of O
the O
epigenetics O
community O
with O
cancer B-Disease
/ O
oncology O
as O
a O
key O
driver O

Variants O
in O
L3MBTL3 O
were O
associated O
with O
colorectal O
, O
overall B-Disease
breast I-Disease
, O
ER-negative O
breast O
, O
clear O
cell O
ovarian B-Disease
, O
and O
overall O
and O
aggressive O
prostate B-Disease
cancer I-Disease
risk O
( O
e O

We O
then O
showed O
supporting O
results O
from O
recent O
association O
studies O
such O
as O
human O
studies O
and O
animal O
models O
in O
terms O
of O
the O
epigenetic O
contribution O
to O
disease B-Disease
susceptibility O
to O
anxiety O
disorders O

134 O
: O
The O
nearly O
neutral O
theory O
emphasizes O
the O
interaction O
of O
drift O
and O
weak O
selection O
in O
evolution O

594 O
: O
In O
recent O
years O
, O
an O
increasing O
number O
of O
studies O
documented O
potential O
links O
between O
parental O
care O
and O
epigenetic O
mechanisms O

This O
review O
discusses O
the O
potential O
for O
the O
use O
of O
low-volume O
liquid O
handling O
robots O
, O
for O
molecular O
biological O
applications O
such O
as O
quantitative O
PCR O
and O
epigenetics O

Accumulating O
evidence O
has O
been O
suggesting O
that O
epigenetic O
control O
is O
a O
key O
factor O
to O
initiate O
and O
sustain O
the O
regenerative O
transcriptional O
response O
and O
that O
it O
might O
contribute O
to O
regenerative O
success O
versus O
failure O

Stable O
isotope O
labeling O
by O
amino O
acid O
in O
cell O
culture O
( O
SILAC O
) O
, O
when O
adapted O
to O
histones O
, O
permits O
the O
accurate O
quantification O
of O
PTM O
changes O
among O
distinct O
functional O
states O
; O
however O
, O
its O
application O
has O
been O
mainly O
confined O
to O
actively O
dividing O
cell O
lines O

To O
study O
early O
and O
unbiased O
epigenetic O
predictors O
of O
longevity O
prospectively O
, O
a O
birth O
cohort O
would O
be O
ideal O

Now O
, O
however O
, O
theoretical O
and O
experimental O
studies O
have O
illuminated O
the O
possible O
roles O
that O
epigenetic O
information O
could O
play O
in O
evolution O
and O
we O
are O
on O
the O
cusp O
of O
testing O
this O
concept O
in O
ecologically O
relevant O
settings O

Two O
contributions O
investigated O
treatment O
response O

These O
studies O
highlight O
that O
in O
time O
loosening O
of O
epigenetic O
control O
increase O
the O
propensity O
of O
joint O
tissues O
to O
engage O
an O
osteoarthritis O
disease B-Disease
phenotype O

0001 O
) O
by O
comparing O
data O
generated O
from O
cytological O
staining O
and O
Infinium O
MethylationEPIC O
arrays O
and O
the O
EpiDISH O
deconvolution O
algorithm O
from O
buccal O
and O
saliva O
samples O
collected O
from O
twenty O
adults O

Some O
aging O
clocks O
that O
have O
been O
proposed O
include O
the O
suprachiasmatic O
nucleus O
, O
the O
hypothalamus O
, O
involution O
of O
the O
thymus O
, O
and O
cellular O
senescence B-Disease

Among O
the O
environmental O
factors O
that O
can O
influence O
genetic O
activity O
are O
parenting O
styles O
, O
diets O
, O
and O
social O
statuses O

We O
present O
Coordinate O
Covariation O
Analysis O
( O
COCOA O
) O
, O
a O
computational O
framework O
that O
uses O
covariation O
of O
epigenetic O
signals O
across O
individuals O
and O
a O
database O
of O
region O
sets O
to O
annotate O
epigenetic O
heterogeneity B-Disease

We O
suggest O
a O
three-step O
process O
for O
using O
epigenetics O
in O
health O
promotion O
research O
that O
emphasizes O
integrating O
epigenetic O
mechanisms O
into O
conceptual O
model O
development O
that O
then O
informs O
selection O
of O
intervention O
approaches O
and O
outcomes O

Indeed O
also O
in O
the O
field O
of O
epigenetics O
, O
virtual O
screening O
( O
VS O
) O
studies O
and O
structure-based O
approaches O
have O
been O
applied O
to O
identify O
novel O
chemical O
modulators O
of O
epigenetic O
targets O
as O
well O
as O
to O
predict O
the O
binding O
mode O
of O
active O
ligands O
and O
to O
study O
the O
protein O
dynamics O

In O
this O
report O
, O
we O
summarize O
some O
of O
the O
main O
advancements O
and O
prospects O
in O
cancer B-Disease
epigenetics O
presented O
at O
this O
meeting O

327 O
: O
The O
identification O
of O
potential O
epigenetic O
targets O
for O
a O
known O
bioactive O
compound O
is O
essential O
and O
promising O
as O
more O
and O
more O
epigenetic O
drugs O
are O
used O
in O
cancer B-Disease
clinical O
treatment O
and O
the O
availability O
of O
chemogenomic O
data O
related O
to O
epigenetics O
increases O

The O
Research O
to O
Accelerate O
Cures O
and O
Equity O
( O
RACE O
) O
for O
Children O
Act O
FDARA O
amendments O
to O
section O
505B O
of O
the O
FD&C O
Act O
was O
implemented O
in O
August O
2020 O
, O
and O
as O
there O
are O
many O
epigenetic O
targets O
on O
the O
FDA O
Paediatric O
Molecular O
Targets O
List O
, O
clinical O
evaluation O
of O

Adverse O
effects O
observed O
in O
the O
OECD O
transgenerational O
assays O
could O
be O
used O
to O
inform O
future O
tests O
specifically O
designed O
to O
investigate O
the O
epigenetic O
mechanism O
of O
action O

We O
evaluated O
candidate O
gene O
as O
well O
as O
epigenome-wide O
association O
studies O
associating O
prenatal O
stress O
and O
DNAm O
changes O
in O
peripheral O
tissues O
; O
however O
, O
most O
of O
these O
findings O
lack O
robust O
replication O

Major O
conclusions O
: O
Nature O
offers O
a O
suite O
of O
enzymes O
with O
biological O
roles O
in O
cytosine O
modification O
in O
organisms O
spanning O
from O
bacteriophages O
to O
mammals O

Advances O
in O
our O
understanding O
of O
chromatin O
and O
gene O
regulatory O
mechanisms O
have O
had O
impact O
on O
drug O
development O
, O
fueling O
excitement O
in O
the O
lay O
public O
about O
the O
prospects O
of O
applying O
this O
knowledge O
to O
address O
health O
issues O

In O
doing O
so O
, O
we O
demonstrate O
that O
it O
is O
essential O
that O
future O
research O
explores O
the O
public O
's O
awareness O
and O
understanding O
of O
epigenetics O
and O
epigenetic O
concepts O

Scope O
of O
review O
: O
This O
study O
reviews O
the O
links O
between O
metabolism O
and O
chromatin O
modification O
, O
in O
particular O
histone O
acetylation O
, O
histone O
methylation O
, O
and O
DNA O
methylation O
, O
in O
plants O
and O
compares O
them O
to O
examples O
from O
the O
mammalian O
field O
, O
where O
the O
relationship O
to O
human O
diseases O

We O
also O
took O
advantage O
of O
the O
large O
number O
of O
samples O
to O
conduct O
an O
epigenome-wide O
association O
study O
of O
age-associated O
DNA O
methylation O
patterns O
in O
skeletal O
muscle O

Large-scale O
efforts O
to O
generate O
genome-wide O
maps O
of O
epigenetic O
modifications O
in O
different O
cell O
types O
, O
as O
well O
as O
in O
physiological O
and O
pathological O
contexts O
, O
illustrate O
the O
increasing O
recognition O
of O
the O
relevance O
of O
epigenetics O

Errors O
in O
this O
process O
can O
lead O
to O
transmission O
of O
epimutations O
through O
the O
germ-line O
, O
which O
have O
the O
potential O
to O
affect O
development O
and O
disease B-Disease
in O
the O
parent O
's O
progeny O

685 O
: O
Genomic O
editing O
technology O
has O
been O
developed O
since O
2010 O
through O
the O
use O
of O
some O
techniques O
, O
such O
as O
the O
clustered O
regularly O
interspaced O
short O
palindromic O
repeat O
( O
CRISPR O
) O
DNA O
sequences O
/ O
CRISPR-associated O
( O
Cas O
) O
type-9 O
method O
, O
or O
through O
genetic O
manipulation O

As O
a O
result O
, O
DNA O
hypomethylation-mediated O
abnormalities O
remained O
relatively O
less O
explored O
, O
and O
currently O
, O
there O
are O
no O
approved O
drugs O
that O
can O
be O
clinically O
used O
to O
target O
hypomethylation O

For O
a O
compilation O
of O
the O
general O
discussion O
at O
the O
marabou O
symposium O
, O
click O
here O
http://www O

Consequently O
, O
planarians O
possess O
remarkable O
regenerative O
capabilities O

Moving O
forward O
, O
it O
will O
be O
important O
to O
establish O
cause O
and O
effect O
in O
epigenetic O
studies O
of O
schizophrenia B-Disease
and O
broaden O
our O
horizons O
beyond O
DNA O
methylation O

Based O
on O
these O
similarities O
, O
we O
argue O
that O
currently O
in O
Latin O
America O
the O
field O
of O
epigenetics O
appears O
on O
the O
scene O
with O
a O
worrisome O
colonial O
shadow O

566 O
: O
Mammalian O
genomes O
are O
intricately O
compacted O
to O
form O
sophisticated O
3-dimensional O
structures O
within O
the O
tiny O
nucleus O
, O
so O
called O
3D O
genome O
folding O

Genetic O
and O
environmental O
factors O
have O
been O
shown O
to O
trigger O
SLE O

This O
study O
establishes O
a O
genome-wide O
metric O
based O
on O
the O
gene-repressive O
trimethylation O
of O
histone O
H3 O
at O
lysine O
27 O
( O
H3K27me3 O
) O
across O
hundreds O
of O
diverse O
cell O
types O
to O
identify O
genetic O
regulators O
of O
cell O
differentiation O

It O
is O
proposed O
that O
increased O
polyamine O
activity O
can O
cause O
disruption O
of O
cellular O
methylation O
, O
which O
can O
lead O
to O
abnormal O
expression O
of O
previously O
sequestered O
genes O
and O
disruption O
of O
other O
methylation-dependent O
cellular O
processes O

Furthermore O
, O
a O
panel O
of O
ncRNAs O
were O
identified O
as O
biomarkers O
that O
discriminated O
between O
disease B-Disease
phenotypes O

To O
better O
understand O
the O
interplay O
between O
etiological O
factors O
, O
cellular O
molecular O
characteristics O
, O
and O
disease B-Disease
evolution O
, O
the O
field O
of O
' O
molecular O
pathological O
epidemiology O
( O
MPE O
) O
' O
has O
emerged O
as O
an O
interdisciplinary O
integration O
of O
' O
molecular O
pathology O
' O
and O
' O
epidemi O

Rejuvenation O
by O
reprogramming O
is O
a O
young O
but O
rapidly O
expanding O
subfield O
in O
the O
biology O
of O
aging O

While O
reliable O
detection O
of O
cancer-specific O
epigenetic O
changes O
has O
proven O
to O
be O
technically O
challenging O
, O
a O
substantial O
progress O
has O
been O
made O
in O
developing O
the O
methodologies O
that O
allow O
an O
efficient O
and O
sensitive O
detection O
of O
epigenomic O
changes O
using O
the O
material O
originating O
from O
body O
fluids O

Notably O
, O
these O
projects O
have O
found O
that O
approximately O
80% O
of O
human O
DNA O
was O
biochemically O
active O
in O
at O
least O
one O
epigenomic O
assay O
while O
only O
approximately O
10% O
of O
the O
sequence O
displayed O
signs O
of O
purifying O
selection O

g O

Computational O
tools O
have O
been O
developed O
apace O
with O
these O
epigenome O
methods O
to O
better O
enable O
accurate O
interpretation O
of O
the O
profiling O
data O

These O
mechanisms O
of O
activity-dependent O
regulation O
of O
gene O
expression O
are O
important O
in O
neural O
development O
, O
plasticity O
, O
and O
in O
neurological O
and O
psychological O
disorders O

In O
addition O
, O
we O
argue O
that O
an O
overemphasized O
clinical O
translation O
of O
epigenetics O
may O
further O
reinforce O
this O
biopolitical O
landscape O
through O
four O
processes O
closely O
related O
to O
neoliberal O
pathways O
of O
thinking O
: O
the O
internalization O
and O
isolation O
( O
aspects O
of O
liberal O
individualism O
) O
of O
socioenvironmental O
determinants O

Some O
investigators O
have O
been O
trying O
to O
illustrate O
the O
mechanism O
of O
acupuncture O
from O
an O
epigenetics O
perspective O
, O
which O
has O
shed O
new O
lights O
on O
the O
mechanisms O
and O
applications O
of O
acupuncture O

The O
progeny O
of O
cold-stressed O
plants O
exhibited O
the O
higher O
rate O
of O
missense O
non-synonymous O
mutations O
as O
compared O
to O
the O
progeny O
of O
control O
plants O

Despite O
these O
significant O
findings O
, O
the O
progress O
in O
understanding O
the O
epigenetic O
mechanisms O
regulating O
tumor B-Disease
heterogeneity B-Disease
has O
been O
impeded O
over O
the O
past O
few O
years O
due O
to O
the O
lack O
of O
appropriate O
technical O
tools O
and O
methodologies O

From O
this O
perspective O
, O
we O
first O
review O
the O
state O
of O
high-throughput O
biological O
data O
acquisition O
( O
i O

In O
particular O
, O
epigenetics O
links O
developmental O
biology O
and O
genetics O
, O
as O
well O
as O
many O
other O
areas O
of O
knowledge O

Epigenetic O
alterations O
are O
innovative O
cancer B-Disease
biomarkers O
owing O
to O
stability O
, O
frequency O
, O
reversibility O
and O
accessibility O
in O
body O
fluids O
, O
entailing O
great O
potential O
of O
assay O
development O
to O
assist O
in O
patient O
management O

Although O
there O
is O
evidence O
to O
suggest O
that O
epigenomic O
dysregulation O
might O
mediate O
effects O
of O
exposures O
to O
endocrine O
disruptors O
, O
it O
is O
uncertain O
as O
to O
whether O
these O
changes O
are O
truly O
predictive O
of O
adverse O
outcome(s) O

We O
present O
cfNOMe O
, O
a O
two-in-one O
method O
of O
measuring O
cfDNA O
cytosine B-Disease
methylation I-Disease
and O
nucleosome O
occupancy O
in O
a O
single O
assay O
using O
non-disruptive O
enzymatic O
cytosine O
conversion O
and O
a O
custom O
bioinformatic O
pipeline O

Multifactorial O
etiology O
, O
of O
which O
the O
candidate O
genes O
have O
been O
studied O
the O
most O
, O
poses O
a O
challenge O
in O
understanding O
this O
disorder B-Disease

231 O
: O
Cytosine O
DNA O
methylation O
( O
5-methylcytsone O
, O
5mC O
) O
is O
the O
major O
DNA O
modification O
found O
in O
the O
genomes O
of O
animals O
and O
plants O

The O
most O
prominent O
evidence O
on O
the O
association O
between O
environment O
and O
autoimmunity O
has O
been O
reported O
in O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
, O
but O
similar O
mechanisms O
were O
proposed O
in O
rheumatoid B-Disease
arthritis I-Disease
, O
systemic B-Disease
sclerosis I-Disease
, O
and O
type O
1 O
diabetes B-Disease

Finally O
, O
epigenetics O
offers O
multiple O
clinical O
applications O
, O
including O
powerful O
diagnostic O
and O
prognostic O
biomarkers O
as O
well O
as O
therapeutic O
targets O

``` O
92 O
: O
Background O
: O
Longitudinal O
data O
and O
repeated O
measurements O
in O
epigenome-wide O
association O
studies O
( O
EWAS O
) O
provide O
a O
rich O
resource O
for O
understanding O
epigenetics O
``` O

While O
the O
underlying O
molecular O
mechanisms O
are O
unclear O
, O
epigenetics-the O
chemical O
changes O
that O
regulate O
genomic O
function O
without O
altering O
the O
genetic O
code-has O
emerged O
as O
a O
key O
link O
between O
environmental O
exposures O
and O
phenotypic O
outcomes O

130 O
: O
Recent O
findings O
in O
epigenetics O
have O
been O
attracting O
much O
attention O
from O
social O
scientists O
and O
bioethicists O
because O
they O
reveal O
the O
molecular O
mechanisms O
by O
which O
exposure O
to O
socioenvironmental O
factors O
, O
such O
as O
pollutants O
and O
social O
adversity O
, O
can O
influence O
the O
expression O
of O
genes O
throughout O

144 O
: O
Epigenetics O
play O
a O
central O
role O
in O
the O
regulation O
of O
many O
important O
cellular O
processes O
, O
and O
dysregulations O
at O
the O
epigenetic O
level O
could O
be O
the O
source O
of O
serious O
pathologies O
, O
such O
as O
neurological B-Disease
disorders I-Disease
affecting O
brain O
development O
, O
neurodegeneration B-Disease
, O
and O
intellectual O

The O
present O
review O
aims O
to O
provide O
an O
overview O
of O
current O
research O
focused O
on O
the O
epigenetic O
mechanisms O
that O
regulate O
gene O
expression O
in O
the O
cyclical O
endometrium O
and O
discuss O
the O
technical O
and O
clinical O
perspectives O
regarding O
this O
topic O

The O
creation O
of O
more O
specific O
and O
effective O
epigenetic O
therapies O
, O
however O
, O
requires O
a O
more O
complete O
understanding O
of O
epigenomic O
landscapes O

For O
genotype O
data O
, O
genetic O
risk O
scores O
( O
GRS O
) O
are O
widely O
used O
for O
risk O
prediction O
as O
well O
as O
in O
association O
and O
interaction O
studies O

Within O
the O
scope O
of O
this O
current O
review O
, O
the O
most O
sought O
after O
epigenetic O
changes O
of O
DNA O
methylation O
and O
histone O
modification O
are O
thoroughly O
scrutinized O
to O
understand O
their O
close O
functional O
association O
with O
the O
broad O
spectrum O
of O
suicide O
phenotype O

Such O
questions O
were O
rooted O
in O
the O
theory O
of O
epigenesis O
and O
set O
the O
scene O
for O
the O
development O
of O
epigenetics O


Monitoring O
such O
epigenetic O
marks O
in O
response O
to O
toxicant O
exposure O
may O
in O
future O
provide O
a O
valuable O
tool O
for O
predicting O
adverse O
outcomes O
, O
but O
a O
more O
robust O
basis O
for O
Test O
Guideline O
recommendations O
is O
still O
needed O

Finally O
, O
our O
model O
reproduced O
previous O
results O
of O
increased O
epigenetic O
age O
acceleration O
in O
cancer B-Disease
patients O
and O
in O
survivors O
treated O
with O
radiation B-Disease
therapy I-Disease
, O
and O
no O
changes O
from O
exercise-based O
interventions O

Oxidative O
stress O
, O
inflammation B-Disease
, O
hyperhomocysteinemia O
, O
and O
uremic O
toxins O
could O
induce O
epimutations O
in O
chronic O
kidney O
disease B-Disease

However O
, O
the O
developed O
epi- O
drugs O
cause O
off-target O
gene O
and O
transposable O
elements O
activation O
; O
promote O
mutagenesis O
and O
carcinogenesis O
in O
normal O
cells O
, O
are O
the O
major O
hurdles O
regarding O
their O
clinical O
use O

Thus O
, O
we O
believe O
that O
studying O
epigenetics O
can O
provide O
previously O
unknown O
causes O
for O
dementia B-Disease
and O
other O
neurodegenerative B-Disease
disorders I-Disease

The O
15 O
newly O
considered O
scores O
consist O
of O
13 O
freshly O
computed O
nucleosome B-Disease
occupancy/positioning I-Disease
scores O
and O
2 O
experimental O
features O
(MNase O
and O
DRIP O
) O

Overall O
, O
significant O
progress O
has O
been O
made O
in O
the O
field O
of O
epigenetics O
and O
obesity B-Disease
and O
the O
first O
potential O
epigenetic O
markers O
for O
obesity B-Disease
that O
could O
be O
detected O
at O
birth O
have O
been O
identified O

In O
this O
study O
, O
we O
focus O
on O
the O
current O
research O
of O
the O
epigenetics O
of O
breast B-Disease
cancer I-Disease
, O
especially O
on O
the O
potential O
of O
epigenetics O
for O
clinical O
application O
in O
diagnostics O
, O
risk O
stratification O
and O
therapy O

It O
is O
an O
ortholog O
of O
Arabidopsis O
genes O
ARR16 O
and O
ARR17 O

com O
/ O
dohlee O
/ O
prism O
) O

A O
thorough O
study O
of O
epigenetic O
mechanisms O
is O
of O
great O
significance O
to O
improve O
crop O
agronomic O
traits O
and O
environmental O
adaptability O

In O
particular O
, O
epigenetic O
strategies O
might O
open O
interesting O
new O
perspectives O
in O
combination O
with O
conventional O
ones O

, O
risk O
of O
discrimination O
, O
patient O
re-identification O
and O
unexpected O
findings O
) O
or O
the O
debate O
in O
the O
distribution O
of O
responsibilities O
for O
health O
( O
i O

, O
case O
vs O
control O
; O
treatments O
vs O
placebo O
, O
accuracy O
is O
not O
crucial O

252 O
: O
Over O
the O
past O
few O
years O
it O
has O
become O
clear O
that O
vitamin O
C O
, O
as O
a O
provider O
of O
reduced O
iron O
, O
is O
an O
essential O
factor O
for O
the O
function O
of O
epigenetic O
regulators O
that O
initiate O
the O
demethylation O
of O
DNA O
and O
histones O

85 O
: O
Epigenetics O
has O
the O
potential O
to O
revolutionize O
diagnosis O
and O
treatment O
in O
psychiatry O
, O
especially O
child O
psychiatry O
, O
as O
it O
may O
offer O
the O
opportunity O
for O
early O
detection O
and O
prevention O
, O
as O
well O
as O
development O
of O
new O
treatments O

We O
also O
focus O
on O
problems O
and O
future O
perspectives O
in O
the O
development O
of O
fluorescent O
probes O
for O
epigenetics O

324 O
: O
Background O
: O
DNA O
methylation O
changes O
at O
a O
discrete O
set O
of O
sites O
in O
the O
human O
genome O
are O
predictive O
of O
chronological O
and O
biological O
age O

The O
analysis O
of O
these O
modifications O
provides O
a O
thorough O
insight O
into O
the O
cardiovascular O
system O
from O
its O
development O
to O
its O
further O
functioning O

Although O
important O
methodological O
advances O
have O
been O
conducted O
in O
the O
previous O
years O
, O
key O
challenges O
such O
as O
the O
development O
of O
sensitivity O
analyses O
, O
dealing O
with O
mediator-mediator O
interactions O
, O
including O
environmental O
mixtures O
as O
exposures O
, O
or O
the O
integration O
of O
different O
omic O
data O
should O
be O
the O
focus O
of O

e O

We O
tested O
the O
hypothesis O
that O
5hmC O
changes O
with O
age O
, O
but O
in O
a O
direction O
opposite O
to O
5-methylcytosine O
( O
5mC O
) O
, O
potentially O
playing O
a O
distinct O
role O
in O
aging O


We O
systematically O
evaluated O
the O
applicability O
of O
five O
scores O
assessing O
the O
variability O
of O
methylation O
patterns O
by O
evaluating O
within-sample O
heterogeneity B-Disease
(WSH) O
to O
construct O
human O
blood O
epigenetic O
clock O
models O
using O
RRBS O
data O

As O
an O
alternative O
link O
between O
genes O
and O
disease B-Disease
, O
recent O
efforts O
have O
focused O
on O
mechanisms O
that O
alter O
the O
function O
of O
genes O
without O
altering O
the O
underlying O
DNA O
sequence O

Concepts O
and O
techniques O
of O
classical O
and O
modern O
breeding O
should O
consider O
integrating O
recent O
progress O
in O
epigenetics O
, O
initially O
by O
identifying O
their O
association O
with O
phenotypic O
variations O
and O
then O
by O
assessing O
their O
heritability O
and O
stability O
in O
subsequent O
generations O

It O
is O
showed O
that O
the O
bivariate O
classifiers O
on O
the O
further O
compressed O
latent O
features O
could O
classify O
the O
subtypes O
accurately O

726 O
: O
Freshwater O
ecosystems O
are O
amongst O
the O
most O
threatened O
ecosystems O
on O
Earth O

Most O
GRS O
approaches O
can O
directly O
be O
transferred O
to O
methylation O
data O

Further O
, O
UBR5 O
, O
RPL35a O
, O
HEG1 O
, O
PLA2G16 O
, O
SETD3 O
displayed O
hypomethylation O
and O
enhanced O
gene O
expression O
following O
loading O
, O
and O
demonstrated O
the O
largest O
increases O
in O
hypomethylation O
, O
gene O
expression O
and O
muscle O
mass O
after O
later O
reloading O
, O
indicating O
an O
epigenetic O
memory O

563 O
: O
Dynamic O
changes O
in O
genomic O
DNA O
methylation O
patterns O
govern O
the O
epigenetic O
developmental O
programs O
and O
accompany O
the O
organism O
's O
aging O

It O
outlines O
how O
epigenetic O
modifications O
, O
including O
DNA O
methylation O
and O
histone/chromatin O
modification O
, O
( O
1 O
) O
respond O
to O
temperature O
and O
regulate O
thermal O
stress O
responses O
in O
different O
kingdoms O
of O
life O
, O
( O
2 O
) O
regulate O
temperature-dependent O
expression O
of O
key O
developmental O
processes O
, O
sex O
determination O
, O

We O
show O
the O
potential O
of O
epigenetic O
changes O
for O
various O
clinical O
applications O
: O
as O
diagnostic O
tools O
, O
to O
assess O
tolerance O
following O
immunotherapy O
or O
possibly O
predict O
the O
success O
of O
therapy O
at O
an O
early O
time O
point O

Although O
Lamarckism O
fell O
out O
of O
favour O
soon O
after O
the O
publication O
of O
Darwin's O
work O
on O
natural O
selection O
and O
evolution O
, O
the O
concept O
of O
transmission O
of O
acquired O
characteristics O
has O
recently O
gained O
renewed O
attention O
and O
has O
led O
to O
some O
rethinking O
of O
the O
standard O
evolutionary O
model O

These O
findings O
have O
triggered O
research O
on O
epigenetic O
functions O
and O
signal O
pathways O
as O
targets O
for O
novel O
drug O
discovery O

However O
, O
more O
data O
are O
becoming O
available O
, O
particularly O
focused O
on O
DNA O
methylation O
changes O
caused O
by O
anthropogenic O
pollutants O
in O
a O
wide O
range O
of O
invertebrates O

One O
of O
the O
concerns O
raised O
is O
that O
MZ O
twins O
are O
not O
100% O
genetically O
and O
epigenetically O
similar O
because O
they O
show O
variations O
in O
their O
genomes O
and O
epigenomes O
leading O
to O
inaccurate O
estimates O
of O
heritability O

Expert O
opinion O
: O
Epigenetic O
alterations O
take O
place O
before O
most O
genetic O
aberrations O
observed O
in O
GC O
and O
may O
have O
an O
initiating O
role O
in O
the O
pathogenesis O
of O
GC O

These O
mechanisms O
act O
on O
the O
level O
of O
chromatin O
, O
by O
modifying O
DNA O
, O
histone O
proteins O
and O
nucleosome O
density/composition O

This O
review O
will O
provide O
an O
overview O
of O
the O
epigenetic O
alterations O
that O
have O
been O
implicated O
in O
all O
aspects O
of O
cancer B-Disease
pathogenesis O
and O
progression O
as O
well O
as O
summarize O
clinical O
applications O
for O
targeting O
epigenetics O
in O
the O
treatment O
of O
lung B-Disease
cancer I-Disease

The O
microflora O
hypothesis O
(MH) O
suggests O
that O
gut O
microbial O
dysbiosis O
in O
early O
life O
might O
trigger O
hypersensitivity O
disorders O

OLP O
inhibited O
the O
epigenetic O
NRF2/KLOTHO O
suppressions O
in O
a O
gain O
of O
DNMT-sensitive O
manner O
in O
cultured O
renal O
cells O
, O
demonstrating O
a O
strong O
DNA-demethylating O
capacity O

Disruptions O
in O
epigenetic O
processes O
can O
lead O
to O
altered O
gene O
function O
and O
cellular O
neoplastic O
transformation O

Here O
, O
we O
review O
major O
model O
systems O
for O
transgenerational O
epigenetic O
inheritance O
via O
the O
germline O
in O
multicellular O
organisms O

ac O

With O
rapid O
aging O
of O
the O
world O
population O
, O
the O
need O
to O
elucidate O
the O
underlying O
mechanisms O
is O
pressing O
, O
now O
more O
so O
than O
ever O

683 O
: O
Forensic O
geneticists O
are O
in O
a O
race O
to O
develop O
methods O
based O
on O
DNA O
methylation O
for O
various O
forensic O
applications O
, O
including O
age O
estimation O

171 O
: O
Immune O
cells O
are O
capable O
of O
sensing O
various O
signals O
in O
the O
microenvironment O
and O
turning O
on O
specific O
immune O
functions O
in O
response O

However O
, O
the O
extent O
to O
which O
observed O
epigenetic O
variation O
occurs O
independently O
of O
genetic O
influences O
remains O
uncertain O
, O
due O
to O
the O
widespread O
impact O
of O
genetics O
on O
epigenetic O
variation O
and O
the O
limited O
availability O
of O
comprehensive O
( O
epi O
) O
genomic O
resources O
from O
most O
species O


In O
addition O
, O
we O
briefly O
mentioned O
recent O
efforts O
to O
study O
lncRNAs O
and O
extracellular O
miRNAs O

The O
decrease O
in O
the O
functional O
β-cell O
mass O
associated O
with O
T2D O
has O
been O
attributed O
primarily O
to O
β-cell O
death B-Disease
; O
however O
, O
studies O
in O
recent O
years O
suggested O
that O
β-cell O
dedifferentiation O
may O
contribute O
to O
this O
decline O

In O
this O
review O
article O
, O
we O
aim O
to O
give O
a O
brief O
introduction O
to O
the O
basic O
molecular O
principals O
of O
epigenetics O
and O
provide O
a O
concise O
summary O
of O
the O
existing O
evidence O
for O
the O
role O
of O
epigenetic O
mechanisms O
in O
gastrointestinal O
health O
and O
disease B-Disease
, O
hepatology O
, O
and O
nutrition O

Although O
an O
individual O
's O
life O
history O
is O
progressive O
and O
continuous O
, O
it O
might O
usefully O
be O
viewed O
as O
the O
cumulation O
of O
divisions O
: O
each O
period O
emerging O
from O
what O
has O
gone O
before O
and O
, O
at O
the O
same O
time O
, O
setting O
the O
stage O
for O
what O
follows O

When O
applying O
it O
to O
imaging O
(epi)genetics O
study O
of O
schizophrenia B-Disease
subjects O
, O
we O
can O
detect O
significant O
(epi)genetic O
variants O
and O
brain O
regions O
, O
which O
are O
consistent O
with O
other O
existing O
reports O

Herein O
, O
we O
have O
summarized O
candidate O
gene O
and O
epigenome-wide O
studies O
which O
have O
investigated O
DNA O
methylation O
in O
relation O
to O
suicidal O
behaviors O
, O
as O
well O
as O
discussed O
some O
of O
the O
limitations O
of O
the O
field O
to O
date O

Here O
, O
we O
used O
the O
European O
sea O
bass O
, O
a O
marine O
fish O
the O
age O
of O
which O
can O
be O
determined O
with O
accuracy O
, O
to O
construct O
a O
piscine O
epigenetic O
clock O
, O
the O
first O
one O
in O
a O
cold-blooded O
vertebrate O

Epigenetics O
plays O
a O
significant O
role O
, O
and O
several O
epigenetic O
interventions O
can O
modulate O
lifespan O

PubMed O
database O
search O
yielded O
3051 O
hits O
on O
epigenetics O
and O
drugs O
, O
starting O
in O
1992 O
and O
peaking O
in O
2016 O

465 O
: O
Epigenetics O
is O
the O
heritable O
phenotypic O
changes O
without O
altering O
the O
genotype O

21 O
: O
Epigenetics O
, O
defined O
as O
' O
the O
study O
of O
mitotically O
and O
/ O
or O
meiotic O
heritable O
changes O
in O
gene O
function O
that O
cannot O
be O
explained O
by O
changes O
in O
DNA O
sequence O
' O
, O
has O
emerged O
as O
a O
promissory O
yet O
controversial O
field O
of O
scientific O
inquiry O
over O
the O

In O
particular O
, O
the O
addition O
of O
functional O
domains O
encoding O
epigenetic O
effectors O
and O
chromatin O
modifiers O
to O
the O
CRISPR/Cas O
ribonucleoprotein O
complex O
opens O
the O
possibility O
to O
introduce O
targeted O
epigenomic O
modifications O
in O
plants O
in O
an O
easily O
programmable O
manner O

Alterations O
in O
DNA O
methylation O
in O
cancer B-Disease
are O
functionally O
important O
and O
clinically O
relevant O
, O
but O
even O
this O
well-studied O
area O
is O
continually O
re-evaluated O
in O
light O
of O
unanticipated O
results O
, O
such O
as O
the O
strong O
association O
between O
aberrant O
DNA O
methylation O
in O
adult O
tumors B-Disease
and O
polycomb O
group O

We O
demonstrate O
the O
feasibility O
of O
WGBS O
on O
ultralow O
DNA O
yields O
from O
serum O
samples O
stored O
up O
to O
48 O
years O

0 O
is O
now O
optimized O
for O
data-independent O
acquisition O
through O
the O
use O
of O
precursor O
and O
fragment O
extracted O
ion O
chromatography O
to O
accurately O
determine O
the O
chromatographic O
profile O
and O
to O
discriminate O
isobaric O
forms O
of O
peptides O

We O
observed O
that O
tissue O
exposed O
to O
perfluorocarbon O
showed O
no O
significant O
DNA O
methylation O
differences O
when O
compared O
to O
unprocessed O
tissue O
, O
while O
formalin O
processing O
altered O
the O
quality O
and O
reliability O
of O
the O
data O
produced O
on O
the O
DNA O
methylation O
array O
platform O

This O
chemical-inducible O
epigenome O
remodeling O
tool O
will O
find O
broad O
use O
in O
interrogating O
cellular O
systems O
without O
altering O
the O
genetic O
code O
, O
as O
well O
as O
in O
probing O
the O
epigenotype-phenotype O
relations O
in O
various O
biological O
systems O

577 O
: O
Over O
the O
past O
decade O
, O
awareness O
of O
the O
importance O
of O
epigenetic O
alterations O
in O
the O
pathogenesis O
of O
rheumatic O
diseases O
has O
grown O
in O
parallel O
with O
a O
general O
recognition O
of O
the O
fundamental O
role O
of O
epigenetics O
in O
the O
regulation O
of O
gene O
expression O

This O
unit O
describes O
procedures O
for O
working O
with O
SV40 O
and O
preparing O
SV40 O
chromatin O
from O
infected O
cells O
and O
virus B-Disease
particles O
, O
as O
well O
as O
procedures O
for O
using O
SV40 O
chromatin O
to O
study O
epigenetic O
regulation O

, O
psychosocial O
stressors O
, O
racism O
, O
discrimination O
, O
socioeconomic O
position O
, O
and O
neighborhood O
social O
environment-to O
DNA O
methylation O
in O
humans O

We O
review O
the O
preferred O
use O
cases O
of O
these O
algorithms O
in O
analyses O
of O
cancer B-Disease
epigenomics O
data O
with O
the O
hope O
to O
provide O
an O
overview O
of O
how O
ML O
approaches O
can O
be O
used O
to O
explore O
fundamental O
questions O
on O
the O
roles O
of O
epigenome O
in O
cancer B-Disease
biology O
and O
medicine O

679 O
: O
The O
importance O
of O
Chromatin O
Immunoprecipitation O
( O
ChIP O
) O
technology O
has O
grown O
exponentially O
along O
with O
an O
increased O
interest O
in O
epigenetic O
regulation O

Population O
health O
represents O
a O
unifying O
paradigm O
for O
understanding O
systematic O
variations O
in O
health O
and O
related O
factors O
, O
informing O
integrated O
action O
, O
and O
reducing O
health O
disparities O

A O
special O
emphasis O
is O
posed O
on O
disclosing O
those O
early O
and O
delayed O
molecular O
events O
, O
which O
translate O
an O
altered O
neurotransmitter O
function O
into O
epigenetic O
events O
, O
which O
are O
derived O
from O
the O
translation O
of O
postsynaptic O
noncanonical O
signaling O
into O
altered O
gene O
regulation O

Methods O
: O
Genome-wide O
DNAm O
was O
measured O
using O
the O
Illumina O
450K O
array O
in O
T O
cells O
, O
monocytes O
, O
granulocytes O
, O
and O
nucleated O
red O
blood O
cells O
( O
nRBCs O
) O
isolated O
from O
cord O
blood O
of O
5 O
term O
and O
5 O
preterm O
( O
< O
31 O
weeks O
gestational O
age O
) O
new O

In O
this O
article O
, O
we O
discuss O
the O
underlying O
concepts O
of O
epigenetics O
and O
address O
its O
current O
and O
potential O
applicability O
for O
primary O
care O
providers O

Dr O
Laird O
published O
the O
first O
demonstration O
of O
the O
causal O
role O
for O
DNA O
methylation O
in O
oncogenesis O
(Cell O
, O
1995 O
) O
[ O
1 O
] O

Metabolomics O
and O
adductomics O
provide O
remarkable O
opportunities O
for O
a O
better O
understanding O
of O
exposure O
and O
prediction O
of O
potential O
adverse O
health O
outcomes O

Novel O
approaches O
to O
measure O
biological O
age O
, O
such O
as O
epigenetic O
clocks O
, O
have O
become O
relevant O

However O
, O
successful O
whole-genome O
bisulphite O
sequencing O
( O
WGBS O
) O
of O
such O
serum O
samples O
has O
the O
potential O
to O
open O
biobanks O
for O
epigenetic O
analyses O
and O
deliver O
novel O
prediagnostic O
biomarkers O

At O
the O
single O
gene O
level O
, O
several O
studies O
have O
identified O
changes O
in O
epigenetic O
modifications O
in O
genes O
expressed O
in O
the O
kidney O
that O
correlate O
with O
the O
development O
of O
hypertension B-Disease

Challenges O
for O
the O
field O
include O
( O
1 O
) O
no O
clear O
consensus O
yet O
regarding O
disease-associated O
changes O
, O
( O
2 O
) O
the O
lack O
of O
cell-specific O
chromatin O
assays O
which O
makes O
it O
difficult O
to O
ascribe O
epigenetic O
alterations O
to O
specific O
cell O
populations O
, O
and O
( O
3 O
) O
lack O
of O
knowledge O

CandiMeth O
takes O
as O
input O
any O
table O
listing O
differences O
in O
methylation O
generated O
by O
either O
ChAMP O
or O
RnBeads O
and O
maps O
these O
to O
the O
human O
genome O

Analyses O
of O
epigenetic O
modification O
is O
of O
great O
significance O
in O
providing O
more O
accurate O
information O
for O
the O
risk O
assessment O
and O
management O
of O
harmful O
factors O

It O
has O
become O
a O
multi-faceted O
notion O
with O
different O
meanings O
, O
depending O
on O
the O
disciplinary O
context O
it O
is O
used O

We O
develop O
a O
theoretical O
description O
of O
such O
crosses O
and O
model O
the O
relationship O
between O
epiallelic O
instability O
, O
recombination O
, O
parent-of-origin O
effects O
, O
as O
well O
as O
transgressive O
segregation O
and O
their O
joint O
impact O
on O
phenotypic O
variation O
across O
generations O

The O
large O
body O
of O
data O
support O
the O
role O
of O
epigenetic O
mechanisms O
in O
neurological O
function O
of O
both O
human O
and O
animals O

Herein O
, O
we O
suggest O
exploring O
the O
genetic O
and O
epigenetic O
patterns O
related O
to O
ageing O
and O
correlate O
them O
with O
the O
ageing-related O
phenotype O
of O
the O
biological O
entities O
in O
order O
to O
establish O
mechanistic O
links O
and O
map O
the O
molecular O
pathways O

Conclusions O
: O
Novel O
therapeutic O
modalities O
leveraging O
epigenetics O
and O
epigenomics O
with O
increased O
precision O
are O
well O
positioned O
to O
advance O
the O
field O
and O
treat O
patients O
across O
disease B-Disease
areas O
in O
the O
coming O
years O

A O
critical O
discussion O
of O
all O
the O
recent O
findings O
on O
this O
topic O
is O
also O
included O

241 O
: O
Previously O
, O
we O
showed O
that O
DNA O
methylation O
defects O
in O
spermatozoa O
from O
male O
partners O
of O
couples O
undergoing O
recurrent O
pregnancy O
loss O
( O
RPL O
) O
could O
be O
a O
contributing O
paternal O
factor O

In O
the O
case O
of O
epigenetics O
, O
complexification O
entails O
a O
reconfiguration O
of O
postgenomic O
experimental O
systems O
in O
ways O
that O
some O
actors O
deem O
' O
better O
' O
at O
enacting O
health O
as O
a O
biosocial O
process O

363 O
: O
Stephen O
B O
Baylin O
is O
a O
codirector O
of O
the O
Cancer B-Disease
Biology O
Program O
at O
The O
Sidney O
Kimmel O
Comprehensive O
Cancer B-Disease
Center O
at O
Johns O
Hopkins O
and O
the O
Virginia O
and O
DK O
Ludwig O
Professor O
of O
Oncology O
and O
Medicine O

Through O
integration O
with O
a O
popular O
and O
efficient O
supervised O
learner O
, O
our O
model O
achieves O
higher O
prediction O
accuracy O
in O
both O
single- O
and O
multi-target O
tasks O
and O
can O
determine O
the O
pleiotropy O
associated O
with O
drugs O
, O
providing O
theoretical O
support O
for O
drug O
combination O
and O
discovery O
research O

167 O
: O
The O
field O
of O
epigenomics O
has O
rapidly O
progressed O
from O
the O
study O
of O
individual O
reference O
epigenomes O
to O
surveying O
epigenomic O
variation O
in O
populations O

We O
will O
discuss O
the O
spread O
and O
amplitude O
of O
the O
potential O
gene O
expression O
changes O
controlled O
by O
5mC O
at O
enhancers O
, O
and O
how O
these O
may O
contribute O
to O
the O
determination O
of O
cell O
identities O
during O
development O

Such O
charge O
transfer O
is O
interrupted O
by O
flipping O
base(s) O
out O
of O
the O
double-strand O
e O

He O
was O
recently O
appointed O
as O
Guest O
Professor O
at O
Central O
South O
University O
in O
Changsha O
, O
China O

485 O
: O
Epigenome O
mapping O
consortia O
are O
generating O
resources O
of O
tremendous O
value O
for O
studying O
epigenetic O
regulation O

ρ O
= O
0 O

While O
in O
GE O
the O
genetic O
information O
is O
changed O
by O
directly O
modifying O
DNA O
, O
intervening O
in O
the O
epigenome O
requires O
modifying O
the O
configuration O
of O
DNA O
, O
for O
example O
, O
how O
it O
is O
folded O

704 O
: O
Longstanding O
racial O
/ O
ethnic O
inequalities O
in O
morbidity O
and O
mortality O
persist O
in O
the O
United O
States O

However O
, O
emerging O
gene O
editing O
approaches O
such O
as O
CRISPR-Cas9 O
, O
in O
which O
the O
DNA O
of O
the O
host O
organism O
is O
edited O
at O
a O
precise O
location O
, O
may O
have O
outperforming O
therapeutic O
potential O

Alteration O
of O
epigenetic O
modifications O
have O
been O
documented O
in O
a O
variety O
of O
brain O
disorders O
, O
including O
neurodevelopmental O
, O
psychiatric B-Disease
, O
and O
neurodegenerative B-Disease
diseases I-Disease

In O
this O
review O
, O
we O
systematically O
summarize O
the O
recent O
developments O
of O
computational O
methods O
and O
software O
tools O
in O
high-throughput O
methylation O
data O
analysis O
with O
focus O
on O
two O
aspects O
: O
differential O
methylation O
analysis O
and O
tumor B-Disease
purity O
estimation O
in O
cancer B-Disease
studies O

Using O
publicly O
available O
datasets O
, O
we O
find O
that O
the O
mouse O
clock O
is O
accurate O
enough O
to O
measure O
effects O
on O
biological O
age O
, O
including O
in O
the O
context O
of O
interventions O

489 O
: O
In O
the O
last O
decade O
epigenetics O
has O
come O
to O
the O
fore O
as O
a O
discipline O
which O
is O
central O
to O
biogerontology O

Many O
databases O
are O
available O
online O
, O
which O
comprises O
huge O
amount O
of O
information O
regarding O
these O
modifications O

451 O
: O
DNA O
methylation O
is O
a O
key O
epigenetic O
modification O
involved O
in O
gene O
regulation O
whose O
contribution O
to O
disease B-Disease
susceptibility O
is O
still O
not O
fully O
understood O

In O
NRF2 O
knockout O
and O
KLOTHO O
knockdown O
D-gal O
mice O
, O
OLP O
exhibited O
reduced O
antiaging O
effects O
with O
KLOTHO O
displaying O
a O
prominent O
gene O
effect O
and O
effect O
size O
; O
consistently O
in O
KLOTHO O
knockdown O
mice O
, O
the O
antiaging O
effects O
of O
SGI-1027 O
were O
largely O
ab O

However O
, O
there O
is O
evidence O
that O
in O
the O
uremic O
milieu O
, O
several O
features O
such O
as O
inflammation B-Disease
, O
dyslipidaemia O
, O
hyperhomocysteinaema O
, O
oxidative O
stress O
as O
well O
as O
vitamin O
and O
nutritional O
deficiencies O
may O
affect O
the O
epigenome O
, O
and O
impact O
patient O
outcome O

Here O
, O
we O
discuss O
the O
impact O
of O
pathogen-induced O
DNA O
methylation O
modifications O
on O
a O
host O
's O
transcriptome O
reprogramming O
and O
genome O
stability O
, O
as O
part O
of O
the O
plant O
's O
defense O
mechanisms O

This O
approach O
can O
be O
used O
with O
any O
genomic O
or O
biological O
data O
set O
applied O
to O
medicine O

A O
total O
of O
660,845 O
methylated O
cytosines O
were O
identified O
within O
the O
CpG O
context O
(CpGs) O
across O
the O
10 O
animals O
sequenced O
(5 O
N O
and O
5 O
A O
) O

Although O
prescriptive O
knowledge O
based O
on O
epigenetic O
findings O
to O
date O
is O
premature O
, O
epigenetics O
is O
a O
new O
and O
exciting O
scientific O
frontier O
not O
too O
different O
in O
spirit O
from O
Lamarck O
's O
observations O
centuries O
ago O

The O
importance O
of O
analytical O
and O
clinical O
validation O
of O
biomarkers O
is O
discussed O
, O
along O
with O
challenges O
and O
opportunities O
in O
this O
field O

56 O
: O
Systemic B-Disease
sclerosis I-Disease
( O
SSc O
) O
is O
a O
prototypical O
inflammatory O
fibrotic O
disease B-Disease
involving O
inflammation B-Disease
, O
vascular O
abnormalities O
and O
fibrosis O
that O
primarily O
affect O
the O
skin O
and O
lungs O

Application O
of O
this O
model O
to O
DNA O
methylation O
data O
measured O
across O
broad O
age O
ranges O
, O
from O
before O
birth O
to O
old O
age O
, O
and O
from O
two O
tissue O
types O
, O
suggests O
a O
universal O
logarithmic O
trend O
characterizes O
epigenetic O
ageing O
across O
entire O
lifespans O

Given O
the O
individualized O
traits O
of O
epigenetic O
biomarkers O
, O
epigenetic O
considerations O
would O
significantly O
refine O
personalized O
nanomedicine O

Drugs O
with O
epigenetic O
mechanisms O
are O
already O
in O
use O
, O
with O
many O
more O
likely O
to O
be O
approved O
within O
the O
next O
few O
years O

In O
this O
chapter O
, O
we O
summarize O
the O
information O
on O
epigenetic O
inheritance O
, O
its O
mechanism O
, O
inheritance O
studies O
on O
various O
organisms O
, O
factors O
affecting O
epigenetic O
modifications O
and O
their O
inheritance O
, O
and O
the O
role O
of O
epigenetic O
inheritance O
in O
the O
heritability O
of O
diseases O

Genetic O
, O
genomic O
, O
and O
epigenetic O
changes O
play O
a O
significant O
role O
in O
the O
pathogenesis O
of O
psoriasis B-Disease

There O
was O
an O
increase O
in O
the O
frequency O
of O
C O
to O
T O
(thymine) O
transitions O
at O
the O
CHH O
positions O
in O
the O
progeny O
of O
cold O
stressed O
plants O
; O
because O
this O
type O
of O
mutations O
is O
often O
due O
to O
the O
deamination O
of O
the O
methylated O
cytosines O
, O
it O
can O
be O
hypothesized O

Pfeifer O
has O
served O
on O
several O
NIH O
advisory O
committees O
and O
has O
published O
over O
300 O
research O
papers O

These O
epigenetic O
mechanisms O
induce O
the O
expression O
of O
genes O
associated O
with O
transcriptional O
regulation O
, O
endometrial O
epithelial O
growth O
, O
angiogenesis O
, O
and O
stromal O
cell O
proliferation O
during O
the O
proliferative O
phase O

Epigenomic O
twin O
studies O
have O
great O
potential O
to O
contribute O
to O
our O
understanding O
of O
complex O
diseases O
, O
such O
as O
cancer B-Disease

Furthermore O
, O
the O
development O
, O
synthesis O
, O
and O
future O
perspectives O
of O
selective O
class O
IIa O
inhibitors O
will O
be O
highlighted O

531 O
: O
Paternal O
aging O
and O
the O
prevalence O
of O
neurodevelopmental O
disorders O
in O
offspring O
are O
well O
documented O

These O
provide O
a O
reasonable O
molecular O
mechanism O
for O
epigenetic O
modifying O
drugs O
in O
the O
treatment O
of O
PTCL O

99 O
) O
detection O
of O
5hmC O
in O
human O
brain O
tissue O
using O
the O
optimised O
oxBS-450K O
protocol O
described O
here O

In O
this O
chapter O
, O
we O
summarized O
several O
popular O
methods O
for O
analyses O
of O
epigenetic O
modifications O
, O
including O
Methylated O
DNA O
Immunoprecipitation O
Sequencing O
( O
MeDIP-Seq O
) O
for O
genome-wide O
DNA O
methylation O
analyses O
, O
Quantitative O
Methylation O
Specific O
PCR O
( O
qMSP O

Assessment O
of O
the O
tumor-derived O
cfDNA O
modifications O
combined O
with O
high-throughput O
analysis O
techniques O
holds O
promise O
for O
developing O
highly O
specific O
noninvasive O
diagnostic O
tests O

The O
study O
of O
ecological O
epigenomics O
holds O
great O
promise O
to O
better O
understand O
the O
linkages O
between O
genotype O
, O
phenotype O
, O
and O
the O
environment O
and O
to O
explore O
mechanisms O
of O
phenotypic O
plasticity O

Introduction O
738 O
II O

00 O
or O
0 O

233 O
: O
Mounting O
epidemiological O
evidence O
indicates O
that O
environmental O
exposures O
in O
early O
life O
have O
roles O
in O
diabetes B-Disease
susceptibility O
in O
later O
life O

uk/mosaics O

Changes O
in O
epigenome O
underlay O
all O
basic O
biological O
processes O
, O
such O
as O
cell O
division O
, O
differentiation O
, O
aging O
, O
and O
cancerous O
transformation O

Possible O
mechanisms O
of O
epigenetic O
modifications O
and O
their O
role O
on O
physiology O
and O
adaptation O
as O
well O
as O
the O
incidence O
of O
intergenerational O
and O
transgenerational O
inheritance O
are O
discussed O

Epigenome O
- O
wide O
association O
studies O
identified O
elephant O
age-related O
CpGs O
and O
their O
proximal O
genes O

Epigenetics O
, O
including O
DNA O
methylation O
, O
histone O
modification O
, O
and O
post-transcriptional O
regulation O
of O
miRNAs O
, O
is O
the O
study O
of O
heritable O
changes O
in O
gene O
expression O
that O
do O
not O
include O
DNA O
sequence O
alterations O

Recent O
advances O
: O
Methods O
for O
DNA O
methylation O
analysis O
differ O
in O
their O
coverage O
and O
sensitivity O
, O
and O
the O
method O
of O
choice O
depends O
on O
the O
intended O
application O
and O
desired O
level O
of O
information O

In O
addition O
, O
miRNAs O
can O
themselves O
repress O
key O
enzymes O
that O
drive O
epigenetic O
remodeling O
, O
generating O
regulatory O
circuits O
that O
have O
a O
significant O
effect O
in O
the O
transcriptional O
landscape O
of O
the O
cell O

One O
integral O
line O
of O
research O
to O
examine O
how O
interpersonal O
and O
societal O
environments O
can O
get O
"under O
the O
skin" O
is O
through O
the O
lens O
of O
epigenetics O

Implications O
for O
nursing O
practice O
are O
explored O
at O
multiple O
levels O
of O
policy O
advocacy O
, O
public O
education O
, O
primary O
prevention O
, O
screening O
and O
intervention O

This O
package O
, O
called O
S3V2-IDEAS O
, O
can O
be O
used O
to O
identify O
epigenetic O
states O
for O
multiple O
features O
, O
or O
identify O
discretized O
signal O
intensity O
levels O
and O
a O
master O
peak O
list O
across O
different O
cell O
types O
for O
a O
single O
feature O

182 O
: O
Epigenetics O
is O
the O
branch O
of O
genetics O
that O
studies O
the O
dynamic O
relationship O
between O
stable O
genotypes O
and O
varying O
phenotypes O

Compared O
to O
other O
cancers B-Disease
, O
DNA O
hypomethylation O
, O
especially O
at O
LINE-1 O
retrotransposons O
, O
and O
mutations O
in O
enzymes O
establishing O
or O
removing O
histone O
acetylation O
or O
methylation O
are O
particularly O
prominent O

Epigenetics O
provides O
an O
additional O
level O
of O
information O
that O
is O
not O
encoded O
in O
the O
DNA O
molecule O
but O
nonetheless O
influences O
its O
activity O
in O
a O
stable O
and O
heritable O
manner O
through O
cell O
divisions O

DNA O
methylation O
stands O
out O
as O
a O
tracer O
of O
cell O
identity O
and O
memory O
, O
as O
B O
cell O
neoplasms B-Disease
show O
epigenetic O
imprints O
of O
their O
cellular O
origin O
and O
proliferative O
history O
, O
which O
can O
be O
quantified O
by O
an O
epigenetic O
mitotic O
clock O

478: O
The O
field O
of O
epigenetics O
is O
currently O
one O
of O
the O
most O
rapidly O
expanding O
in O
biology O
and O
has O
resulted O
in O
increasing O
public O
interest O
in O
its O
applications O
to O
human O
health O

These O
molecular O
changes O
directly O
contribute O
to O
the O
development O
or O
progression O
of O
several O
human O
pathologies O
, O
including O
cancer B-Disease
, O
diabetes B-Disease
, O
osteoporosis B-Disease
, O
neurodegenerative B-Disease
disorders I-Disease
and O
others O
aging-related O
diseases O

We O
have O
generated O
a O
comprehensive O
set O
of O
genome-scale O
base-resolution O
methylation O
maps O
from O
multiple O
mouse O
tissues O
spanning O
a O
wide O
range O
of O
ages O

g O

Dysregulation O
of O
these O
processes O
has O
been O
observed O
in O
many O
psychiatric B-Disease
disorders I-Disease
, O
and O
evidence O
suggests O
that O
they O
may O
also O
be O
involved O
in O
suicidal O
behaviors O

The O
standard O
research O
approaches O
developed O
for O
genetic O
epidemiology O
, O
however O
, O
are O
not O
necessarily O
appropriate O
for O
epigenetic O
studies O
of O
common O
disease B-Disease

02 O
) O

At O
this O
threshold O
, O
we O
were O
able O
to O
confirm O
previously-found O
CpG O
sites O
that O
stratify O
with O
respect O
to O
sex O

The O
strongest O
patterns O
of O
differential O
methylation O
(mostly O
male-biased O
) O
are O
found O
in O
the O
putative O
promoter O
and O
the O
first O
intron O

This O
review O
considers O
how O
epigenetic O
factors O
may O
affect O
rates O
of O
ageing O
of O
muscle O
and O
bone O
and O
provides O
an O
overview O
of O
current O
understanding O
in O
this O
area O

494 O
: O
In O
this O
interview O
, O
Oskar O
Karlsson O
speaks O
with O
Storm O
Johnson O
, O
commissioning O
editor O
for O
Epigenomics O
, O
on O
his O
work O
to O
date O
in O
the O
field O
of O
toxicological O
origins O
of O
disease B-Disease
and O
gene-environment O
interactions O

Stratifying O
patients O
based O
on O
molecular O
mechanisms O
rather O
than O
clinical O
phenotypes O
may O
allow O
for O
target-directed O
and O
individualized O
treatment O

This O
review O
summarizes O
the O
recent O
advances O
in O
our O
understanding O
of O
the O
role O
of O
epigenetics O
in O
CVD O

50 O
: O
Epigenetics O
refers O
to O
the O
study O
of O
heritable O
changes O
in O
gene O
expression O
that O
occur O
without O
a O
change O
in O
DNA O
sequence O

Further O
, O
the O
basic O
notion O
that O
what O
is O
near-random O
at O
one O
level O
may O
be O
almost O
entirely O
predictable O
at O
a O
higher O
level O
is O
an O
emergent O
property O
of O
many O
systems O
, O
from O
particle O
physics O
to O
the O
social O
sciences O

Recent O
findings O
: O
Investigations O
of O
the O
associations O
between O
DNAm O
and O
childhood O
trauma B-Disease
are O
commonly O
performed O
using O
candidate O
gene O
approaches O
, O
specifically O
involving O
genes O
related O
to O
neurological O
and O
stress O
pathways O

198 O
: O
Based O
on O
the O
ideas O
of O
R O


The O
findings O
support O
a O
spatiotemporal O
model O
of O
profound O
and O
widespread O
stress O
hormone-driven O
methylomic O
changes O
that O
emerge O
at O
selected O
CpG O
sites O
, O
are O
more O
likely O
to O
spread O
to O
nearby O
located O
CpGs O
, O
and O
quantitatively O
accrue O
at O
open O
sea O
, O
glucocorticoid O
receptor O
binding O
, O

Second O
, O
I O
go O
back O
to O
the O
first O
ideas O
about O
the O
Baldwin O
effect O
developed O
in O
the O
late O
nineteenth O
century O
to O
show O
that O
the O
efficiency O
of O
this O
mechanism O
was O
already O
linked O
with O
a O
form O
of O
non-genetic O
inheritance O

526 O
: O
Various O
different O
classes O
of O
RNAs O
contained O
in O
sperm O
cells O
have O
emerged O
as O
causal O
vectors O
for O
the O
transmission O
of O
acquired O
information O
from O
father O
to O
offspring O

``` O
Dr O
``` O

Here O
, O
we O
will O
overview O
the O
current O
understanding O
of O
the O
causes O
and O
effects O
of O
the O
altered O
and O
heterogeneous O
epigenomic O
landscape O
in O
cancer B-Disease

This O
is O
now O
changing O
, O
as O
more O
and O
more O
ecologists O
learn O
about O
epigenetic O
processes O
and O
their O
potential O
ecological O
and O
evolutionary O
relevance O
, O
and O
a O
new O
research O
field O
of O
ecological O
epigenetics O
is O
beginning O
to O
take O
shape O

Our O
work O
provides O
a O
comprehensive O
example O
of O
the O
role O
played O
by O
epigenetic O
mechanisms O
on O
gene O
network O
evolution O

Epigenetics O
has O
now O
morphed O
from O
a O
phenomenon O
to O
a O
branch O
of O
science O
whose O
molecular O
underpinnings O
are O
well O
understood O

Indeed O
, O
several O
epigenetic O
biomarkers O
have O
been O
successfully O
developed O
and O
applied O
in O
traditional O
model O
organisms O
( O
e O

We O
also O
found O
that O
genes O
commonly O
believed O
to O
be O
silenced O
via O
hypermethylation O
in O
cancers B-Disease
may O
still O
display O
highly O
variable O
methylation O
levels O
among O
cancer B-Disease
cells O
, O
and O
should O
be O
considered O
while O
using O
them O
as O
epigenetic O
biomarkers O

Importantly O
, O
these O
epigenetic O
changes O
may O
be O
ideal O
targets O
for O
new O
personalized O
treatments O
as O
suggested O
by O
data O
in O
cancer B-Disease

The O
primary O
objective O
of O
this O
article O
is O
to O
provide O
an O
overview O
of O
the O
current O
methods O
for O
assaying O
DNA O
methylation O
, O
the O
most O
commonly O
studied O
epigenetic O
modification O

To O
date O
, O
global O
research O
has O
mainly O
focused O
on O
the O
genetic O
factors O
underlying O
CMP O
pathogenesis O

This O
is O
particularly O
relevant O
in O
the O
plant O
kingdom O
, O
where O
most O
species O
are O
sessile O
and O
exposed O
to O
increasing O
habitat O
fluctuations O
due O
to O
global O
warming O

By O
incorporating O
an O
ultrasonic O
transducer O
with O
a O
microfluidic O
chamber O
, O
we O
implemented O
microscale O
sonication O
for O
both O
shearing O
chromatin/DNA O
and O
mixing/washing O
of O
IP O
beads O

Graphical O
Abstract O

611 O
: O
The O
advent O
of O
functional O
genomics O
powered O
by O
high-throughput O
sequencing O
has O
given O
us O
a O
new O
appreciation O
of O
the O
genomic O
sequences O
that O
lie O
outside O
the O
canonical O
promoter-coding O
sequence O
box O

Lifestyle O
modifications O
including O
dietary O
interventions O
hold O
an O
immense O
promise O
to O
manage O
and O
prevent O
these O
diseases O

However O
, O
with O
the O
rise O
of O
epigenetics O
, O
science O
and O
the O
public O
understanding O
of O
science O
is O
leaving O
an O
era O
in O
which O
the O
DNA O
sequence O
was O
thought O
to O
be O
" O
destiny O
" O
and O
entering O
an O
era O
where O
the O
environment O
shapes O
the O
biology O
and O
behavior O
of O
individuals O
and O
groups O
through O

We O
assess O
here O
the O
opportunities O
and O
limitations O
of O
RRBS O
in O
nonmodel O
plant O
species O

The O
pathways O
connecting O
social O
, O
environmental O
, O
and O
structural O
factors O
and O
various O
health O
outcomes O
have O
been O
illuminated O
by O
the O
emergence O
of O
epigenetic O
and O
epigenomic O
research O
, O
further O
bolstering O
the O
value O
of O
population O
health O
perspectives O
in O
supporting O
clinical O
practice O
, O
community-based O
programs O
, O
and O

We O
have O
organized O
the O
paper O
in O
two O
steps O
: O
first O
, O
we O
analyse O
value O
and O
functions O
of O
the O
concept O
of O
habit O
in O
Darwin O
's O
early O
works O
, O
notably O
in O
his O
Notebooks O
, O
and O
compare O
these O
views O
to O
his O
mature O
understanding O
of O
the O
concept O
in O
the O
Origin O
of O
Species O
and O

In O
addition O
, O
plant-specific O
non-CG O
methylation O
pathways O
are O
particularly O
sensitive O
to O
changes O
in O
folate-mediated O
one-carbon O
metabolism O

519 O
: O
Background O
: O
Localized O
functional O
domains O
within O
chromosomes O
, O
known O
as O
topologically O
associating O
domains O
( O
TADs O
) O
, O
have O
been O
recently O
highlighted O

Although O
the O
causal O
role O
of O
genetic O
mutations O
on O
cancer B-Disease
development O
has O
been O
established O
in O
vivo O
, O
similar O
evidence O
for O
epigenetic O
alterations O
is O
limited O

155 O
: O
Interindividual O
variability O
is O
an O
inherent O
characteristic O
of O
biological O
systems O

A O
plausible O
initial O
application O
of O
rejuvenation O
in O
vivo O
would O
be O
preventing O
adult O
individuals O
from O
aging O
thus O
eliminating O
a O
major O
risk O
factor O
for O
end O
of O
life O
pathologies O

70 O
: O
Epigenetics O
refers O
to O
structural O
modifications O
to O
genes O
that O
do O
not O
change O
the O
nucleotide O
sequence O
itself O
but O
instead O
control O
and O
regulate O
gene O
expression O

We O
have O
constructed O
this O
resource O
by O
selecting O
the O
subset O
of O
epigenetics-specific O
data O
from O
the O
Gene O
Expression O
Omnibus O
( O
GEO O
) O
database O
and O
then O
subjecting O
them O
to O
further O
review O
and O
annotation O

While O
selective O
personalized O
therapies O
are O
conceptually O
impressive O
, O
the O
majority O
of O
cancer B-Disease
therapies O
have O
dismal O
outcome O

27 O
: O
Evolution O
and O
development O
are O
interrelated O
processes O
influenced O
by O
genomic O
, O
epigenetic O
, O
and O
environmental O
factors O

678 O
: O
Background O
: O
One O
of O
the O
fascinating O
aspects O
of O
epigenetic O
regulation O
is O
that O
it O
provides O
means O
to O
rapidly O
adapt O
to O
environmental O
change O

To O
translate O
this O
resulting O
state O
into O
a O
causal O
relationship O
with O
a O
subset O
of O
regulatory O
features O
, O
many O
experiments O
deploy O
an O
array O
of O
laboratory O
assays O
from O
multiple O
modalities O

0 O
, O
an O
extended O
version O
of O
our O
2015 O
software O
( O
v1 O

Our O
review O
provides O
an O
overview O
of O
an O
exciting O
and O
controversially O
discussed O
field O
in O
developmental O
and O
molecular O
biology O

To O
study O
these O
dynamics O
, O
we O
developed O
quantitative O
models O
that O
measure O
the O
effect O
of O
multiple O
factors O
on O
DNA O
methylomes O
including O
, O
age O
, O
sex O
, O
weight O
, O
and O
genetics O

Here O
, O
I O
review O
examples O
of O
epigenetic O
phenomena O
in O
non-model O
organisms O
that O
have O
emerged O
as O
potential O
experimental O
systems O
, O
including O
social O
insects O
, O
fish O
and O
flatworms O
, O
and O
are O
becoming O
accessible O
to O
molecular O
approaches O

Although O
further O
experimental O
research O
is O
needed O
in O
order O
to O
conclusively O
compare O
and O
contrast O
PRS O
and O
non-PRS O
activities O
regarding O
learning O
gain O
, O
we O
propose O
the O
usage O
of O
the O
Sandwich O
Model O
with O
a O
variety O
of O
in-class O
learning O
activities O
, O
both O
PRS O
and O
non-PRS-based O

The O
situated O
perspective O
of O
individual O
researchers O
provides O
in O
fact O
evidence O
for O
a O
conflictual O
( O
moral O
and O
epistemic O
) O
economy O
of O
gendered O
engagements O
with O
parental O
figurations O
in O
DOHaD O
and O
epigenetic O
research O
, O
and O
consequently O
suggests O
a O
more O
fine-grained O
, O
as O
well O
as O

) O
sheds O
light O
on O
the O
characterization O
of O
this O
phenomenon O
in O
a O
complex O
biological O
scenario O

Advances O
in O
high-throughput O
technologies O
, O
like O
gene O
expression O
profiling O
, O
next-generation O
sequencing O
, O
proteomics O
, O
and O
metabolomics O
, O
have O
enabled O
detailed O
molecular O
characterization O
of O
various O
tumors B-Disease

Studies O
have O
shown O
that O
epigenetic O
dysregulation O
is O
associated O
with O
multiple O
steps O
during O
carcinogenesis O

Strikingly O
, O
they O
are O
plastic O
and O
respond O
to O
environmental O
signals O
, O
including O
diet O

This O
Review O
discusses O
some O
of O
the O
key O
statistical O
challenges O
and O
algorithms O
associated O
with O
drawing O
inferences O
from O
DNA O
methylation O
data O
, O
including O
cell-type O
heterogeneity B-Disease
, O
feature O
selection O
, O
reverse O
causation O
and O
system-level O
analyses O
that O
require O
integration O
with O
other O
data O
types O
such O
as O
gene O
expression O
, O
genotype O

This O
research O
evaluated O
longitudinal O
changes O
in O
epigenetic O
age O
before O
and O
after O
exposure O
to O
work-related O
trauma B-Disease
among O
paramedicine O
students O

We O
also O
conduct O
a O
meta-analysis O
to O
assess O
the O
effects O
of O
different O
aspects O
of O
experimental O
protocol O
on O
the O
performance O
of O
epigenetic O
clocks O
for O
non-model O
animals O

These O
trends O
, O
we O
argue O
, O
are O
likely O
to O
favor O
the O
clinical O
translation O
of O
epigenetics O
- O
in O
other O
words O
, O
the O
development O
of O
new O
clinical O
tools O
fostering O
what O
has O
been O
called O
" O
personalized O
" O
or O
" O
precision O
" O
medicine O

A O
single O
point O
of O
intervention O
may O
be O
available O
in O
the O
signaling O
that O
these O
clocks O
use O
to O
coordinate O
information O
about O
the O
age O
of O
the O
body O

In O
conclusion O
, O
we O
provide O
a O
method O
for O
analyzing O
methylation O
variability O
in O
longitudinal O
data O
and O
further O
identified O
age-varying O
methylation O
loci O
in O
a O
longitudinal O
analysis O
using O
these O
methods O

Although O
there O
was O
strong O
agreement O
on O
DNA O
methylation O
, O
histone O
modifications O
, O
3D O
structure O
of O
chromatin O
and O
nucleosomes O
being O
integral O
elements O
of O
the O
field O
, O
there O
was O
considerable O
disagreement O
on O
transcription O
factors O
, O
RNA O
interference O
, O
RNA O
splicing O
and O
prions O

Mutations O
in O
epigenetic O
regulators O
are O
common O
events O
in O
multiple O
cancer B-Disease
types O
and O
epigenetic O
therapies O
are O
emerging O
as O
a O
treatment O
option O
in O
several O
malignancies B-Disease

Evolutionary O
reasoning O
first O
articulated O
by O
G O

In O
this O
issue O
of O
Drug O
Metabolism O
and O
Disposition O
, O
a O
series O
of O
articles O
is O
presented O
to O
demonstrate O
the O
role O
of O
epigenetic O
factors O
in O
regulating O
the O
expression O
of O
genes O
involved O
in O
drug O
absorption O
, O
distribution O
, O
metabolism O
, O
and O
excretion O
in O
organ O
development O
, O
tissue-specific O
gene O
expression O

Risk O
of O
bias O
was O
assessed O
by O
a O
previously O
described O
modification O
of O
the O
CAMARADES O
tool O

This O
has O
invigorated O
research O
and O
raised O
many O
new O
questions O
concerning O
the O
heritability O
of O
disease B-Disease
risk O
and O
the O
ability O
to O
adapt O
to O
novel O
environments O

Finally O
, O
we O
will O
discuss O
how O
to O
leverage O
3D O
genome O
folding O
and O
engineering O
for O
future O
studies O

432 O
: O
Nutrition O
plays O
a O
key O
role O
in O
many O
aspects O
of O
health O
and O
dietary O
imbalances O
are O
major O
determinants O
of O
chronic O
diseases O
including O
cardiovascular O
disease B-Disease
, O
obesity B-Disease
, O
diabetes B-Disease
and O
cancer B-Disease

Integrated O
methylation O
and O
expression O
data O
( O
along O
with O
publicly O
available O
, O
ENCODE-generated O
histone O
ChIP O
Seq O
and O
DNAse O
hypersensitivity O
data O
) O
predict O
that O
epigenetic O
regulation O
is O
a O
primary O
factor O
driving O
transcriptional O
activation O
of O
a O
number O
of O
genes O
crucial O
to O
immunity O
in O
cancer B-Disease
, O
including O
T O

Fortunately O
, O
epigenetic O
phenomena O
are O
dynamic O
and O
rather O
quickly O
reversible O
with O
intensive O
lifestyle O
changes O

After O
analysing O
whether O
the O
classic O
problems O
a O
theory O
of O
identity O
has O
to O
cope O
with O
( O
fictional O
transplants O
; O
conjoined O
twins O
; O
and O
definition O
of O
death B-Disease
) O
also O
affect O
the O
proposed O
epigenetic O
account O
of O
identity O
, O
I O
deal O
with O
three O
topics O
( O
the O
assumption O
of O
moral O

To O
meet O
the O
requirements O
of O
users O
, O
we O
developed O
a O
convenient O
and O
useful O
software O
, O
EWAS2 O

Bone O
studies O
suggest O
similar O
findings O
, O
and O
the O
intriguing O
possibility O
of O
epigenetic O
changes O
in O
subchondral O
bone O
during O
many O
OA O
processes O

161 O
: O
DNA O
methylation O
, O
consisting O
on O
the O
covalent O
addition O
of O
a O
methyl O
group O
in O
cytosines O
, O
plays O
a O
vital O
role O
for O
the O
development O
and O
correct O
functioning O
of O
cells O

This O
review O
puts O
recent O
discoveries O
in O
the O
epigenetics O
of O
non-model O
invertebrates O
in O
historical O
context O
, O
and O
describes O
new O
insight O
into O
the O
patterning O
and O
functions O
of O
DNA O
methylation O
and O
other O
highly O
conserved O
epigenetic O
modifications O

However O
, O
the O
precise O
molecular O
mechanisms O
remain O
to O
be O
elucidated O


The O
cause O
( O
s O
) O
of O
OMP O
are O
unknown O
, O
as O
is O
whether O
these O
individuals O
identify O
a O
clinically O
useful O
subgroup O
of O
patients O
, O
but O
both O
the O
causes O
of O
, O
and O
potential O
consequences O
to O
, O
this O
epigenetically O
distinct O
group O
are O
of O
great O
interest O

The O
information O
gained O
can O
be O
used O
to O
promote O
health O
but O
it O
also O
raises O
a O
variety O
of O
ethical O
, O
legal O
, O
and O
social O
issues O

Epigenetic O
variance O
, O
and O
specifically O
differential O
DNA O
methylation O
, O
have O
emerged O
as O
areas O
of O
particularly O
high O
interest O
to O
ASD O
, O
as O
the O
epigenetic O
markers O
from O
specific O
chromatin O
loci O
collectively O
can O
reflect O
influences O
of O
multiple O
genetic O
and O
environmental O
factors O
and O
can O
also O
result O
in O
differ O

Progress O
has O
been O
limited O
by O
several O
factors O
, O
including O
the O
classical O
approach O
of O
treating O
continuous O
and O
fluid O
phenotypes O
as O
discrete O
and O
static O
across O
time O
and O
environment O
, O
and O
difficulty O
in O
considering O
the O
full O
diversity O
of O
mechanisms O
that O
can O
modulate O
phenotype O
, O
such O
as O
gene O
accessibility O

Results O
implicate O
maternal O
prenatal O
stress O
as O
a O
source O
of O
epigenetic O
mechanisms O
that O
affect O
fetal O
brain O
development O
and O
program O
risk O
for O
emotional O
dysregulation O
and O
mental B-Disease
disorders I-Disease
over O
a O
lifetime O
and O
across O
generations O

We O
discuss O
the O
concepts O
of O
gene O
and O
epigenetic O
editing O
, O
and O
the O
advantages O
and O
disadvantages O
of O
current O
and O
upcoming O
gene-based O
therapies O
for O
treatment O
of O
IEMs O

Here O
, O
we O
focus O
on O
epigenetic O
profiling O
as O
a O
means O
to O
understand O
microglial O
immune O
responses O
beyond O
what O
other O
omics O
methods O
can O
offer O
, O
that O
is O
, O
revealing O
past O
and O
present O
molecular O
responses O
, O
gene O
regulatory O
networks O
and O
potential O
future O
response O
trajectories O
, O
and O
defining O
cell O
sub O

Firstly O
, O
key O
relevant O
epigenetic O
processes O
will O
be O
discussed O

Methyl-binding O
domain O
sequencing O
( O
MBD-seq O
) O
is O
an O
alternative O
approach O
for O
MWAS O
that O
provides O
near-complete O
coverage O
of O
the O
methylome O
at O
similar O
costs O
as O
the O
array-based O
technologies O

By O
summarizing O
the O
molecular O
events O
governing O
DNA O
methylation O
, O
we O
focus O
on O
the O
methods O
that O
have O
facilitated O
mapping O
and O
understanding O
of O
this O
epigenetic O
mark O
in O
healthy O
conditions O
and O
diseases O

With O
comprehensive O
data O
entries O
and O
associated O
web-based O
tools O
, O
our O
database O
will O
be O
a O
valuable O
resource O
for O
future O
epigenetics/epigenomics O
studies O

e O

Ingenuity O
pathway O
analysis O
( O
IPA O
) O
was O
performed O
to O
identify O
molecular O
and O
disease B-Disease
pathways O
that O
were O
epigenetically O
dysregulated O

Now O
, O
also O
epigenomic O
biomarkers O
are O
at O
hand O
and O
together O
genetic O
and O
epigenetic O
biomarkers O
can O
indeed O
improve O
the O
predictability O
of O
drug O
treatment O

Since O
gametes O
and O
zygotes O
are O
in O
the O
process O
of O
resetting O
the O
genome O
in O
order O
to O
create O
embryonic O
stem O
cells O
that O
will O
each O
differentiate O
to O
create O
one O
of O
many O
specific O
tissue O
types O
, O
this O
phase O
of O
life O
is O
now O
viewed O
as O
a O
window O
of O
susceptibility O
to O
epigenetic O

Greenness O
was O
represented O
by O
satellite-derived O
Normalized O
Difference O
Vegetation O
Index O
(NDVI) O
and O
Enhanced O
Vegetation O
Index O
(EVI) O
metrics O
within O
300-, O
500-, O
1,000-, O
and O
2,000-m O
buffers O
surrounding O
participant O
addresses O

This O
review O
summarizes O
emerging O
methods O
for O
assessing O
combinatorial O
epigenomic O
states O
, O
as O
well O
as O
challenges O
and O
opportunities O
for O
their O
refinement O

Here O
we O
review O
the O
current O
state-of-the-art O
technologies O
that O
have O
been O
developed O
to O
decipher O
epigenetic O
patterns O
on O
the O
genomic O
level O
and O
discuss O
how O
these O
methods O
are O
potentially O
useful O
for O
precision O
oncology O

Recent O
advancements O
have O
been O
made O
towards O
translating O
epigenetics O
research O
into O
a O
high O
throughput O
approach O
such O
as O
genome-scale O
profiling O

To O
illustrate O
the O
composability O
of O
these O
elements O
, O
Jacob O
and O
Monod O
linked O
phenotypic O
diversity O
to O
the O
architectures O
of O
regulatory O
circuits O

Thus O
, O
MER-Net O
could O
be O
used O
to O
reveal O
new O
potential O
biomarkers O
and O
therapeutic O
targets O
using O
deep O
learning O
models O
to O
integrate O
and O
analyze O
large O
multiomics O
networks O

e O

The O
products O
of O
these O
genes O
play O
important O
roles O
in O
cellular O
differentiation O
, O
organismal O
development O
, O
metabolism O
, O
and O
circadian O
rhythms O

Publicly O
accessible O
databases O
are O
reviewed O
as O
well O

462 O
: O
Indicine O
and O
taurine O
subspecies O
present O
distinct O
morphological O
traits O
as O
a O
consequence O
of O
environmental O
adaptation O
and O
artificial O
selection O

Therefore O
, O
we O
appraise O
4 O
DNAm O
models O
of O
ternary O
smoking O
status O
( O
that O
is O
, O
current O
, O
former O
and O
never O
smokers O
) O
: O
methylation O
at O
cg05575921 O
( O
AHRR O
model O
) O
, O
weighted O
scores O
from O
13 O
CpGs O
created O
by O
Maas O
et O
al O

Our O
aim O
is O
to O
provide O
researchers O
with O
conceptual O
tools O
to O
sensibly O
design O
their O
studies O
and O
to O
interpret O
their O
results O
in O
the O
admissible O
framework O

714 O
: O
Epigenetics O
has O
transformed O
our O
understanding O
of O
the O
molecular O
basis O
of O
complex O
diseases O
, O
including O
cardiovascular O
and O
metabolic O
disorders O

Tools O
used O
routinely O
to O
determine O
prognosis O
have O
not O
changed O
over O
the O
past O
decade O
; O
classification O
remains O
largely O
morphology O
based O
; O
and O
patients O
continue O
to O
be O
exposed O
to O
potentially O
toxic O
therapy O
with O
no O
indication O
of O
the O
likelihood O
of O
response O

186 O
: O
Background O
: O
In O
mammals O
, O
modifications O
to O
cytosine O
bases O
, O
particularly O
in O
cytosine-guanine O
( O
CpG O
) O
dinucleotide O
contexts O
, O
play O
a O
major O
role O
in O
shaping O
the O
epigenome O

11 O
: O
Infertility O
is O
a O
complex O
pathophysiological O
condition O

No O
associations O
were O
observed O
for O
the O
remaining O
EAA O
estimates O

382 O
: O
Epigenetic O
changes O
during O
ageing O
have O
been O
characterized O
by O
multiple O
epigenetic O
clocks O
that O
allow O
the O
prediction O
of O
chronological O
age O
based O
on O
methylation O
status O

444 O
: O
In O
1961 O
, O
Jacob O
and O
Monod O
proposed O
the O
operon O
model O
of O
gene O
regulation O

351 O
: O
Sequencing-based O
approaches O
now O
allow O
high-resolution O
, O
genome-scale O
investigation O
of O
cellular O
epigenetic O
landscapes O

In O
this O
article O
, O
the O
complexity O
of O
epigenetic O
processes O
and O
the O
current O
level O
of O
proof O
for O
their O
involvement O
in O
CNS O
disorders O
are O
discussed O

DNA O
methylation O
patterns O
depend O
on O
the O
genotype O
and O
can O
be O
reshaped O
by O
environmental O
conditions O
, O
while O
transgenerational O
epigenetic O
inheritance O
has O
been O
reported O
in O
various O
species O

Whether O
these O
public O
policies O
will O
coexist O
or O
, O
in O
contrast O
, O
compete O
with O
strategies O
reinforcing O
the O
personalized O
medicine O
interventions O
needs O
to O
be O
considered O

615 O
: O
Quantitative O
comparison O
of O
epigenomic O
data O
across O
multiple O
cell O
types O
or O
experimental O
conditions O
is O
a O
promising O
way O
to O
understand O
the O
biological O
functions O
of O
epigenetic O
modifications O

We O
then O
discuss O
how O
epigenetics O
has O
changed O
the O
way O
that O
we O
think O
of O
both O
health O
and O
disease B-Disease
, O
offering O
as O
examples O
studies O
examining O
the O
epigenetic O
contributions O
to O
aging O
, O
including O
the O
recent O
development O
of O
an O
epigenetic O
" O
clock O
" O
, O
and O
explore O
how O
antiaging O
therapies O

Apart O
from O
protein-coding O
genes O
, O
studies O
are O
uncovering O
the O
critical O
regulatory O
roles O
played O
by O
noncoding O
RNAs O
and O
noncoding O
regions O
of O
the O
genome O
during O
cancer B-Disease
progression O

Understanding O
the O
dynamic O
interaction O
between O
epigenetics O
and O
stress O
responses O
holds O
immense O
potential O
to O
engineer O
resilient O
crops O
that O
thrive O
in O
environments O
contaminated O
with O
heavy O
metals O
and O
metalloids O

g O

121 O
: O
The O
burgeoning O
field O
of O
epigenetics O
is O
making O
a O
significant O
impact O
on O
our O
understanding O
of O
brain O
evolution O
, O
development O
, O
and O
function O


We O
discuss O
some O
of O
the O
requirements O
, O
merits O
, O
and O
challenges O
that O
should O
be O
considered O
when O
choosing O
a O
methylome O
technology O
to O
ensure O
that O
it O
will O
be O
informative O

Finally O
, O
S3EQ O
showed O
increased O
sensitivity O
for O
correlating O
chromatin B-Disease
modifications I-Disease
with O
gene O
expression O
, O
especially O
for O
lowly O
expressed O
transcripts O

The O
time O
has O
come O
to O
turn O
these O
findings O
into O
clinically O
meaningful O
biomarkers O
, O
capable O
of O
detecting O
tumors B-Disease
through O
noninvasive O
approaches O
, O
establishing O
the O
clinical O
relevance O
of O
each O
bladder O
cancer B-Disease
and O
predicting O
response O
to O
therapy O

326 O
: O
Fetal O
exposures O
can O
induce O
epigenetic O
modifications O
, O
particularly O
DNA O
methylation O
, O
potentially O
predisposing O
individuals O
to O
later O
health O
issues O

The O
present O
study O
assessed O
genome-wide O
DNA O
(CpG) O
methylation O
, O
one O
of O
the O
key O
epigenetic O
mechanisms O
, O
at O
three O
timepoints O
during O
prolonged O
(51-day) O
exposure O
of O
cultured O
human O
fibroblasts O
to O
naturalistic O
cortisol O
levels O
, O
which O
can O
be O
reached O
in O
human O
tissues O
during O
in O

This O
review O
highlights O
an O
emerging O
suite O
of O
tools O
that O
enable O
robust O
yet O
selective O
interrogation O
of O
the O
epigenome O

, O
explaining O
individual O
differences O
in O
health O
outcomes O
to O
interrupt O
optimistic O
biases O
about O
health O
exposures O
) O
; O
( O
2 O
) O
illuminate O
new O
approaches O
to O
targeted O
and O
tailored O
health O
promotion O
interventions O
( O
e O

Reduced O
expression O
is O
due O
to O
factors O
in O
the O
galactose O
( O
GAL O
) O
network O
rather O
than O
global O
factors O

The O
goals O
of O
his O
work O
include O
a O
mechanistic O
understanding O
of O
individual O
susceptibility O
to O
exposure-related O
cancers B-Disease

In O
pace O
with O
the O
rapid O
increase O
in O
interest O
in O
epigenetic O
research O
, O
the O
range O
of O
methods O
has O
greatly O
expanded O
over O
the O
past O
decade O

Since O
the O
1950s O
, O
the O
contribution O
of O
key O
scientists O
( O
Mary O
Lyon O
and O
Eduardo O
Scarano O
) O
, O
as O
well O
as O
the O
discussions O
at O
the O
international O
conference O
of O
Gif-sur-Yvette O
( O
1957 O
) O
paved O
the O
way O
for O
three O
fundamental O
shifts O
of O
focus O
: O
1 O

Over O
the O
last O
decade O
, O
much O
attention O
has O
been O
paid O
to O
the O
roles O
of O
transcription O
and O
chromatin O
regulation O
in O
guiding O
fundamental O
aspects O
of O
neuronal O
function O

We O
find O
that O
DNAm O
can O
classify O
ternary O
smoking O
status O
with O
reasonable O
accuracy O
, O
including O
when O
applied O
to O
external O
data O

Areas O
of O
controversy O
: O
The O
relative O
importance O
of O
epigenetic O
mechanisms O
are O
unknown O
in O
terms O
of O
promoting O
healthy O
ageing O

With O
the O
growing O
numbers O
of O
drugs O
or O
drug O
candidates O
developed O
to O
target O
epigenetic O
regulators O
, O
more O
and O
more O
epigenetic O
therapies O
are O
under O
preclinical O
evaluation O
, O
early O
clinical O
trials O
or O
approved O
by O
FDA O
as O
single O
agent O
or O
in O
combination O
with O
existing O
antitumor O
drugs O

The O
genomic O
positions O
of O
valleys O
pinpoint O
locations O
of O
cis-regulatory O
elements O
such O
as O
enhancers O
and O
insulators O

These O
observations O
suggest O
the O
involvement O
of O
epigenetic O
mechanisms O

This O
impact O
is O
thought O
to O
be O
in O
large O
part O
mediated O
by O
the O
action O
of O
glucocorticoid O
stress O
hormones O
, O
primarily O
cortisol O
in O
humans O

Optimal O
execution O
and O
interpretation O
of O
data O
is O
fundamental O
for O
achieving O
accurate O
and O
reproducible O
results O

marabousymposium O

This O
review O
will O
explore O
the O
interplay O
between O
epigenetics O
and O
aging O
, O
and O
how O
epigenetic O
reprogramming O
can O
be O
harnessed O
for O
age O
reversal O

744 O
) O

Epigenetic O
processes O
, O
such O
as O
DNA O
methylation O
, O
have O
important O
roles O
in O
mediating O
the O
effects O
of O
the O
environment O
on O
behavior O

Autoimmune B-Disease
diseases I-Disease
now O
include O
almost O
100 O
conditions O
and O
are O
estimated O
to O
cumulatively O
affect O
up O
to O
5% O
of O
the O
world O
population O
with O
a O
healthcare O
expenditure O
superior O
to O
cancer B-Disease
worldwide O

Recent O
technological O
advances O
have O
enabled O
genome-wide O
profiling O
of O
DNAme O
in O
large O
human O
cohorts O

In O
our O
analysis O
, O
we O
found O
that O
epigenetic O
proteins O
DNMT3A O
, O
HDAC2 O
, O
KDM6A O
, O
and O
TET2 O
are O
highly O
mutated O
in O
variety O
of O
cancers B-Disease

Additionally O
, O
environmental O
exposures O
are O
being O
held O
responsible O
for O
causing O
epigenetic O
changes O
that O
lead O
to O
a O
disease B-Disease
process O

Assays O
for O
human O
age O
have O
recently O
been O
developed O
based O
on O
age-induced O
changes O
in O
DNA O
methylation O
of O
specific O
genes O

This O
review O
briefly O
explains O
the O
molecular O
nature O
of O
the O
individual O
regulatory O
process O
that O
constitute O
epigenetics O
, O
including O
DNA O
methylation O
, O
histone O
modifications O
, O
chromatin O
remodeling O
, O
transcriptional O
control O
, O
and O
noncoding O
RNAs O

The O
diversity O
in O
eukaryotic O
genome O
architectures O
and O
the O
dynamic O
processes O
are O
only O
possible O
due O
to O
the O
well-developed O
epigenetic O
toolkit O
, O
which O
probably O
existed O
in O
the O
Last O
Eukaryotic O
Common O
Ancestor O
( O
LECA O
) O

Longitudinal O
studies O
are O
crucial O
to O
elucidate O
exposure-epigenome O
interactions O
and O
develop O
prevention O
strategies O

We O
will O
further O
evaluate O
how O
recent O
technological O
advances O
may O
enable O
us O
to O
unravel O
the O
molecular O
mechanisms O
underlying O
these O
phenomena O
, O
which O
will O
be O
crucial O
for O
understanding O
heritability O
in O
health O
and O
disease B-Disease

Differences O
between O
the O
methods O
are O
discussed O
, O
mainly O
with O
respect O
to O
throughput O
and O
target O
coverage O

com O
/ O
harmancilab O
/ O
EpiSAFARI O

45 O
% O
of O
the O
lncRNAs O
and O
51 O

Conclusions O
: O
Our O
rich O
catalogue O
of O
haploid O
methylomes O
across O
multiple O
tissues O
will O
allow O
validation O
of O
epigenome O
association O
studies O
and O
exploration O
of O
new O
biological O
models O
for O
allelic O
exclusion O
in O
the O
human O
genome O

We O
present O
a O
protocol O
for O
genome-wide O
comparative O
analysis O
of O
DNA-IP O
sequencing O
data O
to O
identify O
statistically O
significant O
differential O
sequencing O
coverage O
between O
two O
conditions O
by O
considering O
variation O
across O
replicates O

Hence O
, O
epigenetics O
research O
may O
help O
to O
understand O
the O
mechanisms O
leading O
to O
suicidal B-Disease
ideation I-Disease
and O
behavior O

The O
first O
is O
primarily O
medically O
based O
and O
views O
epigenetic O
mechanisms O
as O
pathways O
for O
disease B-Disease
( O
e O

Yet O
, O
whether O
5mC O
contributes O
more O
broadly O
to O
gene O
expression O
is O
an O
important O
open O
question O

By O
providing O
a O
new O
source O
of O
variation O
, O
DNA O
methylation O
introduces O
novel O
direction O
to O
both O
scientists O
and O
breeders O
with O
its O
potential O
in O
disease B-Disease
resistance O
enhancement O

Sustained O
efforts O
have O
been O
made O
in O
recent O
years O
to O
discover O
how O
environmental O
exposures O
affect O
human O
health O
through O
epigenetic O
phenomena O
, O
such O
as O
DNA O
methylation O
, O
histone O
modifications O
and O
non-coding O
RNA-mediated O
gene O
regulation O


Though O
very O
powerful O
, O
these O
methods O
are O
not O
without O
limitations O

Then O
, O
based O
on O
previous O
studies O
, O
we O
selected O
the O
genes O
related O
to O
the O
immune O
state O
of O
tumor B-Disease
microenvironment O

g O

111 O
: O
Autoimmune B-Disease
diseases I-Disease
now O
include O
over O
100 O
conditions O
and O
are O
estimated O
to O
affect O
over O
20 O
million O
people O
in O
the O
United O
States O
or O
5% O
of O
the O
world O
population O
with O
numerous O
geographical O
differences O
coined O
as O
geoepidemiology O

In O
addition O
, O
the O
laboratory O
is O
also O
involved O
with O
the O
study O
of O
inherited O
susceptibility O
to O
brain O
tumors B-Disease
and O
pancreatic O
cancer B-Disease

These O
advancements O
in O
the O
understanding O
of O
the O
physiopathology O
of O
schizophrenia B-Disease
provide O
exciting O
new O
perspectives O
for O
treatments O

Next O
generation O
sequencing O
( O
NGS O
) O
methods O
have O
been O
broadly O
used O
to O
identify O
these O
target O
sites O
and O
their O
patterns O

In O
this O
paper O
, O
we O
argue O
that O
the O
impetus O
to O
create O
new O
biomedical O
interventions O
to O
manipulate O
and O
reverse O
epigenetic O
variants O
is O
likely O
to O
garner O
more O
attention O
than O
effective O
social O
and O
public O
health O
interventions O
and O
therefore O
also O
to O
garner O
a O
greater O
share O
of O
limited O
public O
resources O

Finally O
, O
we O
describe O
the O
properties O
of O
an O
ideal O
universal O
data O
harmonization O
framework O

The O
majority O
of O
current O
techniques O
are O
invasive O
and O
difficult O
to O
translate O
to O
what O
is O
happening O
within O
a O
human O
brain O
in O
vivo O

The O
hypothesis O
that O
epigenetic O
mechanisms O
may O
link O
such O
nutritional O
imbalances O
with O
altered O
disease B-Disease
risk O
has O
been O
gaining O
acceptance O
over O
recent O
years O

Recent O
studies O
have O
supported O
a O
role O
of O
DNA O
sequences O
in O
recruitment O
of O
epigenetic O
regulators O

His O
research O
findings O
include O
the O
report O
of O
a O
close O
link O
between O
DNA O
methylation O
and O
BRAF O
mutation O
in O
colorectal O
cancer B-Disease
(Nature O
Genetics O
, O
2006 O
) O
[2 O
] O
, O
the O
discovery O
that O
embryonic O
stem O
cell O
polycomb O
repressor O
targets O
are O
predisposed O
to O
abnormal O
DNA O
methylation O

Sparse O
multiple O
canonical O
correlation O
analysis O
(SMCCA) O
is O
a O
multivariate O
model O
widely O
used O
to O
extract O
contributing O
features O
from O
each O
data O
while O
maximizing O
the O
cross-modality O
correlation O

79 O
: O
Environmental O
epigenetics O
is O
increasingly O
employed O
to O
understand O
the O
health O
outcomes O
of O
communities O
who O
have O
experienced O
historical O
trauma B-Disease
and O
structural O
violence O

Although O
the O
determinants O
of O
health O
inequalities O
are O
complex O
, O
social O
and O
structural O
factors O
produced O
by O
inequitable O
and O
racialized O
systems O
are O
recognized O
as O
contributing O
sources O

Moreover O
, O
exposure O
of O
monocytes O
to O
lipids O
persistently O
alters O
their O
epigenetic O
makeup O
resulting O
in O
more O
proinflammatory O
cells O

Distinct O
histone O
modifications O
are O
linked O
with O
specific O
chromatin O
structures O
and O
intranuclear O
positioning O
, O
thereby O
impacting O
replication O
timing O
and O
replication O
initiation O
, O
which O
in O
turn O
are O
related O
to O
gene O
expression O
and O
cell O
differentiation O

DNA O
methylation O
occurs O
as O
part O
of O
the O
typical O
gene O
silencing O
during O
latent O
infection B-Disease
by O
herpesviruses O

In O
this O
mini-review O
we O
introduce O
the O
concept O
of O
epigenetic O
drivers O
of O
cancer B-Disease
and O
discuss O
how O
aberrant O
DNA O
methylation O
, O
histone O
modifications O
, O
and O
chromatin O
states O
are O
being O
targeted O
using O
drugs O
either O
in O
preclinical O
, O
or O
clinical O
development O
, O
and O
how O
they O
fit O
in O
the O

The O
problem O
of O
" O
unfair O
combination O
of O
pairwise O
covariances O
" O
restricts O
the O
power O
of O
SMCCA O
for O
feature O
selection O

75 O
: O
Understanding O
the O
physiological O
and O
metabolic O
underpinnings O
that O
confer O
individual O
differences O
in O
responses O
to O
diet O
and O
diet-related O
chronic O
disease B-Disease
is O
essential O
to O
advance O
the O
field O
of O
nutrition O

We O
have O
also O
analyzed O
the O
selected O
probes O
for O
their O
biological O
relevance O

We O
look O
for O
similarities O
and O
differences O
between O
two O
epigenetic O
models O
, O
by O
Turing O
and O
Edelman O
, O
as O
they O
are O
realized O
in O
Game O
of O
Life O
objects O

COSMIC O
, O
CCLE O
and O
1000-genome O
project O

344 O
: O
DNA O
methylation O
is O
one O
of O
the O
best-known O
epigenetic O
modifications O
in O
mammals O

To O
investigate O
the O
relationship O
between O
the O
19 O
epigenetic O
features O
and O
off-target O
activity O
, O
we O
first O
conducted O
Spearman O
and O
Pearson O
correlation O
analysis O

In O
our O
study O
we O
observed O
decrease O
in O
the O
level O
of O
DNA O
methylation O
under O
the O
influence O
of O
heat O
stress O
, O
especially O
after O
returning O
to O
control O
conditions O

Environmental O
factors O
that O
influence O
early O
life O
critical O
windows O
of O
development O
generally O
do O
not O
have O
the O
capacity O
to O
modify O
genome O
sequence O
, O
nor O
promote O
permanent O
genetic O
modifications O

Potential O
targets O
of O
disruption O
along O
putative O
adverse O
outcome O
pathways O
associated O
with O
the O
signaling O
pathways O
are O
identified O
, O
along O
with O
assays O
that O
show O
promise O
in O
evaluating O
the O
target O
in O
a O
screening O
and O
testing O
program O
such O
that O
in O
vitro O
methods O
are O
used O
where O
possible O
, O
and O
animal O
experiments O

580 O
: O
Introduction O
: O
Epigenetics O
has O
recently O
emerged O
as O
a O
potential O
mechanism O
by O
which O
adverse O
environmental O
stimuli O
can O
result O
in O
persistent O
changes O
in O
gene O
expression O

Conclusions O
: O
Therapeutics O
targeting O
epigenetic O
mechanisms O
may O
be O
helpful O
to O
counter O
immune O
evasion O
and O
improve O
the O
effectiveness O
of O
immunotherapies O

Recent O
findings O
: O
With O
the O
completion O
of O
the O
genome O
project O
in O
2003 O
, O
high O
expectations O
existed O
for O
the O
DNA O
sequence O
information O
to O
provide O
answers O
about O
the O
causative O
mutations O
for O
common O
diseases O

225 O
: O
Epigenetics O
refers O
to O
nucleotide O
sequence-independent O
events O
, O
and O
heritable O
changes O
, O
including O
DNA O
methylation O
and O
histone O
modification O
( O
as O
the O
two O
main O
processes O
) O
, O
contributing O
to O
the O
phenotypic O
features O
of O
the O
cell O

613 O
: O
Studies O
on O
" O
epigenetic O
inheritance O
" O
or O
" O
transgenerational O
epigenetic O
inheritance O
" O
have O
emerged O
at O
ever-increasing O
numbers O
in O
the O
last O
years O
, O
in O
plant O
as O
well O
as O
animal O
systems O
and O
in O
diverse O
contexts O
ranging O
from O
stress O
adaptation O
to O
behavioral O
studies O

Here O
, O
we O
review O
the O
role O
of O
key O
aberrant O
epigenetic O
processes O
- O
DNA O
methylation O
and O
post-translational O
modification O
of O
histones O
- O
in O
tumour B-Disease
immunogenicity O
, O
as O
well O
as O
the O
effects O
of O
epigenetic O
modulation O
on O
antitumour O
immune O
cell O
function O

MethLAB O
accounts O
for O
multiple O
testing O
by O
controlling O
the O
false O
discovery O
rate O
(FDR) O
at O
a O
user-specified O
level O

Early O
diagnosis O
of O
GC O
is O
critical O
in O
terms O
of O
prognosis O
, O
and O
aberrations O
at O
the O
molecular O
level O
, O
especially O
epigenetic O
alterations O
, O
manifest O
much O
earlier O
than O
histological O
findings O

This O
Review O
highlights O
advances O
from O
the O
past O
5 O
years O
in O
the O
field O
of O
epigenetics O
and O
their O
application O
to O
inflammatory O
rheumatic O
diseases O
, O
delineating O
the O
future O
lines O
of O
development O
for O
a O
rational O
use O
of O
epigenetic O
information O
in O
clinical O
settings O
and O
in O
personalized O
medicine O

In O
this O
chapter O
we O
will O
cover O
all O
the O
main O
technologies O
available O
, O
with O
a O
special O
emphasis O
on O
the O
microarray O
technology O
, O
as O
it O
supposes O
a O
perfect O
choice O
taking O
into O
account O
its O
price O
as O
well O
as O
the O
amount O
of O
cytosines O
interrogated O
, O
the O
compatibility O
with O
formalin-fixed O
paraffin- O

Transcriptomic O
studies O
have O
revealed O
that O
gene O
expression O
is O
coordinated O
to O
maintain O
neoblast O
pluripotency O
, O
and O
ensure O
correct O
lineage O
specification O
during O
differentiation O


Conclusions O
: O
Our O
findings O
suggest O
that O
DNAm O
can O
classify O
ternary O
smoking O
status O
with O
close O
to O
65% O
accuracy O

Integration O
of O
chromatin O
conformation O
datasets O
is O
one O
of O
the O
latest O
efforts O
in O
deciphering O
schizophrenia B-Disease
risk O
, O
allowing O
the O
identification O
of O
genes O
in O
contact O
with O
regulatory O
variants O
across O
100s O
of O
kilobases O

, O
genetic O
load O
) O
on O
substance O
abuse O
as O
well O
as O
a O
main O
effect O
of O
CSA O
on O
substance O
abuse O
in O
adulthood O

It O
is O
not O
only O
involved O
in O
many O
basic O
biological O
processes O
, O
but O
also O
considered O
an O
important O
factor O
for O
tumorigenesis B-Disease
and O
other O
human O
diseases O

Future O
studies O
should O
focus O
on O
the O
use O
of O
next O
generation O
sequencing O
tools O
to O
define O
invertebrate O
methylomes O
under O
environmental O
stress O
in O
higher O
resolution O
, O
those O
data O
should O
further O
be O
linked O
to O
gene O
expression O
patterns O
and O
phenotypes O
and O
detailed O
studies O
focusing O
on O
transgenerational O
effects O
are O
encouraged O

, O
those O
leveraging O
synthetic O
and O
chemical O
biology O
and O
optogenetics O
) O
for O
examining O
precisely O
how O
epigenetic O
modifications O
at O
specific O
genomic O
sites O
affect O
disease B-Disease
processes O

Both O
genetic O
and O
environmental O
factors O
impact O
epigenetic O
marks O
, O
generating O
phenotypic O
variation O
that O
ranges O
from O
normal O
variation O
to O
human O
disease B-Disease

Recently O
, O
epigenetic-based O
biomarkers O
have O
brought O
to O
light O
new O
insights O
into O
the O
clinical O
management O
of O
bladder O
cancer B-Disease

Greenness O
was O
also O
inversely O
associated O
with O
three O
of O
the O
eight O
components O
of O
GrimAge O
, O
specifically O
, O
DNA O
methylation-based O
surrogates O
of O
serum O
cystatin-C O
, O
serum O
growth O
differentiation O
factor O
15 O
, O
and O
smoking O
pack O
years O

We O
review O
the O
main O
ideas O
, O
methods O
, O
and O
findings O
in O
each O
direction O
, O
and O
discuss O
the O
implications O
to O
understanding O
the O
regulatory O
functions O
of O
the O
genomes O

Interestingly O
, O
neutrophils O
displayed O
increased O
variability O
compared O
to O
monocytes O
and O
T O
cells O
, O
which O
may O
be O
related O
to O
the O
crucial O
role O
of O
the O
former O
as O
an O
initial O
mediator O
of O
immune O
responses O

108 O
: O
The O
concept O
of O
epigenetics O
has O
evolved O
since O
Waddington O
defined O
it O
from O
the O
late O
1930s O
as O
the O
study O
of O
the O
causal O
mechanisms O
at O
work O
in O
development O

Here O
in O
this O
review O
, O
we O
discuss O
developments O
in O
the O
field O
of O
AML O
biology O
and O
therapeutics O
, O
with O
a O
focus O
on O
advances O
in O
our O
understanding O
of O
how O
genetic O
and O
epigenetic O
determinants O
of O
AML O
have O
influenced O
prognostication O
and O
recent O
shifts O
in O
treatment O
paradigms O
, O

Further O
applications O
about O
VAEs O
should O
focus O
on O
fine-grained O
subtypes O
identification O
for O
precision O
medicine O

Previous O
legal O
and O
ethical O
issues O
in O
genetic O
research O
serve O
as O
a O
guide O
to O
those O
in O
epigenetic O
research O

COCOA O
is O
available O
on O
Bioconductor O
( O
http://bioconductor O

Multiple O
genes/enzymes O
that O
play O
a O
role O
in O
DNA O
and O
histone O
modifications O
are O
also O
altered O
in O
various O
cancers B-Disease
, O
changing O
the O
epigenomic O
landscape O
during O
cancer B-Disease
initiation O
and O
progression O

Lysenkoism O
was O
applied O
to O
agriculture O
during O
the O
Stalin O
era O
with O
disastrous O
consequences O

This O
review O
presents O
a O
link O
between O
the O
methodology O
and O
some O
of O
its O
application O
in O
BEN O
research O
as O
an O
example O
of O
polygenic O
disorders O

We O
profiled O
six O
histone O
modifications O
( O
H3K4me1 O
, O
H3K4me3 O
, O
H3K27ac O
, O
H3K36me3 O
, O
H3K9me3 O
, O
H3K27me3 O
) O
, O
identified O
chromatin O
states O
using O
a O
hidden O
Markov O
model O
, O
produced O
a O
novel O
quantitative O
metric O
for O
model O
selection O
and O
established O

14 O
: O
DNA O
tumor B-Disease
viruses B-Disease
including O
members O
of O
the O
polyomavirus O
, O
adenovirus O
, O
papillomavirus O
, O
and O
herpes O
virus B-Disease
families O
are O
presently O
the O
subject O
of O
intense O
interest O
with O
respect O
to O
the O
role O
that O
epigenetics O
plays O
in O
control O
of O
the O
virus B-Disease
life O
cycle O
and O
the O
transformation O
of O

The O
upstream O
clock O
mechanism O
( O
s O
) O
that O
control O
the O
timing O
of O
growth O
, O
development O
, O
and O
aging O
remain O
obscure O

Here O
, O
we O
provide O
an O
overview O
of O
age-related O
changes O
in O
the O
brain O
's O
chromatin O
structures O
, O
highlight O
potential O
epigenetic O
drug O
targets O
for O
cognitive O
decline O
and O
age-related O
neurodegenerative B-Disease
disease I-Disease
, O
and O
discuss O
opportunities O
and O
challenges O
when O
studying O
epigenetic O
biomarkers O
in O
aging O
research O

It O
has O
been O
demonstrated O
that O
the O
genes O
encoding O
for O
miRNAs O
undergo O
the O
same O
regulatory O
epigenetic O
processes O
of O
protein O
coding O
genes O

This O
article O
comments O
on O
the O
role O
of O
epigenetics O
in O
the O
pharmacotherapy O
, O
psychotherapy O
and O
nutritional O
management O
of O
these O
disorders O

Conclusion O
: O
Existing O
epigenetic O
clocks O
require O
updates O
for O
full O
EPICv2 O
compatibility O

Better O
understanding O
of O
the O
interplay O
between O
multiple O
environmental O
and O
genetic O
factors O
involved O
in O
the O
patogenesis O
of O
bipolar O
disorder B-Disease
could O
provide O
relevant O
information O
for O
treatment O
of O
patients O
with O
this O
complex O
disorder B-Disease

g O

There O
are O
several O
molecular O
techniques O
used O
to O
screen O
methylation O
of O
DNA O
; O
here O
, O
we O
focus O
on O
the O
most O
common O
technique O
, O
methylation-sensitive-AFLP O
( O
MS-AFLP O
) O
, O
which O
is O
used O
to O
identify O
genome-wide O
methylation O
patterns O

In O
this O
review O
, O
we O
will O
first O
describe O
the O
most O
used O
ML O
approaches O
in O
epigenomics O

Active O
domains O
behave O
as O
pure O
polymer O
coils O
, O
while O
inactive O
and O
repressed O
domains O
both O
lie O
at O
the O
coil-globule O
crossover O

Analyses O
of O
genomic O
variations O
in O
many O
organisms O
have O
provided O
insights O
into O
phenotypic O
traits O
, O
evolution O
and O
disease B-Disease
, O
and O
are O
transforming O
medicine O

Converging O
data O
from O
epigenetic O
studies O
of O
primary O
cancers B-Disease
and O
from O
experimental O
studies O
of O
chromatin O
in O
development O
and O
epithelial-mesenchymal O
transition O
suggest O
a O
role O
for O
epigenetic O
stochasticity O
as O
a O
driving O
force O
of O
cancer B-Disease
, O
with O
Darwinian O
selection O
of O
tumour B-Disease
cells O
at O
the O

They O
function O
in O
a O
highly O
orchestrated O
manner O
, O
regulating O
mitotically O
heritable O
differences O
in O
gene O
expression O
potential O
without O
altering O
the O
primary O
DNA O
sequence O

421 O
: O
Background O
: O
DNA O
methylation O
is O
the O
major O
form O
of O
epigenetic O
modifications O
through O
which O
the O
cell O
regulates O
the O
gene O
expression O
and O
silencing O

640 O
: O
Epigenetics O
is O
a O
rapidly O
developing O
science O
that O
has O
gained O
a O
lot O
of O
interest O
in O
recent O
years O
due O
to O
the O
correlation O
between O
characteristic O
epigenetic O
marks O
and O
cardiovascular B-Disease
diseases I-Disease
( O
CVDs O
) O

It O
does O
so O
, O
at O
least O
in O
part O
, O
by O
shaping O
epigenetically O
the O
structure O
and O
function O
of O
brain O
and O
body O
systems O
that O
show O
a O
considerable O
amount O
of O
adaptive O
plasticity O
throughout O
development O
and O
adult O
life O

The O
ATPase O
BRG1 O
and O
the O
SWI/SNF O
chromatin O
remodeling O
complex O
are O
epigenetic O
enzymes O
that O
regulate O
chromatin O
accessibility O
during O
steady O
and O
transitional O
cell O
states O

Analysis O
of O
aberrant O
genome-wide O
methylation O
patterns O
can O
provide O
insights O
into O
how O
these O
affect O
the O
cancer B-Disease
transcriptome O
and O
possible O
clinical O
implications O
for O
cancer B-Disease
diagnosis O
and O
treatment O

, O
excitation-inhibition O
coupling O
and O
activity-dependent O
plasticity O
) O

We O
also O
note O
needs O
for O
future O
genomic O
research O
that O
integrates O
across O
basic O
and O
social O
sciences O

504 O
: O
Epigenetic O
effects O
are O
exerted O
by O
a O
variety O
of O
factors O
and O
evidence O
increases O
that O
common O
drugs O
such O
as O
opioids O
, O
cannabinoids O
, O
valproic O
acid O
, O
or O
cytostatics O
may O
induce O
alterations O
in O
DNA O
methylation O
patterns O
or O
histone O
conformations O

Tost O
has O
an O
H-index O
of O
50 O
and O
is O
the O
author O
or O
co-author O
of O
more O
than O
195 O
publications O

Application O
of O
these O
enzymes O
in O
sequencing O
can O
be O
accomplished O
by O
relying O
on O
their O
natural O
activity O
, O
exploiting O
their O
ability O
to O
discriminate O
between O
cytosine O
modification O
states O
, O
reacting O
them O
with O
functionalized O
substrate O
analogs O
to O
introduce O
chemical O
handles O
, O
or O
engineering O
the O
DNA-modifying O
enzymes O
to O
take O

From O
the O
whole O
embryo O
to O
the O
gene O
; O
2 O

Advances O
over O
the O
past O
10 O
years O
have O
allowed O
large-scale O
assessment O
of O
one O
epigenetic O
mark O
in O
particular O
, O
DNA O
methylation O
, O
in O
human O
populations O
, O
and O
the O
examination O
of O
DNA O
methylation O
is O
becoming O
increasingly O
common O
in O
psychological O
studies O

377 O
: O
Recent O
years O
have O
brought O
the O
interest O
of O
genetic O
research O
to O
the O
human O
epigenome O

The O
principal O
subject O
of O
this O
article O
is O
to O
review O
the O
suitability O
of O
various O
current O
and O
emerging O
technological O
platforms O
to O
study O
oocytes O
and O
early O
embryonic O
epigenome O
with O
more O
emphasis O
on O
studying O
DNA O
methylation O

323 O
: O
In O
recent O
years O
there O
has O
been O
a O
widespread O
interest O
in O
researching O
biomarkers O
of O
aging O
that O
could O
predict O
physiological O
vulnerability O
better O
than O
chronological O
age O

Currently O
available O
in O
silico O
methods O
have O
facilitated O
the O
identification O
, O
positioning O
and O
quantitative O
comparisons O
of O
individual O
modification O
sites O

The O
organisation O
of O
the O
human O
genome O
within O
three-dimensional O
space O
, O
known O
as O
chromosome O
conformation O
, O
has O
recently O
been O
shown O
as O
a O
dynamic O
epigenetic O
regulator O
of O
gene O
expression O
, O
facilitating O
the O
interaction O
of O
distal O
genomic O
regions O
due O
to O
tight O
and O
regulated O
packaging O
of O
chromosomes O
in O
the O
cell O

As O
such O
, O
this O
emergence O
of O
epigenetic O
studies O
is O
somewhat O
" O
old O
wine O
in O
new O
bottles O
" O
and O
represents O
a O
reformulation O
of O
the O
old O
debate O
of O
preformationism O
versus O
epigenesis O
- O
one O
resolved O
in O
the O
1800s O

Gene O
essentiality O
data O
retrieved O
from O
COLT O
database O
further O
highlights O
the O
importance O
of O
various O
epigenetic O
proteins O
for O
cancer B-Disease
survival O

Here O
, O
we O
will O
focus O
on O
recent O
advances O
in O
the O
field O
of O
epigenetic O
germline O
inheritance O
in O
mammals O
, O
with O
a O
particular O
focus O
on O
the O
following O
three O
questions O
: O
( O
1 O
) O
What O
is O
the O
current O
evidence O
for O
an O
involvement O
of O
sperm O
RNAs O
in O
the O
transmission O
of O

These O
processes O
affect O
gene O
transcription O
, O
DNA O
replication O
and O
DNA O
repair O
, O
comprehending O
epigenetics O
as O
a O
key O
factor O
in O
understanding O
Aging O
and O
developing O
new O
avenues O
for O
delaying O
Aging O
, O
clinical O
advancements O
in O
ameliorating O
aging-related O
diseases O
and O
rejuvenating O
health O

Because O
of O
the O
somewhat O
inflationary O
way O
in O
which O
the O
word O
epigenetics O
is O
used O
nowadays O
, O
it O
is O
all O
the O
more O
important O
to O
clarify O
definitions O
and O
terms O
before O
talking O
about O
epigenetic O
studies O

Preterm O
birth O
constitutes O
one O
of O
the O
major O
adverse O
events O
in O
human O
development O

in O
Nature O
529(7586):418-422 O
, O
2016 O
) O
provide O
access O
to O
structural O
features O
of O
these O
domains O
with O
unprecedented O
resolution O
thanks O
to O
super-resolution O
experiments O

Thus O
, O
it O
is O
non-trivial O
to O
unify O
these O
complex O
datasets O
into O
an O
interpretable O
phenotype O

We O
investigated O
the O
cross-sectional O
relationship O
between O
two O
such O
estimates O
of O
biological O
age O
and O
objectively O
measured O
sedentary O
and O
walking O
behavior O
in O
older O
people O

It O
also O
provides O
an O
interface O
between O
environment O
and O
the O
genotype O
leading O
to O
functional O
plasticity O
of O
the O
genome O

We O
propose O
the O
hypothesis O
that O
PbRR9 O
has O
a O
direct O
, O
epigenetically O
mediated O
, O
role O
in O
poplar O
sex O
determination O

These O
insights O
into O
neoblast O
biology O
may O
be O
directly O
relevant O
to O
mammalian O
stem O
cells O
and O
disease B-Disease

CRISPR-Cas9 O
( O
Clustered O
Regularly O
Interspaced O
Palindrome O
Repeats-associated O
protein O
9 O
) O
system-mediated O
gene O
activation O
mechanism O
paves O
new O
methods O
of O
target-specific O
epigenetic O
therapeutics O
to O
cure O
diseases O

Most O
existing O
methods O
for O
data O
normalization O
standardize O
signals O
by O
rescaling O
either O
background O
regions O
or O
peak O
regions O
, O
assuming O
that O
the O
same O
scale O
factor O
is O
applicable O
to O
both O
background O
and O
peak O
regions O

131 O
: O
Health O
starts O
where O
we O
live O
, O
learn O
, O
work O
, O
and O
play O

We O
summarize O
7 O
analytical O
approaches O
to O
the O
GAW20 O
data O
sets O
that O
addressed O
challenges O
and O
potential O
applications O
of O
phenotypic O
and O
epigenetic O
data O

Here O
we O
describe O
a O
protocol O
for O
the O
detection O
and O
quantification O
of O
epigenetic O
signaling O
DNA O
methylation O
modifications O
including O
, O
N6-methyladenine O
( O
6mA O
) O
, O
N4-methylcytosine O
( O
4mC O
) O
and O
C5-methylcytosine O
( O
5mC O
) O
in O
genomic O
DNA O
by O
triple O

Systematic O
analysis O
and O
integration O
of O
epigenetic O
marks O
at O
the O
genome-wide O
scale O
, O
demonstration O
of O
cellular O
and O
physiological O
roles O
of O
specific O
epigenetic O
modifications O
, O
and O
investigation O
of O
inheritance O
are O
among O
the O
major O
challenges O
and O
opportunities O
for O
future O
epigenomic O
and O
epigenetic O
studies O
of O
hypertension B-Disease

Using O
methylation O
data O
, O
six O
artificial O
intelligence O
( O
AI O
) O
platforms O
including O
deep O
learning O
( O
DL O
) O
was O
used O
for O
CoA O
detection O

Summary O
: O
Epigenetic O
studies O
in O
the O
eating B-Disease
disorders I-Disease
corroborate O
the O
idea O
that O
eating O
disorder B-Disease
cause O
is O
multifactorial O
, O
and O
identify O
markers O
that O
could O
help O
inform O
our O
understanding O
of O
illness B-Disease
staging O
and O
subtyping O
that O
may O
explain O
the O
commonly O
progressive O
course O
of O
these O

Epigenetic O
changes O
, O
which O
are O
defined O
as O
heritable O
changes O
in O
gene O
expression O
that O
do O
not O
alter O
the O
primary O
DNA O
sequence O
, O
are O
one O
of O
the O
hallmarks O
of O
cancer B-Disease
, O
and O
prevalent O
in O
all O
types O
of O
cancer B-Disease

Accumulating O
evidence O
suggests O
that O
disturbances O
in O
DNA O
methylation O
, O
histone O
modifications O
and O
noncoding O
RNAs O
may O
contribute O
especially O
to O
altered O
differentiation O
and O
metastatic O
potential O

However O
, O
the O
premature O
rush O
to O
take O
murine O
epigenetic O
findings O
in O
these O
directions O
makes O
impossible O
demands O
on O
prospective O
parents O
and O
triggers O
serious O
social O
and O
ethical O
questions O

The O
current O
approach O
requires O
extensive O
computation O
of O
features O
over O
the O
genome O


73 O
: O
Everyone O
has O
heard O
of O
' O
epigenetics O
' O
, O
but O
the O
term O
means O
different O
things O
to O
different O
researchers O

In O
this O
review O
, O
we O
discuss O
cutting-edge O
strategies O
to O
foster O
the O
chemical O
design O
, O
the O
biological O
rationale O
and O
the O
clinical O
trial O
development O
of O
epidrugs O

The O
fraction O
of O
such O
genes O
with O
a O
common O
proportionality O
coefficient O
increased O
with O
an O
increase O
in O
the O
robustness O
of O
the O
evolved O
network O

Conclusion O
: O
The O
iCloneViz O
approach O
can O
be O
used O
for O
analysis O
of O
clonal O
evolution O
and O
mutational O
dynamics O
of O
multi-omic O
data O
sets O

However O
, O
with O
the O
exception O
of O
melanoma B-Disease
, O
most O
patients O
do O
not O
respond O
to O
immunotherapy O
alone O

We O
also O
provide O
detailed O
information O
on O
bioinformatics O
tools O
and O
computational O
strategies O
responsible O
for O
analyzing O
large O
scale O
data O
in O
epigenetics O

In O
this O
review O
, O
we O
summarize O
the O
progress O
that O
has O
been O
made O
in O
generating O
various O
neuronal O
subtypes O
from O
PSCs O
and O
somatic O
cells O
, O
with O
special O
emphasis O
on O
chemically O
defined O
systems O
, O
transcription O
factor-mediated O
reprogramming O
and O
epigenetic-based O
approaches O

Specifically O
, O
JBR O
supports O
graphical O
interactive O
manual O
region O
selection O
and O
annotation O
, O
thereby O
addressing O
supervised O
learning O
's O
key O
procedural O
challenge O

During O
the O
procedure O
, O
DNA O
binding O
proteins O
are O
covalently O
cross-linked O
to O
DNA O
, O
and O
the O
isolated O
chromatin O
is O
broken O
into O
pieces O
of O
300-500 O
bps O
in O
length O
on O
average O

Some O
evidence O
suggests O
that O
epigenetic O
markings O
, O
which O
have O
been O
established O
around O
conception O
, O
can O
also O
be O
transmitted O
to O
future O
generations O

Although O
there O
have O
been O
tremendous O
advances O
in O
LC O
and O
MS O
instrumentation O
in O
recent O
years O
, O
sample O
preparation O
has O
not O
experienced O
a O
similar O
rate O
of O
development O
and O
is O
often O
a O
bottleneck O
to O
chemical O
analysis O

Here O
, O
we O
review O
recent O
advances O
in O
such O
applications O
, O
including O
the O
methods O
to O
map O
DNA O
sequence O
to O
feature O
space O
, O
sequence O
comparison O
and O
prediction O
models O

Furthermore O
, O
we O
investigated O
whether O
these O
effects O
are O
mediated O
or O
not O
by O
changes O
in O
cellular O
composition O
, O
measured O
by O
deep O
immunophenotyping O

Computational O
studies O
using O
these O
methods O
have O
provided O
important O
insights O
into O
the O
epigenetic O
regulatory O
mechanisms O

This O
includes O
elucidating O
the O
differences O
in O
gene O
expression O
that O
are O
mediated O
through O
programming O
of O
the O
genome O
through O
epigenetic O
chromatin B-Disease
modifications I-Disease

Analogously O
, O
epigenetic O
regulation O
is O
postulated O
to O
regulate O
caste O
differences O
in O
social O
insects O

At O
the O
same O
time O
, O
the O
methylation O
level O
of O
three O
CpG O
sites O
showed O
a O
weak O
relationship O
with O
age O
and O
exhibited O
a O
low O
concordance O
between O
the O
data O
obtained O
from O
the O
two O
technologies O

Due O
to O
the O
limited O
sample O
size O
and O
the O
high O
coincidence O
of O
prematurity O
and O
multiple O
births O
, O
the O
relationship O
between O
cause O
of O
preterm O
birth O
and O
DNAm O
could O
not O
be O
evaluated O

This O
short O
review O
highlights O
key O
epigenetic O
players O
in O
the O
regulation O
of O
aging O
, O
as O
well O
as O
both O
future O
goals O
and O
challenges O
to O
the O
utilization O
of O
epigenetic O
strategies O
to O
delay O
and O
reverse O
the O
main O
diseases O
of O
aging O

Here O
, O
we O
explored O
the O
effects O
of O
the O
changes O
introduced O
in O
the O
new O
EPICv2 O
DNA O
methylation O
array O
on O
existing O
epigenetic O
clocks O

But O
recent O
discoveries O
in O
the O
emerging O
field O
of O
behavioral O
epigenetics O
have O
revealed O
factors O
at O
the O
interface O
between O
genes O
and O
environments O
that O
also O
play O
crucial O
roles O
in O
development O

In O
combination O
with O
other O
-omics O
approaches O
, O
epigenomics O
allows O
an O
improved O
conceptualization O
of O
the O
multifactorial O
nature O
of O
ASD O
, O
and O
opens O
future O
lines O
of O
inquiry O
for O
both O
basic O
research O
and O
clinical O
practice O

Here O
, O
we O
present O
a O
colorimetric O
method O
of O
quantification O
of O
5-hmC O
using O
Brassica O
rapa O
DNA O

Integrating O
histone O
modification O
information O
in O
the O
analysis O
of O
gene O
expression O
traits O
( O
eQTL O
mapping O
) O
has O
been O
shown O
to O
significantly O
enhance O
the O
prediction O
of O
eQTLs O

These O
results O
highlight O
the O
potential O
of O
machine O
learning-based O
imputation O
methods O
to O
advance O
personalized O
epigenomics O

The O
pathways O
enriched O
in O
the O
shared O
transcriptional O
association O
suggested O
links O
between O
epigenetic O
aging O
and O
metabolism O
, O
immunity O
, O
and O
autophagy O

In O
particular O
, O
the O
integration O
of O
epigenomic O
and O
transcriptomic O
data O
in O
the O
normal O
or O
pathological O
heart O
is O
a O
promising O
approach O
to O
identify O
novel O
molecular O
targets O

In O
this O
review O
, O
our O
group O
assessed O
the O
published O
evidence O
on O
the O
tumorigenic O
role O
of O
epigenomics O
in O
Hurthle O
cell O
neoplasms B-Disease
( O
HCN O
) O
, O
highlighting O
the O
yet O
limited O
, O
heteregeneous O
and O
non-validated O
data O
preventing O
its O
current O
use O
in O
clinical O
practice O
, O
despite O

Uncertainty O
as O
to O
which O
epiallele O
an O
observed O
sequencing O
read O
originated O
from O
is O
explicitly O
incorporated O
by O
marginalising O
over O
the O
appropriate O
posterior O
densities O

Additionally O
, O
several O
recent O
studies O
have O
renewed O
interest O
in O
the O
use O
of O
pharmacological O
doses O
of O
vitamin O
C O
injected O
intravenously O
to O
selectively O
kill O
tumor B-Disease
cells O


A O
comprehensive O
and O
integrated O
web O
resource O
ViralEpi O
v1 O

146 O
: O
CTCF O
as O
a O
multivalent O
eukaryotic O
transcription O
factor O
plays O
a O
diverse O
range O
of O
roles O
in O
regulation O
of O
various O
genes O
through O
the O
binding O
of O
its O
11 O
zinc O
fingers O
to O
CTCF O
consensus O
sites O
or O
various O
proteins O

This O
review O
highlights O
the O
current O
knowledge O
on O
emerging O
approaches O
in O
TE/RM O
with O
a O
focus O
on O
the O
effect O
of O
materials O
and O
topography O
on O
the O
epigenetic O
expression O
pattern O
in O
cells O
with O
potential O
impacts O
on O
modulating O
regenerative O
biology O

The O
observed O
methylation O
index O
, O
sensitivity O
and O
specificity O
of O
selected O
molecular O
markers O
( O
viz O

As O
well O
as O
being O
potential O
biomarkers O
for O
epilepsy O
diagnosis O
, O
epigenetic O
changes O
can O
also O
be O
used O
as O
prognostic O
indicators O
of O
treatment O
response O

miRNAs O
expression O
, O
similarly O
to O
that O
of O
protein-coding O
genes O
, O
is O
regulated O
by O
multiple O
transcriptional O
networks O
as O
well O
as O
the O
epigenetic O
machinery O

Therefore O
, O
an O
improved O
understanding O
of O
variations O
at O
the O
single O
cell O
level O
are O
fundamental O
to O
understanding O
biology O
and O
developing O
new O
approaches O
to O
combating O
disease B-Disease


Epigenetics O
may O
also O
enable O
the O
classification O
of O
individuals O
with O
chronic O
disease B-Disease
for O
specific O
dietary O
management O
and/or O
for O
efficacious O
diet-pharmaceutical O
combination O
therapies O

However O
, O
while O
eukaryotic O
systems O
have O
been O
the O
primary O
focus O
of O
DNA O
methylation O
studies O
, O
the O
molecular O
mechanisms O
in O
prokaryotes O
are O
less O
known O

Conclusions O
: O
Discoveries O
in O
neuroscience O
and O
epigenetics O
reveal O
synergistic O
mechanisms O
that O
support O
the O
integration O
of O
psychotherapy O
, O
psychopharmacology O
, O
and O
psychoeducation O
in O
practice O

However O
, O
recent O
progress O
in O
molecular O
imaging O
provides O
new O
, O
noninvasive O
ways O
to O
visualize O
epigenetics O
in O
the O
human O
brain O

False O
discovery O
rate-corrected O
P O
values O
( O
q O
values O
< O
0 O

Characterization O
of O
SNPs O
in O
the O
context O
of O
both O
inherited O
and O
acquired O
conditions O
, O
such O
as O
cancer B-Disease
, O
are O
a O
main O
focus O
of O
many O
genotyping O
procedures O

398 O
: O
Multi-omics O
( O
genomics O
, O
transcriptomics O
, O
epigenomics O
, O
proteomics O
, O
metabolomics O
, O
etc O

, O
phenobarbital O
, O
diethylstilbestrol O
, O
cocaine O
, O
methamphetamine O
, O
ethanol O
, O
dimethyl O
sulfoxide O
) O
, O
as O
well O
as O
anthropogenic O
pollutants O
( O
i O

Please O

Given O
the O
mitotic O
heritability O
of O
epigenetic O
states O
, O
a O
key O
question O
is O
whether O
epigenetic O
information O
can O
also O
be O
transmitted O
through O
generations O

This O
paper O
reviews O
all O
existing O
risk O
factors O
affecting O
DDH O
incidence O
, O
along O
with O
candidate O
genes O
associated O
with O
genetic O
or O
epigenetic O
etiology O
of O
DDH O
in O
various O
studies O

584 O
: O
The O
recent O
deluge O
of O
genome-wide O
technologies O
for O
the O
mapping O
of O
the O
epigenome O
and O
resulting O
data O
in O
cancer B-Disease
samples O
has O
provided O
the O
opportunity O
for O
gaining O
insights O
into O
and O
understanding O
the O
roles O
of O
epigenetic O
processes O
in O
cancer B-Disease

210 O
: O
Until O
a O
few O
years O
ago O
, O
epigenetics O
was O
a O
field O
of O
research O
that O
had O
nothing O
to O
do O
with O
ecology O
and O
that O
virtually O
no O
ecologist O
had O
ever O
heard O
of O

Aberrant O
epigenetic O
signatures O
are O
a O
hallmark O
of O
complex O
multifactorial O
diseases O
( O
including O
neoplasms B-Disease
and O
malignancies B-Disease
such O
as O
leukemias B-Disease
, O
lymphomas B-Disease
, O
sarcomas B-Disease
, O
and O
breast O
, O
lung O
, O
prostate O
, O
liver O
, O
and O
colorectal B-Disease
cancers I-Disease
) O

On O
the O
basis O
of O
this O
reaction O
, O
an O
adenine O
derivative O
with O
a O
tethered O
bipyridine O
moiety O
has O
been O
designed O
for O
sequence-specific O
osmium O
complex O
formation O

Previous O
studies O
used O
epigenetic O
data O
sets O
associated O
with O
the O
germline O
transmission O
of O
epigenetic O
transgenerational O
inheritance O
of O
disease B-Disease
and O
novel O
ML O
approaches O
to O
predict O
genome-wide O
locations O
of O
critical O
epimutations O

Future O
studies O
on O
the O
role O
of O
these O
factors O
in O
psychopathological O
conditions O
, O
subphenotypes O
and O
endophenotypes O
may O
greatly O
benefit O
by O
using O
more O
precise O
clinical O
data O
and O
a O
combined O
approach O
with O
multiple O
research O
tools O
incorporated O
into O
a O
single O
study O

Although O
patterns O
of O
CHH-methylation O
showed O
little O
association O
with O
age O
, O
both O
CpG O
and O
CHG-methylation O
contexts O
were O
strongly O
associated O
with O
ageing O
, O
largely O
becoming O
hypomethylated O
with O
age O

This O
article O
argues O
that O
considering O
the O
impact O
of O
the O
socio-exposome O
in O
the O
biological O
profiling O
for O
precision O
oral B-Disease
health I-Disease
applications O
is O
necessary O
to O
ensure O
that O
definitions O
of O
biological O
risk O
do O
not O
override O
social O
ones O

The O
new O
method O
allows O
reanalysis O
of O
the O
same O
single O
cell O

Recent O
work O
in O
this O
field O
has O
generated O
considerable O
enthusiasm O
, O
yet O
caution O
is O
warranted O
since O
any O
novel O
cross-disciplinary O
approach O
lacks O
a O
set O
of O
established O
conventions O
or O
standards O

406 O
: O
Age-related O
changes O
in O
DNA O
methylation O
do O
occur O

Compelling O
data O
suggested O
a O
strong O
causal O
link O
between O
prenatal O
vulnerability O
of O
future O
parental O
epigenomes O
to O
damaging O
environmental O
factors O
aggravated O
by O
abnormal O
socio-cultural O
conditions O
( O
including O
, O
for O
instance O
, O
malnutrition O
and O
chronic B-Disease
stress I-Disease
) O
and O
the O
alarming O
risk O
of O
developing O
heritable O
complex O
medical O

Here O
, O
we O
perform O
WGBS O
using O
the O
Accel-NGS O
library O
preparation O
kit O
on O
ultralow O
amounts O
of O
DNA O
from O
long-term O
archived O
samples O
with O
diverse O
pretreatments O
from O
the O
Janus O
Serum O
Bank O

Although O
these O
factors O
were O
originally O
thought O
to O
act O
in O
a O
long O
time O
domain O
only O
, O
it O
is O
now O
clear O
that O
they O
can O
also O
be O
highly O
dynamic O
, O
changing O
over O
minutes O

Next O
generation O
sequencing O
techniques O
have O
provided O
us O
an O
exciting O
toolkit O
of O
genome O
wide O
assays O
that O
can O
be O
used O
to O
predict O
and O
annotate O
enhancers O

By O
adopting O
this O
perspective O
, O
this O
paper O
draws O
attention O
to O
the O
role O
of O
exaptation O
in O
the O
evolution O
of O
epigenetics O
in O
the O
RNA O
world O
and O
addresses O
the O
role O
of O
epigenetics O
in O
the O
later O
evolution O
of O
developmental O
processes O
such O
as O
cellular O
differentiation O
, O
learning O
, O
and O
memory O

Next O
, O
the O
possible O
mechanisms O
through O
which O
these O
tools O
could O
be O
employed O
clinically O
are O
discussed O

Charge O
delocalization O
can O
directly O
alter O
DNA O
recognition O
by O
proteins O
or O
indirectly O
by O
DNA O
structural O
changes O
e O

To O
avoid O
confusion O
surrounding O
nomenclature O
, O
special O
care O
is O
needed O
to O
communicate O
results O
accurately O
, O
especially O
between O
scientists O
and O
other O
health O
care O
professionals O

One O
way O
to O
characterize O
normal O
gland O
function O
is O
to O
study O
the O
epigenome O
and O
resulting O
transcriptome O
within O
its O
constituent O
cells O


222 O
: O
The O
interplay O
of O
genetically O
driven O
biological O
processes O
and O
environmental O
factors O
is O
a O
key O
driver O
of O
research O
questions O
spanning O
multiple O
areas O
of O
psychology O

23 O
: O
Allergic B-Disease
diseases I-Disease
are O
on O
the O
rise O
in O
the O
Western O
world O
and O
well-known O
allergy-protecting O
and O
-driving O
factors O
such O
as O
microbial O
and O
dietary O
exposure O
, O
pollution O
and O
smoking O
mediate O
their O
influence O
through O
alterations O
of O
the O
epigenetic O
landscape O

However O
, O
in O
the O
past O
, O
insufficient O
differentiation O
between O
cellular O
and O
cell-free O
DNA O
may O
have O
confounded O
analyses O
of O
genome-wide O
methylation O
levels O
in O
aging O
cells O

The O
pathogenesis O
of O
SLE O
has O
been O
intensively O
studied O
but O
remains O
unclear O

This O
emerging O
evidence O
, O
together O
with O
work O
examining O
related O
biological O
processes O
, O
begins O
to O
shed O
light O
on O
the O
epigenetic O
and O
, O
more O
broadly O
, O
molecular O
underpinnings O
of O
the O
long-hypothesized O
connection O
between O
stress O
and O
aging O

However O
, O
analysis O
of O
single-cell O
methylome O
data O
is O
challenging O
due O
to O
data O
sparsity O
and O
moderate O
correlation O
with O
transcript O
level O

During O
the O
last O
decades O
, O
huge O
advances O
on O
techniques O
to O
measure O
the O
level O
of O
DNA O
methylation O
have O
occurred O
; O
we O
have O
passed O
from O
measuring O
it O
with O
more O
rudimentary O
and O
expensive O
techniques O
to O
nowadays O
the O
ability O
to O
measure O
DNA O
methylation O
at O
a O
single-base O
resolution O
in O

In O
addition O
, O
epigenetic O
marks O
are O
potentially O
heritable O

This O
review O
aims O
to O
dissect O
the O
interface O
of O
personalized O
medicine O
with O
nanomedicine O
and O
epigenetics O

605 O
: O
Epigenetic O
modulation O
captures O
the O
lack O
of O
correlation O
between O
the O
genotype O
and O
the O
phenotype O

These O
results O
highlight O
a O
great O
need O
for O
the O
inclusion O
of O
the O
proteomic O
characterization O
of O
epigenetic O
mechanisms O
in O
the O
study O
of O
gene/disease O
associations O
in O
psychiatric B-Disease
disorders I-Disease

Critical O
studies O
on O
epigenetics O
are O
emerging O
within O
a O
separate O
space O
of O
bioethical O
and O
biopolitical O
investigations O
and O
claims O
, O
with O
scholars O
from O
various O
epistemological O
standpoints O
utilizing O
distinct O
yet O
complementary O
analytical O
approaches O

In O
this O
article O
, O
I O
review O
some O
of O
the O
conceptual O
issues O
and O
currently O
available O
software O
tools O
for O
the O
analysis O
of O
sequencing-based O
whole-genome O
epigenetics O
data O

59 O
: O
Epigenetic O
mechanisms O
are O
believed O
to O
play O
an O
important O
role O
in O
disease B-Disease
, O
development O
and O
ageing O
with O
early O
life O
representing O
a O
window O
of O
particular O
epigenomic O
plasticity O

We O
also O
discuss O
the O
efforts O
that O
are O
being O
made O
to O
increase O
the O
efficiency O
of O
current O
protocols O
and O
address O
the O
potential O
for O
the O
use O
of O
these O
cells O
in O
disease B-Disease
modelling O
, O
drug O
discovery O
and O
regenerative O
medicine O

Supplementary O
information O
: O
Supplementary O
data O
are O
available O
at O
Bioinformatics O
online O

Our O
model O
, O
which O
estimates O
age O
based O
on O
DNA O
methylation O
at O
329 O
unique O
CpG O
sites O
, O
has O
a O
median O
absolute O
error O
of O
3 O

Two O
systems O
to O
evaluate O
threshold O
cycles O
were O
developed O
, O
based O
on O
the O
Derivative O
method O
and O
a O
new O
proposed O
3-point O
exponential O
evaluation O
aim O
to O
reduce O
detection O
time O
simultaneously O

22 O
: O
Proteolysis O
targeting O
chimeras O
( O
PROTACs O
) O
are O
heterobifunctional O
molecules O
and O
allow O
selective O
protein O
degradation O
by O
addressing O
the O
natural O
ubiquitin O
proteasome O
system O

Although O
many O
factors O
complicate O
the O
interpretation O
of O
epigenetic O
variation O
in O
human O
disease B-Disease
, O
cell-specific O
methylation O
patterns O
and O
the O
cellular O
heterogeneity B-Disease
present O
in O
peripheral O
blood O
and O
tissue O
biopsies O
are O
anticipated O
to O
cause O
the O
most O
problems O

274 O
: O
Purpose O
of O
review O
: O
Epigenetic O
changes O
can O
be O
highly O
influenced O
by O
environmental O
factors O
and O
have O
in O
turn O
been O
proposed O
to O
influence O
chronic O
disease B-Disease

In O
this O
systematic O
review O
, O
we O
focused O
on O
the O
potential O
roles O
of O
DNA O
methylation O
on O
mood B-Disease
disorders I-Disease
and O
obesity B-Disease
development O

The O
implications O
of O
stochastic O
epigenetic O
variability O
are O
multifold O
: O
by O
affecting O
development O
and O
subsequently O
phenotype O
, O
random O
changes O
in O
epigenetic O
marks O
may O
provide O
additional O
phenotypic O
diversity O
, O
which O
can O
help O
natural O
populations O
when O
facing O
fluctuating O
environments O

We O
will O
focus O
on O
the O
use O
of O
MS O
in O
the O
discovery O
and O
mapping O
of O
histone O
modifications O
and O
how O
novel O
proteomic O
approaches O
are O
being O
utilized O
to O
identify O
and O
study O
chromatin-associated O
proteins O
and O
multi-subunit O
complexes O

332 O
: O
The O
escalating O
threat O
of O
heavy O
metal O
and O
metalloid O
stress O
on O
plant O
ecosystems O
requires O
innovative O
strategies O
to O
strengthen O
plant O
resilience O
and O
ensure O
agricultural O
sustainability O

This O
is O
a O
very O
promising O
and O
sustainable O
resolution O
to O
the O
obesity B-Disease
pandemic O

Lastly O
, O
as O
proof-of-concept O
, O
we O
apply O
DXM O
to O
a O
cohort O
of O
31 O
DLBCLs O
and O
relate O
allelic O
subpopulation O
methylation O
profiles O
to O
relapse O

Epigenetic O
clocks O
based O
on O
DNA O
methylation O
(DNAm) O
at O
specific O
CpG O
sites O
show O
a O
strong O
correlation O
with O
chronological O
age O
in O
humans O
, O
and O
discrepancies O
between O
inferred O
and O
actual O
chronological O
age O
predict O
morbidity O
and O
mortality O

The O
organizing O
committee O
, O
led O
by O
Jim O
Davie O
( O
Chair O
) O
at O
the O
University O
of O
Manitoba O
( O
Manitoba O
, O
Canada O
) O
, O
consisted O
of O
several O
established O
researchers O
in O
the O
fields O
of O
chromatin O
and O
epigenetics O
from O
across O
Canada O

The O
epigenome O
includes O
DNA O
methylation O
, O
histone O
modifications O
, O
and O
RNA-mediated O
processes O
, O
and O
disruption O
of O
this O
balance O
may O
cause O
several O
pathologies O
and O
contribute O
to O
obesity B-Disease
and O
type B-Disease
2 I-Disease
diabetes I-Disease
( O
T2D O
) O

New O
tools O
furnished O
by O
advances O
in O
basic O
science O
and O
translational O
medicine O
could O
help O
achieve O
this O
goal O

The O
role O
of O
tumor B-Disease
suppressors O
and O
oncogenes O
is O
well O
known O
in O
tumorigenesis B-Disease

Dysregulation O
the O
stage O
of O
formation O
of O
the O
preosteoclast O
from O
late O
monocyte O
was O
noted O
in O
rheumatoid B-Disease
arthritis I-Disease
and O
fracture O
, O
whereas O
dysregulation O
at O
stage O
of O
formation O
of O
late O
monocyte O
from O
early O
monocyte O
was O
noted O
in O
osteopetrosis O
and O
spondyloarthritis O

ChIP-S3EQ O
performance O
was O
comparable O
to O
ChIP-seq O
, O
while O
RNA-S3EQ O
generated O
an O
almost O
identical O
expression O
profile O
to O
nuclear-enriched O
and O
whole O
cell O
RNA-seq O

These O
alterations O
support O
the O
transcriptional O
program O
crucial O
for O
the O
acquisition O
and O
maintenance O
of O
cancer B-Disease
hallmarks O

More O
recently O
, O
expression O
and O
epigenetic O
studies O
in O
IBD O
are O
increasingly O
being O
reported O
, O
and O
have O
shown O
that O
many O
effects O
seem O
to O
be O
highly O
cell-type O
specific O

He O
then O
worked O
for O
2 O
years O
at O
the O
National O
Heart O
and O
Lung O
Institute O
of O
the O
NIH O

Accurate O
quantification O
of O
these O
marks O
is O
an O
ongoing O
challenge O
due O
to O
the O
variety O
of O
modifications O
and O
their O
wide O
dynamic O
range O
of O
abundance O

Technological O
advances O
in O
the O
study O
of O
chromosome O
conformation O
mean O
a O
new O
class O
of O
biomarker-the O
chromosome O
conformation O
signature O
(CCS)-can O
identify O
chromosomal O
interactions O
across O
several O
genomic O
loci O
as O
a O
collective O
marker O
of O
an O
epigenomic O
state O

Contact O
: O
lpinello@mgh O

001 O
) O
, O
which O
suggested O
an O
impending O
role O
of O
minimally O
invasive O
liquid-biopsy O
approach O
in O
the O
diagnosis O
and/or O
therapeutic O
monitoring O
of O
pediatric O
leukemia B-Disease

493 O
: O
DNA O
methylation O
is O
a O
stable O
and O
heritable O
epigenetic O
modification O
in O
the O
mammalian O
genome O
and O
is O
involved O
in O
regulating O
gene O
expression O
to O
control O
cellular O
functions O

36 O
: O
Inheritance O
of O
genomic O
DNA O
underlies O
the O
vast O
majority O
of O
biological O
inheritance O
, O
yet O
it O
has O
been O
clear O
for O
decades O
that O
additional O
epigenetic O
information O
can O
be O
passed O
on O
to O
future O
generations O

83 O
: O
With O
the O
development O
of O
genomic O
, O
transcriptomic O
and O
bioinformatic O
tools O
, O
recent O
advances O
in O
molecular O
technologies O
have O
significantly O
impacted O
bovine O
bioscience O
research O
and O
are O
revolutionising O
animal O
selection O
and O
breeding O

These O
clocks O
use O
non-sequential O
variable O
information O
from O
the O
genome O
and O
employ O
mathematical O
algorithms O
to O
estimate O
biological O
age O
based O
on O
DNA O
methylation O
levels O

62 O
between O
actual O
and O
predicted O
age O
across O
datasets O
( O
vs O

367 O
: O
Interactions O
of O
drugs O
with O
the O
classical O
epigenetic O
mechanism O
of O
DNA O
methylation O
or O
histone O
modification O
are O
increasingly O
being O
elucidated O
mechanistically O
and O
used O
to O
develop O
novel O
classes O
of O
epigenetic O
therapeutics O

Sections O
of O
our O
DNA O
are O
constantly O
being O
turned O
on O
or O
off O
, O
marked O
for O
easy O
access O
, O
or O
secluded O
and O
hidden O
away O
, O
all O
in O
response O
to O
ongoing O
cellular O
activity O

448 O
: O
Type O
2 O
diabetes B-Disease
( O
T2D O
) O
is O
caused O
by O
an O
inherited O
predisposition O
to O
pancreatic O
islet O
β-cell O
failure O
, O
which O
is O
manifested O
under O
cellular O
stress O
induced O
by O
metabolic O
overload O

At O
present O
, O
there O
is O
preliminary O
evidence O
to O
support O
the O
possibility O
of O
epigenetic O
mediation O
: O
environmental O
factors O
are O
reported O
to O
influence O
offspring O
DNAm O
, O
which O
in O
turn O
associate O
with O
child O
and O
adolescent O
psychopathology O

We O
will O
focus O
mainly O
on O
DNA O
methylation O
and O
post-translational O
histone O
modifications O
as O
the O
key O
regulatory O
epigenetic O
signaling O
marks O

With O
the O
discovery O
and O
development O
of O
the O
orthologous O
CRISPR-Cas O
systems O
, O
their O
genome O
editing O
efficiency O
have O
improved O

Reversible O
nature O
of O
the O
epigenetic O
changes O
gives O
a O
unique O
opportunity O
to O
halt O
or O
even O
reverse O
the O
disease B-Disease
process O
through O
targeted O
therapeutic O
strategies O

This O
technology O
can O
be O
utilized O
in O
a O
reversible O
manner O
; O
i O

001 O
) O
higher O
average O
in O
GrimAge O
acceleration O
( O
GAA O
) O
using O
generalized O
estimating O
equations O
, O
respectively O

Epigenetic O
therapies O
include O
epi-drugs O
, O
combinatorial O
therapy O
, O
nanocarriers O
, O
plant-derived O
products O
that O
are O
being O
used O
for O
changing O
the O
epigenetic O
pattern O
to O
reverse O
gene O
expression O

Here O
, O
we O
discuss O
some O
recent O
advances O
in O
the O
regulation O
of O
trained O
immunity O
, O
with O
a O
particular O
focus O
on O
the O
mechanistic O
role O
of O
a O
novel O
class O
of O
long O
non-coding O
RNAs O
in O
the O
establishment O
of O
epigenetic O
marks O
on O
trained O
immune O
gene O
promoters O

Indeed O
, O
several O
types O
of O
RNA O
modifications O
that O
impact O
gene O
expression O
have O
been O
reported O
so O
far O
in O
different O
species O
of O
cellular O
RNAs O
, O
including O
ribosomal O
RNAs O
, O
transfer O
RNAs O
, O
small O
nuclear O
RNAs O
, O
messenger O
RNAs O
, O
and O
long O
non-coding O
RNAs O

In O
this O
review O
, O
we O
suggest O
that O
the O
difficulties O
may O
be O
exaggerated O
and O
we O
explore O
how O
cellular O
heterogeneity B-Disease
may O
be O
embraced O
with O
appropriate O
study O
designs O
and O
analytical O
tools O

Cancer B-Disease
stem O
cells O
are O
an O
important O
subpopulation O
of O
tumor B-Disease
cells O
that O
regulate O
tumor B-Disease
plasticity O
and O
determine O
therapeutic O
resistance O

For O
the O
research O
community O
to O
parse O
the O
scientifically O
and O
clinically O
meaningful O
information O
out O
of O
all O
the O
biological O
data O
being O
generated O
each O
day O
more O
efficiently O
with O
less O
wasted O
resources O
, O
being O
familiar O
with O
and O
comfortable O
using O
advanced O
analytical O
tools O
, O
such O
as O
Google O
Cloud O
Platform O
becomes O
imperative O

In O
the O
present O
study O
, O
we O
investigated O
the O
impact O
of O
the O
Sandwich O
Model O
combined O
with O
PRS O
in O
student O
learning O
, O
engagement O
and O
satisfaction O
by O
a O
randomised O
trial O
in O
a O
large O
undergraduate O
biomedical/medical O
sciences O
class O


In O
this O
review O
, O
we O
summarize O
the O
emerging O
insights O
on O
lncRNA O
expression O
and O
functional O
role O
in O
cancer B-Disease
, O
focusing O
on O
the O
evolutionary O
conserved O
and O
abundantly O
expressed O
metastasis-associated O
lung B-Disease
adenocarcinoma I-Disease
transcript I-Disease
1 I-Disease
( O
MALAT1 O
) O
that O
currently O
represents O
the O
best O
characterized O
lncRNA O

Here O
, O
we O
present O
the O
database O
for O
histone-modifying O
enzymes O
( O
dbHiMo O
; O
http://hme O

We O
conclude O
that O
the O
widely-used O
constrained O
projection O
technique O
may O
not O
always O
be O
optimal O

MeDeCom O
is O
based O
on O
constrained O
non-negative O
matrix O
factorization O
with O
a O
new O
biologically O
motivated O
regularization O
function O

In O
this O
review O
, O
we O
summarize O
the O
proposed O
mediation O
analysis O
methods O
with O
applications O
to O
epigenomic O
data O

Exploiting O
functional O
annotation O
of O
RRBS O
loci O
739 O
IV O

391 O
: O
Background O
: O
Epigenetic O
aging O
is O
associated O
with O
a O
plethora O
of O
negative O
health O
outcomes O
and O
increased O
mortality O

The O
purpose O
of O
this O
article O
is O
to O
introduce O
basic O
concepts O
in O
epigenetics O
and O
their O
recent O
applications O
to O
the O
study O
of O
osteoarthritis O
development O
and O
progression O

Phenotypic O
variation O
in O
regenerated O
plants O
can O
be O
largely O
explained O
by O
the O
inheritance O
of O
tissue-specific O
DNA O
methylation O
imprints O
, O
which O
are O
associated O
with O
specific O
transcriptional O
and O
metabolic O
changes O
in O
sexual O
progeny O
of O
clonal O
plants O

Here O
, O
we O
bring O
the O
increasing O
evidence O
that O
environmental O
exposures O
early O
in O
development O
are O
linked O
to O
diabetes B-Disease
through O
epigenetic O
modifications O

Further O
, O
we O
provided O
evidence O
of O
a O
significant O
epigenetic O
etiology O
in O
isolated O
CoA O
development O

Four O
important O
contemporary O
meanings O
are O
outlined O
in O
this O
paper O

In O
- O
depth O
understanding O
of O
epigenetic O
landscapes O
can O
help O
to O
improve O
protocols O
for O
in O
vitro O
differentiation O
towards O
the O
β-cell O
fate O
, O
enhance O
β-cell O
proliferation O
, O
and O
lead O
to O
the O
discovery O
of O
novel O
therapeutic O
targets O

This O
strategy O
represents O
an O
innovative O
, O
groundbreaking O
approach O
, O
improving O
the O
conservation O
and O
management O
of O
natural O
resources O
in O
the O
oceans O

Biological O
age O
was O
estimated O
using O
two O
measures O
of O
DNA O
methylation-based O
age O
acceleration-i O

However O
, O
there O
are O
changes O
that O
occur O
within O
the O
HSC O
pool O
during O
aging O

Williams O
suggests O
that O
multiple O
, O
redundant O
clocks O
might O
influence O
organismal O
aging O

In O
addition O
, O
the O
dysregulation O
of O
epigenetic O
mechanisms O
commonly O
observed O
in O
cancer B-Disease
may O
alter O
the O
immunogenicity O
of O
tumor B-Disease
cells O
and O
effectiveness O
of O
immunotherapies O

Indeed O
, O
important O
changes O
are O
observed O
on O
the O
DNA O
, O
as O
well O
as O
at O
a O
protein O
level O
, O
that O
are O
influenced O
by O
both O
genetic O
and O
environmental O
parameters O

Pharmacological O
and O
genetic O
manipulation O
of O
epigenetic O
factors O
can O
, O
in O
turn O
, O
induce O
remarkable O
changes O
in O
neural O
cell O
identity O
and O
cognitive O
and O
behavioral O
phenotypes O

30 O
: O
Psychosocial O
stress O
- O
especially O
when O
chronic O
, O
excessive O
, O
or O
occurring O
early O
in O
life O
- O
has O
been O
associated O
with O
accelerated O
aging O
and O
increased O
disease B-Disease
risk O

Additionally O
, O
environmental O
factors O
like O
nutrition O
or O
maternal O
behavior O
in O
early O
childhood O
are O
able O
to O
induce O
epigenetic O
changes O

Next O
, O
we O
detail O
research O
findings O
from O
the O
rapidly O
progressing O
field O
of O
epigenetics O
and O
epigenomics O
, O
highlighting O
ways O
in O
which O
our O
emerging O
understanding O
in O
these O
areas O
could O
guide O
future O
intervention O
and O
research O
efforts O
in O
public O
health O

We O
conclude O
that O
EE O
is O
not O
always O
ethically O
preferable O
to O
GE O
in O
terms O
of O
risks O
, O
and O
end O
with O
suggestions O
for O
next O
steps O
in O
the O
current O
ethical O
debate O
on O
EE O
by O
briefly O
introducing O
ethical O
challenges O
of O
new O
areas O
of O
preventive O
applications O
of O
EE O
( O

Although O
epi-drugs O
have O
convincing O
anti-tumor O
effects O
, O
the O
patient O
's O
sensitivity O
to O
epi-drug O
application O
is O
also O
a O
fundamental O
clinical O
issue O

630 O
: O
A O
critical O
hallmark O
of O
aging O
is O
cellular O
senescence B-Disease
, O
a O
state O
of O
growth O
arrest O
and O
inflammatory O
cytokine O
release O
in O
cells O
, O
caused O
by O
a O
variety O
of O
stresses O

While O
the O
pathogenesis O
of O
IgE-mediated O
food B-Disease
allergy I-Disease
is O
quite O
straightforward O
, O
the O
factors O
that O
lead O
to O
the O
development O
of O
food B-Disease
allergies I-Disease
at O
any O
age O
in O
children O
and O
adults O
are O
unclear O

A O
comprehensive O
understanding O
of O
the O
pertinent O
changes O
in O
the O
epigenetic O
makeup O
of O
suicide O
phenotype O
exhibits O
a O
characteristic O
signature O
with O
the O
possibility O
of O
using O
it O
as O
a O
biomarker O
to O
help O
predict O
the O
risk O
factors O
associated O
with O
suicide O

718 O
: O
Cell-free O
DNA O
( O
cfDNA O
) O
analysis O
has O
become O
essential O
in O
cancer B-Disease
diagnostics O
and O
prenatal O
testing O

These O
facts O
, O
combined O
with O
high O
yields O
of O
virus B-Disease
and O
minichromosomes O
following O
infection B-Disease
and O
ease O
of O
manipulation O
, O
have O
made O
SV40 O
an O
extremely O
useful O
model O
to O
study O
all O
aspects O
of O
eukaryotic O
molecular O
biology O

290 O
: O
The O
" O
CpG O
Island O
Methylator O
Phenotype O
" O
( O
CIMP O
) O
has O
been O
found O
to O
be O
a O
useful O
concept O
in O
stratifying O
several O
types O
of O
human O
cancer B-Disease
into O
molecularly O
and O
clinically O
distinguishable O
subgroups O

This O
is O
an O
access O
pattern O
needed O
to O
create O
training O
batches O
for O
typical O
machine O
learning O
models O
on O
epigenetics O
data O

Additionally O
, O
inclusion O
of O
these O
marks O
as O
biomarkers O
in O
the O
early O
detection O
or O
progression O
monitoring O
of O
disease B-Disease
is O
providing O
novel O
avenues O
for O
future O
biomedical O
research O

The O
ascertainment O
and O
use O
of O
these O
marks O
to O
identify O
at-risk O
patient O
populations O
, O
refine O
diagnostic O
criteria O
, O
and O
provide O
prognostic O
and O
predictive O
factors O
to O
guide O
treatment O
decisions O
are O
of O
growing O
clinical O
relevance O

In O
this O
chapter O
, O
studies O
of O
epigenetic O
abnormality O
and O
its O
clinical O
implication O
in O
lung O
cancers B-Disease
are O
discussed O

In O
light O
of O
these O
breakthroughs O
, O
now O
is O
a O
particularly O
opportune O
time O
to O
develop O
a O
framework O
that O
will O
guide O
and O
facilitate O
exceptional O
studies O
in O
Ecological O
Epigenetics O

Epigenetic O
processes O
are O
such O
as O
histone O
methylation O
, O
acetylation O
, O
ubiquitination O
, O
sumoylation O
, O
phosphorylation O
, O
ADP O
ribosylation O
, O
DNA O
methylation O
and O
non-coding O
RNAs O
interactions O
associated O
with O
structural O
changes O
in O
chromatin O

This O
enables O
us O
to O
identify O
the O
mutual O
constitution O
of O
'prototypes' O
(i O

Most O
DMCs O
clustered O
in O
CpG O
stretches O
nearby O
genes O
involved O
in O
cellular O
and O
anatomical O
structure O
morphogenesis O

In O
particular O
, O
we O
focus O
on O
three O
key O
computational O
topics O
: O
predicting O
enhancer O
locations O
, O
determining O
the O
cell-type-specific O
activity O
of O
enhancers O
, O
and O
linking O
enhancers O
to O
their O
target O
genes O

However O
, O
the O
analysis O
of O
these O
complex O
omic O
data O
requires O
to O
face O
important O
analytic O
issues O

The O
idea O
that O
epigenetic O
mechanisms O
mediate O
the O
life-long O
effects O
of O
perinatal O
adversity O
has O
attractive O
potential O
implications O
for O
early O
detection O
, O
prevention O
, O
and O
intervention O
in O
mental O
health O
disorders O
will O
be O
discussed O

As O
society O
progresses O
in O
understanding O
the O
epigenetic O
mechanisms O
of O
substance O
use O
and O
addiction O
, O
there O
is O
an O
opportunity O
to O
use O
these O
use O
this O
knowledge O
to O
enable O
medical O
, O
behavioral O
, O
and O
environmental O
interventions O
to O
alleviate O
the O
burden O
of O
addiction O

Predictive O
genetic O
testing O
will O
not O
be O
for O
the O
immediate O
future O
for O
the O
majority O
of O
IBD O
patients O

Cancers O
are O
composed O
of O
numerous O
cell O
types O
and O
evolve O
over O
time O

Major O
conclusions O
: O
Due O
to O
conservation O
of O
chromatin-modifying O
mechanisms O
, O
mammals O
and O
plants O
share O
a O
common O
dependence O
on O
metabolic O
intermediates O
that O
serve O
as O
cofactors O
for O
chromatin B-Disease
modifications I-Disease

A O
key O
property O
of O
epigenetic O
marks O
is O
that O
they O
can O
be O
inherited O
along O
mitotic O
cell O
lineages O
, O
and O
epigenetic O
differences O
that O
occur O
during O
early O
development O
can O
have O
lasting O
consequences O
on O
the O
organismal O
phenotypes O

Here O
we O
consider O
how O
gene O
expression O
in O
neurons O
is O
regulated O
by O
specific O
patterns O
of O
action O
potential O
firing O
, O
with O
an O
emphasis O
on O
new O
information O
on O
epigenetic O
regulation O
of O
gene O
expression O

212 O
: O
Recent O
years O
have O
seen O
a O
surge O
of O
methylome-wide O
association O
studies O
( O
MWAS O
) O

105 O
: O
The O
complexity O
of O
male O
reproductive O
impairment O
has O
hampered O
characterization O
of O
the O
underlying O
genetic O
causes O
of O
male O
infertility O

He O
was O
honored O
in O
2006 O
with O
the O
Distinguished O
Achievement O
Award O
from O
the O
College O
of O
Engineering O
at O
the O
University O
of O
Wisconsin-Madison O

Our O
protocol O
provides O
a O
comprehensive O
overview O
of O
flow O
cytometry O
analysis O
following O
transfection O
not O
just O
to O
improve O
transfection O
efficiency O
but O
also O
to O
assess O
the O
expression O
level O
of O
the O
utilized O
construct O

To O
characterize O
enactments O
of O
biosocial O
complexity O
, O
the O
article O
develops O
the O
concepts O
of O
complexity O
work O
and O
complexification O

In O
this O
chapter O
, O
an O
iterative O
VS O
approach O
using O
both O
SBDD O
and O
LBDD O
methods O
, O
which O
was O
successful O
in O
identifying O
Spindlin1 O
inhibitors O
, O
will O
be O
described O

Conclusions O
: O
Quantum O
effects O
in O
DNA O
are O
prone O
to O
triggering O
and O
manipulation O
by O
external O
means O

A O
promising O
frontier O
in O
the O
definition O
of O
glioma O
prognosis O
and O
treatment O
is O
represented O
by O
epigenetics O

The O
first O
submodule O
is O
devoted O
to O
transcriptomics O
analysis O
with O
the O
RNA O
sequencing O
data O
, O
the O
second O
submodule O
focuses O
on O
epigenetics O
analysis O
using O
the O
DNA O
methylation O
data O
, O
and O
the O
third O
submodule O
integrates O
the O
two O
methods O
for O
a O
deeper O
biological O
understanding O

In O
the O
brain O
, O
epigenetic O
processes O
translate O
information O
from O
transient O
cellular O
impulses O
and O
adjustments O
in O
neuronal O
activity O
into O
long-lasting O
impacts O
on O
gene O
expression O

This O
research O
has O
rapidly O
changed O
the O
way O
researchers O
think O
about O
brain O
function O

However O
, O
genetic O
factors O
are O
not O
enough O
to O
explain O
osteoporosis B-Disease
development O
and O
OVF O
occurrence O

Here O
, O
we O
present O
an O
overview O
of O
the O
multifaceted O
roles O
of O
DNA O
methylation O
in O
prokaryotes O
and O
suggest O
research O
directions O
and O
tools O
which O
can O
enable O
us O
to O
better O
understand O
the O
contribution O
of O
DNA O
methylation O
to O
prokaryotic O
genome O
evolution O
and O
adaptation O

Here O
we O
discovered O
that O
treatment O
of O
various O
human O
lung B-Disease
cancer I-Disease
cells O
with O
DAC O
resulted O
in O
activation O
of O
FBW7 O
expression O
, O
decreased O
levels O
of O
Mcl-1 O
protein O
, O
and O
growth O
inhibition O

Elucidating O
its O
pathogenic O
mechanism O
is O
one O
of O
the O
major O
challenges O
that O
we O
face O
currently O

DNA O
methylation O
has O
proven O
to O
be O
of O
significant O
clinical O
utility O
for O
its O
stability O
and O
relative O
ease O
of O
testing O

617 O
: O
To O
fully O
exploit O
the O
potentials O
of O
reprogramming O
the O
epigenome O
through O
CRISPR/dCas9 O
systems O
for O
epigenetic O
editing O
, O
there O
is O
a O
growing O
need O
for O
improved O
transfection O
methods O

In O
this O
study O
, O
we O
use O
pseudotime O
analysis O
to O
determine O
the O
functional O
form O
of O
these O
trajectories O

This O
review O
summarises O
evidence O
pointing O
to O
the O
determinants O
of O
epigenetic O
patterns O
, O
their O
juxtaposition O
at O
the O
interface O
of O
the O
environment O
, O
their O
influence O
on O
gene O
function O
and O
the O
relevance O
of O
this O
information O
to O
child O
health O

Thus O
, O
chromatin O
structure O
has O
become O
a O
principal O
focus O
in O
recent O
genomics O
researches O
that O
strive O
to O
characterize O
regulatory O
functions O
of O
DNA O
variants O
related O
to O
diseases O
or O
other O
traits O

It O
is O
imperative O
that O
promising O
candidates O
are O
validated O
using O
these O
resources O
, O
and O
in O
subsequent O
prospective O
clinical O
trials O
, O
so O
that O
future O
biomarkers O
may O
be O
used O
in O
the O
clinic O
to O
personalize O
patient O
care O

In O
contrast O
to O
population-averaged O
analyses O
, O
single-molecule O
approaches O
potentially O
allow O
the O
mapping O
of O
epigenetic O
linkage O
between O
distantly O
located O
genomic O
regions O
, O
the O
locus-specific O
analysis O
of O
repetitive O
DNA O
elements O
, O
as O
well O
as O
determination O
of O
allele-specific O
DNA O
modification O
patterns O

A O
novel O
paradigm O
is O
emerging O
, O
that O
exposure O
to O
so O
- O
called O
' O
inert O
' O
particulates O
that O
are O
considered O
innocuous O
is O
not O
really O
free O
of O
consequences O

, O
maternal O
depression B-Disease
and O
stress O
) O
and O
post-natal O
( O
e O

Recent O
preclinical O
and O
clinical O
studies O
show O
a O
therapeutic O
benefit O
of O
epigenetically O
active O
drugs O
for O
breast B-Disease
cancer I-Disease
entities O
that O
are O
still O
difficult O
to O
treat O
(triple O
negative O
, O
UICC O
stage O
IV O
) O

We O
found O
that O
a O
multi-layer O
perceptron O
network O
fed O
by O
the O
338 O
probes O
selected O
by O
applying O
both O
expert O
choice O
and O
Boruta O
results O
in O
the O
best O
performance O
, O
achieving O
an O
out-of-sample O
accuracy O
of O
82 O

Implementing O
clustered O
regularly O
interspaced O
short O
palindromic O
repeat-dCas9 O
greatly O
accelerated O
the O
advancement O
of O
epigenetic O
editing O
, O
yielding O
preclinical O
therapeutic O
successes O
using O
a O
variety O
of O
epigenetic O
enzymes O

273 O
: O
Over O
the O
past O
two O
decades O
, O
advances O
in O
genetic O
technologies O
have O
posed O
unexpected O
challenges O
to O
the O
ethical O
and O
legal O
framework O
guiding O
the O
application O
of O
the O
most O
recent O
advances O
in O
healthcare O
technologies O

calibration O
of O
sample-specific O
peak O
calling O
parameters O
by O
leveraging O
manual O
annotation O

Future O
work O
will O
reveal O
if O
the O
approach O
of O
epigenome O
editing O
fulfills O
its O
great O
promise O
in O
basic O
research O
and O
clinical O
applications O

scMET O
is O
a O
hierarchical O
Bayesian O
model O
which O
overcomes O
sparsity O
, O
sharing O
information O
across O
cells O
and O
genomic O
features O
to O
robustly O
quantify O
genuine O
biological O
heterogeneity B-Disease

DNA O
modification O
, O
mediated O
by O
restriction-modification O
systems O
, O
functions O
as O
an O
immune O
response O
against O
antagonistic O
external O
DNA O
, O
and O
bacteriophage-acquired O
methyltransferases O
( O
MTase O
) O
and O
orphan O
MTases O
- O
those O
lacking O
the O
cognate O
restriction O
endonuclease O
- O
facilitate O
evolution O
of O
new O
phenotypes O
via O
gene O

However O
, O
the O
degree O
of O
phenotypic O
variability O
that O
is O
explained O
by O
epigenetic O
processes O
still O
remains O
unclear O

This O
renewed O
interest O
has O
been O
concomitant O
with O
methodological O
progress O
enabling O
, O
for O
example O
, O
high O
coverage O
and O
single O
base O
resolution O
profiling O
of O
the O
mammalian O
methylome O
in O
small O
numbers O
of O
cells O

142 O
: O
Denis O
Noble O
discusses O
Conrad O
Waddington O
's O
classic O
paper O
, O
" O
The O
genetic O
assimilation O
of O
the O
bithorax O
phenotype O
" O
, O
published O
in O
Evolution O
in O
1956 O

Finally O
, O
we O
show O
that O
several O
factors O
moderate O
the O
relationship O
between O
epigenetic O
ages O
and O
real O
ages O
, O
such O
as O
body O
weight O
, O
which O
increases O
epigenetic O
ageing O

We O
provide O
an O
overview O
of O
the O
current O
state O
of O
the O
field O
and O
vision O
for O
deriving O
the O
epigenomics O
of O
autoimmunity O

Such O
mechanisms O
have O
until O
recently O
been O
scarcely O
studied O
in O
invertebrate O
organisms O
, O
mainly O
focusing O
on O
model O
species O
including O
Caenorhabditis O
elegans O
and O
Daphnia O
magna O

689 O
: O
Conrad O
Waddington O
's O
eponymous O
1957 O
diagram O
provided O
a O
metaphorical O
framework O
for O
considering O
how O
sequential O
developmental O
fate O
decisions O
allow O
an O
egg O
to O
develop O
into O
an O
embryo O

His O
research O
focus O
is O
the O
genetics O
and O
epigenetics O
of O
complex O
autoimmune O
and O
inflammatory O
diseases O
, O
including O
lupus B-Disease
and O
systemic O
vasculitis O

557 O
: O
Spectacular O
advances O
in O
the O
throughput O
of O
DNA O
sequencing O
have O
allowed O
genome-wide O
analysis O
of O
epigenetic O
features O
such O
as O
methylation O
, O
nucleosome O
position O
and O
post-translational O
modification O
, O
chromatin O
accessibility O
and O
connectivity O
, O
and O
transcription O
factor O
binding O

441 O
: O
Completion O
of O
the O
human O
genome O
a O
decade O
ago O
laid O
the O
foundation O
for O
: O
using O
genetic O
information O
in O
assessing O
risk O
to O
identify O
individuals O
and O
populations O
that O
are O
likely O
to O
develop O
cancer B-Disease
, O
and O
designing O
treatments O
based O
on O
a O
person O
's O
genetic O
profiling O
( O
precision O
medicine O

The O
reversible O
nature O
of O
epigenetic O
modifications O
holds O
promise O
for O
future O
therapeutic O
strategies O
in O
obesity B-Disease
and O
T2D O

As O
researchers O
more O
precisely O
define O
the O
epigenetic O
landscape O
that O
regulates O
disease B-Disease
progression O
in O
each O
of O
these O
cases O
, O
therapeutics O
can O
be O
designed O
to O
specifically O
target O
the O
molecules O
that O
mediate O
these O
epigenetic O
processes O

com O
/ O
cozygene O
/ O
glint O
/ O
releases O

This O
review O
brings O
the O
essential O
knowledge O
on O
cardiac O
biology O
of O
development O

Given O
the O
increase O
in O
use O
and O
legalization O
, O
these O
findings O
provide O
novel O
insight O
on O
the O
effect O
of O
marijuana O
use O
on O
the O
aging O
process O
as O
captured O
through O
blood O
DNA O
methylation O

These O
online O
tools O
generate O
interactive O
graphical O
outputs O
of O
relevant O
chromosomal O
regions O
, O
showing O
genes O
, O
transcripts O
, O
and O
other O
genomic O
landmarks O
, O
and O
epigenetic O
features O
mapped O
by O
projects O
such O
as O
ENCODE O

Here O
we O
review O
recent O
literature O
in O
this O
area O
, O
and O
discuss O
some O
important O
issues O
raised O
by O
these O
innovative O
analyses O

However O
, O
the O
peculiar O
nature O
of O
early O
embryos O
in O
addition O
to O
their O
scarcity O
poses O
numerous O
technological O
challenges O
that O
are O
slowly O
being O
overcome O

We O
discuss O
critical O
components O
of O
single-cell O
DNA O
methylome O
data O
analysis O
, O
including O
data O
preprocessing O
, O
quality O
control O
, O
imputation O
, O
dimensionality O
reduction O
, O
cell O
clustering O
, O
supervised O
cell O
annotation O
, O
cell O
lineage O
reconstruction O
, O
gene O
activity O
scoring O
, O
and O
integration O
with O
transcriptome O
data O

Recent O
findings O
: O
GWAS O
and O
meta-analyses O
have O
identified O
163 O
loci O
associated O
with O
IBD O
, O
and O
have O
implicated O
key O
pathways O
in O
IBD O
pathogenesis O

However O
, O
at O
the O
current O
time O
, O
their O
impact O
on O
overall O
expense O
for O
CHD O
care O
is O
poorly O
understood O

A O
comprehensive O
study O
of O
plant O
populations O
to O
correlate O
genotype O
to O
epigenotype O
and O
to O
phenotype O
, O
and O
also O
the O
study O
of O
methyl O
quantitative O
trait O
loci O
( O
QTL O
) O
or O
epiGWAS O
, O
is O
possible O
by O
using O
high-throughput O
sequencing O
methods O
, O
which O
will O
further O
accelerate O
molecular O
bre O

357 O
: O
The O
55th O
Annual O
Canadian O
Society O
for O
Molecular O
Biosciences O
Conference O
on O
Epigenetics O
and O
Genomic O
Stability O
in O
Whistler O
, O
Canada O
, O
14-18 O
March O
2012 O
, O
brought O
together O
31 O
speakers O
from O
different O
nationalities O

Multiple O
molecular O
epigenetic O
mechanisms O
exist O
, O
but O
methylation O
of O
DNA O
so O
far O
has O
dominated O
the O
Ecological O
Epigenetic O
literature O

However O
, O
this O
was O
not O
completely O
the O
case O

This O
game O
was O
designed O
to O
explore O
the O
evolution O
of O
ecological O
communities O

Histone O
modification O
alters O
the O
level O
of O
gene O
expression O
by O
regulating O
the O
acetylation O
status O
of O
lysine O
residues O
on O
the O
promoter O
surrounding O
histones O
, O
often O
leading O
to O
the O
silencing O
of O
tumour B-Disease
suppressor O
genes O
or O
the O
overexpression O
of O
proto-oncogenes O
in O
lymphoma B-Disease

We O
specifically O
discuss O
the O
potential O
modulatory O
effect O
of O
several O
genetic O
polymorphisms O
associated O
with O
an O
increased O
risk O
of O
developing O
different O
neurodegenerative B-Disease
diseases I-Disease

217 O
: O
Autoimmune B-Disease
diseases I-Disease
are O
complex O
disorders O
of O
largely O
unknown O
etiology O

DNA O
methylation O
refers O
to O
CpG O
islands O
, O
generally O
leading O
to O
tumour B-Disease
suppressor O
gene O
transcriptional O
silencing O

Furthermore O
, O
in O
this O
study O
, O
we O
developed O
a O
machine O
learning O
classification O
model O
based O
on O
epigenetic O
data O
( O
CpG O
probes O
) O
to O
separate O
patients O
according O
to O
their O
state O
of O
immunosuppression O

Therefore O
, O
the O
KLOTHO O
recovery O
is O
critical O
for O
the O
antiaging O
effects O
of O
DNA O
demethylation O

Current O
therapeutic O
strategies O
for O
AF O
involving O
ablation O
and O
antiarrhythmic O
drugs O
are O
associated O
with O
relatively O
high O
recurrence O
and O
proarrhythmic O
side O
effects O
, O
respectively O

549 O
: O
Epigenetics O
acts O
as O
an O
interface O
between O
environmental/exogenous O
factors O
, O
cellular O
responses O
, O
and O
pathological O
processes O

RRBS O
loci O
as O
genome-wide O
epigenetic O
markers O
739 O
III O

Using O
histone O
marks O
, O
we O
also O
demonstrate O
how O
ViCAR O
improves O
on O
earlier O
approaches O
yielding O
increased O
signal-to-noise O

First O
-in O
-class O
compounds O
have O
successfully O
transitioned O
to O
clinical O
investigation O
, O
importantly O
also O
in O
solid O
tumors B-Disease
and O
pediatric O
malignancies B-Disease

By O
contrast O
, O
epigenetic O
aberrations O
are O
commonly O
found O
in O
RCC O
, O
indicating O
that O
epigenetic O
reprogramming O
is O
an O
important O
event O
in O
RCC O
development O

676 O
: O
Epigenetic O
studies O
increasingly O
require O
analysis O
of O
a O
small O
number O
of O
cells O
that O
are O
of O
one O
specific O
type O
and O
derived O
from O
patients O
or O
animals O

Although O
recent O
methods O
address O
this O
problem O
with O
varying O
degrees O
of O
success O
, O
they O
are O
constrained O
by O
their O
scopes O
or O
limitations O

Waddington O
in O
the O
context O
of O
studies O
on O
development O

The O
entire O
workflow O
including O
cell O
pretreatment O
, O
antibody O
recognition O
, O
pA-Tn5 O
tagmentation O
, O
fragment O
enrichment O
, O
and O
PCR O
amplification O
is O
programmatically O
manipulated O
on O
a O
single O
chip O

564 O
: O
Recent O
studies O
have O
identified O
both O
heritable O
DNA O
methylation O
effects O
and O
differential O
methylation O
in O
disease-discordant O
identical O
twins O

These O
alterations O
were O
associated O
with O
either O
increased O
or O
decreased O
risk O
for O
cancer B-Disease
development O

Here O
we O
detail O
nano-MeDIP-seq O
, O
which O
allows O
methylome O
analysis O
using O
nanogram O
quantities O
of O
starting O
material O

9 O
: O
Psychiatric B-Disease
disorders I-Disease
affect O
millions O
of O
individuals O
and O
their O
families O
worldwide O
, O
and O
the O
costs O
to O
society O
are O
substantial O
and O
are O
expected O
to O
rise O
due O
to O
a O
lack O
of O
effective O
treatments O

A O
number O
of O
studies O
have O
performed O
molecular O
characterization O
of O
these O
different O
microglial O
activation O
states O
over O
the O
last O
years O
making O
use O
of O
"omics" O
technologies O
, O
that O
is O
transcriptomics O
, O
proteomics O
and O
, O
less O
frequently O
, O
epigenomics O
profiling O

In O
this O
review O
, O
we O
propose O
that O
planarians O
represent O
a O
unique O
and O
effective O
system O
to O
study O
the O
epigenetic O
regulation O
of O
these O
processes O
in O
an O
in O
vivo O
context O

61 O
: O
176 O
- O
192 O
, O
2020 O

As O
a O
key O
risk O
factor O
of O
gastric O
cancer B-Disease
, O
H O

We O
caught O
up O
with O
Aydan O
over O
Zoom O
to O
hear O
more O
about O
her O
path O
from O
chemical O
engineering O
to O
molecular O
genetics O
, O
her O
research O
and O
what O
it O
means O
to O
be O
awarded O
these O
prizes O

128 O
: O
The O
term O
epigenetics O
was O
coined O
in O
1942 O
by O
C O

To O
fully O
grasp O
the O
function O
of O
disease-associated O
genetic O
variants O
, O
identifying O
causal O
genes O
and O
translating O
this O
knowledge O
into O
predictive O
biomarkers O
and O
new O
treatments O
, O
we O
should O
now O
integrate O
all O
these O
disciplines O

The O
former O
emphasizes O
the O
social O
, O
technical O
, O
and O
material O
work O
that O
goes O
into O
the O
production O
of O
mixed O
biological O
and O
social O
representations O
of O
stress O
in O
epigenetics O

These O
findings O
suggest O
that O
JMnorm O
effectively O
minimizes O
technical O
noise O
while O
preserving O
true O
biologically O
significant O
relationships O
between O
epigenetic O
datasets O

These O
studies O
provide O
a O
new O
insight O
into O
action O
mechanism O
by O
which O
natural O
compound O
exerts O
its O
bioactivity O
and O
a O
novel O
treatment O
strategy O
, O
demonstrating O
natural O
compound O
a O
promising O
remedy O
for O
clinical O
treatments O

This O
makes O
5hmC O
a O
potential O
contributor O
to O
epigenetically O
mediated O
responses O
to O
environmental O
factors O

This O
themed O
issue O
brings O
together O
a O
diverse O
collection O
of O
interdisciplinary O
reviews O
and O
research O
articles O
that O
showcase O
the O
tremendous O
recent O
advances O
in O
epigenetic O
chemical O
biology O
and O
translational O
research O
into O
epigenetic O
drug O
discovery O

Epigenome-wide O
association O
study O
(EWAS) O
provide O
a O
systematic O
approach O
to O
uncovering O
epigenetic O
variants O
underlying O
common O
diseases O
/ O
phenotypes O

As O
with O
other O
cell O
types O
and O
populations O
, O
endocrine O
cells O
are O
susceptible O
to O
tumour B-Disease
development O
, O
which O
in O
turn O
may O
have O
resulted O
from O
aberration O
of O
epigenetic O
control O

In O
addition O
, O
we O
highlight O
the O
interaction O
of O
epigenetics O
with O
senescent O
physiology O
and O
environmental O
factors O
in O
regulating O
transcription O

Please O

Population O
studies O
, O
formalmodels O
, O
and O
research O
on O
genomic O
and O
ecological O
stressesall O
suggest O
that O
epigenetic O
inheritance O
is O
important O
in O
both O
micro-and O
macroevolutionary O
change O

ChIP O
followed O
by O
microarray O
or O
next-generation O
sequencing O
enables O
the O
precise O
genomic O
localization O
of O
protein-DNA O
interactions O

Despite O
substantial O
progress O
in O
the O
identification O
of O
novel O
CMP-associated O
genetic O
variations O
, O
as O
well O
as O
improved O
clinical O
recognition O
diagnoses O
, O
the O
functional O
consequences O
of O
these O
mutations O
and O
the O
exact O
details O
of O
the O
signaling O
pathways O
leading O
to O
hypertrophy O
, O
dilation O
, O
and/or O
contractile O
imp O

Osmium O
complexation O
is O
then O
achieved O
by O
hybridization O
of O
a O
short O
DNA O
molecule O
containing O
this O
functional O
nucleotide O
to O
a O
target O
DNA O
sequence O
and O
results O
in O
the O
formation O
of O
a O
cross-linked O
structure O

DNA O
methylation O
and O
other O
epigenetic O
marks O
are O
firmly O
entwined O
with O
allergic B-Disease
disease I-Disease
, O
a O
link O
that O
may O
hold O
the O
basis O
for O
future O
allergic B-Disease
disease I-Disease
diagnosis O
and O
treatment O

Techniques O
including O
high-throughput O
sequencing O
and O
array-based O
analysis O
to O
investigate O
these O
changes O
have O
rapidly O
emerged O
and O
are O
continually O
evolving O

Notably O
, O
they O
are O
best O
at O
characterizing O
one O
chromatin O
feature O
at O
a O
time O
, O
yet O
chromatin O
features O
arise O
and O
function O
in O
combination O

These O
findings O
are O
of O
interest O
from O
a O
neurodevelopmental O
perspective O
because O
there O
is O
increasing O
evidence O
that O
epigenetic O
markings O
for O
a O
substantial O
portion O
of O
genes O
and O
loci O
are O
highly O
regulated O
during O
the O
first O
years O
of O
life O

33 O
: O
Purpose O
of O
review O
: O
Autoimmune O
/ O
inflammatory B-Disease
disorders I-Disease
can O
be O
stratified O
along O
a O
spectrum O
based O
on O
the O
primary O
involvement O
of O
innate O
vs O

439 O
: O
Mortality O
and O
morbidity O
from O
cardiovascular B-Disease
diseases I-Disease
( O
CVDs O
) O
represents O
a O
huge O
burden O
to O
society O

Small O
RNA O
sequencing O
of O
sperm O
reveals O
significant O
transcriptional O
differences O
of O
infected O
animals O
compared O
to O
controls O

589 O
: O
Targeted O
modifications O
of O
the O
human O
epigenome O
, O
epigenome O
editing O
( O
EE O
) O
, O
are O
around O
the O
corner O

710 O
: O
Gliomas O
are O
the O
most O
common O
primary O
neoplasm O
of O
the O
central O
nervous B-Disease
system I-Disease

Epigenetics O
is O
related O
to O
various O
biological O
phenomena O

Concerning O
heredity O
, O
both O
narrowly O
epigenetic O
and O
broader O
' O
exogenetic O
' O
systems O
of O
inheritance O
play O
important O
roles O
in O
the O
construction O
of O
phenotypes O

390 O
: O
The O
field O
of O
epigenetics O
is O
now O
on O
a O
geometric O
rise O
, O
driven O
in O
a O
large O
part O
by O
the O
realization O
that O
modifiers O
of O
chromatin O
are O
key O
regulators O
of O
biological O
processes O
in O
vivo O

, O
the O
result O
of O
extra-scientific O
factors O
, O
such O
as O
social O
processes O
and O
the O
self-interest O
of O
the O
discipline O

In O
addition O
, O
most O
of O
these O
alterations O
are O
potentially O
reversible O
, O
so O
they O
also O
provide O
new O
targets O
for O
therapy O

We O
hope O
that O
this O
series O
sparks O
a O
larger O
discussion O
of O
issues O
faced O
by O
underrepresented O
scientists O
and O
ways O
the O
scientific O
community O
can O
foster O
diversity O
and O
better O
support O
underrepresented O
scientists O

Research O
on O
these O
diverse O
forms O
of O
inheritance O
challenges O
the O
notion O
that O
there O
is O
some O
special O
form O
of O
ethical O
concern O
that O
falls O
on O
germline O
interventions O
in O
general O
, O
and O
on O
interventions O
to O
the O
nuclear O
genome O
within O
the O
germline O
in O
particular O

The O
original O
concept O
of O
cancer B-Disease
epigenetics O
basically O
stands O
on O
the O
analysis O
of O
the O
epigenetic O
status O
in O
naturally O
occurring O
cancer B-Disease
cells O
; O
however O
, O
the O
rapidly O
emerging O
technology O
called O
epigenome O
editing O
would O
change O
this O
situation O
drastically O

g O

Lastly O
, O
animal O
models O
of O
neurodegenerative B-Disease
disorders I-Disease
are O
generated O
by O
over-expression O
of O
causal O
genes O
, O
further O
supporting O
the O
conclusion O
that O
increased O
gene O
expression O
is O
related O
to O
pathogenesis O

In O
this O
regard O
, O
there O
is O
extensive O
epidemiologic O
and O
experimental O
data O
showing O
that O
early O
sub-optimal O
nutrition O
can O
have O
health O
consequences O
several O
decades O
later O

``` O
Contact O
: O
nicolas O
``` O

We O
suppose O
that O
epigenetic O
mechanisms O
may O
induce O
higher O
rates O
of O
obesity B-Disease
in O
subjects O
who O
suffer O
from O
mood B-Disease
disorders I-Disease

143 O
: O
Lymphoid O
neoplasms B-Disease
represent O
a O
heterogeneous O
group O
of O
disease B-Disease
entities O
and O
subtypes O
with O
markedly O
different O
molecular O
and O
clinical O
features O

g O

The O
overall O
genesis O
of O
the O
Sandbox O
is O
described O
in O
the O
editorial O
NIGMS O
Sandbox O
[16] O
at O
the O
beginning O
of O
this O
Supplement O

213 O
: O
Epigenetic O
mechanisms O
are O
an O
underappreciated O
and O
often O
ignored O
component O
of O
an O
organism O
's O
response O
to O
environmental O
change O
and O
may O
underlie O
many O
types O
of O
phenotypic O
plasticity O

In O
this O
study O
, O
we O
revisited O
the O
high O
frequency O
longitudinal O
DNA O
methylation O
data O
of O
two O
Japanese O
males O
( O
24 O
time-points O
within O
three O
months O
) O
and O
characterized O
the O
longitudinal O
dynamics O

We O
observed O
that O
the O
relative O
activation O
of O
T O
cells O
and O
other O
immune O
signaling O
pathways O
differs O
across O
cancer B-Disease
types O

Concurrent O
advances O
in O
genome-modulating O
technologies O
, O
like O
gene O
silencing O
and O
genome O
editing O
, O
are O
providing O
ability O
to O
understand O
in O
detail O
the O
process O
of O
cancer B-Disease
initiation O
, O
progression O
, O
and O
signaling O
as O
well O
as O
opening O
up O
avenues O
for O
therapeutic O
targeting O

Epigenetic O
explanations O
were O
invoked O
when O
genetics O
could O
not O
explain O
a O
phenomenon O

We O
also O
use O
published O
data O
from O
redox O
proteomics O
to O
map O
out O
known O
intersections O
between O
oxidative O
stress O
and O
epigenetics O
that O
may O
signpost O
helpful O
directions O
for O
future O
investigation O

In O
this O
paper O
, O
by O
taking O
advantage O
of O
our O
laboratory O
's O
research O
on O
the O
DNA O
methylation O
maintenance O
gene O
, O
OsMET1-2 O
in O
rice O
, O
we O
have O
integrated O
our O
innovative O
findings O
in O
the O
education O
curriculum O
, O
and O
built O
a O
comprehensive O
teaching O
system O
on O
experimentation O
research O
, O
which O

Additionally O
, O
we O
have O
made O
efforts O
to O
enhance O
the O
integration O
between O
the O
Epigenomics O
resource O
and O
other O
NCBI O
databases O
, O
including O
the O
Gene O
database O
and O
PubMed O

Sources O
of O
data O
: O
We O
searched O
multiple O
databases O
to O
produce O
a O
systematic O
review O
on O
the O
role O
of O
epigenetic O
mechanisms O
in O
tendon O
ageing O

Childhood O
trauma B-Disease
is O
defined O
in O
a O
wide O
range O
of O
ways O
in O
several O
societal O
contexts O

Compared O
to O
numerous O
studies O
that O
have O
focused O
on O
the O
field O
of O
genetics O
, O
research O
on O
epigenetics O
is O
fairly O
recent O

New O
classes O
of O
epigenetic O
therapies O
promise O
low O
toxicity O
and O
may O
work O
synergistically O
with O
other O
cancer B-Disease
treatments O
to O
overcome O
drug O
resistance O
mechanisms O

Generally O
less O
investigated O
than O
the O
first O
two O
components O
, O
variation O
lacking O
any O
predictable O
order O
is O
nevertheless O
present O
in O
natural O
populations O
and O
stochastic O
epigenetic O
variation O
, O
also O
referred O
to O
spontaneous O
epimutations O
, O
can O
sustain O
phenotypic O
diversity O

Interference O
in O
any O
of O
these O
interconnected O
mechanisms O
can O
result O
in O
DNA O
breakage O
and O
lead O
to O
the O
activation O
of O
repair O
pathways O

But O
the O
EWAS O
software O
has O
lagged O
behind O
compared O
with O
genome-wide O
association O
study O
( O
GWAS O
) O

harvard O

It O
shows O
that O
our O
current O
understanding O
about O
the O
role O
of O
epigenetics O
in O
regulating O
division O
of O
labor O
in O
social O
insects O
is O
still O
fragmentary O
but O
that O
refined O
methods O
with O
well-replicated O
samples O
and O
targeted O
questions O
offer O
promising O
insights O
into O
this O
emerging O
field O
of O
socio-epigenomics O

Moreover O
, O
we O
show O
why O
germline O
EE O
is O
not O
effective O
and O
reject O
the O
position O
of O
strong O
epigenetic O
determinism O

Most O
notable O
of O
these O
patterns O
are O
the O
valley O
patterns O
that O
are O
prevalently O
observed O
in O
assays O
such O
as O
ChIP O
Sequencing O
and O
bisulfite O
sequencing O

Epigenetic O
modifications O
are O
reversible O
and O
thus O
promising O
therapeutic O
targets O
for O
precision O
medicine O

In O
conclusion O
, O
we O
report O
the O
development O
of O
the O
first O
piscine O
epigenetic O
clock O
, O
paving O
the O
way O
for O
similar O
studies O
in O
other O
species O

At O
the O
current O
stage O
, O
the O
integration O
of O
epigenetic O
substances O
into O
established O
breast B-Disease
cancer I-Disease
therapy O
protocols O
seems O
to O
hold O
the O
greatest O
potential O
for O
a O
clinical O
application O
of O
epigenetic O
research O

Here O
we O
describe O
the O
surgical O
protocol O
utilized O
by O
our O
group O
which O
is O
optimized O
for O
herpes O
simplex O
virus B-Disease
(HSV) O
delivery O
into O
mouse O
brain O

Zygote O
microinjection O
of O
total O
small O
RNA O
from O
sperm O
of O
infected O
mice O
partially O
recapitulates O
the O
behavioral O
phenotype O
of O
naturally O
born O
offspring O
, O
suggesting O
an O
epigenetic O
mechanism O
of O
behavioral O
inheritance O
in O
the O
first O
generation O

By O
building O
on O
this O
knowledge O
, O
the O
present O
work O
provides O
a O
timely O
perspective O
highlighting O
the O
extraordinary O
potential O
of O
environmental O
epigenetic O
analyses O
as O
a O
promising O
source O
of O
rapid O
and O
sensible O
tools O
for O
pollution O
biomonitoring O
, O
using O
marine O
invertebrates O
as O
sentinel O
organisms O

This O
analysis O
highlights O
the O
positive O
characteristics O
defining O
epimutation O
: O
the O
regularity O
, O
oxymoronic O
temporality O
, O
and O
materiality O
of O
stable O
processes O

396 O
: O
Cleavage O
Under O
Targets O
& O
Release O
Using O
Nuclease O
( O
CUT&RUN O
) O
has O
swiftly O
become O
the O
preferred O
procedure O
over O
the O
past O
few O
years O
for O
genomic O
mapping O
and O
detecting O
interactions O
between O
chromatin O
and O
its O
bound O
proteins O

433 O
: O
DNA O
methylation O
is O
the O
most O
studied O
epigenetic O
mark O
in O
both O
plants O
and O
animals O

This O
article O
describes O
the O
ethical O
issues O
associated O
with O
use O
of O
epigenetic O
testing O
for O
alcohol O
, O
tobacco O
, O
and O
cannabis O
and O
the O
implications O
of O
this O
technology O

Seven O
of O
37 O
cytosines O
assayed O
for O
methylation O
level O
in O
humpback O
skin O
had O
significant O
age-related O
profiles O

This O
clonal O
expansion O
leads O
to O
relapse O
, O
therapeutic O
resistance O
and O
eventually O
death B-Disease

Epigenetic O
mechanisms O
are O
adaptations O
made O
to O
our O
genome O
in O
response O
to O
our O
environment O
which O
include O
tags O
placed O
on O
and O
removed O
from O
the O
DNA O
itself O
to O
how O
our O
DNA O
is O
packaged O
, O
affecting O
how O
our O
genes O
are O
read O
, O
transcribed O
, O
and O
interact O

We O
found O
that O
reanalysis O
of O
the O
same O
single O
cell O
is O
feasible O
, O
provides O
confirmation O
of O
the O
epigenetic O
signals O
, O
and O
allows O
application O
of O
statistical O
analysis O
to O
identify O
reproduced O
reads O
using O
data O
sets O
generated O
only O
from O
the O
single O
cell O

We O
further O
provide O
an O
update O
on O
the O
epigenetic O
anomalies O
in O
the O
genesis O
of O
CHD O

Biomedical O
text O
and O
numerical O
data O
mining O
are O
both O
considered O
, O
the O
first O
dealing O
with O
automated O
methods O
for O
analyzing O
research O
content O
and O
information O
extraction O
, O
and O
the O
second O
( O
broadly O
) O
with O
pattern O
recognition O
and O
prediction O

Methods O
: O
In O
this O
minireview O
, O
we O
will O
focus O
on O
reviewing O
the O
fundamentals O
and O
applications O
of O
machine O
learning O
methods O
which O
are O
regularly O
used O
in O
epigenetics O
filed O
and O
explain O
their O
features O

The O
full O
exploitation O
of O
cutting O
edge O
epigenomics O
will O
be O
decisive O
to O
define O
whether O
epigenetics O
will O
contribute O
to O
lower O
the O
burden O
of O
cardiovascular B-Disease
diseases I-Disease

145 O
: O
It O
is O
undeniably O
one O
of O
the O
greatest O
findings O
in O
biology O
that O
( O
with O
some O
very O
minor O
exceptions O
) O
every O
cell O
in O
the O
body O
possesses O
the O
whole O
genetic O
information O
needed O
to O
generate O
a O
complete O
individual O

Cancer B-Disease
cells O
possess O
altered O
epigenomes O
which O
include O
aberrant O
patterns O
of O
DNA O
methylation O
, O
histone O
tail O
modifications O
, O
nucleosome O
positioning O
and O
of O
the O
three-dimensional O
chromatin O
organization O
within O
a O
nucleus O

Machine O
learning O
algorithms O
have O
accelerated O
studies O
in O
precision O
medicine O
targeting O
epigenetics O
diseases O

mutations O
, O
and O
aberrant O
epigenetic O
changes O
, O
e O

cs O

It O
thus O
constitutes O
a O
valuable O
reservoir O
of O
information O
for O
personalized O
medicine O
, O
which O
is O
aimed O
at O
customizing O
health-care O
interventions O
based O
on O
the O
unique O
characteristics O
of O
each O
individual O

Improved O
tools O
for O
early O
detection O
and O
therapeutic O
stratification O
would O
be O
expected O
to O
increase O
the O
survival O
rate O
for O
this O
disease B-Disease

In O
parallel O
, O
we O
discuss O
the O
potential O
of O
combining O
epigenetic O
drugs O
with O
existing O
anticancer O
regimens O
as O
a O
promising O
strategy O
for O
overcoming O
cancer B-Disease
drug O
resistance O

59 O
( O
95% O
CI O
: O
0 O

There O
have O
been O
extensive O
studies O
on O
the O
roles O
of O
DNA O
methylation O
in O
cancers B-Disease
, O
and O
several O
cancer B-Disease
drugs O
were O
developed O
targeting O
this O
process O

In O
this O
paper O
, O
we O
reviewed O
the O
literatures O
that O
has O
demonstrated O
that O
acupuncture O
could O
directly O
or O
indirectly O
affect O
epigenetics O
, O
in O
order O
to O
highlight O
the O
progress O
of O
acupuncture O
studies O
correlated O
to O
epigenetic O
regulations O

Loss O
of O
tissue O
homeostasis O
during O
post-reproductive O
lifespan O
is O
caused O
, O
at O
least O
in O
part O
, O
by O
a O
decline O
in O
stem O
cell O
function O
and O
is O
associated O
with O
an O
increased O
incidence O
of O
diseases O

Future O
integrative O
epigenomic O
analyses O
of O
genetic O
risk O
factors O
with O
environmental O
exposures O
and O
methylome O
analyses O
are O
expected O
to O
be O
important O
for O
understanding O
the O
complex O
etiology O
of O
ASD O

In O
turn O
, O
they O
could O
confer O
a O
selective O
advantage O
to O
mutant O
and O
epigenetically O
drifted O
stem O
cells O
with O
altered O
self-renewal O
and O
functions O
, O
which O
contribute O
to O
the O
development O
of O
ageing-associated O
organ O
dysfunction O
and O
disease B-Disease

Although O
direct O
evidence O
for O
epigenetic O
dysfunction O
in O
bipolar O
disorder B-Disease
is O
still O
limited O
, O
methodological O
technologies O
in O
epigenomic O
profiling O
have O
advanced O
, O
offering O
even O
single O
cell O
analysing O
and O
resolving O
the O
problem O
of O
cell O
heterogeneity B-Disease
in O
epigenetics O
research O

In O
this O
review O
, O
we O
introduce O
new O
technologies O
and O
research O
progresses O
in O
screening O
therapeutic O
targets O
using O
systematic O
omics O
such O
as O
genomics O
, O
transcriptomics O
and O
epigenomics O
, O
and O
also O
discusse O
new O
strategies O
and O
advantages O
of O
integrative O
analysis O
among O
them O

Understanding O
the O
precise O
role O
of O
DNA O
hypomethylation O
is O
not O
only O
crucial O
from O
a O
mechanistic O
point O
of O
view O
but O
also O
for O
the O
development O
of O
pharmacological O
agents O
that O
can O
reverse O
the O
hypomethylated O
state O
of O
the O
DNA O

We O
show O
empirically O
that O
the O
epigenomic O
data O
normalized O
by O
our O
method O
, O
compared O
to O
existing O
methods O
, O
can O
better O
capture O
real O
biological O
variation O
, O
such O
as O
impact O
on O
gene O
expression O
regulation O

html O

The O
review O
ends O
with O
a O
reflection O
on O
the O
main O
challenges O
in O
epigenetic O
research O
, O
some O
of O
them O
in O
a O
technical O
dimension O
( O
e O

Conclusion O
: O
The O
data O
document O
genome-wide O
effects O
of O
foreign O
DNA O
insertions O
on O
the O
epigenetic O
stability O
of O
human O
cells O

Second O
, O
aberrant O
DNA O
methylation O
can O
be O
detected O
with O
high O
sensitivity O
and O
therefore O
it O
is O
used O
to O
detect O
cancer B-Disease
cells O

380 O
: O
Mapping O
genome-wide O
DNA-protein O
interactions O
( O
DPIs O
) O
provides O
insights O
into O
the O
epigenetic O
landscape O
of O
complex O
biological O
systems O
and O
elucidates O
the O
mechanisms O
of O
epigenetic O
regulation O
in O
biological O
progress O

In O
addition O
to O
surveying O
examples O
of O
epivariation O
that O
may O
arise O
stochastically O
or O
in O
response O
to O
unknown O
stimuli O
, O
we O
also O
discuss O
the O
induction O
of O
heritable O
epigenetic O
changes O
by O
genetic O
or O
environmental O
perturbations O

Despite O
these O
shortcomings O
, O
the O
study O
of O
DNA O
and O
histone O
modifications O
in O
chromatin O
extracted O
from O
diseased O
and O
control O
brain O
tissue O
is O
likely O
to O
provide O
valuable O
insight O
into O
the O
genomic O
risk O
architecture O
of O
schizophrenia B-Disease
, O
particularly O
in O
the O
large O
majority O
of O
cases O
for O
which O
a O
straightforward O

Adolescents O
who O
are O
affected O
by O
mental O
health O
conditions O
are O
at O
risk O
of O
suicide O
and O
social O
and O
academic O
impairments O

Recent O
advances O
in O
cancer B-Disease
metabolism O
shed O
light O
on O
how O
aberrations O
in O
metabolites O
and O
metabolic O
enzymes O
modify O
epigenetic O
programs O

However O
, O
children O
and O
adults O
showed O
a O
large O
within-population O
variation O
in O
cellular O
heterogeneity B-Disease

149 O
years O
) O

586 O
: O
Cytosine O
methylation O
in O
DNA O
constitutes O
an O
important O
epigenetic O
layer O
of O
transcriptional O
and O
regulatory O
control O
in O
many O
eukaryotes O

As O
one O
of O
the O
first O
types O
of O
responses O
to O
a O
novel O
environment O
, O
epigenetic O
changes O
may O
have O
also O
facilitated O
early O
self-domestication O
in O
humans O

Meta-analytic O
support O
and O
replicated O
findings O
are O
evident O
for O
several O
genetic O
risk O
factors O
; O
however O
, O
extant O
research O
suggests O
the O
effects O
are O
pleiotropic O

The O
best O
performance O
was O
demonstrated O
by O
the O
model O
based O
on O
a O
metric O
designed O
to O
assess O
DNA O
methylation O
erosion O
with O
an O
MAE O
of O
3 O

In O
this O
review O
, O
we O
focus O
on O
the O
challenges O
and O
opportunities O
of O
clinical O
epigenomics O
in O
cardiovascular O
disease B-Disease


362 O
: O
Epigenetics O
is O
the O
study O
of O
heritable O
changes O
in O
gene O
expression O
that O
occur O
independent O
of O
the O
DNA O
sequence O

The O
review O
identifies O
areas O
of O
future O
research O
in O
epigenetic O
responses O
to O
environmental O
temperature O
change O

We O
also O
review O
the O
most O
efficient O
strategies O
developed O
to O
date O
to O
functionalize O
Cas O
proteins O
with O
both O
catalytic O
and O
non-catalytic O
epigenetic O
effectors O
, O
and O
the O
ability O
of O
these O
domains O
to O
influence O
the O
expression O
of O
endogenous O
genes O
in O
a O
regulatable O
manner O

Research O
also O
suggests O
adverse O
early O
life O
experiences O
are O
associated O
with O
changes O
in O
gene O
expression O
of O
multiple O
known O
candidate O
genes O
, O
genes O
involved O
in O
DNA O
transcription O
and O
translation O
, O
and O
genes O
necessary O
for O
brain O
circuitry O
development O
, O
with O
changes O
in O
gene O
expression O
reported O
in O
key O
brain O
structures O
implicated O
in O

Yet O
, O
the O
existing O
data O
is O
limited O
by O
the O
fact O
that O
epigenetic O
and O
transcriptomic O
changes O
have O
only O
been O
measured O
in O
separate O
cohorts O

The O
GNP O
was O
synthesized O
using O
physical O
synthesis O
method O
of O
pulsed O
laser O
multiphoton O
ionization O
, O
which O
enabled O
the O
shrinking O
of O
GNP O
to O
2 O

347 O
: O
Purpose O
of O
review O
: O
To O
discuss O
recent O
advances O
in O
the O
field O
of O
DNA O
methylation O
and O
their O
impact O
on O
our O
understanding O
of O
the O
role O
of O
this O
epigenetic O
mechanism O
in O
cancer B-Disease
development O
, O
as O
well O
as O
their O
implications O
for O
biomarker O
discovery O
and O
therapy O

In O
a O
timely O
review O
article O
, O
Pishva O
et O
al O

In O
the O
hereafter O
outlined O
protocol O
, O
we O
focus O
on O
optimization O
of O
transfection O
protocols O
by O
comparing O
different O
reagents O
and O
methods O
, O
creating O
a O
streamlined O
setup O
for O
transfection O
efficiency O
optimization O
in O
cultured O
mammalian O
cells O

In O
this O
chapter O
, O
we O
review O
the O
recent O
advances O
in O
the O
field O
of O
" O
computational O
epigenetics O
, O
" O
including O
computational O
methods O
for O
processing O
different O
types O
of O
epigenetic O
data O
, O
prediction O
of O
chromatin O
states O
, O
and O
study O
of O
protein O
dynamics O

In O
plants O
, O
epigenetic O
mechanisms O
can O
help O
to O
stabilize O
hybrid O
genomes O
and O
contribute O
to O
reproductive O
isolation O
, O
but O
the O
relationship O
between O
genetic O
and O
epigenetic O
changes O
in O
animal O
hybrids O
is O
unclear O

381 O
: O
Saliva O
and O
buccal O
samples O
are O
popular O
for O
epigenome O
wide O
association O
studies O
( O
EWAS O
) O
due O
to O
their O
ease O
of O
collection O
compared O
and O
their O
ability O
to O
sample O
a O
different O
cell O
lineage O
compared O
to O
blood O

Specifically O
, O
intergenic O
ncRNAs O
were O
observed O
to O
comprise O
a O
majority O
( O
51 O

We O
discuss O
general O
aspects O
of O
epigenetic O
clocks O
in O
the O
hope O
of O
stimulating O
further O
DNAm-based O
research O
on O
ageing O
, O
and O
perhaps O
more O
importantly O
, O
other O
key O
traits O

Collectively O
, O
our O
data O
reveal O
specific O
pathways O
underpinning O
the O
phenotypic O
and O
molecular O
variation O
that O
arise O
and O
accumulate O
in O
clonal O
plant O
populations O

DNA O
methylation O
is O
a O
common O
epigenetic O
modification O
that O
regulates O
gene O
expression O
, O
and O
aberrant O
DNA O
methylation O
patterns O
are O
considered O
a O
hallmark O
of O
cancer B-Disease

In O
hematological O
cancers B-Disease
, O
such O
as O
acute O
myeloid O
leukemia B-Disease
( O
AML O
) O
and O
myelodysplastic O
syndrome O
( O
MDS O
) O
, O
drugs O
that O
reverse O
epigenetic O
aberrations O
are O
now O
the O
standard O
of O
care O

This O
review O
discusses O
recent O
advances O
in O
unravelling O
this O
interplay O
with O
a O
particular O
focus O
on O
promising O
approaches O
and O
methods O
that O
will O
be O
able O
to O
establish O
causal O
relationships O

By O
projecting O
all O
the O
trajectories O
into O
a O
2-dimensional O
plane O
of O
dimensions O
i O
and O
j O
, O
we O
can O
approximately O
calculate O
the O
quasi-potential O
U(xi,xj,∗)=-ln O
P(xi,xj,∗) O
, O
where O
P(xi,xj,∗) O
is O
the O
estimated O
probability O
of O
an O
equilibrium O
steady O
state O
or O
a O
non-equilibrium O

In O
fact O
, O
these O
changes O
form O
the O
basis O
of O
the O
so O
called O
" O
epigenetic O
clocks O
" O
, O
which O
translate O
the O
genomic O
methylation O
profile O
into O
an O
" O
epigenetic O
age O
" O

For O
example O
, O
in O
prefrontal O
cortex O
of O
subjects O
with O
schizophrenia B-Disease
, O
abnormal O
DNA O
or O
histone O
methylation O
at O
sites O
of O
specific O
genes O
and O
promoters O
is O
associated O
with O
changes O
in O
RNA O
expression O

Drugs O
causing O
epigenetic O
modifications O
have O
been O
shown O
to O
induce O
the O
cardiac O
differentiation O
of O
stem O
cells O

673 O
: O
Epigenetic O
clocks O
are O
valuable O
tools O
for O
estimating O
both O
chronological O
and O
biological O
age O
by O
assessing O
DNA O
methylation O
levels O
at O
specific O
CpG O
dinucleotides O

18 O
, O
1 O

This O
paper O
explores O
the O
views O
of O
epigenetic O
researchers O
about O
some O
of O
these O
discussions O

In O
this O
technical O
commentary O
, O
we O
argue O
that O
the O
method O
used O
in O
the O
original O
study O
inherently O
amplifies O
the O
likelihood O
of O
genetic O
changes O
that O
thereafter O
lead O
to O
the O
heritability O
of O
epigenetic O
changes O

Our O
findings O
are O
anticipated O
to O
help O
advance O
real-time O
epigenomics O
surveillance O
technologies O
such O
as O
nucleus-targeted O
drug O
surveillance O
and O
epigenomic O
prognosis O
and O
diagnostics O

A O
number O
of O
methodological O
and O
clinical O
issues O
await O
resolution O
before O
serum O
epigenetic O
biomarkers O
can O
be O
considered O
a O
routine O
part O
of O
the O
management O
of O
melanoma B-Disease
patients O
following O
primary O
excision O

0 O
is O
a O
universal O
and O
accurate O
platform O
for O
the O
quantification O
of O
histone O
marks O
via O
LC-MS/MS O

Therefore O
, O
in O
attempts O
to O
develop O
novel O
safer O
and O
more O
efficacious O
drugs O
, O
both O
nutritional O
requirements O
and O
epigenetic O
mechanisms O
need O
to O
be O
addressed O

157 O
: O
Environmentally O
sensitive O
molecular O
mechanisms O
in O
the O
brain O
, O
such O
as O
DNA O
methylation O
, O
have O
become O
a O
significant O
focus O
of O
neuroscience O
research O
because O
of O
mounting O
evidence O
indicating O
that O
they O
are O
critical O
in O
response O
to O
social O
situations O
, O
stress O
, O
threats O
, O
and O
behavior O

The O
genome-wide O
distribution O
of O
methylation O
diversifies O
rapidly O
in O
different O
lineages O
, O
and O
DNA O
methylation O
is O
lost O
altogether O
surprisingly O
frequently O

This O
will O
provide O
further O
opportunities O
to O
enhance O
our O
understanding O
of O
the O
biological O
embedding O
of O
prenatal O
stress O
exposure O

It O
is O
generally O
believed O
that O
early O
life O
constitutes O
a O
period O
during O
which O
there O
is O
increased O
sensitivity O
to O
the O
regulatory O
effects O
of O
epigenetic O
mechanisms O

103 O
: O
The O
notion O
of O
epigenetic O
" O
marks O
" O
used O
by O
molecular O
biologists O
is O
conceptually O
disconnected O
from O
the O
idea O
of O
Waddington O
's O
epigenetic O
" O
landscape O
" O
that O
is O
used O
by O
systems O
biologists O
and O
biophysicists O

Taking O
the O
example O
of O
the O
epigenetics O
of O
cardiovascular B-Disease
diseases I-Disease
, O
this O
paper O
illustrates O
how O
common O
understandings O
of O
epigenetic O
biomarkers O
strongly O
lean O
toward O
considering O
them O
as O
mere O
targets O
for O
molecular O
intervention O
, O
rather O
than O
as O
correlates O
of O
a O
complex O
biological O
and O
social O
patterning O
of O

Epigenetic O
alterations O
, O
frequently O
associated O
with O
molecular O
variations O
in O
PCa O
, O
contribute O
to O
the O
acquisition O
of O
a O
radioresistant O
phenotype O

ewas O

631 O
: O
Psoriasis O
is O
a O
chronic O
and O
recurrent O
inflammatory O
skin O
disease B-Disease
, O
involving O
the O
rapid O
proliferation O
and O
abnormal O
differentiation O
of O
keratinocytes O
and O
activation O
of O
T O
cells O

We O
hypothesized O
that O
especially O
the O
insoluble O
, O
non-digestible O
particles O
that O
do O
not O
release O
a O
known O
hazardous O
chemical O
can O
be O
underappreciated O
agents O
acting O
to O
affect O
the O
regulation O
inside O
macrophages O
upon O
phagocytosis O

The O
laboratory O
mainly O
focuses O
on O
the O
analysis O
of O
epigenetic O
changes O
in O
neurodegenerative O
, O
autoimmune O
and O
inflammatory O
diseases O
as O
well O
as O
the O
alteration O
of O
the O
epigenetic O
profiles O
in O
function O
of O
environmental O
exposure O

However O
, O
the O
factors O
that O
determine O
the O
extent O
of O
somaclonal O
variation O
and O
the O
molecular O
changes O
underpinning O
this O
process O
remain O
poorly O
understood O

Understanding O
this O
epigenetic O
drift O
in O
the O
immune O
system O
can O
provide O
essential O
information O
about O
the O
progression O
of O
the O
aging O
process O
and O
the O
immune O
history O
of O
each O
individual O

These O
phenomena O
include O
coherent O
charge O
transfer O
along O
overlapping O
pi-orbitals O
of O
DNA O
bases O
and O
chirality-induced O
spin O
selectivity O

Here O
we O
present O
a O
novel O
framework O
for O
reference-based O
inference O
, O
which O
leverages O
cell-type O
specific O
DNAse O
Hypersensitive O
Site O
( O
DHS O
) O
information O
from O
the O
NIH O
Epigenomics O
Roadmap O
to O
construct O
an O
improved O
reference O
DNA O
methylation O
database O

At O
the O
molecular O
level O
, O
epigenetic O
mechanisms O
regulate O
the O
structure O
and O
activity O
of O
the O
genome O
in O
response O
to O
intracellular O
and O
environmental O
cues O
, O
including O
the O
deployment O
of O
cell O
type-specific O
gene O
networks O
and O
those O
underlying O
synaptic O
plasticity O

Further O
improvements O
are O
likely O
by O
combining O
genetic O
selection O
with O
epigenetic O
selection O
or O
manipulation O

We O
developed O
an O
end-to-end O
analytical O
framework O
named O
"EpiMix" O
for O
population-level O
analysis O
of O
DNAme O
and O
gene O
expression O

Two O
decades O
of O
technological O
developments O
have O
led O
to O
a O
rich O
set O
of O
approaches O
progressively O
pushing O
the O
limits O
of O
epigenetic O
profiling O
towards O
single O
cells O

In O
dbEM O
, O
modifiers O
are O
classified O
on O
functional O
basis O
and O
comprise O
of O
48 O
histone O
methyl O
transferases O
, O
33 O
chromatin O
remodelers O
and O
31 O
histone O
demethylases O

Here O
, O
we O
propose O
a O
new O
approach O
and O
a O
new O
method O
for O
analysis O
of O
several O
components O
of O
the O
epigenome O
in O
the O
same O
single O
cell O

Fisher O
, O
neoDarwinism O
came O
to O
dominate O
evolutionary O
science O
in O
the O
first O
half O
of O
the O
wentieth O
entury O
, O
and O
within O
that O
perspective O
aging O
could O
never O
be O
an O
evolved O
adaptation O

Geneticists O
have O
recently O
identified O
more O
than O
145 O
risk O
loci O
comprising O
hundreds O
of O
common O
variants O
of O
small O
effect O
sizes O
, O
most O
of O
which O
lie O
in O
noncoding O
genomic O
regions O

Epigenetic O
modifications O
, O
including O
deoxyribonucleic O
acid O
( O
DNA O
) O
methylation O
, O
histone O
modifications O
, O
and O
small O
ribonucleic O
acid O
( O
RNA O
) O
engineering O
, O
offer O
innovative O
avenues O
for O
tailoring O
plant O
responses O
to O
mitigate O
the O
impact O
of O
heavy O
metal O
and O
metalloid O
stress O

Recent O
findings O
: O
Epigenetic O
events O
are O
gene O
regulatory O
mechanisms O
that O
contribute O
to O
inflammation B-Disease
across O
inflammatory O
diseases O
and O
resemble O
shared O
mechanisms O
that O
may O
be O
used O
as O
disease B-Disease
biomarkers O
and O
treatment O
targets O

A O
decrease O
in O
the O
level O
of O
DNA O
methylation O
in O
such O
specific O
sites O
suggests O
that O
under O
the O
influence O
of O
heat O
stress O
we O
observe O
active O
demethylation O
phenomenon O
rather O
than O
passive O
demethylation O
, O
which O
is O
not O
locus O
specific O

Conceivably O
, O
newly O
developed O
precision O
epigenetic O
technologies O
could O
drive O
down O
these O
costs O

173 O
: O
Purpose O
of O
review O
: O
To O
summarize O
recently O
developed O
next O
generation O
sequencing-based O
methods O
to O
study O
epigenomics O
and O
epitranscriptomics O

Illumina O
methylation O
arrays O
are O
useful O
for O
epigenome O
research O
using O
the O
common O
marmoset O

Please O

Translational O
tools O
like O
neuroimaging O
by O
PET O
and O
magnetic O
resonance O
imaging O
provide O
the O
best O
way O
to O
link O
our O
current O
understanding O
of O
epigenetic O
changes O
with O
in O
vivo O
function O
in O
normal O
and O
diseased O
brains O

We O
demonstrate O
, O
using O
three O
large-cohort O
450K O
methylation O
array O
data O
sets O
, O
that O
ancestry O
information O
signal O
is O
mirrored O
in O
genome-wide O
DNA O
methylation O
data O
and O
that O
it O
can O
be O
further O
isolated O
more O
effectively O
by O
leveraging O
the O
correlation O
structure O
of O
CpGs O
with O
cis-located O
SNPs O

DNAm O
differences O
in O
hematopoietic O
cells O
between O
term O
and O
<31 O
weeks O
were O
consistent O
with O
the O
hematopoietic O
origin O
of O
these O
cells O
during O
ontogeny O
, O
reflecting O
an O
important O
role O
of O
DNAm O
in O
their O
regulation O

In O
addition O
, O
we O
present O
a O
simple O
procedure O
for O
the O
calculation O
of O
the O
inverse O
of O
this O
matrix O
( O
T-1 O
: O
) O
and O
a O
Gibbs O
sampler O
algorithm O
that O
obtains O
posterior O
estimates O
of O
all O
the O
unknowns O
in O
the O
model O

Epigenetic O
marks O
, O
mostly O
DNA O
methylation O
and O
histone O
post-translational O
modifications O
( O
PTMs O
) O
, O
play O
important O
roles O
in O
chromatin O
structure O
and O
function O

However O
, O
epigenetics O
is O
such O
a O
new O
field O
that O
in O
most O
of O
these O
areas O
the O
impact O
is O
more O
in O
the O
category O
of O
fascinating O
implications O
as O
opposed O
to O
established O
facts O

This O
database O
is O
available O
for O
public O
at O
URL O
: O
http://crdd O

Here O
, O
we O
present O
an O
overview O
of O
the O
promises O
of O
epigenetics O
in O
eventually O
treating O
IEMs O

Determining O
how O
epigenetics O
"connects" O
the O
environment O
to O
cell O
biology O
and O
to O
autoreactivity O
will O
be O
key O
for O
advancing O
our O
understanding O
in O
this O
field O
and O
, O
possibly O
, O
for O
developing O
novel O
preventive O
strategies O

The O
significance O
of O
D'Arcy O
Thompson O
as O
a O
predecessor O
of O
the O
relational O
biology O
and O
of O
the O
epigenetic O
concepts O
of O
evolution O
is O
discussed O

952 O
for O
the O
epigenetic O
target O
prediction O
task O

The O
method O
estimates O
the O
probability O
distribution O
of O
cellular O
states O
by O
collecting O
a O
large O
number O
of O
time-course O
simulations O
with O
random O
initial O
conditions O

In O
this O
review O
, O
we O
describe O
the O
distribution O
of O
DNA O
methylation O
and O
DNA O
hydroxymethylation O
in O
different O
genomic O
contexts O
, O
first O
in O
normal O
cells O
, O
and O
how O
this O
is O
altered O
in O
cancer B-Disease

Summary O
: O
Understanding O
and O
interpretation O
of O
the O
role O
for O
epigenetic O
modifications O
in O
the O
human O
genome O
has O
progressed O
rapidly O
over O
the O
past O
decade O
with O
the O
advancement O
of O
microarray-based O
and O
sequence-based O
technologies O

5 O
: O
Early O
life O
adversity O
is O
associated O
with O
long-term O
effects O
on O
physical O
and O
mental O
health O
later O
in O
life O
, O
but O
the O
mechanisms O
are O
yet O
unclear O

379 O
: O
Heterogeneity O
of O
DNA O
methylation O
status O
among O
alleles O
is O
observed O
in O
various O
cell O
types O
and O
is O
involved O
in O
epigenetic O
gene O
regulation O
and O
cancer B-Disease
biology O

In O
addition O
, O
we O
show O
how O
genome-wide O
methylation O
detection O
arrays O
and O
high-throughput O
sequencing O
have O
provided O
immense O
insight O
into O
ovarian B-Disease
cancer-specific O
methylation O
signatures O
that O
may O
serve O
as O
diagnostic O
biomarkers O
or O
predict O
patient O
response O
to O
epigenetic O
therapy O

Availability O
and O
implementation O
: O
The O
source O
code O
and O
documentation O
manual O
for O
MammalMethylClock O
, O
and O
clock O
coefficient O

We O
also O
discuss O
the O
impact O
of O
current O
and O
future O
epigenetic O
drugs O

All O
designs O
were O
fabricated O
in O
unmodified O
CMOS O
with O
performance O
assessed O
based O
on O
functionality O
as O
well O
as O
pH-resolution O
required O
in O
practice O

In O
this O
review O
, O
we O
discuss O
some O
of O
the O
most O
relevant O
advances O
in O
this O
field O

As O
a O
result O
, O
epigenome O
editing O
has O
helped O
to O
uncover O
the O
causal O
relationships O
between O
epigenetic O
marks O
and O
gene O
expression O

Although O
the O
science O
of O
epigenetics O
is O
still O
in O
its O
infancy O
, O
it O
seems O
that O
it O
may O
help O
elucidate O
the O
pathogenic O
mechanisms O
in O
uraemia B-Disease
, O
and O
allow O
novel O
treatment O
strategies O
to O
be O
developed O

Epigenetics O
provides O
a O
mechanism O
to O
explain O
the O
development O
of O
cancer B-Disease
in O
such O
situations O

This O
pragmatic O
approach O
is O
required O
to O
locate O
clinical O
epigenetics O
out O
of O
the O
experimental O
laboratories O
and O
facilitate O
its O
implementation O
into O
society O

Specifically O
, O
we O
give O
details O
about O
the O
protocol O
, O
discuss O
the O
pros O
and O
cons O
of O
these O
methodologies O
, O
and O
give O
practical O
tips O
for O
achieving O
optimal O
results O
and O
for O
troubleshooting O

However O
, O
the O
mechanisms O
involved O
in O
establishing O
and O
maintaining O
these O
epigenetic O
modifications O
during O
development O
remain O
unclear O

Our O
detailed O
optimization O
protocol O
for O
efficient O
plasmid O
delivery O
and O
measurement O
of O
single-cell O
plasmid O
expression O
provides O
a O
comprehensive O
instruction O
for O
assessing O
both O
transient O
and O
sustained O
effects O
of O
epigenetic O
reprogramming O

011 O
) O
, O
with O
nondrinkers O
exhibiting O
a O
higher O
GAA O
( O
β O
= O
0 O

Here O
, O
we O
analyzed O
the O
dynamics O
of O
changes O
in O
the O
level O
of O
DNA O
methylation O
in O
Arabidopsis O
thaliana O
( O
L O

scMET O
can O
identify O
highly O
variable O
features O
that O
drive O
epigenetic O
heterogeneity B-Disease
, O
and O
perform O
differential O
methylation O
and O
variability O
analyses O

This O
overlapping O
, O
which O
is O
already O
present O
when O
looking O
at O
the O
molecular O
and O
cellular O
events O
promoted O
immediately O
after O
methamphetamine O
intake O
, O
becomes O
impressive O
when O
plastic O
changes O
induced O
in O
the O
brain O
of O
methamphetamine-addicted O
patients O
are O
considered O

Our O
new O
model O
produced O
highly O
accurate O
chronological O
age O
predictions O
, O
comparable O
to O
a O
state-of-the-art O
epiclock O

This O
interplay O
alters O
human O
biology O
and O
developmental O
trajectories O
, O
and O
can O
lead O
to O
programmed O
human O
disease B-Disease
years O
after O
the O
environmental O
exposure O

Tumor-intrinsic O
epigenetic O
and O
genetic O
aberrations O
cooperate O
and O
interact O
with O
microenvironmental O
cells O
to O
shape O
the O
transcriptome O
at O
different O
phases O
of O
lymphoma B-Disease
evolution O
, O
and O
intraclonal O
heterogeneity B-Disease
can O
now O
be O
characterized O
by O
single-cell O
profiling O


This O
information O
combined O
with O
the O
impact O
of O
polarity-related O
proteins O
on O
epigenetic O
mechanisms O
of O
cancer B-Disease
enables O
us O
to O
envision O
how O
to O
guide O
the O
choice O
of O
drugs O
specific O
for O
distinct O
epigenetic O
modifiers O
, O
in O
order O
to O
halt O
cancer B-Disease
development O
and O
counter O
the O
consequences O
of O
polarity O
alterations O

For O
example O
, O
variants O
in O
BABAM1 O
were O
confirmed O
as O
a O
susceptibility O
locus O
for O
squamous B-Disease
cell I-Disease
lung I-Disease
, O
overall B-Disease
breast I-Disease
, O
estrogen B-Disease
receptor I-Disease
( O
ER O
) O
- O
negative B-Disease
breast I-Disease
, O
and O
overall B-Disease
prostate I-Disease
, O
and O
overall B-Disease
serous I-Disease
ovarian I-Disease
cancer I-Disease
; O
the O
most O
significant O
variant O
was O
rs480 O

, O
in O
life O
insurance O
, O
forensics O
, O
immigration O
and O
direct-to-consumer O
testing O

DNA O
methylation O
is O
essential O
for O
proper O
mammalian O
development O
, O
crucial O
for O
imprinting O
and O
plays O
a O
role O
in O
maintaining O
genomic O
stability O

Moreover O
, O
the O
introduction O
of O
epigenetics O
into O
the O
regulatory O
mechanism O
in O
acupuncture O
treatment O
has O
provided O
more O
objective O
and O
scientific O
support O
for O
acupuncture O
theories O
and O
brought O
new O
opportunities O
for O
the O
improvement O
of O
acupuncture O
studies O

In O
this O
review O
, O
we O
highlight O
latest O
discoveries O
in O
the O
mechanistic O
understanding O
of O
epigenetically-induced O
drug O
resistance O

, O
kinking O

Emerging O
technologies O
, O
such O
as O
single-cell O
sequencing O
and O
epigenetic O
editing O
, O
hold O
the O
potential O
to O
further O
enhance O
our O
ability O
to O
dissect O
the O
complex O
interplay O
between O
genetic O
, O
environmental O
, O
and O
lifestyle O
factors O

We O
review O
emerging O
single-cell O
methods O
for O
capturing O
DNA O
methylation O
, O
chromatin O
accessibility O
, O
histone O
modifications O
, O
chromosome O
conformation O
and O
replication O
dynamics O

Conclusion O
: O
Epigenetic O
modification O
of O
gene O
expression O
provides O
a O
mechanism O
for O
understanding O
the O
link O
between O
long-term O
effects O
of O
adverse O
life O
events O
and O
the O
changes O
in O
gene O
expression O
that O
are O
associated O
with O
depression B-Disease

We O
observed O
that O
many O
of O
these O
studies O
suffer O
from O
test O
statistic O
inflation O
that O
is O
most O
likely O
caused O
by O
commonly O
used O
quality O
control O
(QC) O
pipelines O
not O
going O
far O
enough O
to O
remove O
technical O
artefacts O

Although O
these O
drugs O
have O
the O
potential O
to O
be O
highly O
beneficial O
for O
patients O
, O
they O
act O
systemically O
and O
may O
have O
" O
off-target O
" O
effects O
in O
other O
cells O
such O
as O
the O
patients O
' O
sperm O
or O
eggs O

However O
, O
in O
the O
last O
20 O
years O
, O
more O
powerful O
and O
affordable O
tools O
to O
interrogate O
the O
genetic O
and O
epigenetic O
determinants O
of O
male O
infertility O
have O
accelerated O
the O
number O
of O
new O
discoveries O
in O
the O
characterization O
of O
male O
infertility O

These O
epigenetic O
changes O
underscore O
prenatal O
exposures O
' O
enduring O
effects O
on O
health O
trajectories O

Conclusions O
: O
The O
pipeline O
provides O
a O
group O
of O
integrated O
analytical O
methods O
wrapped O
into O
an O
easy-to-use O
interface O

In O
this O
way O
, O
the O
molecular O
trajectories O
that O
underlie O
disease B-Disease
development O
will O
be O
uncovered O

10971037 O

However O
, O
DNA O
co-methylation O
cluster O
has O
not O
been O
examined O
in O
depth O
, O
and O
co-methylation O
in O
multiple O
cancer B-Disease
types O
has O
never O
been O
studied O
previously O

Nevertheless O
, O
the O
valleys O
are O
not O
reported O
by O
majority O
of O
the O
analysis O
pipelines O

In O
addition O
, O
the O
large O
clusters O
of O
histone O
valleys O
are O
found O
to O
be O
enriched O
at O
the O
promoters O
of O
the O
developmentally O
associated O
genes O

We O
discuss O
study O
design O
and O
biological O
and O
analytical O
considerations O
and O
conclude O
by O
discussing O
interpretability O
of O
epigenetic O
findings O
and O
how O
these O
important O
factors O
are O
currently O
being O
applied O
across O
areas O
of O
psychology O

Here O
, O
we O
identified O
lineage-specific O
DNA O
methylation O
signatures O
of O
six O
immune O
cell O
types O
from O
human O
peripheral O
blood O
and O
determined O
their O
relationship O
to O
other O
epigenetic O
and O
transcriptomic O
patterns O

Further O
information O
and O
documentation O
as O
well O
as O
a O
quick O
start O
tutorial O
are O
available O
at O
http://glint-epigenetics O

We O
present O
epigenetic O
clocks O
for O
Asian O
elephants O
(Elephas O
maximus O
), O
African O
elephants O
(Loxodonta O
africana O
), O
and O
both O
elephant O
species O
combined O

The O
next O
steps O
include O
increasing O
the O
specificity O
for O
target O
genes O
, O
the O
development O
of O
biomarkers O
for O
dose O
and O
response O
studies O
, O
and O
establishing O
a O
strategy O
to O
select O
drugs O
for O
combination O
therapy O

The O
results O
of O
the O
four O
epiclocks O
tested O
are O
significantly O
distorted O
by O
the O
EPICv2 O
probeset O
, O
causing O
an O
average O
difference O
of O
up O
to O
25 O
years O

So O
far O
, O
studies O
of O
the O
epigenome O
have O
been O
scarce O
in O
nephrology O

pigenetic O
mechanisms O
regulate O
chromatin O
accessibility O
patterns O
that O
govern O
interaction O
of O
transcription O
machinery O
with O
genes O
and O
their O
cis-regulatory O
elements O

Its O
oxidation O
to O
DNA O
hydroxymethylation O
has O
been O
linked O
to O
DNA O
demethylation O
and O
reactivation O
of O
retrotransposons O

This O
chapter O
describes O
epigenetic O
biomarkers O
that O
are O
being O
used O
to O
study O
the O
epidemiology O
of O
different O
types O
of O
cancer B-Disease

479 O
: O
The O
variable O
predisposition O
of O
patients O
, O
both O
to O
disease B-Disease
susceptibility O
and O
drug O
response O
, O
is O
well O
established O

This O
has O
the O
effect O
of O
biologizing O
early O
childhood O
adversity O
, O
positioning O
it O
as O
a O
consequence O
of O
caregiving O
, O
and O
producing O
epigenetic O
findings O
that O
often O
align O
with O
individually O
oriented O
interventions O
rather O
than O
social O
and O
structural O
change O

07/1 O

692 O
: O
The O
hygiene O
hypothesis O
( O
HH O
) O
proposed O
by O
Strachan O
in O
1989 O
was O
expanded O
to O
explain O
the O
inverse O
association O
between O
the O
occurrence O
of O
allergy O
disorders O
and O
the O
risk O
of O
infectious B-Disease
diseases I-Disease
and O
parasite O
infestation O

487 O
: O
This O
chapter O
discusses O
analysis O
and O
interpretation O
of O
large-scale O
Illumina O
DNA O
methylation O
microarray O
data O
, O
used O
in O
the O
context O
of O
cancer B-Disease
studies O


Scholars O
from O
many O
disciplines O
have O
formulated O
both O
optimistic O
and O
cautionary O
claims O
regarding O
its O
potential O
normative O
implications O

This O
overall O
loss O
of O
DNA O
methylation O
has O
been O
proposed O
as O
a O
valid O
biomarker O
for O
cancer B-Disease

The O
software O
uses O
an O
intelligent O
retention O
time O
prediction O
trained O
on O
the O
analyzed O
samples O
to O
enable O
accurate O
peak O
detection O

These O
contributions O
were O
subdivided O
into O
3 O
categories O
: O
( O
a O
) O
quality O
control O
( O
QC O
) O
methods O
for O
DNA O
methylation O
data O
; O
( O
b O
) O
heritability O
estimates O
pretreatment O
and O
posttreatment O
with O
fenofibrate O
; O
and O
( O
c O
) O
impact O
of O
drug O
response O
pretreatment O
and O
posttreatment O
with O

Since O
their O
inception O
they O
have O
been O
used O
to O
infer O
knowledge O
about O
gene O
regulation O
and O
as O
methods O
of O
computation O

Combined O
with O
NGS O
technology O
, O
live O
imaging O
systems O
can O
now O
be O
used O
to O
track O
epigenetic O
events O
and O
clarify O
their O
casual O
and O
spatiotemporal O
relationships O
to O
cell O
differentiation O
and O
embryonic O
development O

With O
further O
optimization O
of O
the O
SaCas9 O
ortholog O
, O
due O
to O
less O
complex O
PAM O
requirements O
in O
contrast O
to O
CjCas9 O
, O
we O
showed O
that O
N-terminal O
fusion O
with O
DNMT3A O
( O
dSaCas9-DNMT3A O
) O
is O
optimal O
to O
exert O
targeted O
DNA O
methylation O
activity O
comparable O
to O
the O
dSpCas9 O

Proper O
normalization O
is O
required O
prior O
to O
data O
analysis O
to O
gain O
meaningful O
insights O

He O
has O
been O
awarded O
10 O
patents O
related O
to O
DNA O
methylation O
technology O
by O
the O
United O
States O
Patent O
and O
Trademark O
Office O
, O
one O
of O
which O
is O
the O
basis O
for O
the O
first O
US O
FDA-approved O
blood-based O
DNA O
methylation O
assay O
for O
cancer B-Disease
( O
Epi O
proColon O
) O

In O
the O
final O
sections O
of O
the O
paper O
we O
briefly O
outline O
some O
further O
implications O
of O
epigenetics O
for O
medicine O
and O
for O
the O
nature/nurture O
debate O

607 O
: O
Epigenetic O
mechanisms O
control O
gene O
activity O
and O
the O
development O
of O
an O
organism O

Our O
analysis O
shows O
that O
genetics O
and O
embryology O
in O
early O
XX O
century O
-- O
far O
from O
being O
non-communicating O
vessels O
-- O
shared O
similar O
questions O
, O
as O
epitomized O
by O
Thomas O
Hunt O
Morgan O
's O
works O

These O
observations O
indicate O
that O
innate O
and O
adaptive O
immune O
lineages O
are O
specified O
by O
distinct O
epigenetic O
mechanisms O
via O
combinatorial O
and O
context-dependent O
use O
of O
key O
transcription O
factors O

Design O
: O
A O
systematic O
review O
of O
the O
last O
10 O
years O
was O
conducted O
using O
four O
databases O
: O
PubMed/MEDLINE O
, O
Web O
of O
Science O
, O
PsychInfo O
, O
and O
CINAHL O

552 O
: O
Background O
: O
Epigenome-wide O
association O
studies O
using O
DNA O
methylation O
have O
the O
potential O
to O
uncover O
novel O
biomarkers O
and O
mechanisms O
of O
cardiovascular O
disease B-Disease
( O
CVD O
) O
risk O

These O
enzymatic O
activities O
include O
methylation O
by O
DNA O
methyltransferases O
, O
oxidation O
of O
5mC O
by O
TET O
family O
enzymes O
, O
hypermodification O
of O
5hmC O
by O
glucosyltransferases O
, O
and O
the O
generation O
of O
transition O
mutations O
from O
cytosine O
to O
uracil O
by O
DNA O
deaminases O

The O
current O
review O
provides O
an O
introduction O
and O
overview O
of O
epigenetics O
with O
a O
particular O
focus O
on O
preclinical O
and O
clinical O
studies O
relevant O
to O
major O
depressive O
disorder B-Disease
( O
MDD O
) O

In O
this O
chapter O
, O
in O
relation O
to O
gene-environment O
interactions O
, O
a O
variety O
of O
association O
studies O
regarding O
anxiety O
disorders O
were O
surveyed O

Since O
epigenetic O
markings O
provide O
a O
" O
memory O
" O
of O
past O
experiences O
, O
minimizing O
future O
disparities O
in O
health O
will O
be O
partially O
contingent O
upon O
our O
ability O
to O
address O
inequality O
in O
the O
current O
environment O

Altered O
methylome O
signatures O
were O
found O
in O
several O
cell O
types O
in O
RA O
, O
first O
of O
all O
RA O
synovial O
fibroblasts O
, O
and O
contribute O
to O
the O
intrinsic O
fibroblast O
activation O

Second O
, O
babies O
in O
utero O
during O
the O
Famine O
were O
reported O
to O
have O
accounted O
for O
an O
increase O
in O
first O
admissions O
when O
they O
reached O
the O
high-risk O
age O
for O
mental O
illness B-Disease
( O
1860-75 O
) O

Regression O
models O
were O
performed O
for O
health O
outcomes O
in O
later O
life O

In O
recent O
years O
, O
epigenetic O
involvements O
, O
such O
as O
the O
DNA O
methylation O
, O
chromatin B-Disease
modifications I-Disease
, O
and O
noncoding O
RNA O
regulation O
are O
reported O
to O
be O
critical O
for O
the O
pathogenesis O
of O
psoriasis B-Disease

In O
the O
present O
paper O
, O
I O
first O
examine O
the O
links O
that O
exist O
, O
in O
Waddington's O
work O
, O
between O
the O
classical O
notion O
of O
epigenesis O
in O
embryology O
and O
those O
of O
epigenetics O
that O
Waddington O
proposed O
to O
connect O
, O
and O
even O
synthesize O
, O
data O
both O
from O
embryology O
and O

These O
effects O
occur O
via O
chemical O
structural O
interactions O
with O
epigenetic O
enzymes O
, O
through O
interactions O
with O
DNA O
repair O
mechanisms O

Although O
epigenome-wide O
association O
study O
attracts O
increasing O
attention O
, O
currently O
, O
it O
has O
a O
fundamental O
problem O
in O
that O
each O
cell O
within O
one O
individual O
has O
a O
unique O
, O
time-varying O
epigenome O

They O
study O
variation O
of O
DNA O
methylation O
in O
a O
wild O
population O
of O
the O
rare O
, O
long-lived O
violet O
Viola O
cazorlensis O
, O
and O
they O
use O
these O
data O
to O
explore O
interrelations O
between O
environmental O
, O
genetic O
and O
epigenetic O
variation O
, O
and O
in O
particular O
the O
extent O
to O
which O
these O
factors O
are O

csv O
files O
that O
are O
included O
within O
this O
software O
package O
, O
can O
be O
found O
on O
Zenodo O
at O
https://doi O

Thus O
, O
such O
orphan O
target O
proteins O
are O
not O
yet O
druggable O
with O
limited O
report O
of O
active O
modulators O

Exploration O
of O
DNA O
epigenetic O
patterns O
that O
regulate O
gene O
expression O
profiles O
could O
therefore O
provide O
the O
missing O
link O
between O
epigenomic O
state O
and O
FSD O
, O
and O
as O
such O
may O
offer O
a O
new O
biological O
framework O
for O
the O
multifactorial O
pathoetiology O
underlying O
FSD O

371 O
: O
Aim O
: O
To O
assess O
associations O
of O
early O
exposure O
to O
hunger O
with O
depressive B-Disease
symptoms I-Disease
and O
cardiovascular O
disease B-Disease
( O
CVD O
) O
and O
to O
investigate O
possible O
epigenetic O
pathways O

147 O
: O
During O
the O
late O
1940s O
and O
1950s O
, O
a O
pseudo-scientific O
concept O
based O
on O
Marxist-Leninist O
ideology O
became O
internationally O
known O
as O
'Lysenkoism O
' O

It O
can O
also O
change O
dynamically O
in O
response O
to O
developmental O
cues O
or O
environmental O
stimuli O
, O
and O
is O
an O
important O
regulator O
for O
developmental O
switch O
and O
cell O
fate O
determination O

Striking O
new O
evidence O
implicates O
the O
dysregulation O
of O
epigenetic O
mechanisms O
in O
neurodegenerative B-Disease
disorders I-Disease
and O
diseases O

656 O
: O
Purpose O
: O
The O
purpose O
of O
this O
review O
was O
to O
explore O
the O
effects O
of O
psychosocial O
stress O
from O
life O
trauma B-Disease
and O
racial O
discrimination O
on O
epigenetic O
aging O

While O
most O
ovary O
cells O
reach O
the O
close O
of O
their O
metabolic O
life O
span O
with O
low O
risk O
for O
hypertrophy O
, O
enhanced O
lysosomal O
activity O
and O
the O
proinflammatory O
'senescence-associated O
secretory O
phenotype' O
usually O
offsets O
this O
advantage O
over O
time O

732 O
: O
We O
asked O
Dr O

Finally O
, O
using O
multi-tissue O
data O
to O
deconstruct O
the O
epigenetic O
clock O
signals O
, O
we O
developed O
a O
meta-clock O
that O
demonstrated O
improved O
prediction O
for O
mortality O
and O
robustly O
related O
to O
hallmarks O
of O
aging O
in O
vitro O
than O
single O
clocks O

226 O
: O
Epigenetic O
changes O
caused O
by O
DNA O
methylation O
and O
histone O
modifications O
play O
important O
roles O
in O
the O
regulation O
of O
various O
cellular O
processes O
and O
development O

Methylomes O
are O
also O
affected O
by O
genetics O
, O
and O
we O
observe O
multiple O
associations O
between O
SNP O
loci O
and O
methylated O
CpGs O

One O
of O
these O
burgeoning O
fields O
is O
the O
study O
of O
the O
epigenome O

211 O
: O
Epigenetic O
modifications O
direct O
the O
way O
DNA O
is O
packaged O
into O
the O
nucleus O
, O
making O
genes O
more O
or O
less O
accessible O
to O
transcriptional O
machinery O
and O
influencing O
genomic O
stability O

DNA O
methylation O
can O
be O
stably O
inherited O
to O
the O
subsequent O
generation O

Studies O
on O
cross-sectional O
data O
have O
discovered O
a O
change O
in O
methylation O
variability O
in O
association O
with O
age O

565 O
: O
Modern O
humans O
exhibit O
phenotypic O
traits O
and O
molecular O
events O
shared O
with O
other O
domesticates O
that O
are O
thought O
to O
be O
by-products O
of O
selection O
for O
reduced O
aggression O

Furthermore O
, O
the O
potential O
targets O
provided O
by O
the O
epigenome O
for O
the O
development O
of O
future O
diagnostics O
, O
preventive O
strategies O
, O
and O
therapy O
for O
cardiovascular O
disease B-Disease
are O
reviewed O

12 O
: O
All O
animals O
have O
evolved O
solutions O
to O
manage O
their O
genomes O
, O
enabling O
the O
efficient O
organization O
of O
meters O
of O
DNA O
strands O
in O
the O
nucleus O
and O
allowing O
for O
nuanced O
regulation O
of O
gene O
expression O
while O
keeping O
transposable O
elements O
suppressed O

518 O
: O
The O
genetic O
material O
of O
every O
organism O
exists O
within O
the O
context O
of O
regulatory O
networks O
that O
govern O
gene O
expression O
, O
collectively O
called O
the O
epigenome O

Nutrition O
can O
alter O
gene O
expression O
, O
as O
well O
as O
the O
susceptibility O
to O
disease B-Disease
, O
including O
cancer B-Disease
, O
through O
epigenetic O
changes O

Our O
study O
revealed O
that O
multigenerational O
exposure O
to O
cold O
stress O
resulted O
in O
the O
changes O
in O
the O
genome O
and O
epigenome O
( O
DNA O
methylation O
) O
across O
generations O

These O
tags O
are O
affected O
by O
social O
environments O
and O
can O
persist O
over O
time O
; O
this O
may O
aid O
us O
in O
responding O
to O
experiences O
and O
exposures O
, O
both O
the O
enriched O
and O
the O
disadvantageous O

Aberrant O
epigenetic O
patterning O
can O
lead O
to O
a O
variety O
of O
human O
disorders O
, O
including O
subfertility O
and O
imprinting O
disorders O

The O
learning O
module O
consists O
of O
three O
submodules O
that O
guide O
the O
user O
through O
tutorial O
examples O
that O
illustrate O
the O
analysis O
of O
RNA-sequence O
and O
Reduced-Representation O
Bisulfite O
Sequencing O
data O

These O
recent O
advances O
allow O
researchers O
to O
obtain O
virtually O
any O
cell O
type O
found O
in O
the O
human O
brain O
, O
making O
it O
possible O
to O
produce O
and O
study O
functional O
neurons O
in O
laboratory O
conditions O
for O
both O
scientific O
and O
medical O
purposes O

Introduction O
of O
more O
advanced O
approaches O
to O
DNA O
methylation O
analysis O
, O
such O
as O
microarray O
platforms O
and O
massively O
parallel O
sequencing O
, O
has O
brought O
us O
closer O
to O
unveiling O
the O
whole O
methylome O

Congenital O
heart O
diseases O
(CHD) O
are O
the O
most O
prominent O
congenital O
diseases O

694 O
: O
The O
formative O
period O
of O
adolescence O
plays O
a O
crucial O
role O
in O
the O
development O
of O
skills O
and O
abilities O
for O
adulthood O

Using O
systematic O
search O
procedures O
the O
authors O
identified O
and O
reviewed O
41 O
studies O
of O
epigenetic O
mechanisms O
in O
psychiatric B-Disease
and O
behavioral O
phenotypes O
among O
humans O

51: O
The O
understanding O
of O
epigenetic O
mechanisms O
is O
necessary O
for O
assessing O
the O
potential O
impacts O
of O
epigenetics O
on O
plant O
growth O
, O
development O
and O
reproduction O
, O
and O
ultimately O
for O
the O
response O
of O
these O
factors O
to O
evolutionary O
pressures O
and O
crop O
breeding O
programs O

Dr O
Kelsey O
is O
interested O
in O
the O
application O
of O
laboratory-based O
biomarkers O
in O
environmental O
disease B-Disease
, O
with O
experience O
in O
chronic O
disease B-Disease
epidemiology O
and O
tumor B-Disease
biology O

Finally O
, O
the O
Review O
underscores O
the O
great O
potential O
of O
this O
field O
to O
enhance O
the O
effectiveness O
and O
safety O
of O
drug O
treatments O
through O
personalized O
medicine O

We O
display O
its O
utility O
as O
a O
tool O
to O
understand O
the O
contributions O
of O
specific O
histone O
marks O
on O
gene O
expression O
by O
screening O
a O
large O
promoter O
region O
and O
identifying O
differential O
outcomes O
with O
high O
base-pair O
resolution O

Nowadays O
, O
we O
understand O
how O
the O
epigenetic O
machinery O
works O
; O
however O
, O
this O
critical O
mechanism O
might O
promote O
the O
appearance O
of O
certain O
diseases O
if O
dysregulated O
, O
thus O
the O
importance O
of O
studying O
the O
epigenetic O
patterns O
on O
both O
normal O
and O
disease B-Disease
tissues O

Finally O
, O
we O
will O
also O
review O
current O
developments O
regarding O
epi-drug O
usage O
in O
clinical O
and O
experimental O
settings O

In O
the O
brain O
, O
neurons O
encode O
information-in O
effect O
memories-at O
the O
cellular O
level O

We O
believe O
that O
this O
classification O
scheme O
can O
be O
useful O
to O
coherently O
organize O
the O
expanding O
number O
of O
discovered O
RNA O
modifications O

648 O
: O
Computer-based O
approaches O
represent O
a O
powerful O
tool O
which O
helps O
to O
identify O
and O
optimize O
lead O
structures O
in O
the O
process O
of O
drug O
discovery O

In O
mammals O
, O
this O
chain O
of O
events O
occurs O
in O
neurons O
following O
peripheral O
axonal O
injury O
, O
however O
it O
fails O
upon O
axonal O
injury O
in O
the O
central O
nervous B-Disease
system I-Disease
, O
such O
as O
in O
the O
spinal B-Disease
cord I-Disease
and O
the O
brain O

537 O
: O
Lung B-Disease
cancer I-Disease
remains O
the O
primary O
cause O
of O
cancer-related O
deaths O
worldwide O

Sarma O

First O
, O
we O
performed O
a O
simulation O
study O
to O
explore O
methods O
for O
estimating O
methylation O
variability O
in O
longitudinal O
data O

The O
epigenetic O
method O
correctly O
determined O
which O
of O
parent-offspring O
pairs O
is O
the O
parent O
in O
more O
than O
93% O
of O
cases O

In O
this O
study O
, O
we O
summarized O
the O
biological O
properties O
of O
epigenetics O
and O
single-cell O
epigenomic O
profiling O
techniques O
, O
and O
discussed O
future O
challenges O
in O
the O
field O
of O
epigenetics O

This O
review O
discusses O
current O
evidence O
for O
transgenerational O
epigenetic O
inheritance O
, O
confounding O
issues O
associated O
with O
its O
study O
, O
and O
the O
biological O
relevance O
of O
altered O
epigenetic O
states O
for O
subsequent O
generations O

One O
model O
that O
supports O
the O
transition O
from O
traditional O
lecturing O
towards O
active O
learning O
by O
maintaining O
a O
balance O
between O
instruction O
and O
self-learning O
is O
the O
'Sandwich O
Model' O

We O
argue O
that O
Darwin O
's O
lasting O
and O
multifaceted O
interest O
in O
the O
notion O
of O
habit O
, O
throughout O
his O
intellectual O
life O
, O
is O
both O
conceptually O
and O
methodologically O
relevant O

In O
addition O
, O
the O
cancer B-Disease
epigenome O
dictates O
the O
response O
of O
a O
cancer B-Disease
cell O
to O
therapeutic O
intervention O
and O
, O
therefore O
its O
knowledge O
, O
will O
allow O
to O
predict O
response O
to O
different O
therapeutic O
approaches O


It O
could O
be O
helpful O
to O
the O
research O
about O
environmental O
epigenetic O
toxicology O

Here O
, O
we O
examine O
and O
synthesize O
the O
impacts O
of O
climate O
change O
on O
freshwater O
ecosystems O
, O
exploring O
the O
potential O
role O
of O
epigenetic O
mechanisms O
in O
both O
short- O
and O
long-term O
adaptation O
of O
species O

402 O
: O
Nonlinear O
epigenetic O
processes O
are O
conceived O
of O
in O
terms O
of O
self-organizing O
dynamic O
models O
of O
biological O
pattern O
formation O

Users O
can O
use O
EWAS2 O

PRISM O
adopts O
DNA O
methyltransferase O
1-like O
hidden O
Markov O
model-based O
in O
silico O
proofreading O
for O
the O
correction O
of O
erroneous O
methylation O
patterns O

EWAS2 O

From O
the O
mid-seventies O
, O
the O
state O
of O
understanding O
started O
changing O

263 O
: O
Shortly O
after O
gene O
transfer O
technologies O
had O
been O
established O
for O
different O
plant O
species O
, O
the O
first O
reports O
emerged O
about O
transgenes O
showing O
unexpected O
segregation O
patterns O
due O
to O
unstable O
expression O

Dominated O
by O
an O
informational O
myth O
and O
a O
mechanistic O
Cartesian O
body/mind O
and O
form/substance O
dualism O
, O
this O
considers O
the O
genome O
as O
an O
ensemble O
of O
discrete O
units O
of O
information O
governing O
human O
body O
and O
behavior O
, O
and O
remains O
hegemonic O
in O
life O
sciences O
and O
in O
the O
public O
imagination O

More O
specifically O
, O
I O
present O
a O
protocol O
based O
on O
an O
adaptation O
of O
the O
CIBERSORT O
algorithm O
, O
previously O
developed O
for O
gene-expression O
, O
to O
methylation O
data O

476 O
: O
DNA O
methylation O
is O
a O
key O
epigenetic O
modification O
controlling O
the O
transcriptional O
activity O
of O
mammalian O
retrotransposable O
elements O

By O
using O
these O
patterns O
, O
the O
emergence O
of O
diseases O
could O
be O
prognosticated O

The O
primary O
limitation O
in O
ion-semiconductor O
sequencing O
is O
base O
calling O
of O
repeated O
nucleotides O
known O
as O
homopolymers O

) O
Heynh O

Among O
the O
most O
promising O
of O
such O
biomarkers O
is O
DNA O
methylation-based O
biological O
age O

However O
, O
there O
is O
every O
possibility O
that O
blood O
testing O
for O
the O
presence O
of O
methylated O
DNA O
will O
become O
an O
integral O
part O
of O
the O
clinical O
follow-up O
of O
such O
patients O

Moreover O
, O
they O
treat O
as O
a O
given O
crucial O
questions O
that O
are O
far O
from O
resolved O
, O
such O
as O
what O
role O
, O
if O
any O
, O
DNA O
methylation O
plays O
in O
the O
complex O
biochemical O
system O
of O
regulating O
gene O
activity O

These O
arrays O
generate O
enormous O
amounts O
of O
data O
, O
but O
few O
software O
resources O
exist O
for O
efficient O
and O
flexible O
analysis O
of O
these O
data O

Among O
age-associated O
loci O
were O
those O
in O
close O
proximity O
to O
malate O
dehydrogenase O
, O
NADH O
dehydrogenase O
, O
and O
18S O
and O
26S O
ribosomal O
RNA O
genes O

Specific O
epigenetic-modifying O
compounds O
have O
been O
developed O
to O
erase O
these O
modifications O
, O
possibly O
slowing O
down O
the O
onset O
of O
diabetes-related O
complications O

245 O
: O
Contents O
Summary O
738 O
I O

Both O
genetic O
and O
environmental O
factors O
determine O
the O
timing O
of O
puberty O

This O
is O
an O
unfortunate O
limitation O
that O
, O
thanks O
to O
an O
unprecedented O
pace O
of O
technological O
advancements O
especially O
in O
the O
sequencing O
technology O
field O
, O
is O
likely O
to O
be O
overcome O
soon O

It O
is O
generally O
accepted O
that O
the O
central O
pathogenesis O
of O
psoriasis B-Disease
is O
a O
T O
cell-dominant O
immune O
disorder B-Disease
affected O
by O
multiple O
factors O
including O
genetic O
susceptibility O
, O
environmental O
factors O
, O
innate O
and O
adaptive O
immune O
responses O
, O
etc O

However O
, O
the O
association O
of O
epigenetic O
dysfunction O
with O
disease B-Disease
and O
the O
development O
of O
therapeutic O
agents O
for O
treatment O
are O
slow O

To O
test O
this O
, O
we O
used O
in O
silico O
approaches O
to O
compare O
genes O
with O
epigenetic O
changes O
in O
early O
domesticates O
of O
European O
sea O
bass O
with O
genes O
exhibiting O
methylation O
changes O
in O
anatomically O
modern O
humans O
( O
comparison O
1 O
) O
, O
and O
neurodevelopmental O
cognitive O
disorders O
considered O
to O
exhibit O
ab O

Developing O
new O
methodologies O
used O
to O
visualize O
chromatin-modifying O
enzymes O
and O
their O
function O
in O
the O
human O
brain O
would O
be O
valuable O
for O
the O
diagnosis O
of O
brain O
disorders O
and O
drug O
discovery O

8 O
% O
, O
a O
Matthews O
correlation O
coefficient O
of O
0 O

Understanding O
the O
global O
change O
in O
DNA O
methylation O
during O
atherosclerosis O
remains O
a O
challenge O

Whereas O
there O
is O
evidence O
supporting O
this O
hypothesis O
in O
animal O
studies O
, O
human O
studies O
have O
been O
less O
conclusive O

Epigenetic O
changes O
have O
been O
reported O
in O
humans O
with O
MDD O
and O
may O
serve O
as O
biomarkers O
to O
improve O
diagnosis O

Epigenetic O
modifications O
are O
central O
to O
accomplishing O
all O
these O

The O
second O
body O
of O
theories O
employs O
the O
principle O
of O
the O
extraordinary O
plasticity O
of O
the O
(body-)organism O
and O
emphasizes O
the O
value O
of O
the O
(body-)organism-environment O
mutual O
interchange O
, O
known O
as O
' O
the O
epigenetic O
approach O
' O

This O
communication O
provides O
an O
introduction O
to O
the O
fundamentals O
of O
epigenetics O
and O
then O
reviews O
how O
some O
of O
the O
latest O
advances O
in O
this O
technology O
can O
now O
be O
used O
to O
assess O
the O
consumption O
of O
alcohol O
and O
tobacco O

New O
insights O
into O
the O
proteins O
that O
are O
targeted O
by O
therapeutic O
agents O
that O
alter O
epigenetic O
programs O
may O
provide O
important O
inroads O
into O
personalized O
medicine O

Importantly O
, O
the O
coupling O
of O
epigenetic O
editing O
techniques O
, O
such O
as O
clustered O
regularly O
interspersed O
short O
palindromic O
repeat O
( O
CRISPR O
) O
- O
CRISPR-associated O
protein-9 O
( O
Cas9 O
) O
and O
APOBEC-coupled O
epigenetic O
sequencing O
( O
ACE-seq O
) O
with O
epigenetic O
drug O
screens O
, O
will O
allow O

This O
article O
discusses O
the O
history O
behind O
the O
multitude O
of O
definitions O
that O
have O
been O
employed O
since O
the O
conception O
of O
epigenetics O
, O
analyzes O
the O
components O
of O
these O
definitions O
, O
and O
offers O
solutions O
for O
clarifying O
the O
field O
and O
mitigating O
the O
problems O
that O
have O
arisen O
due O
to O
these O
definitional O

We O
summarize O
advances O
in O
the O
effort O
to O
image O
HDACs O
and O
HDAC O
inhibitory O
effects O
in O
the O
brain O
using O
positron O
emission O
tomography O
(PET) O
and O
highlight O
generalizable O
techniques O
that O
can O
be O
adapted O
to O
investigate O
other O
specific O
components O
of O
epigenetic O
machinery O

Methods O
: O
Patient O
tumor B-Disease
samples O
were O
profiled O
by O
Whole O
Exome O
Sequencing O
( O
WES O
) O
and O
RNA-seq O
on O
an O
Illumina O
HiSeq O
2500 O
and O
methylation O
profiling O
was O
performed O
on O
the O
Illumina O
Infinium O
450K O
array O

374 O
: O
Epigenetic O
reprogramming O
underlies O
specification O
of O
immune O
cell O
lineages O
, O
but O
patterns O
that O
uniquely O
define O
immune O
cell O
types O
and O
the O
mechanisms O
by O
which O
they O
are O
established O
remain O
unclear O

525 O
: O
Motivation O
: O
Epigenetic O
clocks O
are O
prediction O
methods O
based O
on O
DNA O
methylation O
levels O
in O
a O
given O
species O
or O
set O
of O
species O

A O
simple O
interface O
then O
allows O
the O
user O
to O
query O
the O
data O
using O
lists O
of O
gene O
names O

Discrimination O
is O
assessed O
by O
AUC O
, O
whilst O
classification O
accuracy O
is O
assessed O
by O
accuracy O
and O
kappa O
, O
derived O
from O
confusion O
matrices O

452 O
: O
Dysregulation O
of O
metabolism O
allows O
tumor B-Disease
cells O
to O
generate O
needed O
building O
blocks O
as O
well O
as O
to O
modulate O
epigenetic O
marks O
to O
support O
cancer B-Disease
initiation O
and O
progression O

Out O
of O
these O
, O
24 O
studies O
investigating O
12 O
different O
skeletal O
disorders O
were O
included O
in O
the O
review O

org O
/ O
10 O

The O
field O
of O
epigenetics O
in O
eating B-Disease
disorders I-Disease
remains O
in O
its O
infancy O

We O
show O
that O
DNA O
methylation O
differs O
substantially O
between O
naïve O
and O
memory O
T O
cells O
, O
supporting O
the O
need O
for O
adjustment O
on O
these O
cell-types O

We O
thus O
demonstrate O
that O
DXM O
can O
robustly O
find O
allelic O
subpopulation O
methylation O
profiles O
that O
may O
contribute O
to O
disease B-Disease
progression O
using O
bisulfite O
sequencing O
data O
of O
any O
heterogeneous O
sample O

126 O
: O
The O
involvement O
of O
epigenetic O
processes O
in O
the O
origin O
and O
progression O
of O
cancer B-Disease
is O
now O
widely O
appreciated O

120 O
: O
Predicting O
differentially O
expressed O
genes O
( O
DEGs O
) O
from O
epigenetics O
signal O
data O
is O
the O
key O
to O
understand O
how O
epigenetics O
controls O
cell O
functional O
heterogeneity B-Disease
by O
gene O
regulation O

Immune O
activation O
due O
to O
infection B-Disease
can O
also O
modulate O
brain O
function O
, O
but O
whether O
this O
experience O
can O
be O
passed O
down O
to O
offspring O
remains O
unknown O

Methods O
: O
PubMed O
and O
Web O
of O
Science O
databases O
were O
interrogated O
from O
January O
1995 O
up O
to O
December O
2012 O
using O
combinations O
of O
search O
terms O
, O
including O
" O
epigenetic O
" O
, O
" O
microRNA O
" O
and O
" O
DNA O
methylation O
" O
cross O
referenced O
with O
" O
depression B-Disease
" O
, O
" O
early O

Nevertheless O
, O
as O
we O
gain O
more O
knowledge O
, O
we O
realize O
that O
the O
DNA-protein O
interactions O
are O
not O
driven O
by O
a O
" O
one O
size O
fits O
all O
" O
rule O

The O
growing O
availability O
of O
genomic O
and O
epigenomic O
sequencing O
across O
organisms O
highlights O
this O
diversity O
but O
also O
illuminates O
potential O
factors O
that O
could O
explain O
why O
both O
the O
DNA O
methylation O
machinery O
and O
its O
genome-wide O
distribution O
evolve O
so O
rapidly O

A O
systematic O
search O
was O
conducted O
in O
MEDLINE O
, O
Scopus O
, O
Web O
of O
Science O
, O
Cochrane O
Central O
database O
, O
EMBASE O
, O
and O
CINHAL O

However O
, O
we O
also O
identify O
novel O
associations O
between O
methylomes O
and O
sex O
, O
weight O
, O
and O
sterilization O
status O
, O
leading O
to O
accurate O
models O
that O
predict O
these O
factors O

Studies O
have O
linked O
allele-specific O
genetic O
changes O
to O
gene O
expression O
, O
DNA O
methylation O
, O
and O
histone O
marks O
but O
these O
investigations O
have O
only O
been O
carried O
out O
in O
a O
limited O
set O
of O
samples O

Herein O
, O
I O
review O
HDACis O
and O
microRNAs O
for O
melanoma B-Disease

Alterations O
in O
chromatin O
structure O
lead O
to O
inaccessibility O
of O
genomic O
DNA O
to O
various O
regulatory O
proteins O
such O
as O
transcription O
factors O
, O
which O
eventually O
modulates O
gene O
expression O

Dietary O
bioactive O
compounds O
such O
as O
curcumin O
, O
epigallocatechin-3-gallate O
, O
genistein O
, O
quercetin O
, O
resveratrol O
, O
and O
sulforaphane O
reactivate O
essential O
tumor B-Disease
suppressor O
genes O
by O
reversing O
aberrant O
DNA O
methylation O
patterns O
, O
and O
therefore O
, O
they O
have O
shown O
potential O
against O
various O
c O

The O
purpose O
of O
this O
review O
was O
to O
present O
and O
summarize O
the O
association O
between O
aberrant O
DNA O
methylation O
of O
immune O
cells O
and O
SLE O
, O
the O
possible O
mechanisms O
of O
immune O
dysfunction O
caused O
by O
DNA O
methylation O
, O
and O
to O
better O
understand O
the O
roles O
of O
aberrant O
DNA O
methylation O
in O

Placental O
DNA O
methylation O
allows O
for O
the O
study O
of O
gene-environment O
interactions O
that O
influence O
the O
fetal O
environment O
and O
development O

com O
/ O
pfizer-opensource O
/ O
bigwig-loader O

Currently O
, O
microRNAs O
have O
been O
found O
to O
be O
regulated O
by O
some O
natural O
compounds O

550 O
: O
Postnatal O
environmental O
factors O
, O
such O
as O
early O
life O
adversity O
, O
cannabis O
use O
, O
and O
social O
stressors O
are O
associated O
with O
increased O
risk O
for O
psychotic B-Disease
disorders O

We O
will O
provide O
a O
comprehensive O
introduction O
into O
the O
topic O
, O
describe O
in O
detail O
how O
ChIP-seq O
data O
are O
analyzed O
and O
elaborate O
on O
how O
to O
integrate O
ChIP-seq O
and O
RNA-seq O
data O
from O
a O
segregating O
disease B-Disease
animal O
model O
for O
the O
identification O
of O
the O
epigenetic O
control O
of O
RNA O
expression O

( O
Brassicaceae O
) O
under O
the O
influence O
of O
heat O
stress O

The O
application O
of O
this O
knowledge O
will O
definitively O
provide O
essential O
information O
to O
understand O
the O
pathological O
mechanisms O
of O
endometrial O
diseases O
, O
such O
as O
endometriosis O
and O
endometrial O
cancer B-Disease
, O
and O
to O
identify O
potential O
therapeutic O
targets O
and O
improve O
women O
's O
health O

Genetics O
is O
not O
sufficient O
to O
explain O
these O
diseases O
or O
the O
impact O
of O
them O
on O
patients O

Research O
directions O
and O
the O
importance O
of O
novel O
computational O
tools O
are O
underlined O

Information O
gained O
from O
GWAS O
and O
EWAS O
has O
potential O
applications O
in O
cancer B-Disease
control O
and O
treatment O

This O
article O
discusses O
the O
current O
status O
, O
challenges O
and O
research O
opportunities O
in O
GWAS O
and O
EWAS O

io O

Furthermore O
, O
critical O
research O
challenges O
are O
defined O
and O
the O
way O
forward O
is O
proposed O

The O
interplay O
between O
the O
epigenome O
and O
metabolome O
contributes O
to O
a O
biological O
system O
that O
is O
responsive O
to O
the O
tumor B-Disease
microenvironment O
and O
possesses O
a O
wealth O
of O
unknown O
biomarkers O
and O
targets O
of O
cancer B-Disease
therapy O

The O
highly O
integrated O
layers O
of O
the O
epigenome O
are O
responsible O
for O
the O
cell O
type O
specific O
and O
exquisitely O
environmentally O
responsive O
deployment O
of O
genes O
and O
functional O
gene O
networks O
that O
underlie O
the O
molecular O
pathophysiology O
of O
epilepsy O
and O
its O
associated O
comorbidities O
, O
including O
but O
not O
limited O
to O
neurotransmitter O

578 O
: O
Barker O
et O
al O

Being O
the O
first O
software O
of O
its O
kind O
, O
we O
anticipate O
that O
EpiProfile O
2 O

However O
, O
such O
methods O
do O
not O
capture O
the O
possible O
involvement O
of O
other O
epigenomic O
features O
such O
as O
G-quadruplex O
DNA O
secondary O
structures O
( O
G4s O
) O

``` O
riceblast O
``` O

In O
this O
opinion O
, O
encompassing O
both O
basic O
and O
clinical O
viewpoints O
, O
we O
focus O
on O
selected O
IEIs O
with O
mutations O
in O
transcription O
factors O
that O
interact O
with O
epigenetic O
enzymes O

Changes O
in O
three-dimensional O
chromatin O
structure O
, O
including O
chromatin O
compaction O
, O
looping O
, O
double-stranded O
DNA O
breaks O
, O
histone O
and O
DNA O
modification O
, O
are O
altered O
by O
action O
potential O
activity O
to O
selectively O
inhibit O
or O
promote O
transcription O
of O
specific O
genes O

A O
wide O
range O
of O
methods O
and O
approaches O
exist O
for O
its O
identification O
, O
quantification O
, O
and O
mapping O
within O
the O
genome O

616 O
: O
Although O
epigenetic O
modifications O
have O
been O
intensely O
investigated O
over O
the O
last O
decade O
due O
to O
their O
role O
in O
crop O
adaptation O
to O
rapid O
climate O
change O
, O
it O
is O
unclear O
which O
epigenetic O
changes O
are O
heritable O
and O
therefore O
transmitted O
to O
their O
progeny O

Unfortunately O
, O
these O
advances O
in O
technology O
have O
not O
been O
applied O
to O
explore O
the O
basis O
for O
cancer B-Disease
health O
disparities O

Against O
this O
backdrop O
, O
comparative O
integrative O
biologists O
are O
particularly O
well-suited O
to O
understand O
epigenetic O
phenomena O
as O
a O
way O
for O
organisms O
to O
respond O
rapidly O
with O
modified O
phenotypes O
( O
relative O
to O
natural O
selection O
) O
to O
changes O
in O
the O
environment O

All O
the O
indications O
are O
that O
future O
research O
will O
continue O
to O
reveal O
new O
epigenetic O
targets O
and O
mechanisms O
that O
will O
advance O
the O
prospects O
for O
selective O
epigenetic O
therapy O
for O
IBD O
and O
other O
complex O
diseases O

The O
reversal O
of O
DNA O
methylation O
, O
or O
DNA O
demethylation O
, O
is O
mediated O
by O
the O
ten-eleven O
translocation O
( O
TET O
) O
protein O
family O
of O
dioxygenases O

However O
, O
thus O
far O
, O
no O
method O
explored O
DNA O
methylation O
variability O
in O
longitudinal O
data O
, O
which O
was O
the O
aim O
of O
this O
study O

We O
show O
that O
this O
leads O
to O
a O
marginal O
but O
statistically O
significant O
improvement O
of O
cell-count O
estimates O
in O
whole O
blood O
as O
well O
as O
in O
mixtures O
involving O
epithelial O
cell-types O

An O
essential O
post-translational O
modification O
is O
the O
histone O
acetylation/deacetylation-process O
which O
is O
regulated O
by O
histone O
acetyltransferases O
(HATs) O
and O
histone O
deacetylases O
(HDACs) O

Further O
analysis O
of O
tumoral O
epigenetic O
alterations O
in O
hematopoietic O
CDRs O
points O
to O
sets O
of O
genes O
that O
are O
tightly O
regulated O
in O
leukemic O
transformations O
and O
commonly O
mutated O
in O
other O
tumors B-Disease

This O
information O
will O
facilitate O
the O
identification O
of O
mechanisms O
and O
discovery O
of O
potential O
epigenetic O
targets O
for O
therapeutic O
interventions O
in O
aging O
and O
age-related O
disease B-Disease

In O
the O
present O
study O
, O
we O
aimed O
to O
determine O
whether O
the O
methylation O
levels O
of O
selected O
imprinted O
genes O
can O
be O
used O
as O
diagnostic O
markers O
to O
identify O
epigenetically O
abnormal O
spermatozoa O
sample O
in O
these O
cases O

Using O
a O
wide O
range O
of O
data O
, O
we O
validate O
the O
performance O
of O
TRIAGE O
in O
identifying O
cell-type-specific O
regulatory O
factors O
across O
diverse O
species O
including O
human O
, O
mouse O
, O
boar O
, O
bird O
, O
fish O
, O
and O
tunicate O

352 O
: O
The O
theme O
of O
the O
Society O
of O
Toxicologic O
Pathology O
2014 O
Annual O
Symposium O
was O
" O
Translational O
Pathology O
: O
Relevance O
of O
Toxicologic O
Pathology O
to O
Human O
Health O

Emerging O
technologies O
, O
such O
as O
single-cell O
sequencing O
, O
promise O
to O
overcome O
some O
of O
these O
limitations O

This O
impacts O
area O
such O
as O
cellular O
differentiation O
, O
tissue O
development O
, O
environmental O
induced O
disease B-Disease
etiology O
, O
epigenetic O
transgenerational O
inheritance O
, O
and O
the O
general O
systems O
biology O
of O
organisms O
and O
evolution O

356 O
: O
This O
article O
describes O
ethnography O
as O
a O
research O
method O
and O
outlines O
how O
it O
excels O
in O
capturing O
the O
salient O
experiences O
of O
individuals O
among O
diverse O
communities O
in O
their O
own O
words O

This O
review O
consolidates O
key O
findings O
of O
chromatin O
state O
changes O
in O
senescence B-Disease
including O
histone O
modifications O
, O
histone O
variants O
, O
DNA O
methylation O
and O
changes O
in O
three-dimensional O
genome O
organization O

Conclusions O
: O
The O
experiences O
of O
life O
trauma B-Disease
, O
post-traumatic O
stress O
, O
and O
discrimination O
may O
be O
associated O
with O
accelerated O
epigenetic O
aging O
that O
can O
be O
consistently O
detected O
using O
different O
epigenetic O
clocks O

g O

From O
the O
gene O
to O
the O
complex O
extranuclear O
processes O
of O
development O
; O
3 O

Finally O
, O
across O
our O
DNAm O
models O
, O
we O
show O
evidence O
of O
enrichment O
for O
biological O
pathways O
and O
human O
phenotype O
ontologies O
relevant O
to O
smoking O
, O
such O
as O
haemostasis O
, O
molybdenum O
cofactor O
synthesis O
, O
body O
fatness O
and O
social O
behaviours O
, O
providing O

Here O
we O
show O
that O
the O
two O
methods O
are O
highly O
correlated O
in O
saliva O
and O
buccal O
samples O
( O
R O
= O
0 O

Finally O
, O
our O
work O
suggests O
that O
optimal O
time O
windows O
exist O
for O
rejuvenating O
the O
transcriptome O
and O
the O
epigenome O

In O
this O
work O
, O
we O
provide O
thorough O
reviews O
and O
discussions O
on O
the O
statistical O
method O
developments O
and O
data O
analysis O
strategies O
for O
using O
cfDNA O
epigenetic O
profiles O
, O
in O
particular O
DNA O
methylation O
, O
to O
construct O
disease B-Disease
diagnostic O
models O

333 O
: O
DNA O
methylation O
at O
cytosine O
is O
a O
major O
epigenetic O
mark O
, O
heavily O
implicated O
in O
controlling O
key O
cellular O
processes O
such O
as O
development O
and O
differentiation O
, O
cellular O
memory O
, O
or O
carcinogenesis O

Through O
altering O
the O
expression O
of O
miRNAs O
and O
influencing O
the O
downstream O
signaling O
pathways O
or O
target O
genes O
, O
several O
natural O
compounds O
exhibit O
its O
bioactivity O
in O
the O
prevention O
, O
diagnosis O
, O
therapy O
, O
prognosis O
and O
drug O
resistance O
of O
human O
diseases O
, O
such O
as O
cancer B-Disease

He O
also O
provides O
clinical O
care O
and O
teaching O
in O
the O
rheumatology O
outpatient O
and O
inpatient O
services O
, O
and O
he O
is O
the O
director O
of O
the O
NIH-funded O
rheumatology O
training O
grant O
at O
the O
University O
of O
Michigan O

It O
can O
also O
use O
different O
hierarchies O
of O
cell O
types O
to O
highlight O
the O
epigenetic O
history O
specific O
to O
any O
particular O
cell O
lineage O

Within O
this O
context O
, O
there O
is O
a O
need O
to O
better O
understand O
the O
biological O
mechanisms O
beyond O
ageing O
in O
order O
to O
optimise O
geriatric O
therapies O
and O
medical O
approaches O

560 O
: O
Fetal O
exposure O
to O
prenatal O
stress O
can O
have O
significant O
consequences O
on O
short- O
and O
long-term O
health O

Additionally O
, O
we O
show O
that O
JMnorm-normalized O
data O
can O
consistently O
improve O
the O
performance O
of O
various O
downstream O
analyses O
, O
which O
include O
candidate O
cis-regulatory O
element O
clustering O
, O
cross-cell-type O
gene O
expression O
prediction O
, O
detection O
of O
transcription O
factor O
binding O
and O
changes O
upon O
perturbations O

Furthermore O
, O
altered O
chromatin O
states O
can O
be O
transmitted O
to O
subsequent O
generations O
, O
thus O
epigenetic O
modifications O
may O
provide O
evolutionary O
mechanisms O
that O
impact O
on O
adaptation O
to O
changed O
environments O

As O
such O
, O
ASD O
research O
has O
broadened O
to O
include O
assessment O
of O
other O
molecular O
biomarkers O
implicated O
in O
the O
condition O
that O
may O
be O
reflective O
of O
environmental O
exposures O
or O
gene O
by O
environment O
interactions O

The O
cumulative O
DNA O
damage O
theory O
of O
aging O
postulates O
that O
as O
an O
animal O
ages O
, O
toxic O
reactive O
oxygen O
species O
generated O
as O
byproducts O
of O
the O
mitochondria O
during O
respiration O
induce O
a O
random O
and O
progressive O
damage O
in O
genes O
thus O
leading O
cells O
to O
a O
progressive O
functional O
decline O

The O
clinical O
and O
forensic O
research O
on O
psychopathy B-Disease
is O
brought O
into O
conversation O
with O
the O
emerging O
field O
of O
epigenetics O
to O
highlight O
critical O
issues O
of O
(1) O
clinical O
definition O
and O
diagnosis O
, O
(2) O
assessment O
, O
(3) O
aetiology O
of O
psychopathic B-Disease
phenotypes O
, O
and O
(4) O
treatment O
and O
rehabilitation O

The O
role O
played O
by O
epigenetic O
mechanisms O
in O
the O
pathogenesis O
of O
childhood O
asthma O
is O
understood O
only O
in O
part O

Limitations O
of O
RRBS O
methods O
for O
nonmodel O
species O
740 O
V O

We O
use O
information O
from O
whole O
genome O
and O
targeted O
bisulfite O
sequencing O
from O
910 O
samples O
to O
perform O
genotype-dependent O
analyses O
of O
allele-specific O
methylation O
( O
ASM O
) O
and O
non-allelic O
methylation O
( O
mQTL O
) O

For O
EE O
, O
techniques O
similar O
to O
genome O
editing O
( O
GE O
) O
techniques O
are O
used O

Differentially O
methylated O
region-representational O
difference O
analysis O
(DMR-RDA) O
is O
a O
sensitive O
and O
powerful O
PCR-based O
technique O
that O
isolates O
DNA O
fragments O
that O
are O
differentially O
methylated O
between O
two O
otherwise O
identical O
genomes O

We O
will O
address O
considerations O
for O
all O
steps O
required O
to O
plan O
and O
conduct O
an O
analysis O
of O
DNA O
methylation O
, O
from O
appropriate O
sample O
collection O
, O
to O
the O
most O
commonly O
used O
methods O
for O
laboratory O
analyses O
of O
locus-specific O
and O
genome-wide O
approaches O
, O
and O
recommendations O
for O
statistical O
analyses O

496 O
: O
The O
study O
of O
epigenetics O
has O
its O
roots O
in O
the O
study O
of O
organism O
change O
over O
time O
and O
response O
to O
environmental O
change O
, O
although O
over O
the O
past O
several O
decades O
the O
definition O
has O
been O
formalized O
to O
include O
heritable O
alterations O
in O
gene O
expression O
that O
are O
not O
a O
result O
of O

More O
recently O
has O
been O
the O
development O
of O
DNA O
hydroxymethylation O
profiling O
techniques O
, O
which O
allows O
differentiation O
between O
5mC O
and O
5hmC O
profiles O
and O
provides O
further O
insights O
into O
DNA O
methylation O
dynamics O
and O
remodeling O
in O
tumorigenesis B-Disease

708 O
: O
Ageing O
is O
defined O
as O
the O
'increasing O
frailty O
of O
an O
organism O
with O
time O
that O
reduces O
the O
ability O
of O
that O
organism O
to O
deal O
with O
stress O
' O

The O
seemingly O
natural O
capability O
of O
cancer B-Disease
to O
adapt O
dynamically O
in O
a O
Darwinian O
manner O
is O
a O
primary O
reason O
for O
therapeutic O
failures O

A O
follow-up O
multistakeholder O
meeting O
focussing O
on O
BET O
inhibitors O
will O
be O
held O
to O
define O
how O
to O
prioritise O
the O
multiple O
compounds O
in O
clinical O
development O
that O
could O
be O
evaluated O
in O
children O
with O
cancer B-Disease

In O
my O
view O
, O
further O
studies O
are O
needed O
to O
understand O
the O
toxicity O
of O
these O
treatments O
in O
order O
to O
improve O
survival O
of O
melanoma B-Disease
patients O

As O
more O
accurate O
and O
powerful O
tools O
for O
epigenetic O
analysis O
become O
available O
for O
application O
in O
a O
broader O
range O
of O
plant O
species O
, O
analysis O
of O
the O
epigenetic O
landscape O
of O
plant O
cell O
cultures O
may O
turn O
out O
to O
be O
crucial O
for O
understanding O
variant O
phenotypes O

Epigenetics O
modify O
the O
expression O
of O
genes O
in O
the O
brain O
and O
body O
in O
response O
to O
circulating O
hormones O
and O
other O
mediators O
, O
which O
are O
activated O
to O
facilitate O
survival O
responses O
through O
a O
process O
called O
allostasis O

Such O
links O
would O
have O
diverse O
implications O
in O
basic O
research O
, O
in O
clinics O
, O
as O
well O
as O
for O
therapeutic O
studies O

Different O
strategies O
have O
been O
discussed O
used O
for O
epigenome O
editing O
based O
on O
their O
efficacy O
and O
complexity O

In O
contrast O
, O
fungi-contaminated O
agricultural O
foods O
are O
a O
source O
of O
potent O
mycotoxins O
that O
induce O
carcinogenesis O

This O
method O
allows O
for O
the O
viral O
expression O
of O
engineered O
DNA-binding O
factors O
, O
particularly O
engineered O
ZFPs O
, O
and O
subsequent O
epigenome O
editing O
in O
rodent O
brain O
with O
excellent O
spatiotemporal O
control O

We O
discuss O
studies O
using O
first-generation O
epigenetic O
clocks O
, O
as O
well O
as O
the O
second-generation O
iterations O
, O
which O
appear O
to O
show O
stronger O
associations O
with O
the O
ageing O
muscle O
phenotype O

01 O
)-year O
decrease O
in O
GrimAge O
acceleration O

Deregulation O
of O
these O
processes O
result O
in O
a O
group O
of O
diseases O
are O
characterized O
by O
growth O
, O
development O
, O
and O
neurological O
dysfunction O

While O
conventional O
epigenetic O
clocks O
rely O
on O
genome-wide O
methylation O
data O
, O
targeted O
approaches O
offer O
a O
more O
efficient O
alternative O

65 O
: O
Epigenetics O
is O
a O
natural O
progression O
of O
genetics O
as O
it O
aims O
to O
understand O
how O
genes O
and O
other O
heritable O
elements O
are O
regulated O
in O
eukaryotic O
organisms O

The O
amplification O
of O
much O
smaller O
short O
tandem O
repeat O
( O
STR O
) O
sequences O
using O
the O
polymerase O
chain O
reaction O
soon O
replaced O
RFLP O
analysis O
and O
advanced O
to O
become O
the O
gold O
standard O
in O
genetic O
identification O

Epi-MSA O
first O
uses O
convolutional O
neural O
networks O
for O
neighborhood O
bins O
information O
embedding O
, O
and O
then O
employs O
multiple O
self-attention O
encoders O
on O
different O
input O
epigenetics O
factors O
data O
to O
learn O
which O
locations O
of O
genes O
are O
important O
for O
predicting O
DEGs O

Deregulated O
epigenetic O
modifiers O
cause O
metabolic O
aberrations O
by O
targeting O
the O
expression O
of O
metabolic O
enzymes O

Currently O
, O
epi-drugs O
undergo O
extensive O
development O
, O
research O
, O
and O
application O

In O
addition O
, O
CUT&Tag O
has O
been O
developed O
as O
a O
strategy O
for O
joint O
profiling O
of O
the O
epigenome O
, O
transcriptome O
or O
proteome O
on O
the O
same O
sample O

This O
effect O
on O
gene O
expression O
results O
from O
variations O
in O
chromatin O
states O
and O
is O
induced O
by O
biochemical O
modifications O
targeting O
the O
DNA O
molecule O
or O
associated O
histone O
proteins O

453 O
: O
Transgenerational O
epigenetic O
inheritance O
in O
mammals O
remains O
a O
controversial O
phenomenon O

However O
, O
comparisons O
between O
these O
studies O
are O
routinely O
hampered O
by O
the O
lack O
of O
consistency O
in O
reporting O
sites O
of O
methylation O
evaluated O

Thus O
, O
a O
number O
of O
bioinformatic O
tools O
have O
been O
developed O
to O
infer O
heterogeneous O
tumor B-Disease
populations O
based O
on O
genomic O
signatures O
such O
as O
mutations O
and O
copy O
number O
variations O

Profiling O
DNA O
methylation O
across O
the O
genome O
is O
critical O
to O
understanding O
the O
influence O
of O
epigenetics O
in O
normal O
biology O
and O
disease B-Disease
, O
such O
as O
cancer B-Disease

96 O
: O
Abnormal O
gene O
regulation O
as O
a O
consequence O
of O
flawed O
epigenetic O
mechanisms O
may O
be O
central O
to O
the O
initiation O
and O
persistence O
of O
many O
human O
diseases O

So O
far O
, O
this O
explosion O
has O
been O
muted O
, O
and O
for O
now O
epigenetic O
data O
protection O
merely O
seems O
to O
be O
"enjoying" O
the O
same O
technological O
and O
legal O
challenges O
experienced O
by O
other O
clinical O
and O
research O
data O

Despite O
several O
new O
disease-associated O
factors O
have O
been O
discovered O
based O
on O
single O
omics O
data O
analysis O
, O
identification O
of O
disease B-Disease
targets O
by O
integrative O
analysis O
of O
multi-omics O
data O
is O
still O
growing O

The O
majority O
of O
such O
disorders O
have O
unknown O
underlying O
causes O

We O
focus O
on O
the O
relevance O
of O
DNA O
methylation O
, O
a O
well O
characterized O
epigenetic O
modification O
of O
the O
genome O
, O
as O
a O
biomarker O
and O
underlying O
mechanism O
of O
atherosclerosis O

First O
, O
we O
describe O
recent O
advances O
in O
newborn O
screening O
( O
NBS O
) O
, O
with O
a O
focus O
on O
the O
practice O
and O
policy O
implications O
of O
current O
and O
future O
efforts O
to O
expand O
NBS O
programs O
( O
e O

We O
summarize O
the O
up-to-date O
findings O
and O
discuss O
the O
implications O
of O
various O
studies O
and O
point O
to O
new O
avenues O
of O
research O
on O
PCOS O
in O
the O
rapidly O
developing O
field O
of O
epigenetics O
and O
epigenomics O

Being O
able O
to O
quantify O
to O
which O
extent O
epigenomic O
processes O
are O
mediators O
of O
the O
association O
between O
environmental O
exposures O
and O
diseases O
is O
of O
interest O
for O
epidemiologic O
research O

In O
fact O
, O
it O
is O
now O
clear O
that O
epigenetic O
mechanisms O
promote O
seminal O
neurobiological O
processes O
, O
ranging O
from O
neural O
stem O
cell O
maintenance O
and O
differentiation O
to O
learning O
and O
memory O

259 O
: O
Methamphetamine O
is O
a O
widely O
abused O
drug O
, O
which O
possesses O
neurotoxic O
activity O
and O
powerful O
addictive O
effects O

Recently O
, O
DNA O
methylation O
has O
been O
demonstrated O
to O
be O
required O
for O
vertebrate O
early O
embryogenesis O

Chromatin O
immunoprecipitation O
is O
the O
most O
popular O
and O
powerful O
approach O
for O
mapping O
chromatin O
, O
and O
other O
enzyme-tethering O
techniques O
have O
recently O
become O
available O
for O
living O
cells O

Significant O
progress O
has O
been O
made O
dissecting O
the O
epigenome O
in O
paediatric O
rheumatic O
diseases O
and O
identifies O
associations O
with O
clinical O
phenotypes O
, O
treatment O
responses O
and O
disease B-Disease
outcomes O

However O
, O
DNA O
methylation O
evolves O
surprisingly O
rapidly O
across O
eukaryotes O

These O
findings O
uncover O
a O
novel O
mechanism O
by O
which O
DAC O
suppresses O
tumor B-Disease
growth O
by O
targeting O
the O
FBW7/Mcl-1 O
signaling O
pathway O

736 O
: O
The O
pathological O
hallmark O
of O
neurodegeneration B-Disease
is O
presence O
of O
intra- O
and O
extra O
neuronal O
inclusion O
bodies O
such O
as O
Lewy O
bodies O
in O
Parkinson's B-Disease
disease I-Disease
, O
senile O
plaques O
and O
neurofibrillary O
tangles O
in O
Alzheimer's B-Disease
disease I-Disease

com O
/ O
andreaskapou O
/ O
scMET O

Pathway O
analysis O
interaction O
for O
TAPBP O
, O
BDNF O
, O
and O
SORBS2 O
confirmed O
the O
relation O
of O
these O
genes O
in O
both O
obesity B-Disease
and O
mood B-Disease
disorders I-Disease

Faced O
with O
these O
two O
concerns O
, O
many O
turn O
away O
from O
epigenetics O
altogether O
, O
refusing O
its O
novelty O
and O
supposed O
benefit O
for O
Indigenous O
health O
equity O
and O
resisting O
the O
pull O
of O
postgenomics O

Since O
life O
is O
a O
complex O
regulatory O
system O
in O
which O
the O
regulation O
of O
gene O
mutations O
, O
epigenetic O
alterations O
, O
abnormal O
gene O
expression O
as O
well O
as O
anomalous O
variations O
in O
signal O
pathway O
are O
related O
with O
the O
occurrence O
and O
development O
of O
diseases O
, O
it O
is O
obvious O
that O
finding O
ther O

For O
this O
purpose O
, O
whole-genome O
sequencing O
of O
sodium O
bisulfite-treated O
DNA O
was O
performed O

Here O
we O
describe O
the O
enzymes O
that O
control O
the O
epigenetic O
state O
of O
the O
cell O
, O
how O
they O
are O
affected O
in O
cancer B-Disease
and O
how O
this O
knowledge O
can O
be O
exploited O
to O
treat O
cancer B-Disease
with O
a O
new O
arsenal O
of O
selective O
therapies O

The O
role O
of O
epigenetics O
in O
normal O
embryonic O
development O
and O
the O
influence O
of O
biological O
and O
environmental O
factors O
altering O
behavior O
through O
epigenetic O
mechanisms O
and O
developmental O
programming O
are O
discussed O

We O
conclude O
with O
a O
discussion O
of O
social O
epigenetics O
as O
a O
mechanistic O
link O
to O
health O
inequalities O
and O
provide O
suggestions O
for O
future O
social O
epigenetics O
research O
on O
health O
inequalities O

Quality O
assessment O
revealed O
a O
high O
risk O
of O
bias O
in O
domains O
pertaining O
to O
randomization O
, O
allocation O
concealment O
, O
blinding O
of O
outcome O
assessors O
and O
determination O
of O
sample O
size O

705 O
: O
Gene O
body O
methylation O
( O
gbM O
) O
is O
an O
epigenetic O
mark O
where O
gene O
exons O
are O
methylated O
in O
the O
CG O
context O
only O
, O
as O
opposed O
to O
CHG O
and O
CHH O
contexts O
( O
where O
H O
stands O
for O
A O
, O
C O
, O
or O
T O
) O

N-terminal O
fusions O
showed O
better O
results O
for O
both O
Cas9 O
orthologs O
, O
SaCas9 O
and O
SpCas9 O
, O
so O
it O
can O
be O
used O
as O
universal O
approach O
for O
linking O
different O
effector O
domains O
in O
order O
to O
obtain O
highly O
active O
fusions O

For O
these O
reasons O
chromatin O
biology O
and O
epigenetic O
research O
have O
a O
rich O
history O
of O
chasing O
discoveries O
in O
a O
variety O
of O
model O
organisms O
, O
including O
yeast O
, O
flies O
, O
plants O
and O
humans O

0_Family O

163 O
: O
Epigenetics O
is O
a O
rapidly O
growing O
field O
describing O
heritable O
alterations O
in O
gene O
expression O
that O
do O
not O
involve O
DNA O
sequence O
variations O

A O
further O
review O
of O
the O
scientific O
basis O
for O
the O
relevance O
of O
epigenetics O
is O
found O
in O
the O
accompanying O
article O
by O
Philibert O
and O
Erwin O
in O
this O
issue O

03-1 O

This O
improved O
control O
promises O
to O
revolutionize O
our O
understanding O
of O
epigenetic O
modifications O
in O
human O
health O
and O
disease B-Disease
states O

Recent O
advances O
in O
clustered O
regularly O
interspaced O
palindromic O
repeats O
( O
CRISPR O
) O
/ O
Cas-based O
epigenome O
editing O
technologies O
have O
enabled O
researchers O
to O
site-specifically O
program O
epigenetic O
modifications O
to O
endogenous O
DNA O
and O
histones O
and O
to O
manipulate O
the O
architecture O
of O
native O
chromatin O

Not O
surprisingly O
, O
it O
is O
also O
becoming O
apparent O
that O
epigenetics O
is O
intimately O
involved O
in O
neurological O
disease B-Disease
pathogenesis O

731 O
: O
Diabetic O
nephropathy O
is O
one O
of O
the O
most O
prevalent O
microvascular O
complication O
in O
patients O
suffering O
from O
diabetes B-Disease
and O
is O
reported O
to O
be O
the O
major O
cause O
of O
renal O
failure O
when O
compared O
to O
any O
other O
kidney O
disease B-Disease

311 O
: O
The O
integration O
of O
genetic O
and O
environmental O
factors O
that O
regulate O
the O
gene O
expression O
patterns O
associated O
with O
exercise O
adaptation O
is O
mediated O
by O
epigenetic O
mechanisms O

These O
have O
implications O
for O
investigating O
the O
link O
of O
the O
phenomena O
to O
human O
diabetes B-Disease
, O
providing O
a O
new O
perspective O
on O
environmentally O
triggered O
diabetes B-Disease
risk O

It O
is O
increasingly O
recognised O
that O
the O
study O
of O
DNA O
methylation O
(DNAm) O
patterns O
along O
the O
genome O
- O
so-called O
'epialleles' O
- O
offers O
greater O
insight O
into O
epigenetic O
dynamics O
than O
conventional O
analyses O
which O
examine O
DNAm O
marks O
individually O

Identification O
and O
comparison O
of O
the O
epigenomic O
landscape O
has O
challenged O
our O
understanding O
of O
the O
regulation O
of O
phenotype O

We O
pay O
special O
attention O
to O
the O
risk O
of O
social O
discrimination O
and O
stigmatization O
as O
a O
consequence O
of O
inferring O
information O
related O
to O
lifestyle O
and O
environmental O
exposures O
potentially O
contained O
in O
epigenetic O
data O

An O
epigenetic O
clock O
developed O
using O
muscle O
samples O
accurately O
predicted O
age O
in O
samples O
of O
testis O
but O
not O
ovaries O
, O
possibly O
reflecting O
the O
reproductive O
biology O
of O
fish O

In O
addition O
, O
MPTR O
fibroblasts O
produced O
youthful O
levels O
of O
collagen O
proteins O
, O
and O
showed O
partial O
functional O
rejuvenation O
of O
their O
migration O
speed O

208: O
Fifth O
International O
cancer B-Disease
Epigenetics O
Conference O
, O
Beijing O
, O
China O
, O
21-23 O
October O
2016 O
This O
meeting O
reported O
many O
new O
findings O
in O
the O
field O
of O
cancer B-Disease
epigenetics O
, O
including O
basic O
science O
, O
translational O
and O
clinical O
studies O

559 O
: O
Transcription O
is O
epigenetically O
regulated O
by O
the O
orchestrated O
function O
of O
chromatin-binding O
proteins O
that O
tightly O
control O
the O
expression O
of O
master O
transcription O
factors O
, O
effectors O
, O
and O
supportive O
housekeeping O
genes O
required O
for O
establishing O
and O
propagating O
the O
normal O
and O
malignant O
cell O
state O

0001 O
, O
0 O

Indeed O
, O
the O
flexibility O
of O
epigenetic O
effects O
and O
stability O
of O
genetic O
coding O
lead O
to O
gene O
regulation O
complexity O
in O
response O
signals O

Aberrant O
DNA O
methylation O
is O
implicated O
in O
immune O
dysfunction O
, O
inflammation B-Disease
, O
and O
insulin O
resistance O

Our O
model O
allows O
for O
variations O
to O
be O
inherited O
, O
randomly O
produced O
, O
or O
environmentally O
induced O
, O
and O
, O
irrespectively O
, O
to O
be O
either O
transmitted O
or O
not O
during O
reproduction O

A O
great O
deal O
of O
this O
work O
has O
centered O
on O
neurodevelopmental O
and O
adulthood O
plasticity O
, O
with O
increased O
focus O
in O
the O
areas O
of O
neuropharmacology O
and O
molecular O
psychiatry O

On O
the O
other O
side O
, O
when O
samples O
are O
pooled O
together O
for O
joint O
analysis O
, O
individual-level O
statistical O
differences O
are O
averaged O
out O

Therefore O
, O
an O
important O
gap O
in O
the O
field O
is O
the O
lack O
of O
a O
universal O
data O
harmonizer O
with O
the O
capability O
to O
arbitrarily O
integrate O
multi-modal O
datasets O

Their O
advantages O
and O
disadvantages O
will O
also O
be O
discussed O

bioconductor O

696 O
: O
Background O
: O
Long-term O
stored O
serum O
is O
considered O
challenging O
for O
epigenomic O
analyses O
: O
as O
there O
are O
no O
cells O
, O
circulating O
DNA O
is O
scarce O
, O
and O
amplification O
removes O
epigenetic O
signals O

More O
research O
in O
epigenetics O
is O
needed O
that O
will O
enhance O
our O
understanding O
of O
the O
determinants O
of O
cancer B-Disease
across O
various O
diverse O
populations O
and O
ultimately O
reduce O
cancer B-Disease
health O
disparities O

Epigenetic O
processes O
, O
in O
particular O
DNA O
methylation O
, O
may O
play O
a O
role O
in O
the O
induction O
of O
phenotypes O
with O
increased O
cancer B-Disease
risk O
due O
to O
exposure O
to O
these O
multiple O
factors O

Herein O
, O
we O
review O
the O
findings O
on O
epigenetics O
associated O
with O
psoriasis B-Disease
, O
and O
discuss O
future O
perspectives O
in O
this O
field O

824 O
) O
and O
precise O
( O
2 O

Then O
, O
we O
discuss O
the O
CRISPR O
based O
methods O
for O
targeted O
transcriptional O
regulation O
, O
epigenome O
editing O
, O
and O
RNA O
editing O

Finally O
, O
genes O
; O
GRIK2 O
, O
TRAF1 O
, O
BICC1 O
, O
STAG1 O
were O
epigenetically O
sensitive O
to O
acute O
exercise O
demonstrating O
hypomethylation O
after O
a O
single O
bout O
of O
resistance O
exercise O
that O
was O
maintained O
22 O
weeks O
later O
with O
the O
largest O
increase O
in O
gene O
expression O
and O
muscle O
mass O
after O
re O

Change O
in O
gene O
expression O
due O
to O
these O
epigenetic O
modifications O
are O
responsible O
for O
new O
traits O
in O
different O
organisms O
leading O
to O
various O
diseases O
including O
cancer B-Disease
, O
diabetic B-Disease
kidney O
disease B-Disease
( O
DKD O
) O
, O
diabetic B-Disease
nephropathy O
( O
DN O
) O
and O
renal O
fibrosis O

However O
, O
for O
rare O
or O
precious O
biological O
samples O
, O
input O
requirements O
of O
many O
of O
these O
methods O
limit O
their O
application O

Overall O
, O
the O
findings O
are O
heterogeneous O

Two O
contributions O
compared O
epigenome-wide O
heritability O
estimates O
pretreatment O
and O
posttreatment O
, O
with O
one O
employing O
a O
Bayesian O
LME O
and O
the O
other O
using O
a O
variance-component O
LME O

( O
Maas O
model O
) O
, O
weighted O
scores O
from O
a O
LASSO O
model O
of O
candidate O
smoking O
CpGs O
from O
the O
literature O
( O
candidate O
CpG O
LASSO O
model O
) O
, O
and O
weighted O
scores O
from O
a O
LASSO O
model O
supplied O
with O
genome-wide O
450K O
data O
( O
agnostic O
LASSO O
model O
) O

Epigenetics O
becomes O
a O
hot O
subject O
of O
research O
on O
the O
cardiac O
differentiation O
mechanism O
of O
stem O
cells O
providing O
new O
theories O
and O
Methods O
for O
stem O
cell O
application O
in O
developmental O
biology O
, O
genetics O
and O
regenerative O
medicine O

Conclusions O
: O
This O
study O
presents O
the O
first O
genome-wide O
mapping O
of O
epigenetic O
differences O
in O
hematopoietic O
cells O
across O
the O
late O
gestational O
period O

471 O
: O
Pheochromocytomas O
and O
paragangliomas O
( O
PPGL O
) O
are O
rare O
neuroendocrine O
tumors B-Disease
arising O
from O
the O
adrenal O
medulla O
or O
extra-adrenal O
paraganglia O

Various O
types O
of O
live-cell O
imaging O
epigenetic O
sensors O
suitable O
for O
conventional O
as O
well O
as O
super-resolution O
fluorescence O
microscopy O
are O
described O

However O
, O
it O
has O
recently O
become O
clear O
that O
changes O
to O
the O
secondary O
modifications O
of O
DNA O
and O
histone O
structures O
( O
epigenetic O
variation O
) O
can O
also O
cause O
neurodevelopmental O
disorders O
via O
alteration O
of O
neural O
gene O
function O

Combined O
treatment O
with O
DAC O
and O
a O
Bcl2 O
inhibitor O
, O
venetoclax O
, O
exhibited O
strong O
synergistic O
potency O
against O
lung B-Disease
cancer I-Disease
without O
normal O
tissue O
toxicity O

New O
research O
highlights O
how O
the O
cell O
cycle O
can O
influence O
DNA O
methylation O
dynamics O
observed O
during O
male O
gametogenesis O
and O
may O
induce O
epigenetic O
variation O
in O
clonally O
propagated O
plants O

Thus O
, O
this O
combination O
can O
correctly O
classify O
control O
samples O
and O
potentially O
identify O
epigenetically O
abnormal O
spermatozoa O
samples O
in O
the O
male O
partners O
of O
couples O
undergoing O
RPL O

The O
large O
number O
of O
differentially O
methylated O
cytosines O
between O
hybrids O
and O
parental O
species O
(n O
= O
5,800 O
) O
suggests O
that O
hybridization O
may O
play O
a O
role O
in O
increasing O
genetic O
and O
epigenetic O
variation O

In O
the O
simple O
tumor B-Disease
viruses B-Disease
like O
the O
polyomaviruses O
, O
adenoviruses O
, O
and O
papillomaviruses O
, O
transformation O
of O
the O
cell O
occurs O
via O
integration O
of O
the O
virus B-Disease
genome O
such O
that O
the O
virus B-Disease
's O
normal O
regulation O
is O
disrupted O

Availability O
and O
implementation O
: O
S3V2-IDEAS O
pipeline O
is O
freely O
available O
as O
open O
source O
software O
released O
under O
an O
MIT O
license O
at O
: O
https O
: O
/ O
/ O
github O

Method O
: O
We O
conducted O
a O
scoping O
review O
based O
on O
a O
systematic O
literature O
search O
in O
PsycINFO O
, O
PubMed O
, O
and O
Embase O
databases O
for O
relevant O
abstracts O
using O
the O
terms O
attachment O
and O
epigenet* O

31 O
: O
Over O
the O
past O
70 O
years O
, O
the O
study O
of O
epigenetics O
has O
evolved O
from O
a O
research O
curiosity O
for O
outsiders O
to O
one O
of O
the O
most O
hyped O
biological O
concepts O

445 O
: O
Diabetic O
retinopathy O
( O
DR O
) O
, O
which O
arises O
as O
a O
result O
of O
an O
increasing O
incidence O
of O
diabetes B-Disease
mellitus O
, O
has O
gradually O
become O
a O
common O
disease B-Disease

Recent O
advances O
in O
experimental O
methods O
led O
to O
the O
identification O
of O
epigenetic O
target O
sites O
in O
various O
organisms O

Although O
distinct O
approaches O
have O
shown O
to O
be O
successful O
in O
directing O
neuronal O
cell O
fate O
in O
vitro O
, O
their O
refinement O
and O
optimization O
, O
as O
well O
as O
the O
search O
for O
alternative O
approaches O
, O
remains O
necessary O
to O
help O
realize O
the O
full O
potential O
of O
the O
eventually O
derived O
neuronal O
populations O

546 O
: O
Metabolic O
deregulation O
is O
a O
key O
factor O
in O
cancer B-Disease
progression O

There O
are O
limited O
studies O
in O
which O
epigenetic O
changes O
have O
been O
explored O
to O
address O
cancer B-Disease
disparities O
in O
various O
racial O
and O
ethnic O
populations O

We O
followed-up O
our O
statistical O
analyses O
with O
a O
literature O
review O
in O
order O
to O
inform O
the O
proposed O
disease B-Disease
implications O
for O
the O
loci O
we O
uncovered O

This O
approach O
could O
reach O
beyond O
the O
practitioners O
'eyeball' O
assessment O
or O
venerable O
markers O
derived O
from O
the O
physical O
examination O
and O
standard O
laboratory O
evaluation O

Monozygotic O
twins O
discordant O
for O
any O
disease B-Disease
offer O
an O
ideal O
study O
design O
as O
they O
are O
matched O
for O
many O
factors O
, O
including O
genetic O
variation O
and O
this O
is O
a O
real O
advantage O
for O
epigenetics O
study O

Due O
emphasis O
should O
be O
given O
to O
epigenetic O
mechanisms O
in O
the O
pharmacotherapy O
, O
psychotherapy O
and O
nutritional O
management O
of O
these O
disorders O

e O

Also O
, O
sequences O
flanking O
DMC O
were O
enriched O
in O
SNPs O
compared O
to O
all O
other O
CpGs O
, O
either O
methylated O
or O
unmethylated O
in O
the O
two O
subspecies O


Methods O
: O
Promoter O
DNA O
methylation O
was O
quantified O
in O
the O
bisulfite O
modified O
blood O
from O
the O
pediatric O
ALL O
patients O
( O
n O
= O
86 O
) O
in O
comparison O
with O
age-matched O
cancer-free O
subjects O
( O
n O
= O
28 O
) O
, O
using O
real-time O
methylation O
specific O
PCR O
followed O
by O
rigorous O
statistical O
validations O

This O
data O
can O
be O
used O
to O
design O
drugs O
against O
diseases O
linked O
to O
epigenetic O
modifications O

( O
4 O
) O
Conclusions O
: O
While O
mechanisms O
linking O
both O
obesity B-Disease
and O
mood B-Disease
disorders I-Disease
to O
epigenetic O
response O
are O
still O
unknown O
, O
we O
have O
already O
known O
chronic B-Disease
inflammation I-Disease
induces O
a O
novel O
epigenetic O
program O

13 O

90 O
: O
Epigenetics O
is O
mainly O
comprised O
of O
features O
that O
regulate O
genomic O
interactions O
thereby O
playing O
a O
crucial O
role O
in O
a O
vast O
array O
of O
biological O
processes O

Discussion O
: O
Higher O
surrounding O
greenness O
was O
associated O
with O
slower O
biological O
aging O
, O
as O
indicated O
by O
GrimAge O
age O
acceleration O
, O
in O
Australian O
women O

132 O
: O
Epigenetics O
, O
a O
field O
that O
links O
genetics O
and O
environmental O
influences O
on O
the O
expression O
of O
phenotypic O
traits O
, O
offers O
to O
increase O
our O
understanding O
of O
the O
development O
and O
trajectory O
of O
disease B-Disease
and O
psychological O
disorders O
beyond O
that O
thought O
of O
traditional O
genetic O
research O
and O
behavioural O

He O
has O
also O
presented O
frequently O
at O
AACR O
conferences O
and O
chaired O
the O
special O
conference O
on O
' O
DNA O
Methylation O
, O
Imprinting O
and O
the O
Epigenetics O
of O
Cancer B-Disease
' O

Additionally O
, O
our O
cohort O
is O
unique O
in O
its O
large O
size O
, O
diversity O
, O
and O
focus O
on O
healthy O
donors O

Aberrant O
DNA O
methylation O
has O
unique O
characteristics O
different O
from O
point O
mutations O
and O
is O
utilized O
as O
a O
diagnostic O
target O

Conclusions O
: O
Detection O
and O
comparison O
of O
epialleles O
within O
multiple O
tumour B-Disease
regions O
enables O
phylogenetic O
analyses O
, O
identification O
of O
differentially O
expressed O
epialleles O
, O
and O
provides O
a O
measure O
of O
epigenetic O
heterogeneity B-Disease

Epigenetic O
conceptions O
of O
aging O
gained O
currency O
with O
the O
development O
of O
methylation O
clocks O
beginning O
in O
2013 O

To O
address O
these O
challenges O
, O
we O
developed O
eDICE O
, O
an O
attention-based O
deep O
learning O
model O
that O
is O
trained O
to O
impute O
missing O
epigenomic O
tracks O
by O
conditioning O
on O
observed O
tracks O

In O
addition O
to O
promoter O
polymorphisms O
, O
epigenetic O
modification O
can O
alter O
downstream O
gene O
expression O


Methods O
: O
This O
article O
highlights O
the O
following O
aspects O
of O
pharmacoepigenetics O
and O
pharmacoepigenomics O
: O
epigenetic O
therapy O
, O
the O
role O
of O
epigenetics O
in O
pharmacokinetics O
, O
the O
relevance O
of O
epigenetics O
to O
adverse O
drug O
reactions O
, O
personalized O
medicine O
, O
drug O
addiction O
, O
and O
drug O
resistance O

J O
Exp O
Zool O
B O
(Mol O
Dev O
Evol O
) O
312:667-678) O
suggests O
to O
interpret O
the O
controversial O
midwife O
toad O
experiments O
of O
the O
early O
20th O
century O
zoologist O
Paul O
Kammerer O
in O
the O
context O
of O
epigenetic O
inheritance O

98 O
: O
About O
80 O
% O
of O
brain O
disorders O
have O
a O
genetic O
basis O

Recent O
studies O
attempted O
to O
link O
epigenetic O
modifications O
with O
genetic O
or O
environmental O
risk O
factors O
for O
RA O

469 O
: O
DNA O
methylation O
is O
a O
chemically O
reversible O
epigenetic O
modification O
that O
regulates O
the O
chromatin O
structure O
and O
gene O
expression O
, O
and O
thereby O
takes O
part O
in O
various O
cellular O
processes O
like O
embryogenesis O
, O
genomic O
imprinting O
, O
X-chromosome O
inactivation O
, O
and O
genome O
stability O

He O
has O
served O
on O
the O
American O
Association O
for O
Cancer B-Disease
Research O
Board O
of O
Directors O
, O
and O
is O
an O
associate O
editor O
of O
Cancer B-Disease
Research O

If O
this O
is O
the O
case O
, O
an O
imperative O
exists O
to O
reconcile O
lifespan/longevity O
associated O
inherited O
epigenetic O
processes O
with O
the O
evolution O
of O
ageing O

Here O
we O
describe O
EpiExplorer O
, O
a O
web O
tool O
for O
exploring O
genome O
and O
epigenome O
data O
on O
a O
genomic O
scale O

We O
summarize O
recent O
findings O
about O
the O
role O
of O
epigenetics O
in O
social O
insects O
, O
focusing O
on O
DNA O
methylation O
and O
histone O
modifications O

301 O
: O
Gene O
expression O
in O
individual O
cells O
is O
epigenetically O
regulated O
by O
DNA O
modifications O
, O
histone O
modifications O
, O
transcription O
factors O
, O
and O
other O
DNA-binding O
proteins O

ocellatus O
(outcrossing) O

Custom O
approaches O
were O
used O
for O
the O
integration O
of O
the O
multi-omic O
datasets O

Nevertheless O
, O
there O
are O
very O
few O
examples O
of O
epigenetic O
biomarkers O
implemented O
in O
the O
clinical O
setting O

As O
the O
cost O
of O
genome O
sequencing O
technologies O
continues O
to O
drop O
, O
it O
will O
soon O
become O
commonplace O
to O
perform O
genome-wide O
quantification O
of O
DNA O
methylation O
at O
a O
single O
base-pair O
resolution O

This O
review O
addresses O
recent O
findings O
examining O
DNA O
methylation O
, O
histone O
modifications O
and O
miRNA O
changes O
in O
aging O
MSC O
populations O

2 O
million O
CpGs O
tested O
for O
ASM O
, O
mQTL O
, O
and O
genotype-independent O
effects O
, O
we O
identify O
~32% O
as O
being O
genetically O
regulated O
( O
ASM O
or O
mQTL O
) O
and O
~14% O
as O
being O
putatively O
epigenetically O
regulated O

These O
results O
show O
the O
variations O
in O
chromatin O
remodeling O
protein O
expression O
have O
a O
strong O
impact O
on O
iPSC O
reprogramming O

This O
will O
be O
followed O
by O
an O
overview O
of O
the O
key O
findings O
to O
date O
investigating O
the O
role O
of O
epigenetics O
in O
ADHD O

675 O
: O
Purpose O
: O
The O
aims O
of O
this O
paper O
are O
to O
synthesize O
and O
report O
research O
findings O
from O
neuroscience O
and O
epigenetics O
that O
contribute O
to O
an O
emerging O
explanatory O
framework O
for O
advanced O
practice O
psychiatric B-Disease
nursing O

However O
, O
it O
is O
possible O
that O
with O
more O
longitudinal O
studies O
and O
better O
characterised O
cohorts O
, O
both O
predictive O
and O
protective O
links O
between O
epigenetic O
processes O
and O
ADHD O
will O
be O
revealed O

In O
central O
nervous B-Disease
system I-Disease
disorders O
, O
CpG O
methylation O
has O
been O
associated O
with O
psychiatric B-Disease
disorders I-Disease
, O
such O
as O
autism B-Disease
and O
schizophrenia B-Disease

204 O
: O
We O
introduce O
the O
special O
section O
on O
" O
Genetics O
and O
Epigenetics O
in O
Family O
Context O

576 O
: O
The O
critical O
role O
of O
dysregulated O
epigenetic O
pathways O
in O
cancer B-Disease
genesis O
, O
development O
, O
and O
therapy O
has O
typically O
been O
established O
as O
a O
result O
of O
scientific O
and O
technical O
innovations O
in O
next O
generation O
sequencing O

With O
MethLAB O
, O
we O
present O
a O
timely O
resource O
that O
will O
allow O
users O
with O
no O
programming O
experience O
to O
implement O
flexible O
and O
powerful O
analyses O
of O
DNA O
methylation O
data O

Despite O
their O
shapes O
reminiscent O
of O
an O
entangled O
yarn O
, O
the O
rapid O
development O
of O
molecular O
and O
next-generation O
sequencing O
technologies O
( O
NGS O
) O
has O
revealed O
that O
mammalian O
genomes O
are O
highly O
organized O
in O
a O
hierarchical O
order O
that O
delicately O
affects O
transcription O
activities O

426 O
: O
Recent O
evidence O
suggests O
that O
DNA O
methylation O
changes O
may O
underlie O
numerous O
complex O
traits O
and O
diseases O

716 O
: O
Introduction O
: O
Gastric O
cancer B-Disease
( O
GC O
) O
is O
the O
fifth O
most O
common O
malignancy O
in O
the O
world O
and O
accounts O
for O
7 O

184 O
: O
Adult O
tissue O
stem O
cells O
have O
a O
pivotal O
role O
in O
tissue O
maintenance O
and O
regeneration O
throughout O
the O
lifespan O
of O
multicellular O
organisms O

A O
new O
quantitative O
genetic O
model O
, O
iFACE O
, O
is O
introduced O
to O
correctly O
identify O
the O
structural O
variation O
generated O
by O
self-organizing O
epigenetic O
processes O

Using O
this O
information O
, O
we O
highlight O
specific O
examples O
where O
neutrophil O
oxidants O
react O
with O
epigenetic O
pathway O
components O

We O
then O
( O
II O
) O
compare O
EE O
and O
GE O
and O
suggest O
that O
the O
severity O
of O
risks O
of O
novel O
gene O
technologies O
depends O
on O
three O
factors O
: O
( O
i O
) O
the O
choice O
of O
an O
ex O
vivo O
versus O
an O
in O
vivo O
editing O
approach O
, O
( O
ii O
) O
the O
time O
of O
inter O

DNA O
methyltransferase O
inhibitors/hypomethylating O
agents O
and O
histone O
deacetylase O
inhibitors O
were O
largely O
excluded O
from O
discussion O
as O
the O
aim O
was O
to O
discuss O
those O
targets O
for O
which O
therapeutic O
agents O
are O
currently O
in O
early O
paediatric O
and O
adult O
development O

513 O
: O
Whole-genome O
methylation O
analysis O
of O
newborns O
and O
centenarians O
reveals O
widespread O
epigenetic O
alterations O
, O
and O
provides O
new O
insight O
into O
age-related O
methylation O
pattern O
changes O

Epigenetics O
may O
be O
the O
missing O
molecular O
evidence O
of O
the O
importance O
of O
using O
preventive O
strategies O
at O
the O
policy O
level O
to O
reduce O
the O
incidence O
and O
prevalence O
of O
common O
diseases O

Finally O
, O
we O
discuss O
how O
fundamental O
insights O
gained O
by O
NGS O
, O
particularly O
the O
discovery O
of O
widespread O
allele-specific O
epigenetic O
variation O
in O
the O
human O
genome O
, O
have O
the O
potential O
to O
significantly O
contribute O
to O
the O
understanding O
of O
human O
common O
complex O
diseases O

The O
purpose O
of O
this O
review O
is O
to O
outline O
the O
contribution O
of O
epigenetic O
mechanisms O
to O
genomic O
function O
, O
particularly O
in O
the O
development O
of O
complex O
behavioral O
phenotypes O
, O
focusing O
on O
the O
sensitive O
periods O

While O
it O
is O
important O
to O
determine O
how O
we O
can O
lower O
the O
risk O
of O
these O
NCDs O
, O
it O
is O
equally O
important O
to O
understand O
how O
the O
public's O
knowledge O
and O
opinion O
of O
DOHaD O
and O
epigenetic O
concepts O
may O
influence O
their O
willingness O
to O
undertake O
such O
interventions O
for O
themselves O

725 O
: O
DNA O
methylation O
is O
an O
important O
epigenetic O
modification O
that O
regulates O
temporal O
and O
spatial O
expression O
of O
genes O
for O
controlling O
cell O
fate O
and O
differentiation O

However O
, O
although O
variations O
in O
DNAm O
are O
frequently O
found O
in O
stress-related O
genes O
, O
unsupervised O
epigenome-wide O
association O
studies O
( O
EWAS O
) O
have O
shown O
limited O
reproducibility O
both O
between O
studies O
and O
in O
relating O
these O
changes O
to O
exposures O

Accurate O
prediction O
of O
CoA O
was O
achieved O
using O
a O
newborn O
blood O
spot O

In O
addition O
, O
concrete O
and O
sustainable O
innovation O
in O
cancer B-Disease
treatment O
ought O
to O
integrate O
epigenome O
targeting O
drugs O
with O
classic O
therapies O
such O
as O
chemotherapy O
and O
immunotherapy O

Exposure O
to O
inorganic O
arsenic O
has O
been O
implicated O
in O
many O
diseases O
ranging O
from O
acute O
toxicities O
to O
malignant O
transformations O

600 O
: O
Crop O
diseases O
, O
in O
conjunction O
with O
climate O
change O
, O
are O
a O
major O
threat O
to O
global O
crop O
production O

However O
, O
the O
functions O
and O
morphologies O
of O
each O
cell O
are O
different O
, O
and O
the O
factors O
that O
determine O
them O
are O
the O
genes O
and O
proteins O
expressed O
in O
the O
cells O

Exciting O
epigenetic O
discoveries O
have O
been O
found O
in O
addiction O
, O
early O
life O
stress O
, O
neurodegeneration B-Disease
, O
post-traumatic O
stress O
disorder B-Disease
, O
and O
depression B-Disease

Furthermore O
, O
the O
global O
content O
of O
specific O
epigenetic O
modifications O
and O
the O
gene O
expression O
of O
non-coding O
RNAs O
and O
epigenetic O
modifiers O
vary O
according O
to O
the O
menstrual O
cycle O
phase O

DNAm O
of O
hematopoietic O
cells O
was O
compared O
globally O
across O
the O
450K O
array O
and O
through O
site-specific O
linear O
modeling O

660 O
: O
Environmental O
research O
and O
public O
health O
in O
the O
21st O
century O
face O
serious O
challenges O
such O
as O
increased O
air O
pollution O
and O
global O
warming O
, O
widespread O
use O
of O
potentially O
harmful O
chemicals O
including O
pesticides O
, O
plasticizers O
, O
and O
other O
endocrine O
disruptors O
, O
and O
radical O
changes O
in O

Recent O
technologies O
for O
high-throughput O
genome-wide O
analyses O
for O
epigenetic O
modifications O
are O
promising O
and O
potent O
tools O
for O
understanding O
the O
global O
dysregulation O
of O
cancer B-Disease
epigenetics O

While O
many O
epigenetic O
features O
have O
correlated O
relationships O
, O
most O
existing O
data O
normalization O
approaches O
analyze O
each O
feature O
independently O

Nutrition O
, O
among O
many O
other O
environmental O
factors O
, O
is O
a O
key O
player O
that O
can O
induce O
epigenetic O
changes O
not O
only O
in O
the O
directly O
exposed O
organisms O
but O
also O
in O
subsequent O
generations O
through O
the O
transgenerational O
inheritance O
of O
epigenetic O
traits O

Increased O
DNA O
damage O
repair O
and O
cell O
cycle O
deregulation O
decreases O
radio-response O
in O
PCa O
patients O

In O
this O
review O
, O
we O
discuss O
various O
fluorescent O
probes O
for O
histone O
modification O
detection O

413 O
: O
Genetic O
, O
environmental O
, O
and O
epigenetic O
influences O
and O
their O
transactions O
were O
examined O
in O
a O
sample O
of O
155 O
women O
from O
the O
Iowa O
adoptee O
sample O
who O
had O
been O
removed O
from O
their O
biological O
parents O
shortly O
after O
birth O
and O
assessed O
when O
participants O
were O
an O
average O
of O
41 O

Epigenetic O
modifications O
precede O
genetic O
changes O
and O
usually O
occur O
at O
an O
early O
stage O
in O
neoplastic O
development O

CandiMeth O
generates O
( O
i O
) O
tracks O
in O
the O
popular O
UCSC O
Genome O
Browser O
with O
an O
intuitive O
visual O
indicator O
of O
where O
differences O
in O
methylation O
occur O
between O
samples O
or O
groups O
of O
samples O
and O
( O
ii O
) O
tables O
containing O
quantitative O
data O
on O
the O
candidate O
regions O
, O
allowing O
interpretation O
of O
significance O

199 O
: O
The O
most O
exciting O
recent O
advance O
for O
achieving O
durable O
management O
of O
advanced O
human O
cancers B-Disease
is O
immunotherapy O
, O
especially O
the O
concept O
of O
immune O
checkpoint O
blockade O

There O
are O
various O
epigenetic O
modifications O
involving O
mechanisms O
such O
as O
DNA O
methylation O
, O
histone O
modification O
, O
and O
noncoding O
RNA O
expression O
, O
all O
of O
which O
are O
inheritable O

The O
workshop O
demonstrated O
the O
advantage O
of O
bringing O
together O
those O
working O
in O
this O
nascent O
field O
and O
highlights O
from O
the O
event O
are O
summarized O
in O
this O
report O
in O
the O
form O
of O
summaries O
from O
invited O
speakers O
and O
organizers O

Both O
the O
ternary O
smoking O
status O
classifiers O
and O
current O
versus O
former O
smoking O
status O
classifiers O
address O
the O
present O
lack O
of O
former O
smoker O
classification O
in O
epigenetic O
literature O
; O
essential O
if O
DNAm O
classifiers O
are O
to O
adequately O
relate O
to O
real-world O
populations O

Among O
the O
protective O
factors O
, O
a O
sense O
of O
psychological O
organisational O
membership O
at O
the O
start O
of O
the O
paramedicine O
course O
as O
measured O
at O
baseline O
significantly O
reduced O
epigenetic O
age O
at O
baseline O
and O
post-trauma B-Disease
exposure I-Disease

141 O
: O
Epigenetic O
patterns O
in O
a O
cell O
control O
the O
expression O
of O
genes O
and O
consequently O
determine O
the O
phenotype O
of O
a O
cell O

214 O
: O
The O
field O
of O
epigenetics O
has O
changed O
the O
way O
we O
look O
at O
both O
DNA O
and O
proteins O

Disorders O
, O
then O
, O
are O
often O
multimorbid O
involving O
both O
brain O
and O
body O
, O
such O
as O
depression B-Disease
with O
diabetes B-Disease
and O
cardiovascular O
disease B-Disease

Although O
findings O
are O
intriguing O
, O
further O
research O
is O
required O
as O
, O
to O
date O
, O
studies O
apply O
modest O
sample O
sizes O
and O
disparate O
methodologies O

Exposures' O
random O
permutations O
were O
performed O
to O
show O
the O
empirical O
p-value O
distributions O

Sequencing O
technologies O
that O
detect O
modification O
coupled O
with O
mass O
spectrometry O
to O
discover O
new O
adducts O
is O
a O
powerful O
tactic O
to O
study O
bacterial O
epigenetics O
, O
which O
is O
poised O
to O
make O
novel O
and O
far-reaching O
discoveries O
that O
link O
biological O
significance O
and O
the O
bacterial O
epigenome O

159 O
: O
Throughout O
centuries O
, O
many O
theories O
have O
been O
proposed O
to O
explain O
the O
origin O
of O
cancer B-Disease

In O
addition O
, O
because O
changes O
in O
the O
epigenome O
may O
constitute O
a O
signature O
of O
specific O
exposure O
to O
certain O
risk O
factors O
, O
they O
have O
the O
potential O
to O
serve O
as O
highly O
specific O
biomarkers O
for O
risk O
assessment O

Research O
on O
epigenetic O
marks O
, O
which O
regulate O
gene O
expression O
independently O
of O
the O
underlying O
genetic O
code O
, O
has O
dramatically O
changed O
our O
understanding O
of O
the O
interplay O
between O
genes O
and O
the O
environment O

, O
from O
0 O

complexity O

Epigenetics O
is O
a O
major O
interface O
between O
genetic O
and O
environmental O
modifiers O
of O
disease B-Disease
and O
strongly O
influence O
transcription O

Therefore O
, O
the O
extent O
to O
which O
DNAm O
could O
represent O
a O
causal O
mechanism O
( O
e O

They O
report O
on O
the O
evidence O
of O
epigenetic O
alterations O
in O
schizophrenia B-Disease
and O
their O
relevance O
to O
pharmacological O
studies O

Two O
broad O
categories O
of O
epigenetic O
modifications O
must O
be O
distinguished O

Epigenetics O
has O
taken O
center O
stage O
in O
the O
study O
of O
diseases O
such O
as O
cancer B-Disease
and O
diabetes B-Disease
, O
but O
its O
integration O
into O
the O
field O
of O
environmental O
health O
is O
still O
emerging O

Such O
analysis O
shows O
that O
some O
computed O
scores O
derived O
from O
training-based O
models O
and O
training-free O
algorithms O
outperform O
all O
experimental O
epigenetic O
features O

The O
study O
enrolled O
a O
cohort O
of O
relatively O
healthy O
individuals O
, O
and O
their O
methylation O
levels O
of O
eight O
specific O
CpG O
dinucleotides O
in O
genes O
SLC12A5 O
, O
LDB2 O
, O
FIGN O
, O
ACSS3 O
, O
FHL2 O
, O
and O
EPHX3 O
were O
evaluated O
using O
the O
iPlex O
MassARRAY O
system O
and O

The O
associated O
transcriptional O
changes O
suggest O
that O
environmentally O
induced O
5hmC O
alterations O
play O
a O
role O
in O
epigenetically O
mediated O
genome O
flexibility O

In O
this O
article O
, O
we O
review O
recent O
findings O
on O
the O
role O
of O
epigenetic O
factors O
in O
eating B-Disease
disorders I-Disease
, O
address O
methodological O
issues O
that O
need O
to O
be O
considered O
when O
interpreting O
research O
findings O
, O
and O
comment O
on O
possible O
clinical O
applications O

The O
application O
of O
behavioral O
epigenetics O
to O
the O
field O
of O
preterm O
studies O
( O
i O

However O
, O
comparisons O
between O
the O
mutation O
and O
the O
epimutation O
rates O
showed O
a O
high O
level O
of O
the O
latter O
, O
suggesting O
a O
significant O
role O
of O
spontaneous O
epimutations O
in O
adaptation O

As O
the O
results O
of O
gene O
enrichment O
, O
pathways O
analysis O
showed O
that O
TAPBP O
, O
BDNF O
, O
and O
SORBS2 O
linked O
together O
by O
inflammatory O
pathways O

The O
objective O
of O
this O
paper O
is O
to O
use O
permutation-based O
inference O
and O
a O
new O
ranked-based O
test O
statistic O
to O
identify O
sex-based O
epigenetic O
differences O
in O
the O
human O
DNA O
methylome O


We O
discuss O
challenges O
and O
barriers O
to O
advancing O
cardiometabolic O
epigenetics O
research O
, O
along O
with O
the O
opportunities O
for O
novel O
preventive O
strategies O
, O
targeted O
therapies O
, O
and O
personalized O
medicine O
approaches O
that O
may O
arise O
from O
a O
better O
understanding O
of O
epigenetic O
processes O

It O
further O
provides O
a O
broad O
background O
on O
epigenetics O
with O
a O
focus O
on O
three-dimensional O
conformation O
of O
chromatin O

Approaches O
are O
also O
described O
for O
batch O
retrieval O
of O
genomic O
information O
, O
performing O
more O
complex O
queries O
, O
and O
analyzing O
larger O
sets O
of O
experimental O
data O
, O
for O
example O
from O
next-generation O
sequencing O
projects O

Supporting O
functional O
relevance O
of O
this O
largely O
unknown O
regulatory O
mechanism O
, O
several O
human O
diseases O
have O
been O
associated O
directly O
to O
RNA O
modifications O
or O
to O
RBPs O
that O
may O
play O
as O
effectors O
of O
epitranscriptomic O
marks O

cn/CFEA O
), O
a O
cell-free O
epigenome O
database O
dedicated O
to O
three O
types O
of O
widely O
adopted O
epigenetic O
modifications O
( O
5mC O
, O
5hmC O
and O
NP O
) O
involved O
in O
27 O
human O
diseases O

We O
specifically O
address O
( O
i O
) O
queen O
versus O
worker O
caste O
differentiation O
, O
( O
ii O
) O
queen O
versus O
worker O
caste O
differences O
, O
and O
( O
iii O
) O
division O
of O
labor O
among O
workers O

SDHx O
mutations O
lead O
to O
the O
accumulation O
of O
succinate O
, O
which O
acts O
as O
an O
oncometabolite O
by O
inhibiting O
iron(II) O
and O
alpha-ketoglutarate-dependent O
dioxygenases O
thereby O
regulating O
the O
cell O
's O
hypoxic O
response O
and O
epigenetic O
processes O

740 O
: O
Drug O
resistance O
, O
either O
intrinsic O
or O
acquired O
, O
represents O
a O
major O
hurdle O
to O
achieving O
optimal O
therapeutic O
outcomes O
during O
cancer B-Disease
treatment O

521 O
: O
Background O
: O
Epigenetic O
modifications O
, O
including O
CG O
methylation O
( O
a O
major O
form O
of O
DNA O
methylation O
) O
and O
histone O
modifications O
, O
interact O
with O
each O
other O
to O
shape O
their O
genomic O
distribution O
patterns O

Relevant O
articles O
were O
selected O
, O
and O
additional O
sources O
were O
located O
from O
ancestry O
searches O
of O
reference O
lists O

Predictive O
genetic O
panels O
for O
these O
adolescents O
presenting O
with O
a O
very O
severe O
disease B-Disease
course O
, O
and O
/ O
or O
families O
with O
high O
penetrance O
of O
disease B-Disease
will O
be O
of O
benefit O

The O
models O
were O
thoroughly O
validated O
, O
showing O
mean O
precisions O
of O
up O
to O
0 O

Despite O
advances O
in O
our O
knowledge O
of O
psychopathic B-Disease
individuals O
, O
the O
construct O
remains O
complex O
and O
is O
hampered O
by O
a O
lack O
of O
integration O
across O
a O
range O
of O
fundamental O
domains O

We O
describe O
the O
potential O
clinical O
applications O
of O
genetics O
, O
and O
provide O
important O
challenges O
in O
the O
field O
and O
the O
future O
steps O
to O
be O
taken O

181 O
: O
Multiple O
genetic O
and O
epigenetic O
events O
characterize O
tumor B-Disease
progression O
and O
define O
the O
identity O
of O
the O
tumors B-Disease

Evidence O
indicates O
epigenetic O
marks O
function O
in O
combinations O
, O
whereby O
a O
given O
modification O
has O
distinct O
effects O
on O
local O
genome O
control O
, O
depending O
on O
which O
additional O
modifications O
are O
locally O
present O

322 O
: O
High-throughput O
single-cell O
measurements O
of O
DNA O
methylomes O
can O
quantify O
methylation O
heterogeneity B-Disease
and O
uncover O
its O
role O
in O
gene O
regulation O

e O

302 O
: O
Epigenetics O
has O
an O
important O
role O
for O
the O
success O
of O
foodborne O
pathogen O
persistence O
in O
diverse O
host O
niches O

In O
this O
chapter O
, O
we O
discuss O
how O
CRISPR/Cas9 O
and O
dCas9 O
have O
recently O
been O
engineered O
for O
epigenome O
editing O

581 O
: O
As O
the O
' O
gateway O
' O
to O
the O
fetus O
, O
the O
placenta O
is O
subject O
to O
a O
myriad O
of O
environmental O
factors O
, O
each O
with O
the O
potential O
to O
alter O
placental O
epigenetic O
and O
gene O
expression O
profile O

He O
served O
as O
the O
Principal O
Investigator O
for O
all O
DNA O
methylation O
data O
production O
for O
the O
Cancer B-Disease
Genome O
Atlas O
( O
TCGA O
) O
and O
led O
many O
TCGA O
analysis O
efforts O

We O
conclude O
by O
discussing O
the O
importance O
of O
establishing O
community O
standards O
to O
maximize O
the O
possibility O
of O
integrative O
computational O
analyses O
, O
such O
as O
was O
clearly O
beneficial O
for O
the O
human O
ENCODE O
project O

622 O
: O
The O
goal O
of O
this O
study O
is O
to O
develop O
an O
epigenetic O
multiplex O
for O
body O
fluid O
identification O
based O
on O
tissue O
specific O
DNA O
methylation O

Since O
epigenetic O
therapy O
is O
now O
in O
clinical O
use O
in O
hematopoietic B-Disease
diseases I-Disease
and O
undergoing O
trials O
for O
lung B-Disease
cancer I-Disease
, O
a O
better O
understanding O
of O
epigenetic O
abnormalities O
is O
desired O

Conclusions O
: O
Our O
comprehensive O
computational O
analysis O
helps O
the O
CRISPR-Cas9 O
community O
better O
understand O
the O
relationship O
between O
epigenetic O
features O
and O
CRISPR-Cas9 O
off-target O
activity O


The O
approach O
we O
chose O
is O
to O
scrutinize O
the O
pathways O
and O
epigenetic O
factors O
predicted O
to O
drive O
immune O
infiltration O
in O
different O
cancer B-Disease
types O
using O
publicly O
available O
TCGA O
transcriptional O
and O
methylation O
datasets O
, O
along O
with O
accompanying O
clinico-pathological O
data O

Because O
epigenetic O
changes O
might O
be O
transmitted O
to O
offspring O
, O
the O
need O
for O
reliable O
and O
cost-effective O
epigenetic O
screening O
tools O
becomes O
acute O

Finally O
, O
we O
make O
specific O
suggestions O
for O
future O
research O
on O
MS-AFLP O
and O
identify O
questions O
that O
are O
most O
compelling O
and O
tractable O
in O
the O
short O
term O

The O
application O
of O
molecular O
epigenetic O
data O
in O
advanced O
machine O
learning O
analysis O
to O
medicine O
is O
the O
focus O
of O
this O
review O

While O
a O
number O
of O
reference-based O
deconvolution O
algorithms O
have O
emerged O
, O
their O
potential O
remains O
underexplored O
and O
a O
comparative O
evaluation O
of O
these O
algorithms O
beyond O
tissues O
such O
as O
blood O
is O
still O
lacking O

Conclusion O
: O
The O
package O
Snapshot O
can O
identify O
all O
distinct O
clusters O
of O
genomic O
locations O
with O
unique O
epigenetic O
signal O
patterns O
during O
cell O
differentiation O

Moreover O
, O
we O
show O
that O
the O
pseudotime O
trajectory O
can O
be O
modeled O
with O
respect O
to O
time O
, O
using O
a O
sum O
of O
two O
exponentials O
, O
with O
coefficients O
that O
are O
close O
to O
the O
timescales O
of O
human O
age-associated O
mortality O

cn O
or O
http://www O

37 O
: O
Epigenetics O
refers O
to O
changes O
in O
phenotype O
that O
are O
not O
rooted O
in O
DNA O
sequence O

Although O
not O
somatically O
heritable O
, O
epigenetic O
modifications O
in O
neurons O
are O
dynamic O
and O
reversible O
, O
which O
makes O
them O
good O
targets O
for O
therapeutic O
intervention O

Around O
40% O
of O
all O
cases O
are O
caused O
by O
a O
germline O
mutation O
in O
a O
susceptibility O
gene O
, O
half O
of O
which O
being O
found O
in O
an O
SDHx O
gene O
( O
SDHA O
, O
SDHB O
, O
SDHC O
, O
SDHD O
or O
SDHAF2 O
) O

Furthermore O
, O
a O
gene-environmental O
interaction O
has O
been O
proposed O
as O
triggering O
mechanism O
, O
through O
epigenetic O
alterations O
: O
In O
particular O
, O
fibromyalgia O
appears O
to O
be O
characterized O
by O
a O
hypomethylated O
DNA O
pattern O
, O
in O
genes O
implicated O
in O
stress O
response O
, O
DNA O
repair O
, O
autonomic O
system O
response O
, O

Moreover O
, O
Listeria O
monocytogenes O
can O
indirectly O
induce O
H3 O
hyperacetylation O
leading O
to O
inflammation B-Disease
in O
human O
endothelial O
cells O
whereas O
Pseudomonas O
aeruginosa O
excretes O
QS O
2-AA O
to O
directly O
induce O
H3 O
deacetylation O
leading O
to O
bacterial O
persistence O
in O
human O
monocytes O

Here O
, O
we O
assessed O
how O
the O
blood O
DNA O
methylome O
of O
884 O
adults O
is O
affected O
by O
DNA O
sequence O
variation O
, O
age O
, O
sex O
and O
139 O
factors O
relating O
to O
life O
habits O
and O
immunity O

Meanwhile O
, O
data O
on O
the O
role O
of O
epigenetical O
factors O
in O
the O
manifestation O
of O
diseases O
have O
been O
emerging O

However O
, O
exactly O
how O
the O
aging O
process O
occurs O
remains O
unknown O

With O
the O
foundations O
now O
in O
place O
, O
we O
foresee O
that O
unprecedented O
advancements O
will O
take O
place O
in O
the O
field O
in O
the O
coming O
years O

It O
is O
now O
clear O
, O
however O
, O
that O
epigenomic O
signature O
is O
also O
largely O
perturbed O
in O
many O
malignancies B-Disease

epidecodeR O
is O
available O
for O
downloading O
as O
an O
R O
package O
at O
https://bioconductor O

227 O
: O
The O
number O
of O
epigenetic O
studies O
is O
exponentially O
increasing O

On O
the O
other O
hand O
, O
receiving O
social O
support O
acted O
as O
a O
protective O
factor O
only O
after O
exposure O
to O
trauma B-Disease
( O
follow-up O
) O
, O
decreasing O
epigenetic O
aging O
at O
follow-up O

It O
requires O
Python O
2 O

We O
briefly O
review O
the O
current O
understanding O
of O
genetic O
and O
epigenetic O
causes O
of O
male O
infertility O
and O
how O
findings O
may O
be O
translated O
into O
a O
practical O
component O
for O
the O
diagnosis O
and O
treatment O
of O
male O
infertility O

671 O
: O
Epigenetic O
changes O
, O
which O
target O
DNA O
and O
associated O
histones O
, O
can O
be O
described O
as O
a O
pivotal O
mechanism O
of O
interaction O
between O
genes O
and O
the O
environment O

There O
is O
now O
increasing O
evidence O
, O
both O
in O
animals O
and O
humans O
, O
that O
such O
developmental O
plasticity O
is O
mediated O
in O
part O
by O
epigenetic O
mechanisms O

He O
is O
now O
Professor O
of O
Epigenetics O
in O
the O
Department O
of O
Biological O
Sciences O
at O
North O
Carolina O
State O
University O
, O
Raleigh O
, O
NC O
, O
USA O

uCoTarget O
reveals O
establishment O
of O
pairing O
of O
HSPC O
enhancers O
(H3K27ac) O
and O
promoters O
(H3K4me3) O
and O
RUNX1 O
engagement O
priming O
for O
H3K27ac O
activation O
along O
the O
HSPC O
path O

Ultimately O
, O
the O
information O
gained O
by O
further O
research O
may O
improve O
the O
clinical O
guidelines O
for O
the O
use O
of O
such O
drugs O
in O
patients O
of O
reproductive O
age O

, O
relapse O
prevention O
targeted O
to O
epigenetic O
responses O
to O
intervention O
participation O
) O
; O
and O
( O
3 O
) O
inform O
more O
sensitive O
measures O
of O
intervention O
impact O
, O
( O
e O

Epigenetic O
modifications O
influence O
transcription O
and O
genome O
stability O
are O
established O
during O
development O
with O
life-long O
consequences O

However O
, O
current O
publications O
have O
been O
limited O
by O
the O
use O
of O
global O
or O
targeted O
methods O
of O
measuring O
DNA O
methylation O

It O
includes O
environmental O
, O
nutritional O
, O
hormonal O
and O
physiological O
factors O
and O
influence O
of O
internal O
structural O
architecture O
of O
chromatin O
nucleosomes O
affecting O
DNA O
and O
histone O
modifications O
in O
both O
male O
and O
female O
gametes O
, O
early O
embryogenesis O
and O
offspring O

Epigenetic O
regulation O
explains O
how O
, O
starting O
from O
a O
unique O
genome O
, O
the O
pluripotent O
embryo O
can O
generate O
a O
variety O
of O
tissues O
and O
maintain O
their O
identity O
throughout O
development O

Recently O
, O
alterations O
in O
epigenetic O
mechanisms O
and O
their O
activity O
have O
been O
associated O
with O
osteoporosis B-Disease
and O
OVF O

In O
this O
paper O
we O
review O
existing O
research O
in O
the O
field O
of O
imaging O
epigenetics O
, O
outline O
important O
caveats O
and O
considerations O
, O
and O
suggest O
a O
set O
of O
guidelines O
for O
researchers O
conducting O
this O
work O

org O

We O
developed O
a O
new O
data O
normalization O
method O
, O
called O
S3norm O
, O
that O
normalizes O
the O
sequencing O
depths O
and O
signal-to-noise O
ratios O
across O
different O
data O
sets O
simultaneously O
by O
a O
monotonic O
nonlinear O
transformation O

However O
, O
an O
exhaustive O
epitranscriptome O
's O
characterization O
, O
aimed O
to O
systematically O
classify O
all O
RNA O
modifications O
and O
clarify O
rules O
, O
actors O
, O
and O
outcomes O
of O
this O
promising O
regulatory O
code O
, O
is O
currently O
not O
available O
, O
mainly O
hampered O
by O
lack O
of O
suitable O
detecting O
technologies O

Conclusions O
: O
Functional O
and O
correlative O
studies O
are O
now O
needed O
to O
elucidate O
the O
potential O
links O
between O
germline O
genotype O
, O
epigenetic O
function O
, O
and O
cancer B-Disease
etiology O

This O
article O
presents O
an O
overview O
of O
this O
new O
synthesis O
, O
using O
as O
an O
example O
emerging O
evidence O
about O
the O
linkages O
between O
systemic O
inflammation B-Disease
, O
insulin O
resistance O
and O
mental O
health O
and O
neurodegenerative B-Disease
diseases I-Disease

We O
put O
a O
special O
focus O
on O
the O
discussion O
of O
molecular O
mechanisms O
underlying O
environmentally O
induced O
alterations O
in O
DNA O
hydroxymethylation O
patterns O
and O
their O
impact O
on O
genetic O
dysfunction O

, O
NICU-related O
pain-related O
stress O
) O
events O
affect O
the O
developmental O
trajectories O
of O
preterm O
infants O
and O
children O
via O
epigenetic O
alterations O
of O
imprinted O
and O
stress-related O
genes O

Using O
a O
statistical O
learning O
algorithm O
we O
find O
that O
it O
is O
possible O
accurately O
to O
assign O
trees O
to O
gender O
using O
genome-wide O
methylation O
patterns O
alone O

Many O
imprinted O
genes O
are O
clustered O
in O
the O
genome O
with O
the O
establishment O
and O
maintenance O
of O
imprinted O
gene O
expression O
governed O
by O
complex O
epigenetic O
mechanisms O

All O
protocol O
steps O
, O
starting O
from O
structure-based O
pharmacophore O
modeling O
, O
protein O
and O
database O
preparation O
along O
with O
docking O
and O
similarity O
search O
, O
will O
be O
explained O
in O
details O

MeDeCom O
is O
a O
new O
unsupervised O
tool O
for O
the O
exploratory O
study O
of O
the O
major O
sources O
of O
methylation O
variation O
, O
which O
should O
lead O
to O
a O
deeper O
understanding O
and O
better O
biological O
interpretation O

Therefore O
, O
in O
the O
present O
study O
, O
we O
comprehensively O
review O
the O
current O
status O
of O
the O
epigenetic O
clocks O
and O
their O
associations O
across O
the O
human O
phenome O

470 O
: O
Sculpting O
the O
epigenome O
with O
a O
combination O
of O
histone O
modifications O
and O
transcription O
factor O
occupancy O
determines O
gene O
transcription O
and O
cell O
fate O
specification O

12 O
at O
genome-wide O
level O
to O
0 O

Through O
ViCAR O
, O
we O
showcase O
the O
first O
G4-3D O
interaction O
landscape O

Additionally O
, O
we O
highlighted O
the O
evolution O
of O
studies O
beyond O
mere O
associations O
to O
establish O
causal O
mechanisms O
between O
epigenetic O
age O
and O
disease B-Disease

Osmium O
in O
the O
oxidized O
state O
reacts O
with O
C5-methylated O
pyrimidines O
in O
the O
presence O
of O
a O
bipyridine O
ligand O
to O
give O
a O
stable O
ternary O
complex O

Genome O
Biol O
18 O
: O
18 O

The O
robustness O
and O
plasticity O
are O
concerned O
with O
changeability O
of O
a O
biological O
system O
against O
external O
perturbations O

For O
high-throughput O
applications O
such O
as O
epigenome-wide O
association O
studies O
, O
the O
Infinium O
HumanMethylation450 O
( O
450K O
) O
BeadChip O
is O
currently O
the O
platform O
of O
choice O

321 O
: O
Planarian O
flatworms O
possess O
pluripotent O
stem O
cells O
( O
neoblasts O
) O
that O
are O
able O
to O
differentiate O
into O
all O
cell O
types O
that O
constitute O
the O
adult O
body O
plan O

A O
spike-in O
strategy O
based O
on O
SILAC O
can O
be O
used O
to O
overcome O
this O
limitation O
and O
profile O
hPTMs O
across O
multiple O
samples O

With O
the O
introduction O
of O
epigenetic O
drugs O
into O
clinical O
use O
in O
the O
last O
decade O
, O
the O
importance O
of O
the O
epigenetic O
background O
of O
GC O
has O
increased O
considerably O

Recent O
evidences O
also O
suggest O
that O
miRNAs O
can O
directly O
modulate O
gene O
transcription O
in O
the O
nucleus O
through O
the O
recognition O
of O
specific O
target O
sites O
in O
promoter O
regions O

cancer B-Disease
cells O
employ O
multiple O
mechanisms O
to O
avoid O
immune O
recognition O
and O
suppress O
antitumor O
immune O
responses O

, O
a O
surrogate O
of O
central O
nervous B-Disease
system I-Disease
function O
) O
or O
a O
biomarker O
( O
i O

Finally O
, O
reactive O
oxygen O
and O
nitrogen O
species O
may O
fine-tune O
epigenetic O
processes O
and O
include O
similar O
signaling O
mechanisms O
involved O
in O
environmental O
stress O
responses O
in O
plants O
as O
well O
as O
animals O

699 O
: O
Genetic O
studies O
have O
attempted O
to O
elucidate O
causal O
mechanisms O
for O
the O
development O
of O
complex O
disease B-Disease
, O
but O
genome-wide O
associations O
have O
been O
largely O
unsuccessful O
in O
establishing O
these O
links O

These O
findings O
are O
encouraging O
, O
and O
although O
the O
risks O
associated O
with O
such O
therapy O
are O
largely O
unknown O
, O
precise O
maps O
of O
epigenetic O
marks O
are O
becoming O
increasingly O
available O
through O
advancements O
in O
sequencing O
protocols O
that O
combine O
chromatin O
immunoprecipitation O
and O
gene O
expression O
analyses O

136 O
: O
Microglia O
, O
the O
major O
population O
of O
brain-resident O
macrophages O
, O
are O
now O
recognized O
as O
a O
heterogeneous O
population O
comprising O
several O
cell O
subtypes O
with O
different O
( O
so O
far O
mostly O
supposed O
) O
functions O
in O
health O
and O
disease B-Disease

Emerging O
insights O
from O
cancer B-Disease
genome O
sequencing O
and O
chromatin O
biology O
have O
identified O
leveraged O
opportunities O
for O
development O
of O
chromatin-directed O
small O
molecules O
as O
cancer B-Disease
therapies O

We O
provide O
an O
overview O
of O
current O
invasive O
and O
noninvasive O
techniques O
for O
measuring O
expression O
and O
functions O
of O
chromatin-modifying O
enzymes O
in O
the O
brain O
, O
emphasizing O
tools O
applicable O
to O
histone O
deacetylase O
( O
HDAC O
) O
enzymes O
as O
a O
leading O
example O

Fortunately O
, O
that O
scenario O
is O
now O
changing O
thanks O
to O
the O
growing O
availability O
of O
complete O
reference O
genome O
sequences O
along O
with O
the O
development O
of O
high-throughput O
DNA O
sequencing O
and O
bioinformatic O
methods O

649 O
: O
DNA O
methylation O
( O
5mC O
) O
is O
an O
essential O
epigenetic O
mark O
associated O
with O
transcriptional O
silencing O

However O
, O
only O
results O
of O
HLA O
phenotyping O
have O
been O
taken O
over O
to O
routine O
clinical O
practice O

267 O
: O
Epigenetics O
has O
drawn O
much O
attention O
as O
a O
mechanism O
of O
transcriptional O
regulation O
involving O
modifications O
to O
genomic O
DNA O
and O
histone O
, O
without O
changes O
to O
nucleotide O
sequences O

Expert O
opinion O
: O
Current O
genetic O
and O
epigenetic O
studies O
are O
finally O
shedding O
light O
on O
the O
biomolecular O
mechanisms O
linked O
to O
the O
core O
pathogenetic O
alterations O
in O
schizophrenia B-Disease
, O
rather O
than O
just O
their O
symptoms O

A O
characterization O
of O
lipid-associated O
genetic O
variants O
suggests O
that O
these O
variants O
exert O
their O
influence O
on O
lipid O
levels O
through O
epigenetic O
changes O
in O
the O
liver O

We O
present O
PRISM O
, O
a O
tool O
for O
inferring O
the O
composition O
of O
epigenetically O
distinct O
subclones O
of O
a O
tumor B-Disease
solely O
from O
methylation O
patterns O
obtained O
by O
reduced O
representation O
bisulfite O
sequencing O

618 O
: O
Epigenetic O
processes O
are O
known O
to O
have O
powerful O
roles O
in O
organ O
development O
across O
biology O

After O
the O
reversal O
of O
crosslinks O
and O
DNA O
isolation O
, O
one O
may O
analyze O
the O
precipitated O
DNA O
fragments O
by O
quantitative O
and O
qualitative O
methods O
to O
assess O
the O
relative O
abundance O
of O
the O
examined O
protein O
in O
a O
region O
or O
within O
the O
genome O
studied O
in O
vivo O

, O
Preterm O
Behavioral O
Epigenetics O
, O
PBE O
) O
is O
rapidly O
growing O
and O
holds O
promises O
to O
provide O
valid O
insights O
for O
research O
and O
clinical O
activity O

Our O
method O
provides O
an O
analytical O
approach O
to O
study O
the O
relationship O
between O
epigenomic O
changes O
and O
cell O
lineage O
differentiation O

CSCs O
are O
correlated O
with O
poor O
clinical O
outcome O
due O
to O
their O
contribution O
to O
chemotherapy O
resistance O
and O
metastasis O

In O
this O
review O
, O
we O
cover O
the O
basics O
of O
DNA O
methylation O
establishment O
and O
control O
, O
and O
the O
methods O
used O
to O
examine O
it O

The O
quest O
for O
personalized O
medicine O
is O
a O
contemporary O
manifestation O
of O
this O
dream O

During O
the O
last O
decade O
it O
became O
clear O
that O
cancer B-Disease
is O
defined O
by O
a O
variety O
of O
epigenetic O
changes O
, O
which O
occur O
in O
early O
stages O
of O
disease B-Disease
and O
parallel O
genetic O
mutations O

Recent O
advances O
in O
genomic O
research O
provide O
evidence O
that O
focussing O
these O
efforts O
on O
individual O
variations O
in O
abilities O
to O
metabolize O
nutrients O
(nutrigenetics) O
and O
exploring O
the O
role O
of O
dietary O
compounds O
on O
gene O
expression O
(nutrigenomics O
and O
nutri-epigenomics) O
can O
lead O
to O
more O
meaningful O
personalized O
dietary O

Very O
often O
, O
these O
experiments O
are O
based O
on O
the O
hypothesis O
that O
epigenetic O
memorization O
of O
events O
or O
conditions O
could O
be O
the O
basis O
of O
an O
altered O
response O
of O
the O
progeny O
upon O
encountering O
the O
same O
or O
a O
similar O
condition O

288 O
: O
The O
field O
of O
mitochondrial O
epigenetics O
has O
received O
increased O
attention O
in O
recent O
years O
and O
changes O
in O
mitochondrial O
DNA O
(mtDNA) O
methylation O
has O
been O
implicated O
in O
a O
number O
of O
diseases O
, O
including O
neurodegenerative B-Disease
diseases I-Disease
such O
as O
amyotrophic O
lateral O
sclerosis O

A O
key O
player O
of O
the O
epigenetic O
modifications O
is O
the O
DNA O
methylation O
, O
a O
process O
involving O
the O
covalent O
transfer O
of O
a O
methyl O
group O
to O
the O
C-5 O
position O
of O
the O
cytosine O
ring O
of O
DNA O
forming O
5-methylcytosine O
( O
5mC O
) O
, O
catalyzed O
by O
DNA O
methyl O

But O
as O
yet O
they O
have O
not O
revealed O
how O
this O
regulation O
of O
expression O
is O
controlled O

Taking O
advantage O
of O
this O
, O
mammalian O
and O
avian O
epigenetic O
clocks O
have O
been O
constructed O
to O
predict O
age O

By O
standardizing O
the O
internal O
data O
structures O
and O
presenting O
a O
common O
interface O
to O
the O
data O
parser O
, O
NGS++ O
offers O
an O
effective O
framework O
for O
epigenomics O
tool O
development O

The O
emergence O
of O
new O
sequencing O
technologies O
and O
tools O
to O
study O
the O
epigenome O
has O
led O
to O
identifying O
predictive O
biomarkers O
for O
earlier O
diagnosis O
, O
opening O
up O
the O
possibility O
of O
prophylactical O
interventions O

In O
this O
review O
, O
we O
discuss O
current O
evidence O
and O
molecular O
mechanisms O
for O
epigenetic O
transgenerational O
inheritance O
of O
obesity B-Disease
susceptibility O

During O
the O
secretory O
phase O
, O
epigenetic O
mechanisms O
promote O
the O
expression O
of O
genes O
associated O
with O
hormone O
response O
, O
insulin O
signaling O
, O
decidualization O
, O
and O
embryo O
implantation O

This O
is O
because O
the O
use O
of O
monozygotic O
twins O
discordant O
for O
cancer B-Disease
enables O
epigenetic O
variation O
analysis O
without O
the O
confounding O
influence O
of O
the O
constitutive O
genetic O
background O
, O
age O
or O
cohort O
effects O

However O
, O
biochemical O
relapse O
occurs O
in O
20-40% O
of O
advanced O
PCa O
treated O
with O
RT O
either O
alone O
or O
in O
combination O
with O
adjuvant-hormonal O
therapy O

We O
consider O
data O
from O
a O
panel O
of O
Arabidopsis O
epigenetic O
recombinant O
inbred O
lines O
and O
explore O
estimates O
of O
the O
number O
of O
quantitative O
trait O
loci O
for O
plant O
height O
that O
resulted O
from O
a O
manipulation O
of O
DNA O
methylation O
levels O
in O
one O
of O
the O
two O
isogenic O
founder O
strains O

Using O
epiNet O
, O
we O
identified O
biologically O
relevant O
epigenetic O
crosstalk O
between O
histone O
H3K36me3 O
, O
H3K4me3 O
, O
and O
CG O
methylation O
in O
mouse O
oocytes O

Novel O
epigenetic-targeted O
drugs O
have O
shown O
good O
tolerance O
and O
therapeutic O
effects O
in O
the O
treatment O
of O
peripheral O
T-cell O
lymphoma B-Disease
as O
monotherapy O
or O
combination O
therapy O
